

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification⁶ : C07D 413/12, 413/14, 498/10, A61K 31/42	A1	(11) International Publication Number: WO 97/33887 (43) International Publication Date: 18 September 1997 (18.09.97)
(21) International Application Number: PCT/US97/04567 (22) International Filing Date: 17 March 1997 (17.03.97) (30) Priority Data: 60/013,539 15 March 1996 (15.03.96) US 08/646,896 8 May 1996 (08.05.96) US 08/816,580 14 March 1997 (14.03.97) US (71) Applicant: THE DU PONT MERCK PHARMACEUTICAL COMPANY [US/US]; 1007 Market Street, Wilmington, DE 19898 (US). (72) Inventors: JADHAV, Prabhakar, Kondaji; 11 Morgan Lane, Wilmington, DE 19808 (US). SMALLHEER, Joanne, Marie; 1215 Delpa Drive, Landenberg, PA 19350 (US). (74) Agent: FERGUSON, Blair, Q.; The du Pont Merck Pharmaceutical Company, Legal/Patent Records Center, 1007 Market Street, Wilmington, DE 19898 (US).		(81) Designated States: AM, AU, AZ, BR, BY, CA, CN, CZ, EE, HU, IL, JP, KG, KR, KZ, LT, LV, MD, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, UA, VN, Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: SPIROCYCLE INTEGRIN INHIBITORS (57) Abstract <p>This invention relates to novel heterocycles, including (S)-2-phenylsulfonylamino-3-[[[8-(2-pyridinylaminomethyl)-]-1-oxa-2-azaspiro-[4,5]-dec-2-en-3-yl]carbonylamino]propionic acid, which are useful as antagonists of the $\alpha_v\beta_3$ integrin and related cell surface adhesive protein receptors, to pharmaceutical compositions containing such compounds, processes for preparing such compounds, and to methods of using these compounds, alone or in combination with other therapeutic agents, for the inhibition of cell adhesion, the treatment of angiogenic disorders, inflammation, bone degradation, cancer metastasis, diabetic retinopathy, thrombosis, restenosis, macular degeneration, and other conditions mediated by cell adhesion and/or cell migration and/or angiogenesis.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgystan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

TITLE

5

Spirocycle Integrin Inhibitors

FIELD OF THE INVENTION

10 This invention relates to novel heterocycles which
are useful as antagonists of the $\alpha_v\beta_3$ integrin and
related cell surface adhesive protein receptors, to
pharmaceutical compositions containing such compounds,
15 processes for preparing such compounds, and to methods
of using these compounds, alone or in combination with
other therapeutic agents, for the inhibition of cell
adhesion, the treatment of angiogenic disorders,
inflammation, bone degradation, cancer metastasis,
20 diabetic retinopathy, thrombosis, restenosis, macular
degeneration, and other conditions mediated by cell
adhesion and/or cell migration and/or angiogenesis.

BACKGROUND OF THE INVENTION

25 Angiogenesis or neovascularization is critical for
normal physiological processes such as embryonic
development and wound repair (Folkman and Shing, J.
Biol. Chem. 1992, 267:10931-10934; D'Amore and Thompson,
Ann. Rev. Physiol. 1987, 49:453-464). However,
30 angiogenesis also occurs pathologically, for example, in
ocular neovascularization (leading to diabetic
retinopathy, neovascular glaucoma, retinal vein
occlusion and blindness), in rheumatoid arthritis and in
solid tumors (Folkman and Shing, J. Biol. Chem., 1992,

267:10931-10934; Blood and Zetter, Biochim. Biophys. Acta., 1990, 1032:118-128).

Tumor dissemination, or metastasis, involves several distinct and complementary components, including the penetration and transversion of tumor cells through basement membranes and the establishment of self-sustaining tumor foci in diverse organ systems. To this end, the development and proliferation of new blood vessels, or angiogenesis, is critical to tumor survival. Without neovascularization, tumor cells lack the nourishment to divide and will not be able to leave the primary tumor site (Folkman and Shing, J. Biol. Chem., 1992, 267:10931-10934).

Inhibition of angiogenesis in animal models of cancer has been shown to result in tumor growth suppression and prevention of metastatic growth (Herblin et al., Exp. Opin. Ther. Patents, 1994, 1-14). Many angiogenic inhibitors have been directed toward blocking initial cytokine-dependent induction of new vessel growth, e.g. antibodies to endothelial cell growth factors. However, these approaches are problematic because tumor and inflammatory cells can secrete multiple activators of angiogenesis (Brooks et al., Cell, 1994, 79:1157-1164). Therefore, a more general approach that would allow inhibition of angiogenesis due to a variety of stimuli would be of benefit.

The integrin $\alpha_v\beta_3$ is preferentially expressed on angiogenic blood vessels in chick and man (Brooks et al., Science, 1994, 264:569-571; Eneastein and Kramer, J. Invest. Dermatol., 1994, 103:381-386). Integrin $\alpha_v\beta_3$ is the most promiscuous member of the integrin family, allowing endothelial cells to interact with a wide variety of extracellular matrix components (Hynes, Cell, 1992, 69:11-25). These adhesive interactions are considered to be critical for angiogenesis since

vascular cells must ultimately be capable of invading virtually all tissues.

While integrin $\alpha_v\beta_3$ promotes adhesive events important for angiogenesis, this receptor also transmits signals from the extracellular environment to the intracellular compartment (Leavesley et al., J. Cell Biol., 1993, 121:163-170, 1993). For example, the interaction between the $\alpha_v\beta_3$ integrin and extracellular matrix components promotes a calcium signal required for cell motility.

During endothelium injury, the basement membrane zones of blood vessels express several adhesive proteins, including but not limited to von Willebrand factor, fibronectin, and fibrin. Additionally, several members of the integrin family of adhesion receptors are expressed on the surface of endothelial, smooth muscle and on other circulating cells. Among these integrins is $\alpha_v\beta_3$, the endothelial cell, fibroblast, and smooth muscle cell receptor for adhesive proteins including von Willebrand factor, fibrinogen (fibrin), vitronectin, thrombospondin, and osteopontin. These integrins initiate a calcium-dependent signaling pathway that can lead to endothelial cell, smooth muscle cell migration and, therefore, may play a fundamental role in vascular cell biology.

Recently, an antibody to the $\alpha_v\beta_3$ integrin has been developed that inhibits the interaction of this integrin with agonists such as vitronectin (Brooks et al., Science, 1994, 264:569-571). Application of this antibody has been shown to disrupt ongoing angiogenesis on the chick chorioallantoic membrane (CAM), leading to rapid regression of histologically distinct human tumor transplanted onto the CAM (Brooks et al., Cell, 1994, 79:1157-1164). In this model, antagonists of the $\alpha_v\beta_3$ integrin induced apoptosis of the proliferating

angiogenic vascular cells, leaving pre-existing quiescent blood vessels unaffected. Thus, $\alpha_v\beta_3$ integrin antagonists have been shown to inhibit angiogenesis and are recognized as being useful as therapeutic agents for the treatment of human diseases such as cancer, restenosis, thromboembolic disorders, rheumatoid arthritis and ocular vasculopathies (Folkman and Shing, J. Biol. Chem., 1992, 267:10931-10934).


Increasing numbers of other cell surface receptors have been identified which bind to extracellular matrix ligands or other cell adhesion ligands thereby mediating cell-cell and cell-matrix adhesion processes. These receptors belong to a gene superfamily called integrins and are composed of heterodimeric transmembrane glycoproteins containing α - and β -subunits. Integrin subfamilies contain a common β -subunit combined with different α -subunits to form adhesion receptors with unique specificity. The genes for eight distinct β -subunits have been cloned and sequenced to date.

The $\alpha_v\beta_3$ heterodimer is a member of the β_3 integrin subfamily and has been described on platelets, endothelial cells, melanoma, smooth muscle cells, and osteoclasts (Horton and Davies, J. Bone Min. Res. 1989, 4:803-808; Davies et al., J. Cell. Biol. 1989, 109:1817-1826; Horton, Int. J. Exp. Pathol., 1990, 71:741-759). Like GPIIb/IIIa, the vitronectin receptor binds a variety of RGD-containing adhesive proteins such as vitronectin, fibronectin, VWF, fibrinogen, osteopontin, bone sialo protein II and thrombospondin in a manner mediated by the RGD sequence. A key event in bone resorption is the adhesion of osteoclasts to the matrix of bone. Studies with monoclonal antibodies have implicated the $\alpha_v\beta_3$ receptor in this process and suggest that a selective $\alpha_v\beta_3$ antagonist would have utility in blocking bone resorption (Horton et al., J. Bone Miner.

Res., 1993, 8:239-247; Helfrich et al., J. Bone Miner. Res., 1992, 7:335-343).

PCT Patent Application Publication Number


- 5 WO95/14683, published June 1, 1995 discloses isoxazoline and isoxazole fibrinogen receptor antagonists of general formula shown below:



10


Copending, commonly assigned U.S. Patent Application Serial Number 08/455,768 filed 5/31/95 discloses integrin inhibitors of the general formula

15 shown below:



PCT Patent Application Publication Number

- 20 WO95/32710, published December 7, 1995 discloses compounds for inhibition of osteoclast-mediated bone resorption of general formula shown below:



25

wherein Aryl is a 6-membered aromatic ring system.

- None of the above references discloses or suggests the spirocyclic compounds of the present invention which
- 30 are described in detail below.

SUMMARY OF THE INVENTION

The present invention provides novel nonpeptide
5 compounds which bind to integrin receptors thereby
altering cell-matrix and cell-cell adhesion processes.
The compounds of the present invention are useful for
the inhibition of cell adhesion and the treatment of
angiogenic disorders, inflammation, bone degradation,
10 cancer metastases, diabetic retinopathy, thrombosis,
restenosis, macular degeneration, and other conditions
mediated by cell adhesion and/or cell migration and/or
angiogenesis.

One aspect of this invention provides novel
15 compounds of Formula I (described below) which are
useful as antagonists of the $\alpha_v\beta_3$ integrin, which is also
referred to as the vitronectin receptor. The compounds
of the present invention inhibit the binding of
vitronectin or other RGD-containing ligands to $\alpha_v\beta_3$ and
20 inhibit cell adhesion. The present invention also
includes pharmaceutical compositions containing such
compounds of Formula I, and methods of using such
compounds for the inhibition of angiogenesis, and/or for
the treatment of disorders mediated by angiogenesis.

25 Another aspect of the present invention comprises
agents that inhibit the binding of vitronectin to the
 $\alpha_v\beta_3$ receptor for the treatment (including prevention) of
thrombosis which do not significantly alter hemostatic
balance and do not significantly inhibit platelet
30 aggregation and do not significantly inhibit
coagulation. Also the compounds of the current
invention can be used for the treatment or prevention of
restenosis.

The present invention also provides novel
35 compounds, pharmaceutical compositions and methods which

may be used in the treatment or prevention of other diseases which involve cell adhesion processes, including, but not limited to, rheumatoid arthritis, asthma, allergies, adult respiratory distress syndrome, 5 graft versus host disease, organ transplantation, septic shock, psoriasis, eczema, contact dermatitis, osteoporosis, osteoarthritis, atherosclerosis, metastasis, wound healing, diabetic retinopathy, ocular vasculopathies, thrombosis, inflammatory bowel disease 10 and other autoimmune diseases.

Also included in the present invention are pharmaceutical kits comprising one or more containers containing pharmaceutical dosage units comprising a compound of Formula I, for the therapeutic inhibition of 15 cell adhesion, the treatment of angiogenic disorders, inflammation, bone degradation, cancer metastasis, diabetic retinopathy, thrombosis, restenosis, macular degeneration, and other conditions mediated by cell adhesion and/or cell migration and/or angiogenesis.

20

DETAILED DESCRIPTION OF THE INVENTION


The present invention provides novel nonpeptide compounds of Formula I (described below) which bind to 25 integrin receptors thereby altering cell-matrix and cell-cell adhesion processes. The compounds of the present invention are useful for the inhibition of cell adhesion and the treatment of angiogenic disorders, inflammation, bone degradation, cancer metastases, 30 diabetic retinopathy, thrombosis, restenosis, macular degeneration, and other conditions mediated by cell adhesion and/or cell migration and/or angiogenesis, in a mammal.

One aspect of this invention provides novel 35 compounds of Formula I which are useful as antagonists

of the $\alpha_v\beta_3$ or vitronectin receptor. The compounds of the present invention inhibit the binding of vitronectin and other RGD-containing ligands to $\alpha_v\beta_3$ and inhibit cell adhesion. The present invention also includes


5 pharmaceutical compositions containing such compounds of Formula I, and methods of using such compounds for the inhibition of angiogenesis, and/or for the treatment of angiogenic disorders.

10 [1] The present invention comprises spirocyclic compounds of Formula I:



15 including stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, or pharmaceutically acceptable salt or prodrug forms thereof wherein:

20 Q is selected from




A is selected from $-\text{N}(\text{R}^{10})-$, $-\text{C}(\text{R}^{11})-$ or $-\text{O}-$;

25

A^1 is selected from $-\text{O}-$ or $-\text{N}(\text{R}^{10})-$;

30 Z is a spiro-fused 4-7 membered ring system (including the spiro atom) containing 0-2 heteroatoms selected from O, S, or N, said ring system optionally being substituted on carbon with keto, or being substituted on carbon or nitrogen independently with 0-2 R^9 or R^{10} or R^{10a} ;

R^1 is selected from:



5

B is independently selected from $-\text{CH}_2-$, $-\text{O}-$, $-\text{N}(\text{R}^2)-$, or $-\text{C}(=\text{O})-$;

10 B¹ is independently selected from -CH₂- or -N(R³)-;

D is $-N(R^2)-$, $-O-$, $-S-$, $-C(=O)-$ or $-SO_2-$;

15 E-F is $-C(R^4)=C(R^5)-$, $-N=C(R^4)-$, $-C(R^4)=N-$, or
 $-C(R^4)_2C(R^5)_2-$;

J, K, L and M are independently selected from $-C(R^4)-$, $-C(R^5)-$ or $-N-$, provided that at least one of J, K, L and M is not $-N-$;

20

- R² is selected from: H, C₁-C₆ alkyl, (C₁-C₆ alkyl)carbonyl, (C₁-C₆ alkoxy)carbonyl; (C₁-C₆ alkyl)aminocarbonyl, C₃-C₆ alkenyl, C₃-C₇ cycloalkyl, C₄-C₁₁ cycloalkylalkyl, aryl, heteroaryl(C₁-C₆ alkyl)carbonyl, heteroarylcarbonyl, aryl C₁-C₆ alkyl, (C₁-C₆ alkyl)carbonyl, arylcarbonyl, C₁-C₆ alkylsulfonyl, arylsulfonyl, aryl(C₁-C₆ alkyl)sulfonyl, heteroarylsulfonyl, heteroaryl(C₁-C₆ alkyl)sulfonyl, aryloxy carbonyl, aryl(C₁-C₆ alkoxy)carbonyl, wherein said aryl groups are substituted with 0-2 substituents independently selected from the group consisting of C₁-C₄ alkyl, C₁-C₄ alkoxy, halo, CF₃, and nitro;
- R³ is selected from: H, C₁-C₆ alkyl, C₃-C₇ cycloalkyl, C₄-C₁₁ cycloalkylalkyl, aryl, aryl(C₁-C₆ alkyl)-, or heteroaryl(C₁-C₆ alkyl)-;
- R⁴ and R⁵ are independently selected from: H, C₁-C₄ alkoxy, NR²R³, halogen, NO₂, CN, CF₃, C₁-C₆ alkyl, C₃-C₆ alkenyl, C₃-C₇ cycloalkyl, C₄-C₁₁ cycloalkylalkyl, aryl, aryl(C₁-C₆ alkyl)-, (C₁-C₆ alkyl)carbonyl, (C₁-C₆ alkoxy)carbonyl, arylcarbonyl;

alternatively, when substituents on adjacent atoms, R⁴ and R⁵ can be taken together with the carbon atoms to which they are attached to form a 5-7 membered carbocyclic or 5-7 membered heterocyclic aromatic or non-aromatic ring system, said carbocyclic or heterocyclic ring being optionally substituted with 0-2 groups independently selected from: C₁-C₄ alkyl, C₁-C₄ alkoxy, halo, cyano, amino, CF₃, or NO₂;

R^6 is selected from: H, C_1 - C_4 alkyl, or benzyl;

R^7 and R^8 are independently selected from: H, C_1 - C_6 alkyl, C_3 - C_7 cycloalkyl, C_4 - C_{11} cycloalkylalkyl, aryl, aryl(C_1 - C_6 alkyl)-, or heteroaryl(C_0 - C_6 alkyl)-;

U is selected from:

- N(R^6)(CH₂)_n-,
- N(R^6)(CH₂)_mO-,
- N(R^6)(CH₂)_mN(R^7)-
- N(R^6)(CH₂)_nS(O)_p-
- N(R^6)C(=O)(CH₂)_n-;
- N(R^6)(CH₂)_mC(=O)-;

V is selected from:

- (CH₂)_n-,
- (CH₂)_mO-(CH₂)_n-,
- (CH₂)_mN(R^7)(CH₂)_n-,
- (CH₂)_nS(O)_p(CH₂)_n-,
- (CH₂)_mN(R^7)C(=O)(CH₂)_n-,
- (CH₂)_nC(=O)N(R^7)(CH₂)_n-,
- (CH₂)_nC(=O)(CH₂)_n-;

R^9 is selected from H, C_1 - C_4 alkyl, C_1 - C_4 alkoxy, aryl, aryl(C_1 - C_6 alkyl)-, (C_1 - C_4 alkoxy)carbonyl, (C_1 - C_4 alkyl)carbonyl, C_1 - C_4 alkylsulfonyl, or C_1 - C_4 alkylaminosulfonyl;

R^{10} is selected from: H, CO₂ R^{17} , C(=O) R^{17} , C(=O)NR¹⁷ R^{20} , -SO₂ R^{17} , -SO₂NR¹⁷ R^{20} , C_1 - C_6 alkyl substituted with 0-1 R^{15} , C_3 - C_6 alkenyl substituted with 0-1 R^{15} , C_3 - C_7 cycloalkyl substituted with 0-1 R^{15} , C_4 - C_{11} cycloalkylalkyl substituted with 0-1 R^{15} , aryl

substituted with 0-1 R^{15} or 0-2 R^{11} , or aryl(C_1 - C_6 alkyl)- substituted with 0-1 R^{15} or 0-2 R^{11} ;


5 R^{10a} is selected from: CO_2R^{17} , $C(=O)R^{17}$, $C(=O)NR^{17}R^{20}$,
 $-SO_2R^{17}$, $-SO_2NR^{17}R^{20}$, C_1 - C_6 alkyl substituted with 0-1 R^{15} , C_3 - C_6 alkenyl substituted with 0-1 R^{15} , C_3 - C_7 cycloalkyl substituted with 0-1 R^{15} , C_4 - C_{11} cycloalkylalkyl substituted with 0-1 R^{15} , aryl substituted with 0-1 R^{15} or 0-2 R^{11} , or aryl(C_1 - C_6 alkyl)- substituted with 0-1 R^{15} or 0-2 R^{11} ;

15 R^{11} is selected from H, C_1 - C_4 alkyl, C_1 - C_4 alkoxy, aryl, aryl(C_1 - C_6 alkyl)-, (C_1 - C_4 alkoxy)carbonyl, (C_1 - C_4 alkyl)carbonyl, C_1 - C_4 alkylsulfonyl, or C_1 - C_4 alkylaminosulfonyl;

W is selected from:
 C_1 - C_4 alkylene,
 $-(C(R^{12})_2)_qO(C(R^{12})_2)_q-$,
 20 $-(C(R^{12})_2)_qC(=O)(C(R^{12})_2)_q-$,
 $-(C(R^{12})_2)_qC(=O)N(R^{13})-$,
 $-C(=O)-N(R^{13})-(C(R^{12})_2)_q-$;

25 X is $-(C(R^{12})_2)_qC(R^{12})(R^{14})-C(R^{12})(R^{15})-$;

alternatively, W and X can be taken together to be



30 R^{12} is selected from H, C_1 - C_6 alkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_3 - C_7 cycloalkyl, C_4 - C_{10} cycloalkylalkyl, (C_1 - C_4 alkyl)carbonyl, aryl, or aryl(C_1 - C_6 alkyl)-;

R¹³ is selected from H, C₁-C₆ alkyl, C₃-C₇ cycloalkylmethyl, or aryl(C₁-C₆ alkyl)-

R¹⁴ is selected from:

5 H, C₁-C₆ alkylthio(C₁-C₆ alkyl)-, aryl(C₁-C₁₀ alkylthioalkyl)-, aryl(C₁-C₁₀ alkoxyalkyl)-, C₁-C₁₀ alkyl, C₁-C₁₀ alkoxyalkyl, C₁-C₆ hydroxyalkyl, C₂-C₁₀ alkenyl, C₂-C₁₀ alkynyl, C₃-C₁₀ cycloalkyl, C₃-C₁₀ cycloalkylalkyl, aryl(C₁-C₆ alkyl)-, 10 heteroaryl(C₁-C₆ alkyl)-, aryl, heteroaryl, CO₂R¹⁷, C(=O)R¹⁷, or CONR¹⁷R²⁰, provided that any of the above alkyl, cycloalkyl, aryl or heteroaryl groups may optionally be substituted independently with 0-1 R¹⁶ or 0-2 R¹¹;


15

R¹⁵ is selected from:

H, R¹⁶, C₁-C₁₀ alkyl, C₁-C₁₀ alkoxyalkyl, C₁-C₁₀ alkylaminoalkyl, C₁-C₁₀ dialkylaminoalkyl, (C₁-C₁₀ alkyl)carbonyl, aryl(C₀-C₆ alkyl)carbonyl, 20 C₁-C₁₀ alkenyl, C₁-C₁₀ alkynyl, C₃-C₁₀ cycloalkyl, C₃-C₁₀ cycloalkylalkyl, aryl(C₁-C₆ alkyl)-, heteroaryl(C₁-C₆ alkyl)-, aryl, heteroaryl, CO₂R¹⁷, C(=O)R¹⁷, CONR¹⁷R²⁰, SO₂R¹⁷, or SO₂NR¹⁷R²⁰, provided that any of the above alkyl, cycloalkyl, aryl or 25 heteroaryl groups may optionally be substituted independently with 0-2 R¹¹;

Y is selected from:

-COR¹⁹, -SO₃H, -PO₃H, tetrazolyl, -CONHNHSO₂CF₃, 30 -CONHSO₂R¹⁷, -CONHSO₂NHR¹⁷, -NHCOCF₃, -NHCONHSO₂R¹⁷, -NHSO₂R¹⁷, -OPO₃H₂, -OSO₃H, -PO₃H₂, -SO₃H, -SO₂NHCOR¹⁷, -SO₂NHCO₂R¹⁷,



R^{16} is selected from:

5

$-N(R^{20})-C(=O)-O-R^{17},$
 $-N(R^{20})-C(=O)-R^{17},$
 $-N(R^{20})-C(=O)-NH-R^{17},$
 $-N(R^{20})SO_2-R^{17},$ or
 $-N(R^{20})SO_2-NR^{20}R^{17};$

10 R^{17} is selected from:

C₁-C₁₀ alkyl, C₃-C₁₁ cycloalkyl, aryl(C₁-C₆ alkyl)-, (C₁-C₆ alkyl)aryl, heteroaryl(C₁-C₆ alkyl)-, (C₁-C₆ alkyl)heteroaryl, arylaryl(C₁-C₆ alkyl)-, heteroarylaryl(C₁-C₆ alkyl)-, arylheteroaryl(C₁-C₆ alkyl)-, heteroarylheteroaryl(C₁-C₆ alkyl)-, heteroaryl, or aryl, wherein said aryl or heteroaryl groups are optionally substituted with 0-3 substituents independently selected from the group consisting of: C₁-C₄ alkyl, C₁-C₄ alkoxy, aryl, halo, cyano, amino, CF₃, and NO₂;

R^{18} is selected from:


25

H,
-C(=O)-O-R¹⁷,
-C(=O)-R¹⁷,
-C(=O)-NH-R¹⁷,
-SO₂-R¹⁷, or
-SO₂-NR²⁰R¹⁷;

30 R¹⁹ is selected from:
hydroxy,
C₁-C₁₀ alkyloxy,

- C₃-C₁₁ cycloalkyloxy,
 aryloxy,
 aryl(C₁-C₆ alkoxy)-,
 C₃-C₁₀ alkylcarbonyloxyalkyloxy,
 5 C₃-C₁₀ alkoxy carbonyloxyalkyloxy,
 C₂-C₁₀ alkoxy carbonylalkyloxy,
 C₅-C₁₀ cycloalkylcarbonyloxyalkyloxy,
 C₅-C₁₀ cycloalkoxy carbonyloxyalkyloxy,
 C₅-C₁₀ cycloalkoxy carbonylalkyloxy,
 10 C₇-C₁₁ aryloxy carbonylalkyloxy,
 C₈-C₁₂ aryloxy carbonyloxyalkyloxy,
 C₈-C₁₂ arylcarbonyloxyalkyloxy,
 C₅-C₁₀ alkoxyalkylcarbonyloxyalkyloxy,
 C₅-C₁₀ (5-alkyl-1,3-dioxo-cyclopenten-2-one-
 15 yl)methyloxy,
 C₁₀-C₁₄ (5-aryl-1,3-dioxo-cyclopenten-2-one-
 yl)methyloxy, or
 (R¹¹) (R¹²)N-(C₁-C₁₀ alkoxy)-;
- 20 R²⁰ is selected from: H, C₁-C₆ alkyl, C₃-C₇ cycloalkyl,
 C₄-C₁₁ cycloalkylalkyl, aryl, aryl(C₁-C₆ alkyl)-, or
 heteroaryl(C₁-C₆ alkyl)-;
- m is 1-2;
 25 n is 0-2;
 p is 0-2;
 q is 0-2; and
 r is 0-2;
- 30 provided that:
 n, q, and r are chosen such that the number of in-chain
 atoms between R¹ and Y is in the range of 8-18.

[2] Preferred compounds of the invention as described above are spirocyclic compounds of Formula I:




(I)

5




including stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, or pharmaceutically acceptable salt or prodrug forms thereof wherein:

10

Q is selected from



R¹ is selected from:



5

D is $-N(R^2)-$, $-O-$, $-S-$, $-C(=O)-$ or $-SO_2-$;

E-F is $-C(R^4)=C(R^5)-$, $-N=C(R^4)-$, $-C(R^4)=N-$, or $-C(R^4)_2C(R^5)_2-$;

10

J, K, L and M are independently selected from $-C(R^4)-$, $-C(R^5)-$ or $-N-$, provided that at least one of J, K, L and M is not $-N-$;

15 R² is selected from: H, C₁-C₆ alkyl, (C₁-C₆ alkyl)carbonyl, (C₁-C₆ alkoxy)carbonyl; (C₁-C₆ alkyl)aminocarbonyl, C₃-C₆ alkenyl, C₃-C₇ cycloalkyl, C₄-C₁₁ cycloalkylalkyl, aryl, heteroaryl(C₁-C₆ alkyl)carbonyl, heteroarylcarbonyl, aryl(C₁-C₆ alkyl)-, (C₁-C₆ alkyl)carbonyl, arylcarbonyl, C₁-C₆ alkylsulfonyl,

20

- arylsulfonyl, aryl(C₁-C₆ alkyl)sulfonyl, heteroarylsulfonyl, heteroaryl(C₁-C₆ alkyl)sulfonyl, aryloxy carbonyl, or aryl(C₁-C₆ alkoxy)carbonyl, wherein said aryl groups are substituted with 0-2 substituents independently selected from the group consisting of C₁-C₄ alkyl, C₁-C₄ alkoxy, halo, CF₃, and nitro;
- 5
- R³ is selected from: H, C₁-C₆ alkyl, C₃-C₇ cycloalkyl, C₄-C₁₁ cycloalkylalkyl, aryl, aryl(C₁-C₆ alkyl)-, or heteroaryl(C₁-C₆ alkyl)-;
- 10
- R⁴ and R⁵ are independently selected from: H, C₁-C₄ alkoxy, NR²R³, halogen, NO₂, CN, CF₃, C₁-C₆ alkyl, C₃-C₆ alkenyl, C₃-C₇ cycloalkyl, C₄-C₁₁ cycloalkylalkyl, aryl, aryl(C₁-C₆ alkyl)-, (C₁-C₆ alkyl)carbonyl, (C₁-C₆ alkoxy)carbonyl, arylcarbonyl, or
- 15
- alternatively, when substituents on adjacent atoms, R⁴ and R⁵ can be taken together with the carbon atoms to which they are attached to form a 5-7 membered carbocyclic or 5-7 membered heterocyclic aromatic or non-aromatic ring system, said carbocyclic or heterocyclic ring being optionally substituted with 0-2 groups independently selected from: C₁-C₄ alkyl, C₁-C₄ alkoxy, halo, cyano, amino, CF₃, or NO₂;
- 20
- 25
- 30 R⁶ is selected from: H, C₁-C₄ alkyl, or benzyl;
- R⁷ and R⁸ are independently selected from: H, C₁-C₆ alkyl, C₃-C₇ cycloalkyl, C₄-C₁₁ cycloalkylalkyl, aryl, aryl(C₁-C₆ alkyl)-, or heteroaryl(C₁-C₆ alkyl)-;
- 35

U is selected from:

- N(R⁶)(CH₂)_n-,
- N(R⁶)(CH₂)_mO-
- 5 -N(R⁶)(CH₂)_mN(R⁷)-
- N(R⁶)(CH₂)_nS(O)_p-
- N(R⁶)C(=O)(CH₂)_n;

V is selected from:

- 10 -(CH₂)_n-,
- (CH₂)_mO-(CH₂)_n-,
- (CH₂)_mN(R⁷)(CH₂)_n-,
- (CH₂)_nS(O)_p(CH₂)_n-,
- (CH₂)_mN(R⁷)C(=O)(CH₂)_n-,
- 15 -(CH₂)_nC(=O)N(R⁷)(CH₂)_n-,
- (CH₂)_nC(=O)(CH₂)_n;

R⁹ is selected from H, C₁-C₄ alkyl, C₁-C₄ alkoxy, aryl,
 20 aryl(C₁-C₆ alkyl)-, (C₁-C₄ alkoxy)carbonyl, (C₁-C₄
 alkyl)carbonyl, C₁-C₄ alkylsulfonyl, or C₁-C₄
 alkylaminosulfonyl;

R¹⁰ is selected from: H, CO₂R¹⁷, C(=O)R¹⁷, C(=O)NR¹⁷R²⁰,
 25 -SO₂R¹⁷, -SO₂NR¹⁷R²⁰, C₁-C₆ alkyl substituted with 0-
 1 R¹⁵, C₃-C₆ alkenyl substituted with 0-1 R¹⁵, C₃-C₇
 cycloalkyl substituted with 0-1 R¹⁵, C₄-C₁₁
 cycloalkylalkyl substituted with 0-1 R¹⁵, aryl
 substituted with 0-1 R¹⁵ or 0-2 R¹¹, or aryl(C₁-C₆
 alkyl)- substituted with 0-1 R¹⁵ or 0-2 R¹¹;

30

R^{10a} is selected from: CO₂R¹⁷, C(=O)R¹⁷, C(=O)NR¹⁷R²⁰,
 -SO₂R¹⁷, -SO₂NR¹⁷R²⁰, C₁-C₆ alkyl substituted with 0-
 1 R¹⁵, C₃-C₆ alkenyl substituted with 0-1 R¹⁵, C₃-C₇
 cycloalkyl substituted with 0-1 R¹⁵, C₄-C₁₁
 35 cycloalkylalkyl substituted with 0-1 R¹⁵, aryl


substituted with 0-1 R^{15} or 0-2 R^{11} , or aryl(C_1 - C_6 alkyl)- substituted with 0-1 R^{15} or 0-2 R^{11} ;

5 R^{11} is selected from H, C_1 - C_4 alkyl, C_1 - C_4 alkoxy, aryl, aryl(C_1 - C_6 alkyl)-, (C_1 - C_4 alkoxy)carbonyl, (C_1 - C_4 alkyl)carbonyl, C_1 - C_4 alkylsulfonyl, or C_1 - C_4 alkylaminosulfonyl;

10 W is selected from:
 C_1 - C_4 alkylene,
 $-(C(R^{12})_2)_qO(C(R^{12})_2)_q-$,
 $-(C(R^{12})_2)_qC(=O)(C(R^{12})_2)_q-$,
 $-(C(R^{12})_2)_qC(=O)N(R^{13})-$,
 $-C(=O)-N(R^{13})-(C(R^{12})_2)_q-$;

15 X is $-(C(R^{12})_2)_qC(R^{12})(R^{14})-C(R^{12})(R^{15})-$;

alternatively, W and X can be taken together to be



20 R^{12} is selected from H, C_1 - C_6 alkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_3 - C_7 cycloalkyl, C_4 - C_{10} cycloalkylalkyl, (C_1 - C_4 alkyl)carbonyl, aryl, or aryl(C_1 - C_6 alkyl)-;

25 R^{13} is selected from H, C_1 - C_6 alkyl, C_3 - C_7 cycloalkylmethyl, or aryl(C_1 - C_6 alkyl)-;

30 R^{14} is selected from:
H, C_1 - C_6 alkylthio(C_1 - C_6 alkyl)-, aryl(C_1 - C_{10} alkylthioalkyl)-, aryl(C_1 - C_{10} alkoxyalkyl)-, C_1 - C_{10} alkyl, C_1 - C_{10} alkoxyalkyl, C_1 - C_6 hydroxyalkyl, C_2 - C_{10} alkenyl, C_2 - C_{10} alkynyl, C_3 - C_{10} cycloalkyl,

5 C₃-C₁₀ cycloalkylalkyl, aryl(C₁-C₆ alkyl)-, heteroaryl(C₁-C₆ alkyl)-, aryl, heteroaryl, CO₂R¹⁷, C(=O)R¹⁷, or CONR¹⁷R²⁰, provided that any of the above alkyl, cycloalkyl, aryl or heteroaryl groups may optionally be substituted independently with 0-1 R¹⁶ or 0-2 R¹¹;




R¹⁵ is selected from:

10 H, R¹⁶, C₁-C₁₀ alkyl, C₁-C₁₀ alkoxyalkyl, C₁-C₁₀ alkylaminoalkyl, C₁-C₁₀ dialkylaminoalkyl, (C₁-C₁₀ alkyl)carbonyl, aryl(C₀-C₆ alkyl)carbonyl, C₁-C₁₀ alkenyl, C₁-C₁₀ alkynyl, C₃-C₁₀ cycloalkyl, C₃-C₁₀ cycloalkylalkyl, aryl(C₁-C₆ alkyl)-, heteroaryl(C₁-C₆ alkyl)-, aryl, heteroaryl, CO₂R¹⁷,
 15 C(=O)R¹⁷, CONR¹⁷R²⁰, SO₂R¹⁷, or SO₂NR¹⁷R²⁰, provided that any of the above alkyl, cycloalkyl, aryl or heteroaryl groups may optionally be substituted independently with 0-2 R¹¹;

20 Y is selected from:


-COR¹⁹, -SO₃H, -PO₃H, tetrazolyl, -CONHNHSO₂CF₃,
 -CONHSO₂R¹⁷, -CONHSO₂NHR¹⁷, -NHCOCF₃, -NHCONHSO₂R¹⁷,
 -NHSO₂R¹⁷, -OPO₃H₂, -OSO₃H, -PO₃H₂, -SO₃H,
 -SO₂NHCOR¹⁷, -SO₂NHCO₂R¹⁷,

25



R¹⁶ is selected from:

30 -N(R²⁰)-C(=O)-O-R¹⁷,
 -N(R²⁰)-C(=O)-R¹⁷,
 -N(R²⁰)-C(=O)-NH-R¹⁷,
 -N(R²⁰)SO₂-R¹⁷, or



R¹⁷ is selected from:

- 5 C₁-C₁₀ alkyl, C₃-C₁₁ cycloalkyl, aryl(C₁-C₆ alkyl)-, (C₁-C₆ alkyl)aryl, heteroaryl(C₁-C₆ alkyl)-, (C₁-C₆ alkyl)heteroaryl, arylaryl(C₁-C₆ alkyl)-, heteroarylaryl(C₁-C₆ alkyl)-, arylheteroaryl(C₁-C₆ alkyl)-, heteroarylheteroaryl(C₁-C₆ alkyl)-, heteroaryl, or aryl, wherein said aryl or
- 10 heteroaryl groups are optionally substituted with 0-3 substituents independently selected from the group consisting of: C₁-C₄ alkyl, C₁-C₄ alkoxy, aryl, halo, cyano, amino, CF₃, and NO₂;

15 R¹⁸ is selected from:


- H,
-C(=O)-O-R¹⁷,
-C(=O)-R¹⁷,
-C(=O)-NH-R¹⁷,
20 -SO₂-R¹⁷, or
-SO₂-NR²⁰R¹⁷;

R¹⁹ is selected from:


- hydroxy,
25 C₁-C₁₀ alkyloxy,
C₃-C₁₁ cycloalkyloxy,
aryloxy,
aryl(C₁-C₆ alkoxy)-,
C₃-C₁₀ alkylcarbonyloxyalkyloxy,
30 C₃-C₁₀ alkoxy carbonyloxyalkyloxy,
C₂-C₁₀ alkoxy carbonylalkyloxy,
C₅-C₁₀ cycloalkylcarbonyloxyalkyloxy,
C₅-C₁₀ cycloalkoxy carbonyloxyalkyloxy,
C₅-C₁₀ cycloalkoxy carbonylalkyloxy,
35 C₇-C₁₁ aryloxy carbonylalkyloxy,

- C₈-C₁₂ aryloxycarbonyloxyalkyloxy,
C₈-C₁₂ arylcarbonyloxyalkyloxy,
C₅-C₁₀ alkoxyalkylcarbonyloxyalkyloxy,
C₅-C₁₀ (5-alkyl-1,3-dioxo-cyclopenten-2-one-
5 yl)methyloxy,
C₁₀-C₁₄ (5-aryl-1,3-dioxo-cyclopenten-2-one-
yl)methyloxy, or
(R¹¹)(R¹²)N-(C₁-C₁₀ alkoxy)-;
- 10 R²⁰ selected from: H, C₁-C₆ alkyl, C₃-C₇ cycloalkyl, C₄-
C₁₁ cycloalkylalkyl, aryl, aryl(C₁-C₆ alkyl)-, or
heteroaryl(C₁-C₆ alkyl)-;
- m is 1-2;
15 n is 0-2;
p is 0-2;
q is 0-2; and
r is 0-2;
- 20 provided that:
n, q, and r are chosen such that the number of in-
chain atoms between R¹ and Y is in the range of 8-
18.
- 25 [3] Further preferred compounds of the invention as
described above are compounds of the Formula I including
stereoisomeric forms thereof, or mixtures of
stereoisomeric forms thereof, or pharmaceutically
30 acceptable salt or prodrug forms thereof wherein:

Q is selected from:



5 R¹ is selected from:



wherein the above heterocycles are optionally substituted with 0-2 substituents selected from the group consisting of: NH_2 , halogen, NO_2 , CN , CF_3 , $\text{C}_1\text{-C}_4$ alkoxy, $\text{C}_1\text{-C}_6$ alkyl, and $\text{C}_3\text{-C}_7$ cycloalkyl;

R^2 is selected from: H , $\text{C}_1\text{-C}_4$ alkyl or benzyl;

U is $-\text{NH}(\text{CH}_2)_n-$;

10

V is $-(\text{CH}_2)_n-$;

R^{10} is selected from: H , CO_2R^{17} , $\text{C}(=\text{O})\text{R}^{17}$, $\text{CONR}^{17}\text{R}^{20}$, $-\text{SO}_2\text{R}^{17}$, $-\text{SO}_2\text{NR}^{17}\text{R}^{20}$, $\text{C}_1\text{-C}_6$ alkyl substituted with 0-1 R^{15} , $\text{C}_3\text{-C}_6$ alkenyl substituted with 0-1 R^{15} , $\text{C}_3\text{-C}_7$ cycloalkyl substituted with 0-1 R^{15} , $\text{C}_4\text{-C}_{11}$ cycloalkylalkyl substituted with 0-1 R^{15} , aryl substituted with 0-1 R^{15} or 0-2 R^{11} , or aryl($\text{C}_1\text{-C}_6$ alkyl)- substituted with 0-1 R^{15} or 0-2 R^{11} ;

15

20

R^{10a} is selected from: CO_2R^{17} , $\text{C}(=\text{O})\text{R}^{17}$, $\text{CONR}^{17}\text{R}^{20}$, $-\text{SO}_2\text{R}^{17}$, $-\text{SO}_2\text{NR}^{17}\text{R}^{20}$, $\text{C}_1\text{-C}_6$ alkyl substituted with 0-1 R^{15} , $\text{C}_3\text{-C}_6$ alkenyl substituted with 0-1 R^{15} , $\text{C}_3\text{-C}_7$ cycloalkyl substituted with 0-1 R^{15} , $\text{C}_4\text{-C}_{11}$ cycloalkylalkyl substituted with 0-1 R^{15} , aryl substituted with 0-1 R^{15} or 0-2 R^{11} , or aryl($\text{C}_1\text{-C}_6$ alkyl)- substituted with 0-1 R^{15} or 0-2 R^{11} ;

25

R^{11} is selected from H , $\text{C}_1\text{-C}_4$ alkyl, $\text{C}_1\text{-C}_4$ alkoxy, aryl, aryl($\text{C}_1\text{-C}_6$ alkyl)-, ($\text{C}_1\text{-C}_4$ alkoxy)carbonyl, ($\text{C}_1\text{-C}_4$ alkyl)carbonyl, $\text{C}_1\text{-C}_4$ alkylsulfonyl, or $\text{C}_1\text{-C}_4$ alkylaminosulfonyl;

30

W is $-\text{C}(=\text{O})-\text{N}(\text{R}^{13})-$;

35

X is $-\text{CH}(\text{R}^{14})-\text{CH}(\text{R}^{15})-$;

R^{13} is H or CH_3 ;

5 R^{14} is selected from:

H, $\text{C}_1\text{-C}_{10}$ alkyl, aryl, or heteroaryl, wherein said aryl or heteroaryl groups are optionally substituted with 0-3 substituents independently selected from the group consisting of: $\text{C}_1\text{-C}_4$ alkyl, $\text{C}_1\text{-C}_4$ alkoxy, aryl, halo, cyano, amino, CF_3 , and NO_2 ;

R^{15} is H or R^{16} ;

15 Y is $-\text{C}(=\text{O})\text{R}^{19}$;

R^{16} is selected from:

$-\text{N}(\text{R}^{20})-\text{C}(=\text{O})-\text{O}-\text{R}^{17}$,
 $-\text{N}(\text{R}^{20})-\text{C}(=\text{O})-\text{R}^{17}$,
20 $-\text{N}(\text{R}^{20})-\text{C}(=\text{O})-\text{NH}-\text{R}^{17}$,
 $-\text{N}(\text{R}^{20})\text{SO}_2-\text{R}^{17}$, or
 $-\text{N}(\text{R}^{20})\text{SO}_2-\text{N}(\text{R}^{20})\text{R}^{17}$;

R^{17} is selected from:

25 $\text{C}_1\text{-C}_{10}$ alkyl, $\text{C}_3\text{-C}_{11}$ cycloalkyl, aryl($\text{C}_1\text{-C}_6$ alkyl)-, ($\text{C}_1\text{-C}_6$ alkyl)aryl, heteroaryl($\text{C}_1\text{-C}_6$ alkyl)-, ($\text{C}_1\text{-C}_6$ alkyl)heteroaryl, arylaryl($\text{C}_1\text{-C}_6$ alkyl)-, heteroarylaryl($\text{C}_1\text{-C}_6$ alkyl)-, arylheteroaryl($\text{C}_1\text{-C}_6$ alkyl)-, heteroarylheteroaryl($\text{C}_1\text{-C}_6$ alkyl)-, heteroaryl, or aryl, wherein said aryl or heteroaryl groups are optionally substituted with 0-3 substituents independently selected from the group consisting of: $\text{C}_1\text{-C}_4$ alkyl, $\text{C}_1\text{-C}_4$ alkoxy, aryl, halo, cyano, amino, CF_3 , and NO_2 ;

35

R¹⁹ is selected from:

hydroxy,

C₁-C₁₀ alkoxy,

methylcarbonyloxymethoxy-,

5 ethylcarbonyloxymethoxy-,

t-butylcarbonyloxymethoxy-,

cyclohexylcarbonyloxymethoxy-,

1-(methylcarbonyloxy)ethoxy-,

1-(ethylcarbonyloxy)ethoxy-,

10 1-(t-butylcarbonyloxy)ethoxy-,

1-(cyclohexylcarbonyloxy)ethoxy-,

i-propyloxycarbonyloxymethoxy-,

t-butyloxycarbonyloxymethoxy-,

1-(i-propyloxycarbonyloxy)ethoxy-,

15 1-(cyclohexyloxycarbonyloxy)ethoxy-,

1-(t-butyloxycarbonyloxy)ethoxy-,

dimethylaminoethoxy-,

diethylaminoethoxy-,

(5-methyl-1,3-dioxacyclopenten-2-on-4-yl)methoxy-,

20 (5-(t-butyl)-1,3-dioxacyclopenten-2-on-4-

yl)methoxy-,

(1,3-dioxa-5-phenyl-cyclopenten-2-on-4-yl)methoxy-,

or;

1-(2-(2-methoxypropyl)carbonyloxy)ethoxy-;

25

R²⁰ is H or CH₃; and

n is 0-1.


30

[4] Still further preferred compounds of the above invention as described above are compounds of the Formula I including stereoisomeric forms thereof, or mixtures of stereoisomeric forms thereof, or


pharmaceutically acceptable salt or prodrug forms thereof wherein:

Q is selected from:

5



R¹ is selected from:



R^2 is selected from: H, C_1 - C_4 alkyl, or benzyl;

5

U is $-NH(CH_2)_n-$;

V is $-(CH_2)_n-$;

- 10 R^{10} is selected from: H, CO_2R^{17} , $C(=O)R^{17}$, $C(=O)NR^{17}R^{20}$, $-SO_2R^{17}$, $-SO_2NR^{17}R^{20}$, C_1 - C_6 alkyl substituted with 0-1 R^{15} , C_3 - C_6 alkenyl substituted with 0-1 R^{15} , C_3 - C_7 cycloalkyl substituted with 0-1 R^{15} , C_4 - C_{11} cycloalkylalkyl substituted with 0-1 R^{15} , aryl

substituted with 0-1 R¹⁵ or 0-2 R¹¹, or aryl(C₁-C₆ alkyl)- substituted with 0-1 R¹⁵ or 0-2 R¹¹;

5 R^{10a} is selected from: CO₂R¹⁷, C(=O)R¹⁷, CONR¹⁷R²⁰,
-SO₂R¹⁷, -SO₂NR¹⁷R²⁰, C₁-C₆ alkyl substituted with 0-
1 R¹⁵, C₃-C₆ alkenyl substituted with 0-1 R¹⁵, C₃-C₇
cycloalkyl substituted with 0-1 R¹⁵, C₄-C₁₁
cycloalkylalkyl substituted with 0-1 R¹⁵, aryl
substituted with 0-1 R¹⁵ or 0-2 R¹¹, or aryl(C₁-C₆
10 alkyl)- substituted with 0-1 R¹⁵ or 0-2 R¹¹;

R¹¹ is selected from H, C₁-C₄ alkyl, C₁-C₄ alkoxy, aryl,
aryl(C₁-C₆ alkyl)-, (C₁-C₄ alkoxy)carbonyl, (C₁-C₄
alkyl)carbonyl, C₁-C₄ alkylsulfonyl, or C₁-C₄
15 alkylaminosulfonyl;

W is -C(=O)-N(R¹³)-;

20 X is -CH(R¹⁴)-CH(R¹⁵)-;

R¹³ is H or CH₃;

R¹⁴ is selected from:
H, C₁-C₁₀ alkyl, aryl, or heteroaryl, wherein said
25 aryl or heteroaryl groups are optionally
substituted with 0-3 substituents independently
selected from the group consisting of: C₁-C₄ alkyl,
C₁-C₄ alkoxy, aryl, halo, cyano, amino, CF₃, and
NO₂;

30 R¹⁵ is H or R¹⁶;

Y is -C(=O)R¹⁹;

35 R¹⁶ is selected from:

-N(R²⁰)-C(=O)-O-R¹⁷,
-N(R²⁰)-C(=O)-R¹⁷,
-N(R²⁰)SO₂-R¹⁷,

5 R¹⁷ is selected from:

C₁-C₁₀ alkyl, C₃-C₁₁ cycloalkyl, aryl(C₁-C₆ alkyl)-,
(C₁-C₆ alkyl)aryl, heteroaryl(C₁-C₆ alkyl)-, (C₁-C₆
alkyl)heteroaryl, arylaryl(C₁-C₆ alkyl)-,
heteroarylaryl(C₁-C₆ alkyl)-, arylheteroaryl(C₁-C₆
10 alkyl)-, heteroarylheteroaryl(C₁-C₆ alkyl)-,
heteroaryl, or aryl, wherein said aryl or
heteroaryl groups are optionally substituted with
0-3 substituents independently selected from the
group consisting of: C₁-C₄ alkyl, C₁-C₄ alkoxy,
15 aryl, halo, cyano, amino, CF₃, and NO₂;

R¹⁹ is selected from:

hydroxy,
C₁-C₁₀ alkoxy,
20 methylcarbonyloxymethoxy-,
ethylcarbonyloxymethoxy-,
t-butylcarbonyloxymethoxy-,
cyclohexylcarbonyloxymethoxy-,
1-(methylcarbonyloxy)ethoxy-,
25 1-(ethylcarbonyloxy)ethoxy-,
1-(t-butylcarbonyloxy)ethoxy-,
1-(cyclohexylcarbonyloxy)ethoxy-,
i-propyloxycarbonyloxymethoxy-,
t-butyloxycarbonyloxymethoxy-,
30 1-(i-propyloxycarbonyloxy)ethoxy-,
1-(cyclohexyloxycarbonyloxy)ethoxy-,
1-(t-butyloxycarbonyloxy)ethoxy-,
dimethylaminoethoxy-,
diethylaminoethoxy-,
35 (5-methyl-1,3-dioxacyclopenten-2-on-4-yl)methoxy-,

(5-(*t*-butyl)-1,3-dioxacyclopenten-2-on-4-yl)methoxy-,
(1,3-dioxa-5-phenyl-cyclopenten-2-on-4-yl)methoxy-,
or
5 1-(2-(2-methoxypropyl)carbonyloxy)ethoxy-;

R²⁰ is H or CH₃; and

n is 0-1.

10

[5] Specifically preferred compounds of the above invention are compounds including enantiomeric or diastereomeric forms thereof, or mixtures of
15 enantiomeric or diastereomeric forms thereof, or pharmaceutically acceptable salt or prodrug forms thereof, selected from the group consisting of:

20 (S)-2-phenylsulfonylamino-3-[[[8-(2-pyridinylaminomethyl)-]-1-oxa-2-azaspiro-[4,5]-dec-2-en-3-yl]carbonylamino]propionic acid,

25 (S)-2-benzyloxycarbonylamino-3-[[[8-(2-pyridinylaminomethyl)-]-1-oxa-2-azaspiro-[4,5]-dec-2-en-3-yl]carbonylamino]propionic acid,

30 (S)-2-[(2,4,6-trimethylphenyl)sulfonyl]amino-3-[[[8-(2-pyridinylaminomethyl)-]-1-oxa-2-azaspiro-[4,5]-dec-2-en-3-yl]carbonylamino]propionic acid,

(S)-2-[(3,5-dimethylisoxazol-4-yl)sulfonyl]amino-3-[[[8-(2-pyridinylaminomethyl)-]-1-oxa-2-azaspiro-[4,5]-dec-2-en-3-yl]carbonylamino]propionic acid,

- (S)-2-phenylsulfonylamino-3-[[[8-[(6-aminopyridin-2-yl)methyl]-]-1-oxa-2,8-diazaspiro-[4,5]-dec-2-en-3-yl]carbonylamino]propionic acid,
- 5 (S)-2-phenylsulfonylamino-3-[[[8-[(6-aminopyridin-2-yl)methyl]]-]-1-oxa-2,8-diazaspiro-[4,4]-non-2-en-3-yl]carbonylamino]propionic acid,
- 10 (S)-2-phenylsulfonylamino-3-[[[8-(2-pyridinylaminomethyl)-]-1-oxa-2-azaspiro-[4,4]-non-2-en-3-yl]carbonylamino]propionic acid,
- (S)-2-phenylsulfonylamino-3-[[[8-[2-(4,5-dihydroimidazol-2-yl)aminomethyl]-]-1-oxa-2-azaspiro-[4,5]-dec-2-en-3-yl]carbonylamino]propionic acid,
- 15 (S)-2-[(2-methylphenyl)sulfonyl]amino-3-[[[8-(2-pyridinylaminomethyl)-]-1-oxa-2-azaspiro-[4,5]-dec-2-en-3-yl]carbonylamino]propionic acid,
- 20 (S)-2-[(2-chloro-4-methylphenyl)sulfonyl]amino-3-[[[8-(2-pyridinylaminomethyl)-]-1-oxa-2-azaspiro-[4,5]-dec-2-en-3-yl]carbonylamino]propionic acid,
- 25 (S)-2-[(4-biphenyl)sulfonyl]amino-3-[[[8-(2-pyridinylaminomethyl)-]-1-oxa-2-azaspiro-[4,5]-dec-2-en-3-yl]carbonylamino]propionic acid,
- 30 (S)-2-[(2-bromophenyl)sulfonyl]amino-3-[[[8-(2-pyridinylaminomethyl)-]-1-oxa-2-azaspiro-[4,5]-dec-2-en-3-yl]carbonylamino]propionic acid,
- (S)-2-[(2-naphthyl)sulfonyl]amino-3-[[[8-(2-pyridinylaminomethyl)-]-1-oxa-2-azaspiro-[4,5]-dec-2-en-3-yl]carbonylamino]propionic acid,

- (S)-2-[(1-naphthyl)sulfonyl]amino-3-[[[8-(2-pyridinylaminomethyl)-]-1-oxa-2-azaspiro-[4,5]-dec-2-en-3-yl]carbonylamino]propionic acid.
- 5 (S)-2-phenylsulfonylamino-3-[[[8-(2-imidazolylaminomethyl)-]-1-oxa-2-azaspiro-[4,5]-dec-2-en-3-yl]carbonylamino]propionic acid,
- 10 (S)-2-benzyloxycarbonylamino-3-[[[8-(2-imidazolylaminomethyl)-]-1-oxa-2-azaspiro-[4,5]-dec-2-en-3-yl]carbonylamino]propionic acid,
- 15 (S)-2-[(2,4,6-trimethylphenyl)sulfonyl]amino-3-[[[8-(2-imidazolylaminomethyl)-]-1-oxa-2-azaspiro-[4,5]-dec-2-en-3-yl]carbonylamino]propionic acid,
- 20 (S)-2-[(2,6-dimethylphenyl)sulfonyl]amino-3-[[[8-(2-imidazolylaminomethyl)-]-1-oxa-2-azaspiro-[4,5]-dec-2-en-3-yl]carbonylamino]propionic acid,
- 25 (S)-2-[(2,6-dichlorophenyl)sulfonyl]amino-3-[[[8-(2-imidazolylaminomethyl)-]-1-oxa-2-azaspiro-[4,5]-dec-2-en-3-yl]carbonylamino]propionic acid,
- 30 (S)-2-[(2,6-dimethyl-4-phenyl)phenylsulfonyl]amino-3-[[[8-(2-imidazolylaminomethyl)-]-1-oxa-2-azaspiro-[4,5]-dec-2-en-3-yl]carbonylamino]propionic acid,
- (S)-2-[(2-naphthyl)sulfonyl]amino-3-[[[8-(2-imidazolylaminomethyl)-]-1-oxa-2-azaspiro-[4,5]-dec-2-en-3-yl]carbonylamino]propionic acid,
- (S)-2-[biphenylsulfonyl]amino-3-[[[8-(2-imidazolylaminomethyl)-]-1-oxa-2-azaspiro-

- [4,5]-dec-2-en-3-yl]carbonylamino]propionic acid,
- 5 (S)-2-phenylsulfonylamino-3-[[7-benzyloxycarbonyl-8-(2-imidazolylaminomethyl)-1-oxa-2,7-diazaspiro-[4,4]-non-2-en-3-yl]carbonylamino]propionic acid,
- 10 (S)-2-benzyloxycarbonylamino-3-[[7-benzyloxycarbonyl-8-(2-imidazolylaminomethyl)-1-oxa-2,7-diazaspiro-[4,4]-non-2-en-3-yl]carbonylamino]propionic acid,
- 15 (S)-2-[(2,4,6-trimethylphenyl)sulfonyl]amino-3-[[7-benzyloxycarbonyl-8-(2-imidazolylaminomethyl)-1-oxa-2,7-diazaspiro-[4,4]-non-2-en-3-yl]carbonylamino]propionic acid,
- 20 (S)-2-[(2,6-dimethylphenyl)sulfonyl]amino-3-[[7-benzyloxycarbonyl-8-(2-imidazolylaminomethyl)-1-oxa-2,7-diazaspiro-[4,4]-non-2-en-3-yl]carbonylamino]propionic acid,
- 25 (S)-2-[(2,6-dichlorophenyl)sulfonyl]amino-3-[[7-benzyloxycarbonyl-8-(2-imidazolylaminomethyl)-1-oxa-2,7-diazaspiro-[4,4]-non-2-en-3-yl]carbonylamino]propionic acid,
- 30 (S)-2-[(2,6-dimethyl-4-phenyl)phenylsulfonyl]amino-3-[[7-benzyloxycarbonyl-8-(2-imidazolylaminomethyl)-1-oxa-2,7-diazaspiro-[4,4]-non-2-en-3-yl]carbonylamino]propionic acid,
- 35 (S)-2-[(2-naphthyl)sulfonyl]amino-3-[[7-benzyloxycarbonyl-8-(2-imidazolylaminomethyl)-1-oxa-2,7-diazaspiro-[4,4]-non-2-en-3-yl]carbonylamino]propionic acid,

- (S)-2-phenylsulfonylamino-3-[[8-(2-imidazolylaminomethyl)-1-oxa-2,7-diazaspiro-[4,4]-non-2-en-3-yl]carbonylamino]propionic acid,
- 5 (S)-2-benzyloxycarbonylamino-3-[[8-(2-imidazolylaminomethyl)-1-oxa-2,7-diazaspiro-[4,4]-non-2-en-3-yl]carbonylamino]propionic acid,
- 10 (S)-2-[(2,4,6-trimethylphenyl)sulfonyl]amino-3-[[8-(2-imidazolylaminomethyl)-1-oxa-2,7-diazaspiro-[4,4]-non-2-en-3-yl]carbonylamino]propionic acid,
- 15 (S)-2-[(2,6-dimethylphenyl)sulfonyl]amino-3-[[8-(2-imidazolylaminomethyl)-1-oxa-2,7-diazaspiro-[4,4]-non-2-en-3-yl]carbonylamino]propionic acid,
- 20 (S)-2-[(2,6-dichlorophenyl)sulfonyl]amino-3-[[8-(2-imidazolylaminomethyl)-1-oxa-2,7-diazaspiro-[4,4]-non-2-en-3-yl]carbonylamino]propionic acid,
- (S)-2-[(2,6-dimethyl-4-phenyl)phenylsulfonyl]amino-3-[[8-(2-imidazolylaminomethyl)-1-oxa-2,7-diazaspiro-[4,4]-non-2-en-3-yl]carbonylamino]propionic acid,
- 25 (S)-2-[(2-naphthyl)sulfonyl]amino-3-[[8-(2-imidazolylaminomethyl)-1-oxa-2,7-diazaspiro-[4,4]-non-2-en-3-yl]carbonylamino]propionic acid,
- 30 (S)-2-[biphenylsulfonyl]amino-3-[[8-(2-imidazolylaminomethyl)-1-oxa-2,7-diazaspiro-[4,4]-non-2-en-3-yl]carbonylamino]propionic acid,
- (S)-2-phenylsulfonylamino-3-[[7-benzyloxycarbonyl-8-(2-pyridinylaminomethyl)-1-oxa-2,7-

- diazaspiro-[4,4]-non-2-en-3-yl]carbonylamino]propionic acid,
(S)-2-benzyloxycarbonylamino-3-[[7-benzyloxycarbonyl-8-(2-pyridinylaminomethyl)-1-oxa-2,7-diazaspiro-[4,4]-non-2-en-3-yl]carbonylamino]propionic acid,
5 (S)-2-[(2,4,6-trimethylphenyl)sulfonyl]amino-3-[[7-benzyloxycarbonyl-8-(2-pyridinylaminomethyl)-1-oxa-2,7-diazaspiro-[4,4]-non-2-en-3-yl]carbonylamino]propionic acid,
10 (S)-2-[(2,6-dimethylphenyl)sulfonyl]amino-3-[[7-benzyloxycarbonyl-8-(2-pyridinylaminomethyl)-1-oxa-2,7-diazaspiro-[4,4]-non-2-en-3-yl]carbonylamino]propionic acid,
15 (S)-2-[(2,6-dichlorophenyl)sulfonyl]amino-3-[[7-benzyloxycarbonyl-8-(2-pyridinylaminomethyl)-1-oxa-2,7-diazaspiro-[4,4]-non-2-en-3-yl]carbonylamino]propionic acid,
20 (S)-2-[(2,6-dimethyl-4-phenyl)phenylsulfonyl]amino-3-[[7-benzyloxycarbonyl-8-(2-pyridinylaminomethyl)-1-oxa-2,7-diazaspiro-[4,4]-non-2-en-3-yl]carbonylamino]propionic acid,
25 (S)-2-[(2-naphthyl)sulfonyl]amino-3-[[7-benzyloxycarbonyl-8-(2-pyridinylaminomethyl)-1-oxa-2,7-diazaspiro-[4,4]-non-2-en-3-yl]carbonylamino]propionic acid,
30 (S)-2-[biphenylsulfonyl]amino-3-[[7-benzyloxycarbonyl-8-(2-pyridinylaminomethyl)-1-oxa-2,7-diazaspiro-[4,4]-non-2-en-3-yl]carbonylamino]propionic acid,
35 (S)-2-phenylsulfonylamino-3-[[7-benzyloxycarbonyl-8-(4,5-dihydroimidazol-2-yl)aminomethyl-1-oxa-2,7-diazaspiro-[4,4]-non-2-en-3-yl]carbonylamino]propionic acid,

- (S)-2-benzyloxycarbonylamino-3-[[7-benzyloxycarbonyl-8-(4,5-dihydroimidazol-2-yl)aminomethyl-1-oxa-2,7-diazaspiro-[4,4]-non-2-en-3-yl]carbonylamino]propionic acid,
- 5 (S)-2-[(2,4,6-trimethylphenyl)sulfonyl]amino-3-[[7-benzyloxycarbonyl-8-(4,5-dihydroimidazol-2-yl)aminomethyl-1-oxa-2,7-diazaspiro-[4,4]-non-2-en-3-yl]carbonylamino]propionic acid,
- 10 (S)-2-[(2,6-dimethylphenyl)sulfonyl]amino-3-[[7-benzyloxycarbonyl-8-(4,5-dihydroimidazol-2-yl)aminomethyl-1-oxa-2,7-diazaspiro-[4,4]-non-2-en-3-yl]carbonylamino]propionic acid,
- 15 (S)-2-[(2,6-dichlorophenyl)sulfonyl]amino-3-[[7-benzyloxycarbonyl-8-(4,5-dihydroimidazol-2-yl)aminomethyl-1-oxa-2,7-diazaspiro-[4,4]-non-2-en-3-yl]carbonylamino]propionic acid,
- 20 (S)-2-[(2,6-dimethyl-4-phenyl)phenylsulfonyl]amino-3-[[7-benzyloxycarbonyl-8-(4,5-dihydroimidazol-2-yl)aminomethyl-1-oxa-2,7-diazaspiro-[4,4]-non-2-en-3-yl]carbonylamino]propionic acid,
- 25 (S)-2-[(2-naphthyl)sulfonyl]amino-3-[[7-benzyloxycarbonyl-8-(4,5-dihydroimidazol-2-yl)aminomethyl-1-oxa-2,7-diazaspiro-[4,4]-non-2-en-3-yl]carbonylamino]propionic acid,
- 30 (S)-2-[biphenylsulfonyl]amino-3-[[7-benzyloxycarbonyl-8-(4,5-dihydroimidazol-2-yl)aminomethyl-1-oxa-2,7-diazaspiro-[4,4]-non-2-en-3-yl]carbonylamino]propionic acid,
- 35 (S)-2-benzyloxycarbonylamino-3-[[8-(4,5-dihydroimidazol-2-yl)aminomethyl-1-oxa-2,7-

- diazaspiro-[4,4]-non-2-en-3-yl]carbonylamino]propionic acid,
(S)-2-[(2,4,6-trimethylphenyl)sulfonyl]amino-3-[[8-(4,5-dihydroimidazol-2-yl)aminomethyl-1-oxa-2,7-diazaspiro-[4,4]-non-2-en-3-yl]carbonylamino]propionic acid,
5 (S)-2-[(2,6-dimethylphenyl)sulfonyl]amino-3-[[8-(4,5-dihydroimidazol-2-yl)aminomethyl-1-oxa-2,7-diazaspiro-[4,4]-non-2-en-3-yl]carbonylamino]propionic acid,
10 (S)-2-[(2,6-dichlorophenyl)sulfonyl]amino-3-[[8-(4,5-dihydroimidazol-2-yl)aminomethyl-1-oxa-2,7-diazaspiro-[4,4]-non-2-en-3-yl]carbonylamino]propionic acid,
15 (S)-2-[(2,6-dimethyl-4-phenyl)phenylsulfonyl]amino-3-[[8-(4,5-dihydroimidazol-2-yl)aminomethyl-1-oxa-2,7-diazaspiro-[4,4]-non-2-en-3-yl]carbonylamino]propionic acid,
20 (S)-2-[(2-naphthyl)sulfonyl]amino-3-[[8-(4,5-dihydroimidazol-2-yl)aminomethyl-1-oxa-2,7-diazaspiro-[4,4]-non-2-en-3-yl]carbonylamino]propionic acid,
25 (S)-2-[biphenylsulfonyl]amino-3-[[8-(4,5-dihydroimidazol-2-yl)aminomethyl-1-oxa-2,7-diazaspiro-[4,4]-non-2-en-3-yl]carbonylamino]propionic acid, and
(S)-2-[(2,4,6-trimethylphenyl)sulfonyl]amino-3-[[8-(2-benzimidazolyl)aminomethyl-1-oxa-2,7-diazaspiro-[4,4]-non-2-en-3-yl]carbonylamino]propionic acid.
30

In the present invention it has been discovered that the compounds of Formula I above are useful as inhibitors of cell-matrix and cell-cell adhesion
35 processes. The present invention includes novel

compounds of Formula I and methods for using such compounds for the prevention or treatment of diseases resulting from abnormal cell adhesion to the extracellular matrix which comprises administering to a
5 host in need of such treatment a therapeutically effective amount of such compound of Formula I. In the present invention it has also been discovered that the compounds of Formula I above are useful as inhibitors of $\alpha_v\beta_3$. The compounds of the present
10 invention inhibit the binding of vitronectin to $\alpha_v\beta_3$ and inhibit cell adhesion.

The present invention also provides pharmaceutical compositions comprising a compound of Formula I and a pharmaceutically acceptable carrier.

15 The compounds of Formula I of the present invention are useful for the treatment (including prevention) of angiogenic disorders. The term "angiogenic disorders" as used herein includes conditions involving abnormal neovascularization, such
20 as tumor metastasis and ocular neovascularization, including, for example, diabetic retinopathy, neovascular glaucoma, age-related macular degeneration, and retinal vein occlusion, comprising administering to a mammal in need of such treatment a therapeutically
25 effective amount of a compound of Formula I described above.

The compounds of Formula I of the present invention may be useful for the treatment or prevention of other diseases which involve cell adhesion processes,
30 including, but not limited to, inflammation, bone degradation, thromboembolic disorders, restenosis, rheumatoid arthritis, asthma, allergies, adult respiratory distress syndrome, graft versus host disease, organ transplantation rejection, septic shock,
35 psoriasis, eczema, contact dermatitis, osteoporosis,

osteoarthritis, atherosclerosis, inflammatory bowel disease and other autoimmune diseases. The compounds of Formula I of the present invention may also be useful for wound healing.

5 The term "thromboembolic disorders" as used herein includes conditions involving platelet activation and aggregation, such as arterial or venous cardiovascular or cerebrovascular thromboembolic disorders, including, for example, thrombosis, unstable
10 angina, first or recurrent myocardial infarction, ischemic sudden death, transient ischemic attack, stroke, atherosclerosis, venous thrombosis, deep vein thrombosis, thrombophlebitis, arterial embolism, coronary and cerebral arterial thrombosis, myocardial
15 infarction, cerebral embolism, kidney embolisms, pulmonary embolisms, or such disorders associated with diabetes, comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of Formula I described above.

20 The compounds of the present invention may be used for other *ex vivo* applications to prevent cellular adhesion in biological samples.
The compounds of the present invention can also be administered in combination with one or more additional
25 therapeutic agents selected from: anti-coagulant or coagulation inhibitory agents, such as heparin or warfarin; anti-platelet or platelet inhibitory agents, such as aspirin, piroxicam, or ticlopidine; thrombin inhibitors such as boro-peptides, hirudin or argatroban;
30 or thrombolytic or fibrinolytic agents, such as plasminogen activators, anistreplase, urokinase, or streptokinase.

 The compounds of Formula I of the present invention can be administered in combination with one or
35 more of the foregoing additional therapeutic agents,

thereby to reduce the doses of each drug required to achieve the desired therapeutic effect. Thus, the combination treatment of the present invention permits the use of lower doses of each component, with reduced
5 adverse, toxic effects of each component. A lower dosage minimizes the potential of side effects of the compounds, thereby providing an increased margin of safety relative to the margin of safety for each component when used as a single agent. Such combination
10 therapies may be employed to achieve synergistic or additive therapeutic effects for the treatment of thromboembolic disorders.

By "therapeutically effective amount" it is meant an amount of a compound of Formula I that when
15 administered alone or in combination with an additional therapeutic agent to a cell or mammal is effective to prevent or ameliorate the thromboembolic disease condition or the progression of the disease.

By "administered in combination" it is meant that
20 the compound of Formula I and one or more additional therapeutic agents are administered concurrently to the mammal being treated. When administered in combination each component may be administered at the same time or sequentially in any order at different points in time.
25 Thus, each component may be administered separately but sufficiently closely in time so as to provide the desired therapeutic effect.

The term anti-coagulant agents (or coagulation inhibitory agents), as used herein, denotes agents that
30 inhibit blood coagulation. Such agents include warfarin (available as COUMADIN®) and heparin.

The term anti-platelet agents (or platelet inhibitory agents), as used herein, denotes agents that inhibit
platelet function such as by inhibiting the aggregation,
35 adhesion or granular secretion of platelets. Such

agents include the various known non-steroidal anti-inflammatory drugs such as aspirin, ibuprofen, naproxen, sulindac, indomethacin, mefenamate, droxicam, diclofenac, sulfinpyrazone, and piroxicam, including
5 pharmaceutically acceptable salts or prodrugs thereof. Other suitable anti-platelet agents include ticlopidine, including pharmaceutically acceptable salts or prodrugs thereof. Ticlopidine is also a preferred compound since it is known to be gentle on the gastro-intestinal tract
10 in use. Still other suitable platelet inhibitory agents include thromboxane-A₂-receptor antagonists and thromboxane-A₂-synthetase inhibitors, as well as pharmaceutically acceptable salts or prodrugs thereof. The phrase thrombin inhibitors (or anti-thrombin
15 agents), as used herein, denotes inhibitors of the serine protease thrombin. By inhibiting thrombin, various thrombin-mediated processes, such as thrombin-mediated platelet activation (that is, for example, the aggregation of platelets, and/or the
20 granular secretion of plasminogen activator inhibitor-1 and/or serotonin) and/or fibrin formation are disrupted. Such inhibitors include boroarginine derivatives and boro-peptides, hirudin and argatroban, including pharmaceutically acceptable salts and prodrugs thereof.
25 Boroarginine derivatives and boro-peptides include N-acetyl and peptide derivatives of boronic acid, such as C-terminal α -aminoboronic acid derivatives of lysine, ornithine, arginine, homoarginine and corresponding isothiuronium analogs thereof. The term hirudin, as
30 used herein, includes suitable derivatives or analogs of hirudin, referred to herein as hirulogs, such as disulfatohirudin. Boro-peptide thrombin inhibitors include compounds described in Kettner et al., U.S. Patent No. 5,187,157 and European Patent Application
35 Publication Number 293 881 A2, the disclosures of which

are hereby incorporated herein by reference. Other suitable boroarginine derivatives and boro-peptide thrombin inhibitors include those disclosed in PCT Application Publication Number 92/07869 and European Patent Application Publication Number 471 651 A2, the disclosures of which are hereby incorporated herein by reference, in their entirety.

The phrase thrombolytics (or fibrinolytic) agents (or thrombolytics or fibrinolytics), as used herein, denotes agents that lyse blood clots (thrombi). Such agents include tissue plasminogen activator, anistreplase, urokinase or streptokinase, including pharmaceutically acceptable salts or prodrugs thereof. Tissue plasminogen activator (tPA) is commercially available from Genentech Inc., South San Francisco, California. The term anistreplase, as used herein, refers to anisoylated plasminogen streptokinase activator complex, as described, for example, in European Patent Application No. 028,489, the disclosures of which are hereby incorporated herein by reference herein, in their entirety. The term urokinase, as used herein, is intended to denote both dual and single chain urokinase, the latter also being referred to herein as prourokinase.

Administration of the compounds of Formula I of the invention in combination with such additional therapeutic agent, may afford an efficacy advantage over the compounds and agents alone, and may do so while permitting the use of lower doses of each. A lower dosage minimizes the potential of side effects, thereby providing an increased margin of safety.

The compounds of the present invention are also useful as standard or reference compounds, for example as a quality standard or control, in tests or assays involving the binding of vitronectin or fibrinogen to

$\alpha_v\beta_3$. Such compounds may be provided in a commercial kit, for example, for use in pharmaceutical research involving $\alpha_v\beta_3$. The compounds of the present invention may also be used in diagnostic assays involving $\alpha_v\beta_3$.

5

The compounds herein described may have asymmetric centers. Unless otherwise indicated, all chiral, diastereomeric and racemic forms are included in the present invention. Many geometric isomers of olefins, C=N double bonds, and the like can also be present in the compounds described herein, and all such stable isomers are contemplated in the present invention. It will be appreciated that compounds of the present invention that contain asymmetrically substituted carbon atoms may be isolated in optically active or racemic forms. It is well known in the art how to prepare optically active forms, such as by resolution of racemic forms or by synthesis, from optically active starting materials. All chiral, diastereomeric, racemic forms and all geometric isomeric forms of a structure are intended, unless the specific stereochemistry or isomer form is specifically indicated.

When any variable (for example but not limited to, R^2 , R^4 , R^6 , R^7 , R^8 , R^{12} , and R^{14} , n, etc.) occurs more than one time in any constituent or in any formula, its definition on each occurrence is independent of its definition at every other occurrence. Thus, for example, if a group is shown to be substituted with 0-2 R^4 , then said group may optionally be substituted with up to two R^4 and R^4 at each occurrence is selected independently from the defined list of possible R^4 . Also, by way of example, for the group $-N(R^{5a})_2$, each of the two R^{5a} substituents on N is independently selected from the defined list of possible R^{5a} . Similarly, by way of example, for the group $-C(R^7)_2-$, each of the two

R⁷ substituents on C is independently selected from the defined list of possible R⁷.

When a bond to a substituent is shown to cross the bond connecting two atoms in a ring, then such substituent may be bonded to any atom on the ring. When a bond joining a substituent to another group is not specifically shown or the atom in such other group to which the bond joins is not specifically shown, then such substituent may form a bond with any atom on such other group.

When a substituent is listed without indicating the atom via which such substituent is bonded to the rest of the compound of Formula I, then such substituent may be bonded via any atom in such substituent. For example, when the substituent is piperazinyl, piperidinyl, or tetrazolyl, unless specified otherwise, said piperazinyl, piperidinyl, tetrazolyl group may be bonded to the rest of the compound of Formula I via any atom in such piperazinyl, piperidinyl, tetrazolyl group.

Combinations of substituents and/or variables are permissible only if such combinations result in stable compounds. By stable compound or stable structure it is meant herein a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic agent.

The term "substituted", as used herein, means that any one or more hydrogen on the designated atom is replaced with a selection from the indicated group, provided that the designated atom's normal valency is not exceeded, and that the substitution results in a stable compound. When a substituent is keto (i.e., =O), then 2 hydrogens on the atom are replaced.

As used herein, "alkyl" is intended to include both branched and straight-chain saturated aliphatic

hydrocarbon groups having the specified number of carbon atoms (for example, "C₀-C₁₀" denotes alkyl having 0 to 10 carbon atoms; thus, C₀ denotes a direct bond between the groups linked by the C₀ group); "haloalkyl" is intended to include both branched and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms, substituted with 1 or more halogen (for example -C_vF_w where v = 1 to 3 and w = 1 to (2v+1)); "alkoxy" represents an alkyl group of indicated number of carbon atoms attached through an oxygen bridge; "cycloalkyl" is intended to include saturated ring groups, including mono-, bi- or poly-cyclic ring systems, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, and adamantyl; and "bicycloalkyl" is intended to include saturated bicyclic ring groups such as [3.3.0]bicyclooctane, [4.3.0]bicyclononane, [4.4.0]bicyclodecane (decalin), [2.2.2]bicyclooctane, and so forth. "Alkenyl" is intended to include hydrocarbon chains of either a straight or branched configuration and one or more unsaturated carbon-carbon bonds which may occur in any stable point along the chain, such as ethenyl, propenyl and the like; and "alkynyl" is intended to include hydrocarbon chains of either a straight or branched configuration and one or more triple carbon-carbon bonds which may occur in any stable point along the chain, such as ethynyl, propynyl and the like.

The terms "alkylene", "alkenylene", "phenylene", and the like, refer to alkyl, alkenyl, and phenyl groups, respectively, which are connected by two bonds to the rest of the structure of Formula I. Such "alkylene", "alkenylene", "phenylene", and the like, may alternatively and equivalently be denoted herein as "-(alkyl)-", "-(alkenyl)-" and "-(phenyl)-", and the like.

"Halo" or "halogen" as used herein refers to fluoro, chloro, bromo and iodo; and "counterion" is used to represent a small, negatively charged species such as chloride, bromide, hydroxide, acetate, sulfate and the like.

As used herein, "aryl" or "aromatic residue" is intended to mean phenyl or naphthyl; the term "arylalkyl" represents an aryl group attached through an alkyl bridge.

As used herein, "carbocycle" or "carbocyclic residue" is intended to mean any stable 3- to 7-membered monocyclic or bicyclic or 7- to 14-membered bicyclic or tricyclic or an up to 26-membered polycyclic carbon ring, any of which may be saturated, partially unsaturated, or aromatic. Examples of such carbocycles include, but are not limited to, cyclopropyl, cyclopentyl, cyclohexyl, phenyl, biphenyl, naphthyl, indanyl, adamantyl, or tetrahydronaphthyl (tetralin).

As used herein, the term "heterocycle" or "heterocyclic" is intended to mean a stable 5- to 7-membered monocyclic or bicyclic or 7- to 10-membered bicyclic heterocyclic ring which may be saturated, partially unsaturated, or aromatic, and which consists of carbon atoms and from 1 to 4 heteroatoms independently selected from the group consisting of N, O and S and wherein the nitrogen and sulfur heteroatoms may optionally be oxidized, and the nitrogen may optionally be quaternized, and including any bicyclic group in which any of the above-defined heterocyclic rings is fused to a benzene ring. The heterocyclic ring may be attached to its pendant group at any heteroatom or carbon atom which results in a stable structure. The heterocyclic rings described herein may be substituted on carbon or on a nitrogen atom if the resulting compound is stable. Examples of such heterocycles

include, but are not limited to, pyridyl (pyridinyl),
pyrimidinyl, furanyl (furyl), thiazolyl, thienyl,
pyrrolyl, pyrazolyl, imidazolyl, tetrazolyl,
benzofuranyl, benzothiophenyl, indolyl, indolenyl,
5 isoxazolinyll, isoxazolyl, quinolinyll, isoquinolinyll,
benzimidazolyl, piperidinyl, 4-piperidonyl,
pyrrolidinyl, 2-pyrrolidonyl, pyrrolinyll,
tetrahydrofuranyl, tetrahydroquinolinyll,
tetrahydroisoquinolinyll, decahydroquinolinyll or
10 octahydroisoquinolinyll, azocinyll, triazinyl, 6H-1,2,5-
thiadiazinyl, 2H,6H-1,5,2-dithiazinyl, thianthrenyl,
pyranlyl, isobenzofuranyl, chromenyl, xanthenyl,
phenoxathiinyl, 2H-pyrrolyl, pyrrolyl, imidazolyl,
pyrazolyl, isothiazolyl, isoxazolinyll, isoxazolyl,
15 oxazolyl, pyridinyl, pyrazinyl, pyrimidinyl,
pyridazinyl, indolizinyll, isoindolyl, 3H-indolyl,
indolyl, 1H-indazolyl, purinyl, 4H-quinolizinyll,
isoquinolinyll, quinolinyll, phthalazinyl, naphthyridinyl,
quinoxalinyll, quinazolinyll, cinnolinyll, pteridinyl,
20 4aH-carbazole, carbazole, β -carbolinyll, phenanthridinyl,
acridinyl, perimidinyl, phenanthrolinyll, phenazinyl,
phenarsazinyl, phenothiazinyl, furazanyl, phenoxazinyl,
isochromanyl, chromanyl, pyrrolidinyl, pyrrolinyll,
imidazolidinyl, imidazolinyll, pyrazolidinyl,
25 pyrazolinyll, piperidinyl, piperazinyl, indolinyll,
isoindolinyll, quinuclidinyl, morpholinyll or
oxazolidinyl. Also included are fused ring and spiro
compounds containing, for example, the above
heterocycles.

30 As used herein, the term "heteroaryl" refers to
aromatic heterocyclic groups. Such heteroaryl groups
are preferably 5-6 membered monocyclic groups or 8-10
membered fused bicyclic groups. Examples of such
heteroaryl groups include, but are not limited to
35 pyridyl (pyridinyl), pyrimidinyl, furanyl (furyl),

thiazolyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, indolyl, isoxazolyl, oxazolyl, pyrazinyl, pyrimidinyl, pyridazinyl, benzofuranyl, benzothienyl, benzimidazolyl, quinolinyl, or isoquinolinyl.

5

As used herein, "prodrugs" refer to any covalently bonded carriers which release the active parent drug according to Formula I *in vivo* when such prodrug is administered to a mammalian subject. Prodrugs of the compounds of Formula I are prepared by modifying functional groups present in the compounds in such a way that the modifications are cleaved, either in routine manipulation or *in vivo*, to the parent compounds. Prodrugs include compounds of Formula I wherein hydroxyl, amino, sulfhydryl, or carboxyl groups are bonded to any group that, when administered to a mammalian subject, cleaves to form a free hydroxyl, amino, sulfhydryl, or carboxyl group respectively. Examples of prodrugs include, but are not limited to, acetate, formate and benzoate derivatives of alcohol and amine functional groups in the compounds of Formula I, and the like.

As used herein, "pharmaceutically acceptable salts" refer to derivatives of the disclosed compounds wherein the parent compound of Formula I is modified by making acid or base salts of the compound of Formula I. Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like.

The pharmaceutically acceptable salts of the compounds of Formula I include the conventional non-toxic salts or the quaternary ammonium salts of the compounds of Formula I formed, for example, from non-

toxic inorganic or organic acids. For example, such conventional non-toxic salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like; and
5 the salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pamoic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, sulfanilic, 2-acetoxybenzoic, fumaric,
10 toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, isethionic, and the like.

The pharmaceutically acceptable salts of the present invention can be synthesized from the compounds of Formula I which contain a basic or acidic moiety by
15 conventional chemical methods. Generally, the salts are prepared by reacting the free base or acid with stoichiometric amounts or with an excess of the desired salt-forming inorganic or organic acid or base in a suitable solvent or various combinations of solvents.

20 The pharmaceutically acceptable salts of the acids of Formula I with an appropriate amount of a base, such as an alkali or alkaline earth metal hydroxide e.g. sodium, potassium, lithium, calcium, or magnesium, or an organic base such as an amine, e.g.,
25 dibenzylethylenediamine, trimethylamine, piperidine, pyrrolidine, benzylamine and the like, or a quaternary ammonium hydroxide such as tetramethylammonium hydroxide and the like.

As discussed above, pharmaceutically acceptable
30 salts of the compounds of the invention can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid, respectively, in water or in an organic solvent, or in a mixture of the two;
35 generally, nonaqueous media like ether, ethyl acetate,

ethanol, isopropanol, or acetonitrile are preferred.
Lists of suitable salts are found in *Remington's
Pharmaceutical Sciences*, 17th ed., Mack Publishing
Company, Easton, PA, 1985, p. 1418, the disclosure of
5 which is hereby incorporated by reference.

The disclosures of all of the references cited
herein are hereby incorporated herein by reference in
their entirety.

10


Synthesis

The compounds of the present invention can be
prepared in a number of ways well known to one skilled
15 in the art of organic synthesis. The compounds of the
present invention can be synthesized using the methods
described below, together with synthetic methods known
in the art of synthetic organic chemistry, or variations
thereon as appreciated by those skilled in the art.
20 Preferred methods include, but are not limited to, those
described below. All references cited herein are hereby
incorporated in their entirety herein by reference.

Compounds of Formula I wherein Q includes an
25 isoxazoline ring as one ring of the spirocycle can be
conveniently prepared by dipolar cycloaddition of
nitrile oxides with appropriate dipolarophiles (for
reviews of 1,3-dipolar cycloaddition chemistry, see 1,3-
Dipolar Cycloaddition Chemistry (Padwa, ed.), Wiley, New
30 York, 1984; Kanemasa and Tsuge, Heterocycles 1990, 30,
719). The requisite nitrile oxides are in turn prepared
from commercially available precursors or appropriately
substituted aldehydes via the intermediate oximes.

Scheme 1 illustrates one synthetic sequence which
35 will provide compounds of Formula I of this invention.

Scheme 1



5

Treatment of a methylenecycloalkylmethanol with ethyl chlorooximidoacetate in a suitable solvent, such as tetrahydrofuran or dichloromethane, in the presence of a mild base, such as sodium bicarbonate or

triethylamine, provides a spirocycle intermediate, 1(a). Alternately, the cycloaddition can be carried out by thermal decomposition of diethyl nitromalonate in refluxing mesitylene by the method of Shimizu et al. (Bull Chem. Soc. Jpn., 1985, 58, 2519-2522). The hydroxyl group in 1(a) can be subsequently oxidized to the corresponding aldehyde by any of a number of known methods for carrying out this transformation, i.e., (See Manacuso & Swern, Synthesis, 1981, 165; Tidwell, Synthesis, 1990, 857; D.B. Dess & J.C. Martin, J. Org. Chem., 1983, 48, 4155; op cit. J. Amer. Chem. Soc., 1991, 72, 77; R.E. Ireland & L. Liu, J. Org. Chem., 1993, 58, 2899). Reductive amination of the resulting aldehyde with an appropriate aminoheterocycle, such as 2-aminopyridine, can be achieved using sodium triacetoxyborohydride (Abdel-Magid, A. F.; Maryanoff, C. A. Synlett, 1990, 2, 537) to provide a secondary amine. Optional protection of the nitrogen as its BOC derivative yields 1(c). Subsequent hydrolysis of the ethyl ester using conventional methods known to one skilled in the art of organic synthesis gives the corresponding acid 1(d). Coupling of compound 1(d) to an appropriately substituted α - or β -amino ester, 1(e) affords compounds of formula 1(f).


25

The coupling is carried out using any of the many methods for the formation of amide bonds known to one skilled in the art of organic synthesis. These methods include but are not limited to conversion of the acid to the corresponding acid chloride or fluoride, or use of standard coupling procedures such as the azide method, mixed carbonic acid anhydride (isobutyl chloroformate) method, carbodiimide (dicyclohexylcarbodiimide, diisopropylcarbodiimide, or water-soluble carbodiimides) method, active ester (p-nitrophenyl ester, N-

35

- hydroxysuccinic imido ester) method, carbonyldiimidazole method, or coupling with phosphorus reagents such as BOP-Cl. Some of these methods (especially the carbodiimide) can be enhanced by the addition of 1-hydroxybenzotriazole. Deprotection of compound 1(f) is carried out using standard methods of removal of carboxy and amino protecting groups to provide target compounds of formula 1(g).
- Additional compounds of formula I can be prepared as shown in Scheme 2. Cycloaddition product, 1(a) can be converted to the corresponding amino compound by conversion to azide 2(a) using diphenylphosphoryl azide under Mitsunobu conditions (Mitsunobu, O. *Synthesis* 1981, 1) and reduction of the resulting azide with triphenylphosphine (Staudinger, H.; Meyer, J. *Helv. Chim. Acta.* 1919, 2, 635) Protection of the resulting amino group as its BOC derivative provides intermediate 2(b). Alternately, the amine function can be introduced prior to cycloaddition by conversion of the starting methylenecycloalkylmethanol to the corresponding tosylate, displacement of the tosyl group with sodium azide, reduction to the amine and treatment with di-*t*-butyldicarbonate. Subsequent 1,3 dipolarcycloaddition provides 2(a). Ester hydrolysis and amide coupling as described above provides compounds of formula 2(d). Hydrolysis of the ester, removal of the BOC protecting group and treatment of the free amine with an appropriate heterocyclic isothiuronium salt, such as those listed in the scheme, provides compounds of Formula 2(f).

Scheme 2




5

Compounds of Formula I, wherein R^1 is a 7-azabenzimidazol-2-yl, group can also be prepared from cycloaddition product **1(a)** as depicted in Scheme 3.

Jones oxidation of the primary hydroxyl group provides acid **3(a)** which is condensed with 2,3-diaminopyridine to provide the 7-azabenzimidazole derivative, **3(b)**. This intermediate is converted to compounds of the invention by the steps of ester hydrolysis, coupling to compounds of formula **1(e)** and deprotection described in detail above.

Scheme 3


10




The appropriately substituted racemic β -amino acids may be purchased commercially or, as is shown in Scheme 4, Method 1, prepared from the appropriate aldehyde, malonic acid and ammonium acetate according to the procedure of Johnson and Livak (J. Am. Chem. Soc. 1936, 58, 299). Racemic β -substituted- β -amino esters may be prepared through the reaction of dialkylcuprates or alkylolithiums with 4-benzoyloxy-2-azetidinone followed by treatment with anhydrous ethanol (Scheme 4, Method 2) or by reductive amination of β -keto esters as is described in WO9316038. (Also see Rico et al., J. Org. Chem. 1993, 58, 7948-51.) Enantiomerically pure β -substituted- β -amino acids can be obtained through the optical resolution of the racemic mixture or can be prepared using numerous methods, including: Arndt-Eistert homologation of the corresponding α -amino acids as shown in Scheme 4, Method 3 (see Meier, and Zeller, Angew. Chem. Int. Ed. Engl. 1975, 14, 32; Rodriguez, et al. Tetrahedron Lett. 1990, 31, 5153; Greenlee, J. Med. Chem. 1985, 28, 434 and references cited within); and through an enantioselective hydrogenation of a dehydroamino acid as is shown in Scheme 4, Method 4 (see Asymmetric Synthesis, Vol. 5, (Morrison, ed.) Academic Press, New York, 1985). A comprehensive treatise on the preparation of β -amino acid derivatives may be found in patent application WO 93/07867, the disclosure of which is hereby incorporated by reference.

Scheme 4


Method 1




Method 2



Method 3



Method 4




- 5 The synthesis of N²-substituted diaminopropionic acid derivatives can be carried out via Hoffman rearrangement of a wide variety of asparagine derivatives as described in Synthesis, 266-267, (1981) or by manipulation of the commercially available 3-amino-2-benzyloxycarbonylamino-
10 propionic acid.

Additional dipolarophiles useful for the preparation of the compounds of this invention are either commercially available or may be prepared by
15 numerous methods. Synthesis of representative examples and their conversion into compounds of Formula I are illustrated in the following schemes.

Heating a neat mixture of 8-aza-1,4-dioxaspiro(4,5)decane and 2,6-dibromopyridine provides
20

bromopyridine intermediate 5(a) as shown in Scheme 5. Hydrolysis of the acetal protecting group gives the ketone, 5(b) which can then undergo olefination to compound 5(c). The olefination can be carried out by a number of methods known to one skilled in the art. (For suitable olefination methods, see S. H. Pine et al., *Synthesis* 1991, 165; *Bull. Chem Soc. Jpn.*, 1980, 53, 1698; or *J. Org. Chem.* 1968, 33, 780.) The alkene is then subjected to the 1,3-dipolar cycloaddition conditions described above to provide the spirocyclic system, 5(d). Amination with potassium amide in liquid ammonia followed by protection of the resulting amine as its BOC derivative gives compound 5(e). This intermediate is then carried on to compounds of Formula 5(g) using the steps previously described.


Scheme 5



5 Preparation of the analogous (4,4) spiro system is outlined in Scheme 6. Hydrogenation of commercially


available 1-benzyl-3-hydroxypyrolidine and selective reprotection of the amine as the t-butylcarbamate provides 6(a). Oxidation of the hydroxyl to the ketone 6(b) by Swern oxidation or other standard methods
5 followed by olefination as described above provides alkene 6(c). This alkene is then subjected to 1,3-dipolar cycloaddition as previously described to provide the spirocycle 6(d). Ester hydrolysis and coupling to a suitable β -amino ester gives 6(e). Removal of the BOC
10 protecting group and treatment with 2-bromo-6-t-butoxycarbonylaminopyridine (*Aust. J. Chem.* **1982**, 35, 2025) gives intermediate 6(f). Finally, deprotection provides compounds of this invention of Formula 6(g).

Scheme 6




A further class of spirocycles useful in the present invention is prepared as outlined in Scheme 7. Reduction of N-Cbz 4-hydroxyproline with borane-dimethyl sulfide complex in tetrahydrofuran provides diol 7(a). The primary hydroxyl is then selectively protected as its t-butyldimethylsilyl ether, 7(b). Oxidation of the remaining secondary alcohol using methods described above provides ketone 7(c) which can be converted to alkene 7(d) by olefination. Compound 7(d) then undergoes 1,3-dipolarcycloaddition to provide spirocycle 7(e). Deprotection of the silyl ether by treatment with fluoride ion followed by Swern oxidation of the resulting alcohol provides aldehyde 7(f). Reductive amination with 2-aminopyridine followed by Boc protection of the resulting secondary amine yields 7(g). Ester hydrolysis, coupling to the desired 2,3-diaminopropionate derivative and deprotection gives 7(h). Alternately prior to deprotection the Cbz group can be selectively removed and alternate R¹⁰ groups introduced using standard methods known to one skilled in the art to provide compounds 7(i).

Scheme 7



Compounds of Formula I wherein Q includes a 1,2,4-oxadiazoline as one ring of the spirocycle are prepared as shown in Scheme 8. Protection of 4-methylenecyclohexylmethanol as its t-butyldimethylsilyl ether followed by ozonolysis of the double bond provides ketone **8(a)**. Treatment of compound **8(a)** with a suitable amine provides an imine **8(b)** which can undergo 1,3-dipolarcycloaddition with a nitrile oxide to provide spirocycle **8(c)**. Further elaboration as described above would provide additional compounds of the present invention of Formula **8(h)**.


Scheme 8



Additional spirocyclic compounds useful in the present invention can be prepared as outlined in Scheme 9 wherein 1,3-dipolarcycloaddition is carried using ethyl diazoacetate (E. Keller et al., *Tetrahedron*, **1993**, 49, 8899) to provide spirocycle 9(b) ($R^{10} = H$). The nitrogen of the resulting pyrazole ring may be optionally functionalized using standard methodology prior to carrying out the remaining steps leading to compounds of formula 9(g).


10

Scheme 9



Fully saturated spirocycles are obtained by 1,3-dipolarcycloaddition of α -methoxycarbonylnitrones to an appropriately substituted alkene as illustrated in Scheme 10. (Y. Inouye et al., *Bull Chem. Soc. Jpn*,
5 1979, 52, 3763; J. Hara et al., *ibid.*, 1981, 54, 3871).

Scheme 10



- 5 The detailed processes for preparing the compounds of Formula I are illustrated by the following Examples. It is, however, understood that this invention is not

limited to the specific details of these examples. Melting points (mp) are uncorrected. Proton nuclear magnetic resonance spectra (NMR) were measured in chloroform-d (CDCl₃) unless otherwise specified and the peaks are reported in parts per million (ppm) downfield from tetramethylsilane (TMS). The coupling patterns are reported as follows: s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; bs, broad singlet; bm, broad multiplet. Infrared spectra are reported in reciprocal centimeters (cm⁻¹). All final compounds gave satisfactory nmr and HRMS data and were analyzed to be >98% pure by reverse phase analytical HPLC.

Examples

15

Example 1081

(S)-2-benzyloxycarbonylamino-3-[[8-(2-pyridinylamino)methyl-1-oxa-2-azaspiro-[4.5]-dec-2-en-3-yl]carboxylaminolpropionic acid

Ethyl [(8-hydroxymethyl)-1-oxa-2-azaspiro-[4.5]-dec-2-en-3-yl]carboxylate: 1(a)
Method A: 4-Methylenecyclohexylmethanol (2.52g, 20mmol, Wiley Organics, 63% purity) and sodium bicarbonate (8.4g, 100mmol) in 45ml of 2:1 THF:H₂O was cooled in an ice bath. Ethyl chlorooximidoacetate (5.00g, 33mmol) in 30ml 2:1 THF:H₂O was then added, and the mixture stirred at room temperature for 18 hours. The mixture was then diluted with ethyl acetate and washed with water. The aqueous layer was extracted with one more portion of ethyl acetate. The organic layers were combined, dried (MgSO₄), filtered, concentrated and the residue purified by flash chromatography (silica gel column/1:1 EtOAc:Hexane) to afford 1(a) as a colorless oil (57.6%

yield). HRMS calcd. for $C_{12}H_{19}NO_4$ ($[M+H]^+$): 242.139233;
found: 242.140376.

Method B: A mixture of 4-Methylenecyclohexylmethanol
(10g, mol, Wiley Organics, 63% purity, 0.051 mol) and
5 diethylnitromalonate (14 ml, 0.08 mol) in 100 ml
mesitylene was refluxed for 4-5 hrs under a nitrogen
atmosphere with stirring. The resulting yellow solution
was evaporated on a rotary evaporator in vacuo and the
residue purified by flash chromatography (silica
10 gel/70:30 Hexane/ethyl acetate) to provide 6.4 g of 1(a)
(52%) as 3/2 mixture of diastereomers by nmr.

Ethyl [(8-formyl)-1-oxa-2-azaspiro-[4.5]-dec-2-en-3-yl]carboxylate: 1(b) : Oxalyl chloride (0.70ml, 8mmol)
15 in 5ml CH_2Cl_2 was cooled to $-78^\circ C$ in dry ice-acetone bath
and treated with dimethylsulfoxide (0.74ml, 10.4mmol) in
10ml CH_2Cl_2 and stirred at $-78^\circ C$ for 15 minutes.
Intermediate 1(a) (992mg, 4mmol) in 10ml CH_2Cl_2 was then
added, and the mixture stirred at $-78^\circ C$ for 1 hour.
20 Triethylamine (2.0g, 20mmol) in 5 ml CH_2Cl_2 was then
added, and the mixture stirred at $-78^\circ C$ for 15 minutes.
The bath was removed and the mixture allowed to warm up
over a 30 minute period, diluted with CH_2Cl_2 (50ml) and
washed with water followed by brine. The organic layer
25 was separated, dried over anhydrous magnesium sulfate,
filtered and concentrated to afford 0.68g of 1(b) as a
clear oil. HRMS calcd. for $C_{12}H_{17}NO_4$ ($[M+H]^+$):
240.123583; found: 240.123665.

30 Ethyl [8-[(N-t-butoxycarbonyl)-(N-2-pyridinyl)aminomethyl]-1-oxa-2-azaspiro-[4.5]-dec-2-en-3-yl]carboxylate 1(c): The intermediate 1(b) (1.068g, 4
mmol crude) and acetic acid (240mg, 4mmol) in 15ml 1,2-
dichloroethane were treated with sodium
35 triacetoxyborohydride (1.19g, 5.6mmol), and the mixture

stirred at room temperature for 18 hours. The mixture was diluted with ethyl acetate and washed with sat. sodium bicarbonate and then brine. The organic layer was separated, dried over anhydrous magnesium sulfate, filtered and concentrated to afford 1.32g of amine as an oil. HRMS calcd. for $C_{17}H_{23}N_3O_3$ ($[M+H]^+$): 318.181767; found: 318.183254.

The crude amine and triethylamine (1.0g, 10mmol) in 20ml dichloromethane were treated with di-t-butylidicarbonate (2.18g, 10mmol), and stirred at room temperature for 18 hours. The mixture was diluted with dichloromethane and washed with water and brine. The organic layer was separated, dried over anhydrous magnesium sulfate, filtered, concentrated and the residue purified by flash chromatography (silica gel/1:3 EtOAc:Hexane) to afford 845mg of **1(c)** as a colorless oil (50.6% yield from **1(a)**). HRMS calcd. for $C_{22}H_{31}N_3O_5$ ($[M+H]^+$): 418.234197; found: 418.233666.

18-[(N-t-Butoxycarbonyl)-(N-2-pyridinyl)aminomethyl]-1-oxa-2-azaspiro-[4.5]-dec-2-en-3-yl]carboxylic acid **1(d)**:

The intermediate **1(c)** (209mg, 0.5mmol) in 4.5ml of 2:1 THF:H₂O was treated with lithium hydroxide monohydrate (25mg, 0.6mmol) and the mixture stirred at room temperature for 18 hours. The mixture was quenched with 0.6ml of 1 N HCl and extracted with ethyl acetate (2x25ml). The organic layer was separated, dried over anhydrous magnesium sulfate, filtered, concentrated to afford 199mg of **1(d)** as a colorless foam. HRMS calcd. for $C_{20}H_{27}N_3O_5$ ($[M+H]^+$): 390.202896; found: 390.202306.

Methyl (S)-2-benzyloxycarbonylamino-3-[[18-[(N-(t-butoxycarbonyl)-N-(2-pyridinyl)aminomethyl)-1-oxa-2-azaspiro-[4.5]-dec-2-en-3-yl]carbonylamino]propionate
1(f) ($R^{15} = \text{NHCBz}$, $R = \text{Me}$): The intermediate **1(d)**

(199mg, 0.5mmol crude), **1(e)** (R^{15} = NHCbz, R = Me, 144mg, 0.5mmol) and BOP Reagent (265 mg, 0.6 mmol) in 3ml DMF were treated with 4-N-methylmorpholine (152 mg, 1.5 mmol) in 2ml DMF and the mixture stirred at room temperature for 18 hours. The mixture was diluted with ethyl acetate and washed with sat. sodium bicarbonate, water and then brine. The organic layer was separated, dried over anhydrous magnesium sulfate, filtered, concentrated and the residue purified by flash chromatography (silica gel column/1:1 EtOAc:Hexane followed by 10:1:10 EtOAc:EtOH:Hexane) to afford 213mg of **1(f)** (R^{15} = NHCbz, R = Me) as a white solid (68.3% yield from **1(c)**). HRMS calcd. for $C_{32}H_{41}N_5O_8$ ($[M+H]^+$): 624.303339; found: 624.303031.

(S)-2-benzoyloxycarbonylamino-3-[[8-(2-pyridinylamino)methyl-1-oxa-2-azaspiro-[4.5]-dec-2-en-3-yl]carbonylamino]propionic acid **1(g)** (R^{15} = NHCbz): The intermediate **1(f)** (205mg, 0.33mmol crude) in 4ml of 1:1 MeOH:H₂O was treated with lithium hydroxide monohydrate (21mg, 0.5mmol) and the mixture stirred at room temperature for 18 hours. The mixture was neutralised with 0.5ml of 1 N HCl and extracted with EtOAc. The organic layer was separated, dried over anhydrous magnesium sulfate, filtered, concentrated to afford 205mg of the free acid as a white solid. HRMS calcd. for $C_{31}H_{39}N_5O_8$ ($[M+H]^+$): 610.287689; found: 610.290115. Crude acid was treated with 3ml of 4M HCl in dioxane and stirred at room temperature for 18 hours. The mixture was concentrated in vacuo and the residue purified by preparative HPLC (C18/80% CH₃CN:20% H₂O:0.05% TFA) to afford 132mg of a white solid. The compound was lyophilized from 2ml of 1:1 CH₃CN:H₂O to afford 107mg of **1(g)** (R^{15} = NHCbz) as a white solid (52.0% yield from **1(f)**). ¹H NMR (DMSO-D₆; Mixture of diastereoisomers) d

7.8 (m, 2H), 7.35 (bs, 5H), 6.8 (m, 2H), 5.11 (s, 2H),
4.44 (s, 1H), 3.4 (bm, 2H), 3.2 (m, 2H), 2.8 (s, 2H), 2.0
- 1.2 (bm, 8H) ; HRMS calcd. for C₂₆H₃₁N₅O₆ ([M+H]⁺):
510.235259; found: 510.236039.

5

Similarly prepared from 1(d) were the following:

Example 1111

10

(S)-2-phenylsulfonylamino-3-[[8-(2-
pyridinylamino)methyl-1-oxa-2-azaspiro-[4.5]-dec-2-en-3-
yl]carbonylamino]propionic acid

¹H NMR (DMSO-D₆) δ 8.8 (bs, 1H), 8.23 (t, 1H, J = 6),
15 8.18 (d, 1H, J = 9), 7.85-7.40 (m, 5H), 7.03 (d, 1H, J =
9), 6.8 (t, 1H, J = 7), 3.93 (dd, 1H, J = 13, 7), 3.38
(m, 1H), 3.19 (bm, 3H), 2.8 (s, 2H), 1.85-1.2 (bm, 8H);
MS calcd. for C₂₄H₂₉N₅O₆S ([M+H]⁺): 516.2; found: 516.1.

Example 1121

20 (S)-2-[(2,5-dimethylisoxazol-2-yl)sulfonylamino-3-[[8-
(2-pyridinylamino)methyl-1-oxa-2-azaspiro-[4.5]-dec-2-
en-3-yl]carbonylamino]propionic acid

¹H NMR (DMSO-D₆) δ 8.8 (bs, 1H), 8.54 (d, 1H, J = 9),
8.27 (t, 1H, J = 6), 7.86 (m, 1H), 7.03 (d, 1H, J = 9),
25 3.94 (m, 1H), 3.44 (m, 1H), 3.19 (bm, 3H), 2.8 (s, 2H),
2.45 (s, 3H), 2.5 (s, 3H), 2.9 - 1.2 (bm, 8H); MS calcd.
for C₂₃H₃₀N₆O₇S ([M+H]⁺): 535.2; found: 535.1.

Example 3055

30 (S)-2-[(2,4,6-trimethylphenyl)sulfonylamino-3-[[7-
benzyloxycarbonyl-8-(2-imidazolylamino)methyl-1-oxa-2,7-
diazaspiro-[4.4]-non-2-en-3-yl]carbonylamino]propionic
acid

Part A: N-Cbz-4-hydroxy-L-prolinol: A solution of N-
35 Cbz-4-hydroxy-L-proline (50 gm, 0.188 mol) in

tetrahydrofuran (400 ml) was cooled to 0 °C in an ice bath under nitrogen and a solution of borane dimethylsulfide complex (2.0M in THF, 122 ml, 0.244 mol) was added dropwise over 1h. The resulting mixture is
5 then allowed to stir overnight at room temperature. the reaction mixture was recooled to 0 °C and a second portion of borane-dimethylsulfide complex was added as described above. Reaction was again stirred at room temperature overnight, then cooled to 0 °C and quenched
10 by addition of approximately 200ml of 1:1 methanol/water. Solvents were removed on rotary evaporator and residue diluted with water and extracted 4X with ethyl acetate. The combined extracts were washed with saturated aqueous sodium bicarbonate
15 solution (2X) and brine (1X) then dried over anhydrous magnesium sulfate, filtered and evaporated to a clear oil (46.77 g, 99%) which was used without purification in part B below.

Part B. 1-benzyloxycarbonyl-2-(S)-t-
20 butyldimethylsilyloxymethyl-4-hydroxypyrrolidine: A mixture of the compound of Part A above (46.77 g, 0.186 mol), triethylamine (51.8 g, 0.372 mol), and t-butyldimethylsilylchloride (30.86 g, 0.205 mol) in methylene chloride (375 ml) was stirred under nitrogen
25 overnight at room temperature. An additional aliquot of silyl chloride (5 g, 0.033 mol) was added and stirring continued for 4-5 h. Reaction mixture was transferred to a separatory funnel and washed with water (4X) and brine (1X) then dried over anhydrous sodium sulfate,
30 filtered and solvent removed in vacuo. The residue was chromatographed on silica gel (hexane - hexane/ethyl acetate 8:2 - hexane/ethyl acetate 7:3) to provide the silyl ether (47.11 g, 69%)

Part C. 1-benzyloxycarbonyl-2(S)-t-
35 butyldimethylsilyloxymethyl-4-pyrrolidinone: To a

solution of oxalyl chloride (12.4 ml, 0.142 mol) in methylene chloride (330 ml) precooled to -70 °C in an acetone/dry ice bath was added a solution of anhydrous dimethylsulfoxide (20.60ml, 0.29 mol) in methylene chloride (66 ml) dropwise under nitrogen over 30 min at T < -65°C. The resulting mixture was stirred 15 min, followed by dropwise addition of a solution of the compound of part B above in methylene chloride (130 ml) over 45 min at T < -65°C. The reaction was stirred for 30 min followed by dropwise addition of triethylamine (119.2 ml, 0.855 mol) over 30 min again at T < -65°C. The cooling bath was removed and the reaction temperature was allowed to rise to 5-10°C, and then quenched by addition of 645 ml of 10% aqueous potassium hydrogen sulfate solution. The mixture was then transferred to a separatory funnel and layers separated. The aqueous was extracted with methylene chloride and the combined organic layers are washed with 10% citric acid solution (3X) and brine (1X) then dried over anhydrous sodium sulfate, filtered and concentrated to a clear oil (46.8 g, 100%) which was used without purification in part D below.

Part D. 1-benzylloxycarbonyl-2(S)-t-butyl
dimethylsilyloxymethyl-4-methylenepyrrolidine:

Methyltriphenylphosphonium bromide (68.98 g, 0.193 mol) is added to a suspension of potassium t-butoxide (20.27 g, 0.181 mol) in anhydrous ether (700 ml) with stirring at 0°C under nitrogen. The resulting bright yellow solution is stirred for an additional 15 min. To this is added a solution of the compound of part D above (46.8 g, 0.129 mol) in ether (100 ml). The mixture is allowed to assume room temperature and stirred overnight. The resulting mixture was cooled in an ice bath and quenched by addition 700 ml of a saturated solution of ammonium chloride. The phases were

separated and aqueous reextracted 2X with ether. The combined organics were washed with brine and dried over anhydrous sodium sulfate, filtered and evaporated in vacuo. The crude product was purified by flash chromatography (silica gel, hexane-ether 9:1) to provide the olefin (42.6 g, 91%) as a pale yellow oil.

5 Part E: 7-benzyloxycarbonyl-8-t-butyltrimethylsilyloxy-methyl-3-ethoxycarbonyl-1-oxa-2,7-diazaspiro-[4.4]-non-2-ene: The compound of part D above (13.04 g, 0.036 mol) was dissolved in methylene chloride (50 ml), treated with ethyl chlorooximidoacetate (8.18 g., 0.054 mol), and the mixture was cooled to 0°C followed by dropwise addition of triethylamine (7.53 ml, 0.054 mol). The reaction was allowed to come to room temperature

15 over several hours then stirred overnight. An additional 1.5 eq. of the chlorooxime was then added, and the mixture was cooled to 0°C and treated with triethylamine (1.5 eq) as described above. Resulting mixture was stirred at room temperature for 48 h, then

20 diluted with additional methylene chloride and washed with 10% aqueous citric acid (3X), and brine (1X) then dried over anhydrous sodium sulfate, filtered and evaporated in vacuo. The crude was charged to silica gel and eluted first with Hexane/ether(80:20) to provide

25 unreacted starting material (6.64 g, 51%) and then with hexane/ethyl acetate (75:25) to provide the two diastereomers of the product (S,S isomer, 5.54 g, 32%; S,R isomer, 1.34 g, 8%). Anal. Calcd. for C₂₄H₃₆N₂O₆Si: C, 60.48; H, 7.61; N, 5.89. Found: C, 60.46; H, 7.33; N, 5.96.

30 Part F: 7-benzyloxycarbonyl-8-t-butyltrimethylsilyloxy-methyl-3-carboxy-1-oxa-2,7-diazaspiro-[4.4]-non-2-ene: The compound of Part E above (18.7 g, 0.038 mol) was dissolved in methanol (200 ml) and treated at room

35 temperature with a solution of lithium hydroxide

monohydrate (2.4 g, 0.057 mol) in water (50 ml). The whole was stirred for 5 h and then solvent removed in vacuo. Water was added and the pH of the solution was adjusted to 4.4 with 10% aq. citric acid solution. The resulting mixture was extracted 3X with ethyl acetate with adjustment of pH back to 4.4 between extractions. The combined extracts were washed with brine and dried over anhydrous sodium sulfate, filtered and evaporated. The residue was dried under vacuum to provide the acid (16.2 g, 95%) as a foam which was used without purification in Part G below. MS(es) m/z 449.4 (M+H)⁺, 335.2 (M+H-TBMDs)⁺

Part G: t-Butyl (S)-2-[(2,4,6-trimethylphenyl)sulfonyl]-amino-3-[[7-benzoyloxycarbonyl-8-(t-butyl dimethylsilyl)-oxy)methyl]-1-oxa-2,7-diazaspiro-[4.4]-non-2-en-3-yl]carboxylaminolpropionic acid: A mixture of the compound of Part F above (10 g, 0.022 mol), t-butyl 3-amino-2-(2,4,6-trimethylphenylsulfonylamino)propionate (7.6 g, 0.022 mol), N-methylmorpholine (5.4 ml, (0.049 mol) and Castro's reagent (14.8 g, 0.033 mol) in N,N-dimethylformamide (100 ml) was stirred under nitrogen at room temperature overnight. The DMF was removed in vacuo and the residue diluted with 500 ml water and extracted 3X with ethyl acetate. The combined extracts were washed with water (2X), 10% citric acid (1X), saturated sodium bicarbonate (1X) and brine (1X) then dried over anhydrous sodium sulfate, filtered and evaporated. The coupling product was purified by filtration through a pad of silica gel eluted with hexane/ethyl acetate (4:1) to provide the product as a white foam (15 gm, 88%). MS(es) m/z 773.4 (M+H)⁺ 795.4 (M+Na)⁺.

Part H: t-Butyl (S)-2-[(2,4,6-trimethylphenyl)sulfonyl]-amino-3-[[7-benzoyloxycarbonyl-8-hydroxymethyl]-1-oxa-2,7-diazaspiro-[4.4]-non-2-en-3-yl]carboxylaminolpropionic

acid: The compound of Part G above (2.8 g, 3.62 mmol) was dissolved in tetrahydrofuran (12 ml) and treated with tetra-n-butylammonium fluoride (5.8 ml of a 1.0 M solution in THF, 5.8 mmol). The resulting solution was stirred overnight at room temperature. Reaction was quenched by addition of water and THF removed on rotary evaporator. The remaining aqueous was extracted 3X with ethyl acetate. The combined extracts were washed with water and brine, dried over anhydrous sodium sulfate, filtered and evaporated. Chromatography on silica gel (hexane/ethyl acetate 1:1 followed by methylene chloride/methanol 95:5) provided the alcohol (2.02 g., 85%) ms m/z 659.3 (M+H)+.

Part I: t-Butyl (S)-2-[(2,4,6-trimethylphenyl)sulfonyl]-amino-3-[[7-benzoyloxycarbonyl-8-formyl-1-oxa-2,7-diazaspiro-[4,4]-non-2-en-3-yl]carbonylamino]propionic acid: A solution of the compound of Part H above (0.8 g, 1.21 mmol) in anhydrous methylene chloride (1 ml) was added dropwise to a solution of Dess-Martin periodinane (0.59g, 1.30 mmol) in approximately 4 ml of dry methylene chloride at room temperature under nitrogen. The resulting mixture was stirred for 1 hr, then diluted with ethyl acetate and poured into a solution of saturated sodium bicarbonate (20 ml) containing 5 g sodium thiosulfate. This was stirred for 10 min. The phases were separated, aqueous reextracted with ethyl acetate, and combined organics washed with saturated sodium bicarbonate, water and brine, then dried over anhydrous magnesium sulfate, filtered and evaporated to give the aldehyde as a clear oil (0.74 g, 93%).

Part J: t-Butyl (S)-2-[(2,4,6-trimethylphenyl)sulfonyl]-amino-3-[[7-benzoyloxycarbonyl-8-(imidazol-2-ylamino)methyl-1-oxa-2,7-diazaspiro-[4,4]-non-2-en-3-yl]carbonylamino]propionic acid: To a solution of the

- compound of Part I above (0.73 g, 1.11 mmol) in benzene was added anhydrous magnesium sulfate (0.588 g, 4.88 mmol) and 2-amino-1-tritylimidazole (0.398 g, 1.22 mmol) and the whole was refluxed for 4 hrs under nitrogen.
- 5 The mixture was cooled to room temperature, filtered under nitrogen and benzene removed in vacuo. The residue was taken up in 1,2-dichloroethane, treated under nitrogen at room temperature with sodium triacetoxyborohydride (0.588 g, 2.78 mmol), and the
- 10 whole was stirred overnight. The reaction was quenched by addition of water and then diluted with ethyl acetate. Aqueous was reextracted with ethyl acetate, and combined organic layers were washed with saturated sodium bicarbonate, water and brine, then dried over
- 15 anhydrous magnesium sulfate, filtered and evaporated. Filtration through silica gel provided the desired product (0.682 g, 63%) as an off-white foam which was used without further purification in part K below.
- 20 Part K: (S)-2-[(2,4,6-trimethylphenyl)sulfonyl]-amino-3-[[7-benzyloxycarbonyl-8-(imidazol-2-ylamino)methyl-1-oxa-2,7-diazaspiro-[4.4]non-2-en-3-yl]carboxylaminol-propionic acid: The compound of part J above (0.3 g, 0.31 mmol) was dissolved in 20% acetic acid in methanol (10 ml) and refluxed for 24 h under nitrogen. The
- 25 reaction was cooled to room temperature, methanol removed by evaporation and residue diluted with ethyl acetate. This solution was washed with saturated sodium bicarbonate (2X), water and brine then dried over anhydrous magnesium sulfate, filtered and evaporated.
- 30 Filtration through silica gel (eluted with (1) methylene chloride/methanol 95:5; (2) methylene chloride/methanol/conc. ammonium hydroxide 95:5:0/5; (3) 90/10/1) provided the intermediate detritylated t-butyl ester 0.139 mg, 62%). This was taken up in methylene
- 35 chloride (8 ml) and trifluoroacetic acid (2 ml) was

added. The solution was stirred for 72 h, then evaporated and triturated with ether. The resulting solid was purified by prep HPLC (C18, gradient from 100% A to 100% B: A=90/10/0.05 H₂O/CH₃CN/TFA; B=90/10/0.05 CH₃CN/H₂O/TFA) to provide the title compound (0.078g, 50%). MS m/z 690.4 (M+Na)⁺ 668.4 (M+H)⁺.

Example 3063: (S)-2-[(2,4,6-trimethylphenyl)sulfonyl]-
amino-3-[[8-(imidazol-2-ylamino)methyl]-1-oxa-2,7-
10 diazaspiro-[4.4]-non-2-en-3-yl]carboxylaminol-propionic
acid

The compound of Example 3055, Part J, (0.1 g, 0.1 mmol) was taken up in neat trifluoroacetic acid (3 ml) and the mixture refluxed for 1.5 h. Reaction was cooled to room
15 temperature and TFA removed *in vacuo*. The residue was purified by prep HPLC using the system described under Ex. 3055, Part K above to provide the title compound (0.043 g, 80%). MS m/z 534.4 (M+H)⁺.

20 Using the methods described above and modifications thereof known to one skilled in the art of organic synthesis, additional compounds of the present invention can be prepared, including, but not limited to the representative compounds listed in the Tables below.

25

Utility

The compounds of Formula I of the present invention possess activity as antagonists of integrins such as,
30 for example, the $\alpha_v\beta_3$ or vitronectin receptor, $\alpha_v\beta_5$ or $\alpha_5\beta_1$, and as such have utility in the treatment and diagnosis of cell adhesion, angiogenic disorders, inflammation, bone degradation, cancer metastases, diabetic retinopathy, thrombosis, restenosis, macular
35 degeneration, and other conditions mediated by cell

adhesion and/or cell migration and/or angiogenesis. The integrin antagonist activity of the compounds of the present invention is demonstrated using assays which measure the binding of a specific integrin to a native
5 ligand, for example, using the ELISA assay described below for the binding of vitronectin to the $\alpha_v\beta_3$ receptor.

The compounds of the present invention possess selectivity for the $\alpha_v\beta_3$ receptor relative to the
10 GPIIb/IIIa receptor as demonstrated by their lack of activity in standard assays of platelet aggregation, such as the platelet aggregation assay described below.

One of the major roles of integrins *in vivo* is to mediate cellular interactions with adjacent cells. Cell
15 based adhesion assays can be used to mimic these interactions *in vitro*. A cell based assay is more representative of the *in vivo* situation than an ELISA since the receptor is maintained in membranes in the native state. The compounds of the present invention
20 have activity in cell-based assays of adhesion, for example as demonstrated in using the cell adhesion assays described below.

The compounds of Formula I of the present invention
25 may be useful for the treatment or prevention of other diseases which involve cell adhesion processes, including, but not limited to, osteoporosis, rheumatoid arthritis, autoimmune disorders, bone degradation, rheumatoid arthritis, asthma, allergies, adult
30 respiratory distress syndrome, graft versus host disease, organ transplantation, septic shock, psoriasis, eczema, contact dermatitis, osteoarthritis, atherosclerosis, metastasis, wound healing, inflammatory bowel disease and other angiogenic disorders.

The compounds of Formula I have the ability to suppress/inhibit angiogenesis *in vivo*, for example, as demonstrated using animal models of ocular neovascularization.

5 The compounds provided by this invention are also useful as standards and reagents in determining the ability of a potential pharmaceutical to inhibit integrin-ligand binding. These may be provided in a commercial kit comprising a compound of this invention.

10

As used herein "μg" denotes microgram, "mg" denotes milligram, "g" denotes gram, "μL" denotes microliter, "mL" denotes milliliter, "L" denotes liter, "nM" denotes nanomolar, "μM" denotes micromolar, "mM" denotes millimolar, "M" denotes molar and "nm" denotes nanometer. "Sigma" stands for the Sigma-Aldrich Corp. of St. Louis, MO.

20 The utility of the compounds of the present invention may be assessed by testing in one or more of the following assays as described in detail below: Purified $\alpha_v\beta_3$ (human placenta) - Vitronectin ELISA, $\alpha_v\beta_3$ -Vitronectin Binding Assay, Human Aortic Smooth Muscle Cell Migration Assay, In Vivo Angiogenesis Model, 25 Pig Restenosis Model, Mouse Retinopathy Model. A compound of the present invention is considered to be active if it has an IC_{50} or K_i value of less than about 10 μM for the inhibition of $\alpha_v\beta_3$ -Vitronectin Binding Assay, with compounds preferably having K_i values of 30 less than about 0.1 μM. Tested compounds of the present invention are active in the $\alpha_v\beta_3$ -Vitronectin Binding Assay as well as in cell-based assays of integrin adhesion mediated by the $\alpha_v\beta_3$ -receptor.

35 Purified $\alpha_v\beta_3$ (human placenta) - Vitronectin ELISA

The $\alpha_v\beta_3$ receptor was isolated from human placental extracts prepared using octylglucoside. The extracts were passed over an affinity column composed of anti- $\alpha_v\beta_3$ monoclonal antibody (LM609) to Affigel. The column was
5 subsequently washed extensively at pH 7 and pH 4.5 followed by elution at pH 3. The resulting sample was concentrated by wheat germ agglutinin chromatography to provide two bands on SDS gel which were confirmed as $\alpha_v\beta_3$ by western blotting.

10 Affinity purified protein was diluted at different levels and plated to 96 well plates. ELISA was performed using fixed concentration of biotinylated vitronectin (approximately 80 nM/well). This receptor preparation contains the $\alpha_v\beta_3$ with no detectable levels of $\alpha_v\beta_5$
15 according to the gel ($\alpha_v\beta_3$) and according to effects of blocking antibodies for the $\alpha_v\beta_3$ or $\alpha_v\beta_5$ in the ELISA.

A submaximal concentration of biotinylated vitronectin was selected based on conc. response curve with fixed receptor conc. and variable concentrations of
20 biotinylated vitronectin.

$\alpha_v\beta_3$ -Vitronectin Binding Assay

The purified receptor is diluted with coating buffer (20 mM Tris HCl, 150 mM NaCl, 2.0 mM CaCl₂, 1.0 mM
25 MgCl₂·6H₂O, 1.0 mM MnCl₂·4H₂O) and coated (100 μ L/well) on Costar (3590) high capacity binding plates overnight at 4°C. The coating solution is discarded and the plates washed once with blocking/binding buffer (B/B
buffer, 50 mM Tris HCl, 100 mM NaCl, 2.0 mM CaCl₂, 1.0 mM
30 MgCl₂·6H₂O, 1.0 mM MnCl₂·4H₂O). Receptor is then blocked (200 μ L/well) with 3.5% BSA in B/B buffer for 2 hours at room temperature. After washing once with 1.0% BSA in B/B buffer, biotinylated vitronectin (100 μ L) and either
inhibitor (11 μ L) or B/B buffer w/1.0% BSA (11 μ L) is
35 added to each well. The plates are incubated 2 hours at

room temperature. The plates are washed twice with B/B buffer and incubated 1 hour at room temperature with anti-biotin alkaline phosphatase (100 μ L/well) in B/B buffer containing 1.0% BSA. The plates are washed twice
5 with B/B buffer and alkaline phosphatase substrate (100 μ L) is added. Color is developed at room temperature. Color development is stopped by addition of 2N NaOH (25 μ L/well) and absorbance is read at 405 nm. The IC₅₀ is the concentration of test substance needed to block 50%
10 of the vitronectin binding to the receptor.

Integrin Cell-Based Adhesion Assays

In the adhesion assays, a 96 well plate was coated with the ligand (i.e., fibrinogen) and incubated
15 overnight at 4° C. The following day, the cells were harvested, washed and loaded with a fluorescent dye. Compounds and cells were added together and then were immediately added to the coated plate. After incubation, loose cells are removed from the plate, and
20 the plate (with adherent cells) is counted on a fluorometer. The ability of test compounds to inhibit cell adhesion by 50% is given by the IC₅₀ value and represents a measure of potency of inhibition of integrin mediated binding. Compounds were tested for
25 their ability to block cell adhesion using assays specific for $\alpha_v\beta_3$, $\alpha_v\beta_5$ and $\alpha_5\beta_1$ integrin interactions.

Platelet Aggregation Assay

Venous blood was obtained from anesthetized mongrel
30 dogs or from healthy human donors who were drug- and aspirin-free for at least two weeks prior to blood collection. Blood was collected into citrated Vacutainer tubes. The blood was centrifuged for 15 minutes at 150
x g (850 RPM in a Sorvall RT6000 Tabletop Centrifuge
35 with H-1000 B rotor) at room temperature, and platelet-

rich plasma (PRP) was removed. The remaining blood was centrifuged for 15 minutes at 1500 x g (26,780 RPM) at room temperature, and platelet-poor plasma (PPP) was removed. Samples were assayed on a PAP-4 Platelet Aggregation Profiler, using PPP as the blank (100% transmittance). 200 μ L of PRP (5×10^8 platelets/mL) were added to each micro test tube, and transmittance was set to 0%. 20 μ L of ADP (10 μ M) was added to each tube, and the aggregation profiles were plotted (% transmittance versus time). Test agent (20 μ L) was added at different concentrations prior to the addition of the platelet agonist. Results are expressed as % inhibition of agonist-induced platelet aggregation.

15 Human Aortic Smooth Muscle Cell Migration Assay

A method for assessing $\alpha_v\beta_3$ -mediated smooth muscle cell migration and agents which inhibit $\alpha_v\beta_3$ -mediated smooth muscle cell migration is described in Liaw et al., *J. Clin. Invest.* (1995) 95: 713-724).

20

In Vivo Angiogenesis Model

A quantitative method for assessing angiogenesis and antiangiogenic agents is described in Passaniti et al., *Laboratory Investigation* (1992) 67: 519-528

25

Pig Restenosis Model

A method for assessing restenosis and agents which inhibit restenosis is described in Schwartz et al., *J. Am. College of Cardiology* (1992) 19: 267-274.

30

Mouse Retinopathy Model

A method for assessing retinopathy and agents which inhibit retinopathy is described in Smith et al., *Invest. Ophthalm. & Visual Science* (1994) 35: 101-111.

35

Dosage and Formulation

The compounds of this invention can be administered by any means that produces contact of the active agent with the agent's site of action, the $\alpha_v\beta_3$ integrin, in the body of a mammal. They can be administered by any conventional means available for use in conjunction with pharmaceuticals, either as individual therapeutic agents or in a combination of therapeutic agents, such as a antiplatelet agent such as aspirin, piroxicam, or ticlopidine which are agonist-specific, or an anti-coagulant such as warfarin or heparin, or a thrombin inhibitor such as a boro-peptide, hirudin or argatroban, or a thrombolytic agent such as tissue plasminogen activator, anistreplase, urokinase or streptokinase, or combinations thereof. The compounds of the invention, or compounds of the invention in combination with other therapeutic agents, can be administered alone, but generally administered with a pharmaceutical carrier selected on the basis of the chosen route of administration and standard pharmaceutical practice.

The dosage of the novel cyclic compounds of this invention administered will, of course, vary depending upon known factors, such as the pharmacodynamic characteristics of the particular agent and its mode and route of administration; the age, health and weight of the recipient; the nature and extent of the symptoms; the kind of concurrent treatment; the frequency of treatment; and the effect desired. A daily dosage of active ingredient can be expected to be about 0.001 to 10 milligrams per kilogram of body weight.

Dosage forms (compositions suitable for administration) contain from about 0.1 milligram to about 100 milligrams of active ingredient per unit. In

these pharmaceutical compositions the active ingredient will ordinarily be present in an amount of about 0.5-95% by weight based on the total weight of the composition.

5 The active ingredient can be administered orally in solid dosage forms, such as capsules, tablets, and powders, or in liquid dosage forms, such as elixirs, syrups, and suspensions. It can also be administered parenterally, in sterile liquid dosage forms.

10 Gelatin capsules contain the active ingredient and powdered carriers, such as lactose, starch, cellulose derivatives, magnesium stearate, stearic acid, and the like. Similar diluents can be used to make compressed tablets. Both tablets and capsules can be manufactured as sustained release products to provide for continuous
15 release of medication over a period of hours. Compressed tablets can be sugar coated or film coated to mask any unpleasant taste and protect the tablet from the atmosphere, or enteric coated for selective disintegration in the gastrointestinal tract.

20 Liquid dosage forms for oral administration can contain coloring and flavoring to increase patient acceptance.

In general, water, a suitable oil, saline, aqueous dextrose (glucose), and related sugar solutions and
25 glycols such as propylene glycol or polyethylene glycols are suitable carriers for parenteral solutions. Solutions for parenteral administration preferably contain a water soluble salt of the active ingredient, suitable stabilizing agents, and if necessary, buffer
30 substances. Antioxidizing agents such as sodium bisulfite, sodium sulfite, or ascorbic acid, either alone or combined, are suitable stabilizing agents. Also used are citric acid and its salts and sodium EDTA. In addition, parenteral solutions can contain

preservatives, such as benzalkonium chloride, methyl- or propyl-paraben, and chlorobutanol.

Suitable pharmaceutical carriers are described in *Remington's Pharmaceutical Sciences*, Mack Publishing Company, a standard reference text in this field.

Useful pharmaceutical dosage-forms for administration of the compounds of this invention can be illustrated as follows:

10 Capsules

A large number of unit capsules are prepared by filling standard two-piece hard gelatin capsules each with 10 milligrams of powdered active ingredient, 150 milligrams of lactose, 50 milligrams of cellulose, and 6 milligrams magnesium stearate.

Soft Gelatin Capsules

A mixture of active ingredient in a digestable oil such as soybean oil, cottonseed oil or olive oil is prepared and injected by means of a positive displacement pump into gelatin to form soft gelatin capsules containing 10 milligrams of the active ingredient. The capsules are washed and dried.

25 Tablets

A large number of tablets are prepared by conventional procedures so that the dosage unit was 10 milligrams of active ingredient, 0.2 milligrams of colloidal silicon dioxide, 5 milligrams of magnesium stearate, 275 milligrams of microcrystalline cellulose, 11 milligrams of starch and 98.8 milligrams of lactose. Appropriate coatings may be applied to increase palatability or delay absorption.

The combination products of this invention, such as the novel $\alpha_v\beta_3$ antagonist compounds of this invention in combination with an anti-coagulant agent such as warfarin or heparin, or an anti-platelet agent such as aspirin, piroxicam or ticlopidine, or a thrombin inhibitor such as a boro-peptide, hirudin or argatroban, or a thrombolytic agent such as tissue plasminogen activator, anistreplase, urokinase or streptokinase, or combinations thereof, can be in any dosage form, such as those described above, and can also be administered in various ways, as described above.

In a preferred embodiment, the combination products of the invention are formulated together, in a single dosage form (that is, combined together in one capsule, tablet, powder, or liquid, etc.). When the combination products are not formulated together in a single dosage form, the $\alpha_v\beta_3$ antagonist compounds of this invention and the anti-coagulant agent, anti-platelet agent, thrombin inhibitor, and/or thrombolytic agent may be administered at the same time (that is, together), or in any order, for example the compounds of this invention are administered first, followed by administration of the anti-coagulant agent, anti-platelet agent, thrombin inhibitor, and/or thrombolytic agent. When not administered at the same time, preferably the administration of the compound of this invention and any anti-coagulant agent, anti-platelet agent, thrombin inhibitor, and/or thrombolytic agent occurs less than about one hour apart, more preferably less than about 30 minutes apart, even more preferably less than about 15 minutes apart, and most preferably less than about 5 minutes apart. Preferably, administration of the combination products of the invention is oral. The terms oral agent, oral inhibitor, oral compound, or the like, as used herein, denote compounds which may be

orally administered. Although it is preferable that the $\alpha_v\beta_3$ antagonist compounds of this invention and the anti-coagulant agent, anti-platelet agent, thrombin inhibitor, and/or thrombolytic agent are both

5 administered in the same fashion (that is, for example, both orally), if desired, they may each be administered in different fashions (that is, for example, one component of the combination product may be administered orally, and another component may be administered

10 intravenously). The dosage of the combination products of the invention may vary depending upon various factors such as the pharmacodynamic characteristics of the particular agent and its mode and route of administration, the age, health and weight of the

15 recipient, the nature and extent of the symptoms, the kind of concurrent treatment, the frequency of treatment, and the effect desired, as described above.

As discussed above, where two or more of the foregoing therapeutic agents are combined or

20 co-administered with the compounds of this invention, generally the amount of each component in a typical daily dosage and typical dosage form may be reduced relative to the usual dosage of the agent when administered alone, in view of the additive or

25 synergistic effect which would be obtained as a result of addition of further agents in accordance with the present invention.

Particularly when provided as a single dosage form, the potential exists for a chemical interaction between

30 the combined active ingredients (for example, a novel compound of this invention and an anti-coagulant such as warfarin or heparin, or a novel compound of this invention and an anti-platelet agent such as aspirin, piroxicam or ticlopidine, or a novel compound of this

35 invention and a thrombin inhibitor such as a

boropeptide, hirudin or argatroban, or a novel compound of this invention and a thrombolytic agent such as tissue plasminogen activator, anistreplase, urokinase or streptokinase, or combinations thereof). For this
5 reason, the preferred dosage forms of the combination products of this invention are formulated such that although the active ingredients are combined in a single dosage form, the physical contact between the active ingredients is minimized (that is, reduced).

10 In order to minimize contact, one embodiment of this invention where the product is orally administered provides for a combination product wherein one active ingredient is enteric coated. By enteric coating one of the active ingredients, it is possible not only to
15 minimize the contact between the combined active ingredients, but also, it is possible to control the release of one of these components in the gastrointestinal tract such that one of these components is not released in the stomach but rather is released in
20 the intestines. Another embodiment of this invention where oral administration is desired provides for a combination product wherein one of the active ingredients is coated with a sustained-release material which effects a sustained-release throughout the
25 gastrointestinal tract and also serves to minimize physical contact between the combined active ingredients. Furthermore, the sustained-released component can be additionally enteric coated such that the release of this component occurs only in the
30 intestine. Still another approach would involve the formulation of a combination product in which the one component is coated with a sustained and/or enteric release polymer, and the other component is also coated with a polymer such as a low viscosity grade of
35 hydroxypropyl methylcellulose (HPMC) or other

appropriate materials as known in the art, in order to further separate the active components. The polymer coating serves to form an additional barrier to interaction with the other component.


- 5 Dosage forms of the combination products of the present invention wherein one active ingredient is enteric coated can be in the form of tablets such that the enteric coated component and the other active ingredient are blended together and then compressed into
10 a tablet or such that the enteric coated component is compressed into one tablet layer and the other active ingredient is compressed into an additional layer. Optionally, in order to further separate the two layers, one or more placebo layers may be present such that the
15 placebo layer is between the layers of active ingredients. In addition, dosage forms of the present invention can be in the form of capsules wherein one active ingredient is compressed into a tablet or in the form of a plurality of microtablets, particles, granules
20 or non-perils, which are then enteric coated. These enteric coated microtablets, particles, granules or non-perils are then placed into a capsule or compressed into a capsule along with a granulation of the other active ingredient.
- 25 These as well as other ways of minimizing contact between the components of combination products of the present invention, whether administered in a single dosage form or administered in separate forms but at the same time by the same manner, will be readily apparent
30 to those skilled in the art, once armed with the present disclosure.

Pharmaceutical kits useful in, for example, the inhibition of thrombus formation, the prevention of
35 blood clots, and/or the treatment of thromboembolic

disorders, which comprise a therapeutically effective amount of a compound according to the method of the present invention along with a therapeutically effective amount of an anti-coagulant agent such as warfarin or
5 heparin, or an antiplatelet agent such as aspirin, piroxicam or ticlopidine, or a thrombin inhibitor such as a boro peptide, hirudin or argatroban, or a thrombolytic agent such as tissue plasminogen activator, anistreplase, urokinase or streptokinase, or
10 combinations thereof, in one or more sterile containers, are also within the ambit of the present invention. Sterilization of the container may be carried out using conventional sterilization methodology well known to those skilled in the art. The sterile containers of
15 materials may comprise separate containers, or one or more multi-part containers, as exemplified by the UNIVIAL™ two-part container (available from Abbott Labs, Chicago, Illinois), as desired. The compounds according to the method of the invention and the anti-coagulant
20 agent, anti-platelet agent, thrombin inhibitor, thrombolytic agent, and/or combinations thereof, may be separate, or combined into a single dosage form as described above. Such kits may further include, if desired, one or more of various conventional
25 pharmaceutical kit components, such as for example, one or more pharmaceutically acceptable carriers, additional vials for mixing the components, etc., as will be readily apparent to those skilled in the art. Instructions, either as inserts or as labels, indicating
30 quantities of the components to be administered, guidelines for administration, and/or guidelines for mixing the components, may also be included in the kit.

Representative compounds of the present invention
35 are listed in the Tables below.

Table 1



Ex. No.	R ¹	r	R ¹⁴	R ¹⁵	MS
1001	imidazol-2-yl- aminomethyl	1	H	H	
1002	imidazol-2-yl- aminomethyl	1	H	NHCO ₂ Bn	
1003	imidazol-2-yl- aminomethyl	1	H	NHCO ₂ CH ₂ C ₆ H ₄ -(2- CH ₃)	
1004	imidazol-2-yl- aminomethyl	1	H	NHCO ₂ CH ₂ C ₆ H ₄ -(3- CH ₃)	
1005	imidazol-2-yl- aminomethyl	1	H	NHCO ₂ CH ₂ C ₆ H ₄ - (4-CH ₃)	
1006	imidazol-2-yl- aminomethyl	1	H	NHCO ₂ CH ₂ (2- pyridinyl)	
1007	imidazol-2-yl- aminomethyl	1	H	NHCO ₂ CH ₂ (3- pyridinyl)	
1008	imidazol-2-yl- aminomethyl	1	H	NHCO ₂ CH ₂ (4- pyridinyl)	
1009	imidazol-2-yl- aminomethyl	1	H	NHCO ₂ CH ₂ (2- thiazolyl)	
1010	imidazol-2-yl- aminomethyl	1	H	NHCO ₂ CH ₂ (4- thiazolyl)	
1011	imidazol-2-yl- aminomethyl	1	H	NHCO ₂ CH ₂ (5- thiazolyl)	
1012	imidazol-2-yl- aminomethyl	1	H	NHCO ₂ CH ₂ (4- isoxazolyl)	

1013	imidazol-2-yl- aminomethyl	1	H	NHCO ₂ CH ₂ (2- thienyl)
1014	imidazol-2-yl- aminomethyl	1	H	NHCO ₂ CH ₂ (5- isoxazolyl)
1015	imidazol-2-yl- aminomethyl	1	H	NHCO ₂ n-Bu
1016	imidazol-2-yl- aminomethyl	1	H	NHCO ₂ i-Bu
1017	imidazol-2-yl- aminomethyl	1	H	NHCO ₂ t-Bu
1018	imidazol-2-yl- aminomethyl	1	H	NHCOCH ₂ Ph
1019	imidazol-2-yl- aminomethyl	1	H	NHCOCH ₂ C ₆ H ₄ - (2- CH ₃)
1020	imidazol-2-yl- aminomethyl	1	H	NHCOCH ₂ C ₆ H ₄ - (3- CH ₃)
1021	imidazol-2-yl- aminomethyl	1	H	NHCOCH ₂ C ₆ H ₄ - (4- CH ₃)
1022	imidazol-2-yl- aminomethyl	1	H	NHCOCH ₂ (2- pyridinyl)
1023	imidazol-2-yl- aminomethyl	1	H	NHCOCH ₂ (3- pyridinyl)
1024	imidazol-2-yl- aminomethyl	1	H	NHCOCH ₂ (4- pyridinyl)
1025	imidazol-2-yl- aminomethyl	1	H	NHCOCH ₂ (2- thiazolyl)
1026	imidazol-2-yl- aminomethyl	1	H	NHCOCH ₂ (4- thiazolyl)
1027	imidazol-2-yl- aminomethyl	1	H	NHCOCH ₂ (5- thiazolyl)
1028	imidazol-2-yl- aminomethyl	1	H	NHCOCH ₂ (4- isoxazol)
1029	imidazol-2-yl- aminomethyl	1	H	NHCOCH ₂ (2- thienyl)

1030	imidazol-2-yl- aminomethyl	1	H	NHCON-Bu	
1031	imidazol-2-yl- aminomethyl	1	H	NHCot-Bu	
1032	imidazol-2-yl- aminomethyl	1	H	NHSO ₂ Ph	505.2
1033	imidazol-2-yl- aminomethyl	1	H	NHSO ₂ C ₆ H ₄ -(2- CH ₃)	
1034	imidazol-2-yl- aminomethyl	1	H	NHSO ₂ C ₆ H ₄ -(3- CH ₃)	
1035	imidazol-2-yl- aminomethyl	1	H	NHSO ₂ C ₆ H ₄ -(4- CH ₃)	
1036	imidazol-2-yl- aminomethyl	1	H	NHSO ₂ (2-pyridyl)	
1037	imidazol-2-yl- aminomethyl	1	H	NHSO ₂ (3-pyridyl)	
1038	imidazol-2-yl- aminomethyl	1	H	NHSO ₂ (4-pyridyl)	
1039	imidazol-2-yl- aminomethyl	1	H	NHSO ₂ (2-thiaz- olyl)	
1040	imidazol-2-yl- aminomethyl	1	H	NHSO ₂ (3- thiazolyl)	
1041	imidazol-2-yl- aminomethyl	1	H	NHSO ₂ (4- isoxazolyl)	
1042	imidazol-2-yl- aminomethyl	1	H	NHSO ₂ {4-(3,5- dimethyl)isoxaz olyl}	
1043	imidazol-2-yl- aminomethyl	1	H	NHSO ₂ C ₆ H ₄ -(2- Br)	
1044	imidazol-2-yl- aminomethyl	1	H	NHSO ₂ C ₆ H ₄ -(3- Br)	
1045	imidazol-2-yl- aminomethyl	1	H	NHSO ₂ C ₆ H ₄ -(4- Br)	
1046	imidazol-2-yl- aminomethyl	1	H	NHSO ₂ C ₆ H ₄ -(2-F)	

1047	imidazol-2-yl- aminomethyl	1	H	NHSO ₂ C ₆ H ₄ -(3-F)	
1048	imidazol-2-yl- aminomethyl	1	H	NHSO ₂ C ₆ H ₄ -(4-F)	
1049	imidazol-2-yl- aminomethyl	1	H	NHSO ₂ (2- naphthyl)	555.2
1050	imidazol-2-yl- aminomethyl	1	H	NHSO ₂ (1- naphthyl)	
1051	imidazol-2-yl- aminomethyl	1	H	NHSO ₂ CH=CHPh	
1052	imidazol-2-yl- aminomethyl	1	H	NHSO ₂ CH ₂ Ph	
1053	imidazol-2-yl- aminomethyl	1	H	NHSO ₂ CH ₂ CH=CH-Ph	
1054	imidazol-2-yl- aminomethyl	1	H	NHSO ₂ -n-Bu	
1055	imidazol-2-yl- aminomethyl	1	H	NHSO ₂ -i-Bu	
1056	imidazol-2-yl- aminomethyl	1	H	NHSO ₂ -t-Bu	
1057	imidazol-2-yl- aminomethyl	1	H	NHSO ₂ NHPh	
1058	imidazol-2-yl- aminomethyl	1	H	NHSO ₂ NHC ₆ H ₄ -(2- CH ₃)	
1059	imidazol-2-yl- aminomethyl	1	H	NHSO ₂ NHC ₆ H ₄ -(3- CH ₃)	
1060	imidazol-2-yl- aminomethyl	1	H	NHSO ₂ NHC ₆ H ₄ -(4- CH ₃)	
1061	imidazol-2-yl- aminomethyl		H	NHSO ₂ NH(2- pyridyl)	
1062	imidazol-2-yl- aminomethyl	1	H	NHSO ₂ NH(3- pyridyl)	
1063	imidazol-2-yl- aminomethyl	1	H	NHSO ₂ NH(4- pyridyl)	

1064	imidazol-2-yl- aminomethyl	1	H	NHSO ₂ NH(2- thiazolyl)
1065	imidazol-2-yl- aminomethyl	1	H	NHSO ₂ NH(4- thiazolyl)
1066	imidazol-2-yl- aminomethyl	1	H	NHSO ₂ NH(4- isoxazolyl)
1067	imidazol-2-yl- aminomethyl	1	H	NHSO ₂ [4-(3,5- dimethyl)isoxaz olyl]
1068	imidazol-2-yl- aminomethyl	1	H	NHSO ₂ NHC ₆ H ₄ -(2- Br)
1069	imidazol-2-yl- aminomethyl	1	H	NHSO ₂ NHC ₆ H ₄ -(3- Br)
1070	imidazol-2-yl- aminomethyl	1	H	NHSO ₂ NHC ₆ H ₄ -(4- Br)
1071	imidazol-2-yl- aminomethyl	1	H	NHSO ₂ NHC ₆ H ₄ -(3- F)
1072	imidazol-2-yl- aminomethyl	1	H	NHSO ₂ NHC ₆ H ₄ -(4- F)
1073	imidazol-2-yl- aminomethyl	1	H	NHSO ₂ NH(2- naphthyl)
1074	imidazol-2-yl- aminomethyl	1	H	NHSO ₂ NH(1- naphthyl)
1075	imidazol-2-yl- aminomethyl	1	H	NHSO ₂ NHCH=CH-Ph
1076	imidazol-2-yl- aminomethyl	1	H	NHSO ₂ NHCH ₂ Ph
1077	imidazol-2-yl- aminomethyl	1	H	NHSO ₂ NHCH ₂ CH=CH- Ph
1078	imidazol-2-yl- aminomethyl	1	H	NHSO ₂ NH-n-Bu
1079	imidazol-2-yl- aminomethyl	1	H	NHSO ₂ NH-i-Bu
1080	imidazol-2-yl- aminomethyl	1	H	NHSO ₂ NH-t-Bu

1081	pyridin-2-yl- aminomethyl	1	H	NHCO ₂ Bn	510.2
1082	pyridin-2-yl- aminomethyl	1	H	NHCO ₂ CH ₂ C ₆ H ₄ -(2- CH ₃)	
1083	pyridin-2-yl- aminomethyl	1	H	NHCO ₂ CH ₂ C ₆ H ₄ - (3-CH ₃)	
1084	pyridin-2-yl- aminomethyl	1	H	NHCO ₂ CH ₂ C ₆ H ₄ - (4-CH ₃)	
1085	pyridin-2-yl- aminomethyl	1	H	NHCO ₂ CH ₂ (2- pyridinyl)	
1086	pyridin-2-yl- aminomethyl	1	H	NHCO ₂ CH ₂ (3- pyridinyl)	
1087	pyridin-2-yl- aminomethyl	1	H	NHCO ₂ CH ₂ (4- pyridinyl)	
1088	pyridin-2-yl- aminomethyl	1	H	NHCO ₂ CH ₂ (2- thiazolyl)	
1089	pyridin-2-yl- aminomethyl	1	H	NHCO ₂ CH ₂ (4- thiazolyl)	
1090	pyridin-2-yl- aminomethyl	1	H	NHCO ₂ CH ₂ (5- thiazolyl)	
1091	pyridin-2-yl- aminomethyl	1	H	NHCO ₂ CH ₂ (4- isoxazolyl)	
1092	pyridin-2-yl- aminomethyl	1	H	NHCO ₂ CH ₂ (2- thienyl)	
1093	pyridin-2-yl- aminomethyl	1	H	NHCO ₂ n-Bu	
1094	pyridin-2-yl- aminomethyl	1	H	NHCO ₂ i-Bu	
1095	pyridin-2-yl- aminomethyl	1	H	NHCO ₂ t-Bu	
1096	pyridin-2-yl- aminomethyl	1	H	NHCOCH ₂ Ph	
1097	pyridin-2-yl- aminomethyl	1	H	NHCOCH ₂ C ₆ H ₄ -(2- CH ₃)	

1098	pyridin-2-yl- aminomethyl	1	H	NHCOCH ₂ -C ₆ H ₄ - (3-CH ₃)	
1099	pyridin-2-yl- aminomethyl	1	H	NHCOCH ₂ C ₆ H ₄ -(4- CH ₃)	
1100	pyridin-2-yl- aminomethyl	1	H	NHCOCH ₂ (2- pyridinyl)	
1101	pyridin-2-yl- aminomethyl	1	H	NHCOCH ₂ (3- pyridinyl)	
1102	pyridin-2-yl- aminomethyl	1	H	NHCOCH ₂ (4- pyridinyl)	
1103	pyridin-2-yl- aminomethyl	1	H	NHCOCH ₂ (2- thiazolyl)	
1104	pyridin-2-yl- aminomethyl	1	H	NHCOCH ₂ (4- thiazolyl)	
1105	pyridin-2-yl- aminomethyl	1	H	NHCOCH ₂ (5- thiazolyl)	
1106					
1107	pyridin-2-yl- aminomethyl	1	H	NHCOCH ₂ (4- isoxazolyl)	
1108	pyridin-2-yl- aminomethyl	1	H	NHCOCH ₂ (2- thienyl)	
1109	pyridin-2-yl- aminomethyl	1	H	NHCO ⁿ -Bu	
1110	pyridin-2-yl- aminomethyl	1	H	NHCO ^t -Bu	
1111	pyridin-2-yl- aminomethyl	1	H	NHSO ₂ Ph	516.1
1112	pyridin-2-yl- aminomethyl	1	H	NHSO ₂ C ₆ H ₄ -(2- CH ₃)	
1113	pyridin-2-yl- aminomethyl	1	H	NHSO ₂ C ₆ H ₄ -(3- CH ₃)	
1114	pyridin-2-yl- aminomethyl	1	H	NHSO ₂ C ₆ H ₄ -(4- CH ₃)	

1115	pyridin-2-yl-aminomethyl	1	H	NHSO ₂ (2-pyridyl)	
1116	pyridin-2-yl-aminomethyl	1	H	NHSO ₂ (3-pyridyl)	
1117	pyridin-2-yl-aminomethyl	1	H	NHSO ₂ (4-pyridyl)	
1118	pyridin-2-yl-aminomethyl	1	H	NHSO ₂ (2-thiazolyl)	
1119	pyridin-2-yl-aminomethyl	1	H	NHSO ₂ (4-thiazolyl)	
1120	pyridin-2-yl-aminomethyl	1	H	NHSO ₂ (4-isoxazolyl)	
1121	pyridin-2-yl-aminomethyl	1	H	NHSO ₂ -{4-(3,5-dimethyl)isoxazolyl}	535.1
1122	pyridin-2-yl-aminomethyl	1	H	NHSO ₂ C ₆ H ₄ -(2-Br)	
1123	pyridin-2-yl-aminomethyl	1	H	NHSO ₂ C ₆ H ₄ -(3-Br)	
1124	pyridin-2-yl-aminomethyl	1	H	NHSO ₂ C ₆ H ₄ -(4-Br)	
1125	pyridin-2-yl-aminomethyl	1	H	NHSO ₂ C ₆ H ₄ -(2-F)	
1126	pyridin-2-yl-aminomethyl	1	H	NHSO ₂ C ₆ H ₄ -(3-F)	
1127	pyridin-2-yl-aminomethyl	1	H	NHSO ₂ C ₆ H ₄ -(4-F)	
1128	pyridin-2-yl-aminomethyl	1	H	NHSO ₂ (2-naphthyl)	
1129	pyridin-2-yl-aminomethyl	1	H	NHSO ₂ (1-naphthyl)	
1130	pyridin-2-yl-aminomethyl	1	H	NHSO ₂ CH=CH-Ph	
1131	pyridin-2-yl-aminomethyl	1	H	NHSO ₂ CH ₂ Ph	

1132	pyridin-2-yl- aminomethyl	1	H	NHSO ₂ -CH ₂ CH=CH- Ph
1133	pyridin-2-yl- aminomethyl	1	H	NHSO ₂ -n-Bu
1134	pyridin-2-yl- aminomethyl	1	H	NHSO ₂ -i-Bu
1135	pyridin-2-yl- aminomethyl	1	H	NHSO ₂ -t-Bu
1136	pyridin-2-yl- aminomethyl	1	H	NHSO ₂ NHPh
1137	pyridin-2-yl- aminomethyl	1	H	NHSO ₂ NHC ₆ H ₄ -(2- CH ₃)
1138	pyridin-2-yl- aminomethyl	1	H	NHSO ₂ NHC ₆ H ₄ -(3- CH ₃)
1139	pyridin-2-yl- aminomethyl	1	H	NHSO ₂ NHC ₆ H ₄ -(4- CH ₃)
1140	pyridin-2-yl- aminomethyl	1	H	NHSO ₂ NH(2- pyridyl)
1141	pyridin-2-yl- aminomethyl	1	H	NHSO ₂ NH(3- pyridyl)
1142	pyridin-2-yl- aminomethyl	1	H	NHSO ₂ NH(4- pyridyl)
1143	pyridin-2-yl- aminomethyl	1	H	NHSO ₂ NH(2- thiazolyl)
1144	pyridin-2-yl- aminomethyl	1	H	NHSO ₂ NH-(4- thiazolyl)
1145	pyridin-2-yl- aminomethyl	1	H	NHSO ₂ NH(4- isoxazolyl)
1146	pyridin-2-yl- aminomethyl	1	H	NHSO ₂ -[4-(3,5- dimethyl)isoxaz olyl]
1147	pyridin-2-yl- aminomethyl	1	H	NHSO ₂ NHC ₆ H ₄ -(2- Br)

1148	pyridin-2-yl-aminomethyl	1	H	NHSO ₂ NHC ₆ H ₄ - (3-Br)
1149	pyridin-2-yl-aminomethyl	1	H	NHSO ₂ NHC ₆ H ₄ - (4-Br)
1150	pyridin-2-yl-aminomethyl	1	H	NHSO ₂ NHC ₆ H ₄ - (3-F)
1151	pyridin-2-yl-aminomethyl	1	H	NHSO ₂ NHC ₆ H ₄ - (4-F)
1152	pyridin-2-yl-aminomethyl	1	H	NHSO ₂ NH(2-naphthyl)
1153	pyridin-2-yl-aminomethyl	1	H	NHSO ₂ NH(1-naphthyl)
1154	pyridin-2-yl-aminomethyl	1	H	NHSO ₂ NHCH=CH-Ph
1155	pyridin-2-yl-aminomethyl	1	H	NHSO ₂ NHCH ₂ Ph
1156	pyridin-2-yl-aminomethyl	1	H	NHSO ₂ NHCH ₂ CH=CH-Ph
1157	pyridin-2-yl-aminomethyl	1	H	NHSO ₂ NH-n-Bu
1158	pyridin-2-yl-aminomethyl	1	H	NHSO ₂ NH-i-Bu
1159	pyridin-2-yl-aminomethyl	1	H	NHSO ₂ NH-t-Bu
1160	tetrahydropyrimidin-2-ylaminomethyl	1	H	NHCOOBn
1161	tetrahydropyrimidin-2-ylaminomethyl	1	H	NHCO ₂ CH ₂ C ₆ H ₄ - (2-CH ₃)
1162	tetrahydropyrimidin-2-ylaminomethyl	1	H	NHCO ₂ CH ₂ C ₆ H ₄ - (3-CH ₃)
1163	tetrahydropyrimidin-2-ylaminomethyl	1	H	NHCO ₂ CH ₂ C ₆ H ₄ - (4-CH ₃)
1164	tetrahydropyrimidin-2-ylaminomethyl	1	H	NHCO ₂ CH ₂ (2-pyridinyl)

1165	tetrahydropyrimidin	1	H	NHCO ₂ CH ₂ (3- -2-ylaminomethyl pyridinyl)	
1166	tetrahydropyrimidin	1	H	NHCO ₂ CH ₂ (4- -2-ylaminomethyl pyridinyl)	
1167	tetrahydropyrimidin		H	NHCO ₂ CH ₂ (2- -2-ylaminomethyl thiazolyl)	
1168	tetrahydropyrimidin	1	H	NHCO ₂ CH ₂ (4- -2-ylaminomethyl thiazolyl)	
1169	tetrahydropyrimidin	1	H	NHCO ₂ CH ₂ (5- -2-ylaminomethyl thiazolyl)	
1170	tetrahydropyrimidin	1	H	NHCO ₂ CH ₂ (4- -2-ylaminomethyl isoxazolyl)	
1171	tetrahydropyrimidin	1	H	NHCO ₂ CH ₂ (2- -2-ylaminomethyl thienyl)	
1172	tetrahydropyrimidin	1	H	NHCO ₂ n-Bu -2-ylaminomethyl	
1173	tetrahydropyrimidin	1	H	NHCO ₂ i-Bu -2-ylaminomethyl	
1174	tetrahydropyrimidin	1	H	NHCO ₂ t-Bu -2-ylaminomethyl	
1175	tetrahydropyrimidin	1	H	NHSO ₂ Ph -2-ylaminomethyl	521.3
1176	tetrahydropyrimidin	1	H	NHSO ₂ C ₆ H ₄ - (2- -2-ylaminomethyl CH ₃)	
1177	tetrahydropyrimidin	1	H	NHSO ₂ C ₆ H ₄ - (3- -2-ylaminomethyl CH ₃)	
1178	tetrahydropyrimidin	1	H	NHSO ₂ C ₆ H ₄ - (4- -2-ylaminomethyl CH ₃)	
1179	tetrahydropyrimidin	1	H	NHSO ₂ (2-pyridyl) -2-ylaminomethyl	
1180	tetrahydropyrimidin	1	H	NHSO ₂ (3-pyridyl) -2-ylaminomethyl	
1181	tetrahydropyrimidin	1	H	NHSO ₂ (4-pyridyl) -2-ylaminomethyl	

1182	tetrahydropyrimidin	1	H	NHSO ₂ (2- -2-ylaminomethyl thiazolyl)
1183	tetrahydropyrimidin	1	H	NHSO ₂ (4- -2-ylaminomethyl thiazolyl)
1184	tetrahydropyrimidin	1	H	NHSO ₂ (4- -2-ylaminomethyl isoxazolyl)
1185	tetrahydropyrimidin	1	H	NHSO ₂ -(4-(3,5- dimethyl)isoxaz olyl)
1186	tetrahydropyrimidin	1	H	NHSO ₂ C ₆ H ₄ -(2- Br)
1187	tetrahydropyrimidin	1	H	NHSO ₂ C ₆ H ₄ -(3- Br)
1188	tetrahydropyrimidin	1	H	NHSO ₂ C ₆ H ₄ -(2-F)
1189	tetrahydropyrimidin	1	H	NHSO ₂ C ₆ H ₄ -(3-F)
1190	tetrahydropyrimidin	1	H	NHSO ₂ C ₆ H ₄ -(4-F)
1191	tetrahydropyrimidin	1	H	NHSO ₂ (2- naphthyl)
1192	tetrahydropyrimidin	1	H	NHSO ₂ (1- naphthyl)
1193	tetrahydropyrimidin	1	H	NHSO ₂ CH=CHPh
1194	tetrahydropyrimidin	1	H	NHSO ₂ CH ₂ Ph
1195	tetrahydropyrimidin	1	H	NHSO ₂ CH ₂ CH=CHPh
1196	tetrahydropyrimidin	1	H	NHSO ₂ -n-Bu
1197	tetrahydropyrimidin	1	H	NHSO ₂ -i-Bu
1198	imidazolin-2-yl- aminomethyl	1	H	NHCOOBn

1199	imidazolin-2-yl- aminomethyl	1	H	NHCO ₂ CH ₂ C ₆ H ₄ -(2- CH ₃)	
1200	imidazolin-2-yl- aminomethyl	1	H	NHCO ₂ CH ₂ C ₆ H ₄ -(3- CH ₃)	
1201	imidazolin-2-yl- aminomethyl	1	H	NHCO ₂ CH ₂ C ₆ H ₄ -(4- CH ₃)	
1202	imidazolin-2-yl- aminomethyl	1	H	NHCO ₂ CH ₂ (2- pyridinyl)	
1203	imidazolin-2-yl- aminomethyl	1	H	NHCO ₂ CH ₂ (3- pyridinyl)	
1204	imidazolin-2-yl- aminomethyl	1	H	NHCO ₂ CH ₂ (4- pyridinyl)	
1205	imidazolin-2-yl- aminomethyl	1	H	NHCO ₂ CH ₂ (2- thiazolyl)	
1206	imidazolin-2-yl- aminomethyl	1	H	NHCO ₂ CH ₂ (4- thiazolyl)	
1207	imidazolin-2-yl- aminomethyl	1	H	NHCO ₂ CH ₂ (5- thiazolyl)	
1208	imidazolin-2-yl- aminomethyl	1	H	NHCO ₂ CH ₂ (4- isoxazolyl)	
1209	imidazolin-2-yl- aminomethyl	1	H	NHCO ₂ CH ₂ (2- thienyl)	
1210	imidazolin-2-yl- aminomethyl	1	H	NHCO ₂ n-Bu	
1211	imidazolin-2-yl- aminomethyl	1	H	NHCO ₂ i-Bu	
1212	imidazolin-2-yl- aminomethyl	1	H	NHCO ₂ t-Bu	
1213	imidazolin-2-yl- aminomethyl	1	H	NHSO ₂ Ph	507.3
1214	imidazolin-2-yl- aminomethyl	1	H	NHSO ₂ C ₆ H ₄ -(2- CH ₃)	
1215	imidazolin-2-yl- aminomethyl	1	H	NHSO ₂ C ₆ H ₄ -(3- CH ₃)	

1216	imidazolin-2-yl- aminomethyl	1	H	NHSO ₂ C ₆ H ₄ -(4- CH ₃)
1217	imidazolin-2-yl- aminomethyl	1	H	NHSO ₂ (2-pyridyl)
1218	imidazolin-2-yl- aminomethyl	1	H	NHSO ₂ (3-pyridyl)
1219	imidazolin-2-yl- aminomethyl	1	H	NHSO ₂ (4-pyridyl)
1220	imidazolin-2-yl- aminomethyl	1	H	NHSO ₂ (2-thiaz- olyl)
1221	imidazolin-2-yl- aminomethyl	1	H	NHSO ₂ (4- isoxazoly1)
1222	imidazolin-2-yl- aminomethyl	1	H	NHSO ₂ -(4-(3,5- dimethyl)isoxaz olyl]
1223	imidazolin-2-yl- aminomethyl	1	H	NHSO ₂ C ₆ H ₄ -(2- Br)
1224	imidazolin-2-yl- aminomethyl	1	H	NHSO ₂ C ₆ H ₄ -(3- Br)
1225	imidazolin-2-yl- aminomethyl	1	H	NHSO ₂ C ₆ H ₄ -(2-F)
1226	imidazolin-2-yl- aminomethyl	1	H	NHSO ₂ C ₆ H ₄ -(3-F)
1227	imidazolin-2-yl- aminomethyl	1	H	NHSO ₂ C ₆ H ₄ -(4-F)
1228	imidazolin-2-yl- aminomethyl	1	H	NHSO ₂ (2- naphthyl)
1229	imidazolin-2-yl- aminomethyl	1	H	NHSO ₂ (1- naphthyl)
1230	imidazolin-2-yl- aminomethyl	1	H	NHSO ₂ CH=CHPh
1231	imidazolin-2-yl- aminomethyl	1	H	NHSO ₂ CH ₂ Ph
1232	imidazolin-2-yl- aminomethyl	1	H	NHSO ₂ CH ₂ CH=CHPh

1233	imidazolin-2-yl- aminomethyl	1	H	NHSO ₂ -n-Bu
1234	imidazolin-2-yl- aminomethyl	1	H	NHSO ₂ -i-Bu
1235	benzimidazol-2-yl- aminomethyl	1	H	NHSO ₂ Ph
1236	benzimidazol-2-yl- aminomethyl	1	H	NHSO ₂ C ₆ H ₄ -(2- CH ₃)
1237	benzimidazol-2-yl- aminomethyl	1	H	NHSO ₂ C ₆ H ₄ -(3- CH ₃)
1238	benzimidazol-2-yl- aminomethyl	1	H	NHSO ₂ C ₆ H ₄ -(4- CH ₃)
1239	benzimidazol-2-yl- aminomethyl	1	H	NHSO ₂ (2-pyridyl)
1240	benzimidazol-2-yl- aminomethyl	1	H	NHSO ₂ (3-pyridyl)
1241	benzimidazol-2-yl- aminomethyl	1	H	NHSO ₂ (4-pyridyl)
1242	benzimidazol-2-yl- aminomethyl	1	H	NHSO ₂ (2- thiazolyl)
1243	benzimidazol-2-yl- aminomethyl	1	H	NHSO ₂ (4- isoxazolyl)
1244	benzimidazol-2-yl- aminomethyl	1	H	NHSO ₂ -(4-(3,5- dimethyl)isoxaz olyl)
1245	benzimidazol-2-yl- aminomethyl	1	H	NHSO ₂ C ₆ H ₄ -(2- Br)
1246	benzimidazol-2-yl- aminomethyl	1	H	NHSO ₂ C ₆ H ₄ -(3- Br)
1247	benzimidazol-2-yl- aminomethyl	1	H	NHSO ₂ C ₆ H ₄ -(2-F)
1248	benzimidazol-2-yl- aminomethyl	1	H	NHSO ₂ C ₆ H ₄ -(3-F)
1249	benzimidazol-2-yl- aminomethyl	1	H	NHSO ₂ C ₆ H ₄ -(4-F)

1250	benzimidazol-2-yl- aminomethyl	1	H	NHCO ₂ CH ₂ Ph	
1251	benzimidazol-2-yl- aminomethyl	1	H	NHCO ₂ n-Bu	
1252	benzimidazol-2-yl- aminomethyl	1	H	NHCO ₂ i-Bu	
1253	2-aminopyridin-6- ylmethyl	1	H	NHSO ₂ Ph	
1254	2-aminopyridin-6- ylmethyl	1	H	NHSO ₂ C ₆ H ₄ -(2- CH ₃)	
1255	2-aminopyridin-6- ylmethyl	1	H	NHSO ₂ C ₆ H ₄ -(3- CH ₃)	
1256	2-aminopyridin-6- ylmethyl	1	H	NHSO ₂ C ₆ H ₄ -(4- CH ₃)	
1257	2-aminopyridin-6- ylmethyl	1	H	NHSO ₂ (2-pyridyl)	
1258	2-aminopyridin-6- ylmethyl	1	H	NHSO ₂ (3-pyridyl)	
1259	2-aminopyridin-6- ylmethyl	1	H	NHSO ₂ (4-pyridyl)	
1260	2-aminopyridin-6- ylmethyl	1	H	NHSO ₂ (2- thiazolyl)	
1261	2-aminopyridin-6- ylmethyl	1	H	NHSO ₂ (4- isoxazolyl)	
1262	2-aminopyridin-6- ylmethyl	1	H	NHSO ₂ -[4-(3,5- dimethyl)isoxaz olyl]	535.1
1263	2-aminopyridin-6- ylmethyl	1	H	NHSO ₂ C ₆ H ₄ -(2- Br)	
1264	2-aminopyridin-6- ylmethyl	1	H	NHSO ₂ C ₆ H ₄ -(3- Br)	
1265	2-aminopyridin-6- ylmethyl	1	H	NHSO ₂ C ₆ H ₄ -(2-F)	
1266	2-aminopyridin-6- ylmethyl	1	H	NHSO ₂ C ₆ H ₄ -(3-F)	

1267	2-aminopyridin-6-ylmethyl	1	H	NHSO ₂ C ₆ H ₄ -(4-F)	
1268	2-aminopyridin-6-ylmethyl	1	H	NHCO ₂ CH ₂ Ph	
1269	2-aminopyridin-6-ylmethyl	1	H	NHCO ₂ n-Bu	
1270	2-aminopyridin-6-ylmethyl	1	H	NHCO ₂ i-Bu	
1271	7-azabenzimidazol-2-yl	1	H	NHSO ₂ Ph	
1272	7-azabenzimidazol-2-yl	1	H	NHSO ₂ C ₆ H ₄ -(2-CH ₃)	
1273	7-azabenzimidazol-2-yl	1	H	NHSO ₂ C ₆ H ₄ -(3-CH ₃)	
1274	7-azabenzimidazol-2-yl	1	H	NHSO ₂ C ₆ H ₄ -(4-CH ₃)	
1275	7-azabenzimidazol-2-yl	1	H	NHSO ₂ (2-naphthyl)	
1276	7-azabenzimidazol-2-yl	1	H	NHSO ₂ (1-naphthyl)	
1277	7-azabenzimidazol-2-yl	1	H	NHSO ₂ (biphenyl)	
1278	7-azabenzimidazol-2-yl	1	H	NHSO ₂ C ₆ H ₄ -(2,4,6-(CH ₃) ₃)	569.4
1279	7-azabenzimidazol-2-yl	1	H	NHSO ₂ (2-thienyl)	
1280	7-azabenzimidazol-2-yl	1	H	NHSO ₂ -[4-(3,5-dimethyl)isoxazoly]	
1281	7-azabenzimidazol-2-yl	1	H	NHSO ₂ C ₆ H ₄ -(2-Br)	
1282	7-azabenzimidazol-2-yl	1	H	NHSO ₂ C ₆ H ₄ -(3-Br)	
1283	7-azabenzimidazol-2-yl	1	H	NHSO ₂ C ₆ H ₄ -(2-F)	

1284	7-azabenzimidazol-2-yl	1	H	NHSO ₂ C ₆ H ₄ -(3-F)	
1285	7-azabenzimidazol-2-yl	1	H	NHSO ₂ C ₆ H ₄ -(4-F)	
1286	7-azabenzimidazol-2-yl	1	H	NHCO ₂ CH ₂ Ph	
1287	7-azabenzimidazol-2-yl	1	H	NHCO ₂ n-Bu	
1288	7-azabenzimidazol-2-yl	1	H	NHCO ₂ i-Bu	
1289	4,5,6,7-tetrahydro- benzimidazol-2-yl- aminomethyl	1	H	NHSO ₂ Ph	561.4
1290	4,5,6,7-tetrahydro- benzimidazol-2-yl- aminomethyl	1	H	NHSO ₂ C ₆ H ₄ -(2- CH ₃)	
1291	4,5,6,7-tetrahydro- benzimidazol-2-yl- aminomethyl	1	H	NHSO ₂ C ₆ H ₄ -(3- CH ₃)	
1292	4,5,6,7-tetrahydro- benzimidazol-2-yl- aminomethyl	1	H	NHSO ₂ C ₆ H ₄ -(4- CH ₃)	
1293	4,5,6,7-tetrahydro- benzimidazol-2-yl- aminomethyl	1	H	NHSO ₂ (2- naphthyl)	
1294	4,5,6,7-tetrahydro- benzimidazol-2-yl- aminomethyl	1	H	NHSO ₂ (1- naphthyl)	
1295	4,5,6,7-tetrahydro- benzimidazol-2-yl- aminomethyl	1	H	NHSO ₂ (biphenyl)	
1296	4,5,6,7-tetrahydro- benzimidazol-2-yl- aminomethyl	1	H	NHSO ₂ C ₆ H ₄ - (2,4,6-(CH ₃) ₃)	

1297	4,5,6,7-tetrahydro- benzimidazol-2-yl- aminomethyl	1	H	NHSO ₂ (2-thienyl)	
1298	4,5,6,7-tetrahydro- benzimidazol-2-yl- aminomethyl	1	H	NHSO ₂ -[4-(3,5- dimethyl)isoxaz olyl]	
1299	4,5,6,7-tetrahydro- benzimidazol-2-yl- aminomethyl	1	H	NHSO ₂ C ₆ H ₄ -(2- Br)	
1300	4,5,6,7-tetrahydro- benzimidazol-2-yl- aminomethyl	1	H	NHSO ₂ C ₆ H ₄ -(3- Br)	
1301	4,5,6,7-tetrahydro- benzimidazol-2-yl- aminomethyl	1	H	NHSO ₂ C ₆ H ₄ -(2-F)	
1302	4,5,6,7-tetrahydro- benzimidazol-2-yl- aminomethyl	1	H	NHSO ₂ C ₆ H ₄ -(3-F)	
1303	4,5,6,7-tetrahydro- benzimidazol-2-yl- aminomethyl	1	H	NHSO ₂ C ₆ H ₄ -(4-F)	
1304	4,5,6,7-tetrahydro- benzimidazol-2-yl- aminomethyl	1	H	NHCO ₂ CH ₂ Ph	
1305	4,5,6,7-tetrahydro- benzimidazol-2-yl- aminomethyl	1	H	NHCO ₂ n-Bu	
1306	4,5,6,7-tetrahydro- benzimidazol-2-yl- aminomethyl	1	H	NHCO ₂ i-Bu	
1307	4-oxo-3,4,5,6- tetrahydro- pyrimidin-2-yl- aminomethyl	1	H	NHSO ₂ Ph	549.3

1308	4-oxo-3,4,5,6-tetrahydro-pyrimidin-2-yl-aminomethyl	1	H	NHSO ₂ C ₆ H ₄ -(2-CH ₃)
1309	4-oxo-3,4,5,6-tetrahydro-pyrimidin-2-yl-aminomethyl	1	H	NHSO ₂ C ₆ H ₄ -(3-CH ₃)
1310	4-oxo-3,4,5,6-tetrahydro-pyrimidin-2-yl-aminomethyl	1	H	NHSO ₂ C ₆ H ₄ -(4-CH ₃)
1311	4-oxo-3,4,5,6-tetrahydro-pyrimidin-2-yl-aminomethyl	1	H	NHSO ₂ (2-naphthyl)
1312	4-oxo-3,4,5,6-tetrahydro-pyrimidin-2-yl-aminomethyl	1	H	NHSO ₂ (1-naphthyl)
1313	4-oxo-3,4,5,6-tetrahydro-pyrimidin-2-yl-aminomethyl	1	H	NHSO ₂ (biphenyl)
1314	4-oxo-3,4,5,6-tetrahydro-pyrimidin-2-yl-aminomethyl	1	H	NHSO ₂ C ₆ H ₄ -(2,4,6-(CH ₃) ₃)
1315	4-oxo-3,4,5,6-tetrahydro-pyrimidin-2-yl-aminomethyl	1	H	NHSO ₂ (2-thienyl)

1316	4-oxo-3,4,5,6-tetrahydro-pyrimidin-2-yl-aminomethyl	1	H	NHSO ₂ -(4-(3,5-dimethyl)isoxazolylyl)
1317	4-oxo-3,4,5,6-tetrahydro-pyrimidin-2-yl-aminomethyl	1	H	NHSO ₂ C ₆ H ₄ -(2-Br)
1318	4-oxo-3,4,5,6-tetrahydro-pyrimidin-2-yl-aminomethyl	1	H	NHSO ₂ C ₆ H ₄ -(3-Br)
1319	4-oxo-3,4,5,6-tetrahydro-pyrimidin-2-yl-aminomethyl	1	H	NHSO ₂ C ₆ H ₄ -(2-F)
1320	4-oxo-3,4,5,6-tetrahydro-pyrimidin-2-yl-aminomethyl	1	H	NHSO ₂ C ₆ H ₄ -(3-F)
1321	4-oxo-3,4,5,6-tetrahydro-pyrimidin-2-yl-aminomethyl	1	H	NHSO ₂ C ₆ H ₄ -(4-F)
1322	4-oxo-3,4,5,6-tetrahydro-pyrimidin-2-yl-aminomethyl	1	H	NHCO ₂ CH ₂ Ph
1323	4-oxo-3,4,5,6-tetrahydro-pyrimidin-2-yl-aminomethyl	1	H	NHCO ₂ n-Bu

1324	4-oxo-3,4,5,6-tetrahydro-pyrimidin-2-yl-aminomethyl	1	H	NHCO ₂ i-Bu
1325	2-iminoazepin-7-ylmethyl	1	H	NHSO ₂ Ph
1326	1,2-pyrazol-3-ylaminomethyl		H	NHSO ₂ Ph
1327	1,2,4-triazol-5-ylaminomethyl	1	H	NHSO ₂ Ph
1328	imidazol-4-ylaminomethyl	1	H	NHSO ₂ Ph
1329	1,3,4-oxadiazol-2ylaminomethyl	1	H	NHSO ₂ Ph
1330	1,2,4-thiadiazol-5-ylaminomethyl	1	H	NHSO ₂ Ph
1331	1,2,5-oxadiazol-3-ylaminomethyl	1	H	NHSO ₂ Ph
1332	1,2,4-oxadiazol-5-ylaminomethyl	1	H	NHSO ₂ Ph
1333	2-iminoazepin-7-ylmethyl	1	H	NHSO ₂ (4-isoxazolyl)
1334	1,2-pyrazol-3-ylaminomethyl	1	H	NHSO ₂ (4-isoxazolyl)
1335	1,2,4-triazol-5-ylaminomethyl	1	H	NHSO ₂ (4-isoxazolyl)
1336	imidazol-4-ylaminomethyl	1	H	NHSO ₂ (4-isoxazolyl)
1337	1,3,4-oxadiazol-2ylaminomethyl	1	H	NHSO ₂ (4-isoxazolyl)
1338	1,2,4-thiadiazol-5-ylaminomethyl	1	H	NHSO ₂ (4-isoxazolyl)
1339	1,2,5-oxadiazol-3-ylaminomethyl	1	H	NHSO ₂ (4-isoxazolyl)

1340	1,2,4-oxadiazol-5-ylaminomethyl	1	H	NHSO ₂ (4-isoxazolyl)
1341	2-iminoazepin-7-ylmethyl	1	H	NHSO ₂ -[4-(3,5-dimethyl)isoxazoly]
1342	1,2-pyrazol-3-ylaminomethyl	1	H	NHSO ₂ -[4-(3,5-dimethyl)isoxazoly]
1343	1,2,4-triazol-5-ylaminomethyl	1	H	NHSO ₂ -[4-(3,5-dimethyl)isoxazoly]
1344	imidazol-4-ylaminomethyl	1	H	NHSO ₂ -[4-(3,5-dimethyl)isoxazoly]
1345	1,3,4-oxadiazol-2ylaminomethyl	1	H	NHSO ₂ -[4-(3,5-dimethyl)isoxazoly]
1346	1,2,4-thiadiazol-5-ylaminomethyl	1	H	NHSO ₂ -[4-(3,5-dimethyl)isoxazoly]
1347	1,2,5-oxadiazol-3-ylaminomethyl	1	H	NHSO ₂ -[4-(3,5-dimethyl)isoxazoly]
1348	1,2,4-oxadiazol-5-ylaminomethyl	1	H	NHSO ₂ -[4-(3,5-dimethyl)isoxazoly]
1349	imidazol-2-yl-aminomethyl	1	3-pyridinyl	H
1350	pyridin-2-ylaminomethyl	1	3-pyridinyl	H
1351	imidazolin-2-yl-aminomethyl	1	3-pyridinyl	H
1352	tetrahydropyrimidin-2-ylaminomethyl	1	3-pyridinyl	H

1353	benzimidazol-2-yl- aminomethyl	1	3-pyridinyl	H
1354	2-aminopyridin-6- ylmethyl	1	3-pyridinyl	H
1355	2-iminoazepin-7- ylmethyl	1	3-pyridinyl	H
1356	1,2-pyrazol-3- ylaminomethyl	1	3-pyridinyl	H
1357	1,2,4-triazol-5- ylaminomethyl	1	3-pyridinyl	H
1358	imidazol-4- ylaminomethyl	1	3-pyridinyl	H
1359	1,3,4-oxadiazol- 2ylaminomethyl	1	3-pyridinyl	H
1360	1,2,4-thiadiazol-5- ylaminomethyl	1	3-pyridinyl	H
1361	1,2,5-oxadiazol-3- ylaminomethyl	1	3-pyridinyl	H
1362	1,2,4-oxadiazol-5- ylaminomethyl	1	3-pyridinyl	H
1363	imidazol-2-yl- aminomethyl	1	(3,4- methylene- dioxy)phenyl	H
1364	pyridin-2- ylaminomethyl	1	(3,4- methylene- dioxy)phenyl	H
1365	imidazolin-2-yl- aminomethyl	1	(3,4- methylene- dioxy)phenyl	H
1366	tetrahydropyrimidin -2-ylaminomethyl	1	(3,4- methylene- dioxy)phenyl	H
1367	benzimidazol-2-yl- aminomethyl	1	(3,4- methylene- dioxy)phenyl	H

1368	2-aminopyridin-6-ylmethyl	1	(3,4-methylene-dioxy)phenyl	H
1369	2-iminoazepin-7-ylmethyl	1	(3,4-methylene-dioxy)phenyl	H
1370	1,2-pyrazol-3-ylaminomethyl	1	(3,4-methylene-dioxy)phenyl	H
1371	1,2,4-triazol-5-ylaminomethyl	1	(3,4-methylene-dioxy)phenyl	H
1372	imidazol-4-ylaminomethyl	1	(3,4-methylene-dioxy)phenyl	H
1373	1,3,4-oxadiazol-2ylaminomethyl	1	(3,4-methylene-dioxy)phenyl	H
1374	1,2,4-thiadiazol-5-ylaminomethyl	1	(3,4-methylene-dioxy)phenyl	H
1375	1,2,5-oxadiazol-3-ylaminomethyl	1	(3,4-methylene-dioxy)phenyl	H
1376	1,2,4-oxadiazol-5-ylaminomethyl	1	(3,4-methylene-dioxy)phenyl	H
1377	imidazol-2-yl-aminomethyl	1	3-pyridinyl	NHSO ₂ Ph
1378	pyridin-2-ylaminomethyl	1	3-pyridinyl	NHSO ₂ Ph
1379	imidazol-2-yl-aminomethyl	1	(3,4-methylene-dioxy)phenyl	NHSO ₂ Ph

1380	pyridin-2-ylamino	1	(3,4-methylene-dioxy)phenyl	NHSO ₂ Ph
1381	imidazol-2-yl-amino	1	H	NHSO ₂ Ph
1382	pyridin-2-ylamino	1	H	NHSO ₂ Ph
1383	imidazolin-2-yl-amino	1	H	NHSO ₂ Ph
1384	tetrahydropyrimidin-2-ylamino	1	H	NHSO ₂ Ph
1385	benzimidazol-2-yl-amino	1	H	NHSO ₂ Ph
1386	2-aminopyridin-6-ylmethyl	1	H	NHSO ₂ Ph
1387	2-iminoazepin-7-yl	1	H	NHSO ₂ Ph
1388	1,2-pyrazol-3-ylamino	1	H	NHSO ₂ Ph
1389	1,2,4-triazol-5-ylamino	1	H	NHSO ₂ Ph
1390	imidazol-4-ylamino	1	H	NHSO ₂ Ph
1391	1,3,4-oxadiazol-2-ylaminomethyl	1	H	NHSO ₂ Ph
1392	1,2,4-thiadiazol-5-ylaminomethyl	1	H	NHSO ₂ Ph
1393	1,2,5-oxadiazol-3-ylaminomethyl	1	H	NHSO ₂ Ph
1394	1,2,4-oxadiazol-5-ylaminomethyl	1	H	NHSO ₂ Ph
1395	imidazol-2-yl-aminoethyl	1	H	NHSO ₂ Ph
1396	pyridin-2-ylaminoethyl	1	H	NHSO ₂ Ph
1397	imidazolin-2-yl-aminoethyl	1	H	NHSO ₂ Ph
1398	tetrahydropyrimidin-2-ylaminoethyl	1	H	NHSO ₂ Ph


1399	benzimidazol-2-yl- aminoethyl	1	H	NHSO ₂ Ph
1400	2-aminopyridin-6- ylethyl	1	H	NHSO ₂ Ph
1401	2-iminoazepin-7- ylethyl	1	H	NHSO ₂ Ph
1402	1,2-pyrazol-3- ylaminoethyl	1	H	NHSO ₂ Ph
1403	1,2,4-triazol-5- ylaminoethyl	1	H	NHSO ₂ Ph
1404	imidazol-4- ylaminoethyl	1	H	NHSO ₂ Ph
1405	1,3,4-oxadiazol- 2ylaminoethyl	1	H	NHSO ₂ Ph
1406	1,2,4-thiadiazol-5- ylaminoethyl	1	H	NHSO ₂ Ph
1407	1,2,5-oxadiazol-3- ylaminoethyl	1	H	NHSO ₂ Ph
1408	1,2,4-oxadiazol-5- ylaminoethyl	1	H	NHSO ₂ Ph
1409	imidazol-2-yl- aminomethyl	2	H	NHSO ₂ Ph
1410	pyridin-2- ylaminomethyl	2	H	NHSO ₂ Ph
1411	imidazolin-2-yl- aminomethyl	2	H	NHSO ₂ Ph
1412	tetrahydropyrimidin -2-ylaminomethyl	2	H	NHSO ₂ Ph
1413	benzimidazol-2-yl- aminomethyl	2	H	NHSO ₂ Ph
1414	7-azabenimidazol-2- yl	2	H	NHSO ₂ Ph
1415	4,5,6,7-tetrahydro- benzimidazol-2-yl- aminomethyl	2	H	NHSO ₂ Ph

1416	4-oxotetrahydro- pyrimidin-2-yl- aminomethyl	2	H	NHSO ₂ Ph
1417	2-aminopyridin-6- ylmethyl	2	H	NHSO ₂ Ph
1418	2-iminoazepin-7- ylmethyl	2	H	NHSO ₂ Ph
1419	1,2-pyrazol-3- ylaminomethyl	2	H	NHSO ₂ Ph
1420	1,2,4-triazol-5- ylaminomethyl	2	H	NHSO ₂ Ph
1421	imidazol-4- ylaminomethyl	2	H	NHSO ₂ Ph
1422	1,3,4-oxadiazol- 2ylaminomethyl	2	H	NHSO ₂ Ph
1423	1,2,4-thiadiazol-5- ylaminomethyl	2	H	NHSO ₂ Ph
1424	1,2,5-oxadiazol-3- ylaminomethyl	2	H	NHSO ₂ Ph
1425	1,2,4-oxadiazol-5- ylaminomethyl	2	H	NHSO ₂ Ph
1426	imidazol-2-yl- aminomethyl	0	H	NHSO ₂ Ph
1427	pyridin-2- ylaminomethyl	0	H	NHSO ₂ Ph
1428	imidazolin-2-yl- aminomethyl	0	H	NHSO ₂ Ph
1429	tetrahydropyrimidin -2-ylaminomethyl	0	H	NHSO ₂ Ph
1430	benzimidazol-2-yl- aminomethyl	0	H	NHSO ₂ Ph
1431	7-azabenimidazol-2- yl	0	H	NHSO ₂ Ph

1432	4,5,6,7-tetrahydro- benzimidazol-2-yl- aminomethyl	0	H	NHSO ₂ Ph	
1433	4-oxotetrahydro- pyrimidin-2-yl- aminomethyl	0	H	NHSO ₂ Ph	
1434	2-aminopyridin-6- ylmethyl	0	H	NHSO ₂ Ph	
1435	2-iminoazepin-7- ylmethyl	0	H	NHSO ₂ Ph	
1436	1,2-pyrazol-3- ylaminomethyl	0	H	NHSO ₂ Ph	
1437	1,2,4-triazol-5- ylaminomethyl	0	H	NHSO ₂ Ph	
1438	imidazol-4- ylaminomethyl	0	H	NHSO ₂ Ph	
1439	1,3,4-oxadiazol- 2ylaminomethyl	0	H	NHSO ₂ Ph	
1440	1,2,4-thiadiazol-5- ylaminomethyl	0	H	NHSO ₂ Ph	
1441	1,2,5-oxadiazol-3- ylaminomethyl	0	H	NHSO ₂ Ph	
1442	1,2,4-oxadiazol-5- ylaminomethyl	0	H	NHSO ₂ Ph	
1443	benzimidazol-2- ylaminomethyl	1	H	NHSO ₂ (2,4,6- trimethyl phenyl)	597.4
1444	2- quinolinylaminometh yl	1	H	NHSO ₂ (2,4,6- trimethyl phenyl)	608.5
1445	benzimidazol-2- ylaminocarbonyl	1	H	NHSO ₂ (2,4,6- trimethyl phenyl)	611.3

1446	benzimidazol-2-yl	1	H	NHSO ₂ (2,4,6-trimethylphenyl)	568.5
1447	imidazol-2-ylaminocarbonyl	1	H	NHSO ₂ (2,4,6-trimethylphenyl)	561.4
1448	imidazol-2-ylaminocarbonyl	1	H	NHSO ₂ (2-naphthyl)	569.2
1449	imidazol-2-ylaminocarbonyl	1	H	NHSO ₂ (2,6-dichlorophenyl)	587.3/ 589.4
1450	pyridin-2-ylaminomethyl	1	H	NHSO ₂ (2,4,6-trimethylphenyl)	547.3
1451	imidazol-2-ylaminomethyl	1	H	NHSO ₂ (2,4,6-trimethylphenyl)	547.2
1452	imidazol-2-ylaminomethyl	1	H	NHSO ₂ biphenyl	581.2
1453	imidazol-2-ylaminomethyl	1	H	NHSO ₂ [(2,6-dichloro-4-phenyl)phenyl]	649.1
1454	imidazol-2-ylaminomethyl	1	H	NHSO ₂ [(2,6-dimethyl-4-phenyl)phenyl]	609.2
1455	imidazol-2-ylaminomethyl	1	H	NHSO ₂ (2,6-dimethylphenyl)	533.2
1456	imidazol-2-ylaminomethyl	1	H	NHSO ₂ (2-chloro-6-methylphenyl)	553.2
1457	imidazol-2-ylaminomethyl	1	H	NHSO ₂ (2,6-dichlorophenyl)	573.1

Table 2



Ex. No.	R ^{1a}	r	R ¹⁴	R ¹⁵	MS
2001	2-aminopyridin-6-yl	0	H	H	
2002	2-aminopyridin-6-yl	0	H	NHCO ₂ Bn	
2003	2-aminopyridin-6-yl	0	H	NHCO ₂ CH ₂ C ₆ H ₄ -(2-CH ₃)	
2004	2-aminopyridin-6-yl	0	H	NHCO ₂ CH ₂ C ₆ H ₄ -(3-CH ₃)	
2005	2-aminopyridin-6-yl	0	H	NHCO ₂ CH ₂ C ₆ H ₄ -(4-CH ₃)	
2006	2-aminopyridin-6-yl	0	H	NHCO ₂ CH ₂ (2-pyridinyl)	
2007	2-aminopyridin-6-yl	0	H	NHCO ₂ CH ₂ (3-pyridinyl)	
2008	2-aminopyridin-6-yl	0	H	NHCO ₂ CH ₂ (4-pyridinyl)	
2009	2-aminopyridin-6-yl	0	H	NHCO ₂ CH ₂ (2-thiazolyl)	
2010	2-aminopyridin-6-yl	0	H	NHCO ₂ CH ₂ (4-thiazolyl)	
2011	2-aminopyridin-6-yl	0	H	NHCO ₂ CH ₂ (5-thiazolyl)	
2012	2-aminopyridin-6-yl	0	H	NHCO ₂ CH ₂ (4-isoxazolyl)	
2013	2-aminopyridin-6-yl	0	H	NHCO ₂ CH ₂ (2-thienyl)	
2014	2-aminopyridin-6-yl	0	H	NHCO ₂ CH ₂ (5-isoxazolyl)	
2015	2-aminopyridin-6-yl	0	H	NHCO ₂ n-Bu	
2016	2-aminopyridin-6-yl	0	H	NHCO ₂ i-Bu	

2017	2-aminopyridin-6-yl	0	H	NHCO ₂ t-Bu
2018	2-aminopyridin-6-yl	0	H	NHCOCH ₂ Ph
2019	2-aminopyridin-6-yl	0	H	NHCOCH ₂ C ₆ H ₄ -(2-CH ₃)
2020	2-aminopyridin-6-yl	0	H	NHCOCH ₂ C ₆ H ₄ -(3-CH ₃)
2021	2-aminopyridin-6-yl	0	H	NHCOCH ₂ C ₆ H ₄ -(4-CH ₃)
2022	2-aminopyridin-6-yl	0	H	NHCO(CH ₂) ₂ Ph
2023	2-aminopyridin-6-yl	0	H	NHCON-Bu
2024	2-aminopyridin-6-yl	0	H	NHCot-Bu
2025	2-aminopyridin-6-yl	0	H	NHSO ₂ Ph
2026	2-aminopyridin-6-yl	0	H	NHSO ₂ C ₆ H ₄ -(2-CH ₃)
2027	2-aminopyridin-6-yl	0	H	NHSO ₂ C ₆ H ₄ -(3-CH ₃)
2028	2-aminopyridin-6-yl	0	H	NHSO ₂ C ₆ H ₄ -(4-CH ₃)
2029	2-aminopyridin-6-yl	0	H	NHSO ₂ (2-pyridyl)
2030	2-aminopyridin-6-yl	0	H	NHSO ₂ (3-pyridyl)
2031	2-aminopyridin-6-yl	0	H	NHSO ₂ (4-pyridyl)
2032	2-aminopyridin-6-yl	0	H	NHSO ₂ (2-thiaz-olyl)
2033	2-aminopyridin-6-yl	0	H	NHSO ₂ (3-thiazolyl)
2034	2-aminopyridin-6-yl	0	H	NHSO ₂ (4-isoxazolyl)
2035	2-aminopyridin-6-yl	0	H	NHSO ₂ [4-(3,5-dimethyl)isoxazolyl]
2036	2-aminopyridin-6-yl	0	H	NHSO ₂ C ₆ H ₄ -(2-Br)
2037	2-aminopyridin-6-yl	0	H	NHSO ₂ C ₆ H ₄ -(3-Br)
2038	2-aminopyridin-6-yl	0	H	NHSO ₂ C ₆ H ₄ -(4-Br)
2039	2-aminopyridin-6-yl	0	H	NHSO ₂ C ₆ H ₄ -(2-F)
2040	2-aminopyridin-6-yl	0	H	NHSO ₂ C ₆ H ₄ -(3-F)
2041	2-aminopyridin-6-yl	0	H	NHSO ₂ C ₆ H ₄ -(4-F)
2042	2-aminopyridin-6-yl	0	H	NHSO ₂ (2-naphthyl)
2043	2-aminopyridin-6-yl	0	H	NHSO ₂ (1-naphthyl)
2044	2-aminopyridin-6-yl	0	H	NHSO ₂ CH=CHPh
2045	2-aminopyridin-6-yl	0	H	NHSO ₂ CH ₂ Ph
2046	2-aminopyridin-6-yl	0	H	NHSO ₂ CH ₂ CH=CH-Ph
2047	2-aminopyridin-6-yl	0	H	NHSO ₂ -n-Bu
2048	2-aminopyridin-6-yl	0	H	NHSO ₂ -i-Bu
2049	2-aminopyridin-6-yl	0	H	NHSO ₂ -t-Bu
2050	2-aminopyridin-6-yl	0	H	NHSO ₂ NHPh

2051	2-aminopyridin-6-yl	0	H	NHSO ₂ NHC ₆ H ₄ -(2-CH ₃)	
2052	2-aminopyridin-6-yl	0	H	NHSO ₂ NHC ₆ H ₄ -(3-CH ₃)	
2053	2-aminopyridin-6-yl	0	H	NHSO ₂ NHC ₆ H ₄ -(4-CH ₃)	
2054	2-aminopyridin-6-yl	0	H	NHSO ₂ NH(2-pyridyl)	
2055	2-aminopyridin-6-yl	0	H	NHSO ₂ NH(3-pyridyl)	
2056	2-aminopyridin-6-yl	0	H	NHSO ₂ NH(4-pyridyl)	
2057	2-aminopyridin-6-yl	0	H	NHSO ₂ NH(2-thiazolyl)	
2058	2-aminopyridin-6-yl	0	H	NHSO ₂ NH(4-thiazolyl)	
2059	2-aminopyridin-6-yl	0	H	NHSO ₂ NH(4-isoxazolyl)	
2060	2-aminopyridin-6-yl	0	H	NHSO ₂ [4-(3,5-dimethyl)isoxazolyl]	
2061	2-aminopyridin-6-yl	0	H	NHSO ₂ NHC ₆ H ₄ -(2-Br)	
2062	2-aminopyridin-6-yl	0	H	NHSO ₂ NHC ₆ H ₄ -(3-Br)	
2063	2-aminopyridin-6-yl	0	H	NHSO ₂ NHC ₆ H ₄ -(4-Br)	
2064	2-aminopyridin-6-yl	0	H	NHSO ₂ NHC ₆ H ₄ -(3-F)	
2065	2-aminopyridin-6-yl	0	H	NHSO ₂ NHC ₆ H ₄ -(4-F)	
2066	2-aminopyridin-6-yl	0	H	NHSO ₂ NH(2-naphthyl)	
2067	2-aminopyridin-6-yl	0	H	NHSO ₂ NH(1-naphthyl)	
2068	2-aminopyridin-6-yl	0	H	NHSO ₂ NHCH=CH-Ph	
2069	2-aminopyridin-6-yl	0	H	NHSO ₂ NHCH ₂ Ph	
2070	2-aminopyridin-6-yl	0	H	NHSO ₂ NHCH ₂ CH=CH-Ph	
2071	2-aminopyridin-6-yl	0	H	NHSO ₂ NH-n-Bu	
2072	2-aminopyridin-6-yl	0	H	NHSO ₂ NH-i-Bu	
2073	2-aminopyridin-6-yl	0	H	NHSO ₂ NH-t-Bu	
2074	2-aminopyridin-6-yl	1	H	NHCO ₂ Bn	497.2
2075	2-aminopyridin-6-yl	1	H	NHCO ₂ CH ₂ C ₆ H ₄ -(2-CH ₃)	
2076	2-aminopyridin-6-yl	1	H	NHCO ₂ CH ₂ C ₆ H ₄ -(3-CH ₃)	
2077	2-aminopyridin-6-yl	1	H	NHCO ₂ CH ₂ C ₆ H ₄ -(4-CH ₃)	
2078	2-aminopyridin-6-yl	1	H	NHCO ₂ CH ₂ (2-pyridinyl)	
2079	2-aminopyridin-6-yl	1	H	NHCO ₂ CH ₂ (3-pyridinyl)	

2080	2-aminopyridin-6-yl	1	H	NHCO ₂ CH ₂ (4-pyridinyl)
2081	2-aminopyridin-6-yl	1	H	NHCO ₂ CH ₂ (2-thiazolyl)
2082	2-aminopyridin-6-yl	1	H	NHCO ₂ CH ₂ (4-thiazolyl)
2083	2-aminopyridin-6-yl	1	H	NHCO ₂ CH ₂ (5-thiazolyl)
2084	2-aminopyridin-6-yl	1	H	NHCO ₂ CH ₂ (4-isoxazolyl)
2085	2-aminopyridin-6-yl	1	H	NHCO ₂ CH ₂ (2-thienyl)
2086	2-aminopyridin-6-yl	1	H	NHCO ₂ n-Bu
2087	2-aminopyridin-6-yl	1	H	NHCO ₂ i-Bu
2088	2-aminopyridin-6-yl	1	H	NHCO ₂ t-Bu
2089	2-aminopyridin-6-yl	1	H	NHCOCH ₂ Ph
2090	2-aminopyridin-6-yl	1	H	NHCOCH ₂ C ₆ H ₄ - (2-CH ₃)
2091	2-aminopyridin-6-yl	1	H	NHCOCH ₂ -C ₆ H ₄ - (3-CH ₃)
2092	2-aminopyridin-6-yl	1	H	NHCOCH ₂ C ₆ H ₄ - (4-CH ₃)
2093	2-aminopyridin-6-yl	1	H	NHCOCH ₂ (2-pyridinyl)
2094	2-aminopyridin-6-yl	1	H	NHCOCH ₂ (3-pyridinyl)
2095	2-aminopyridin-6-yl	1	H	NHCOCH ₂ (4-pyridinyl)
2096	2-aminopyridin-6-yl	1	H	NHCOCH ₂ (2-thiazolyl)
2097	2-aminopyridin-6-yl	1	H	NHCOCH ₂ (4-thiazolyl)
2098	2-aminopyridin-6-yl	1	H	NHCOCH ₂ (5-thiazolyl)
2099	2-aminopyridin-6-yl	1	H	NHCOCH ₂ (4-isoxazolyl)
2100	2-aminopyridin-6-yl	1	H	NHCOCH ₂ (2-thienyl)
2101	2-aminopyridin-6-yl	1	H	NHCON-Bu
2102	2-aminopyridin-6-yl	1	H	NHCOT-Bu
2103	2-aminopyridin-6-yl	1	H	NHSO ₂ Ph
2104	2-aminopyridin-6-yl	1	H	NHSO ₂ C ₆ H ₄ - (2-CH ₃)
2105	2-aminopyridin-6-yl	1	H	NHSO ₂ C ₆ H ₄ - (3-CH ₃)
2106	2-aminopyridin-6-yl	1		NHSO ₂ C ₆ H ₄ - (4-CH ₃)
2107	2-aminopyridin-6-yl	1	H	NHSO ₂ (2-pyridyl)

2108	2-aminopyridin-6-yl	1	H	NHSO ₂ (3-pyridyl)
2109	2-aminopyridin-6-yl	1	H	NHSO ₂ (4-pyridyl)
2110	2-aminopyridin-6-yl	1	H	NHSO ₂ (2-thiazolyl)
2111	2-aminopyridin-6-yl	1	H	NHSO ₂ (4-thiazolyl)
2112	2-aminopyridin-6-yl	1	H	NHSO ₂ (4-isoxazolyl)
2113	2-aminopyridin-6-yl	1	H	NHSO ₂ -[4-(3,5-dimethyl) isoxazolyl]
2114	2-aminopyridin-6-yl	1	H	NHSO ₂ C ₆ H ₄ -(2-Br)
2115	2-aminopyridin-6-yl	1	H	NHSO ₂ C ₆ H ₄ -(3-Br)
2116	2-aminopyridin-6-yl	1	H	NHSO ₂ C ₆ H ₄ -(4-Br)
2117	2-aminopyridin-6-yl	1	H	NHSO ₂ C ₆ H ₄ -(2-F)
2118	2-aminopyridin-6-yl	1	H	NHSO ₂ C ₆ H ₄ -(3-F)
2119	2-aminopyridin-6-yl	1	H	NHSO ₂ C ₆ H ₄ -(4-F)
2120	2-aminopyridin-6-yl	1	H	NHSO ₂ (2-naphthyl)
2121	2-aminopyridin-6-yl	1	H	NHSO ₂ (1-naphthyl)
2122	2-aminopyridin-6-yl	1	H	NHSO ₂ CH=CH-Ph
2123	2-aminopyridin-6-yl	1	H	NHSO ₂ CH ₂ Ph
2124	2-aminopyridin-6-yl	1	H	NHSO ₂ -CH ₂ CH=CH-Ph
2125	2-aminopyridin-6-yl	1	H	NHSO ₂ -n-Bu
2126	2-aminopyridin-6-yl	1	H	NHSO ₂ -i-Bu
2127	2-aminopyridin-6-yl	1	H	NHSO ₂ -t-Bu
2128	2-aminopyridin-6-yl	1	H	NHSO ₂ NHPh
2129	2-aminopyridin-6-yl	1	H	NHSO ₂ NHC ₆ H ₄ -(2-CH ₃)
2130	2-aminopyridin-6-yl	1	H	NHSO ₂ NHC ₆ H ₄ -(3-CH ₃)
2131	2-aminopyridin-6-yl	1	H	NHSO ₂ NHC ₆ H ₄ -(4-CH ₃)
2132	2-aminopyridin-6-yl	1	H	NHSO ₂ NH(2-pyridyl)
2133	2-aminopyridin-6-yl	1	H	NHSO ₂ NH(3-pyridyl)
2134	2-aminopyridin-6-yl	1	H	NHSO ₂ NH(4-pyridyl)
2135	2-aminopyridin-6-yl	1	H	NHSO ₂ NH(2-thiazolyl)
2136	2-aminopyridin-6-yl	1	H	NHSO ₂ NH-(4-thiazolyl)
2137	2-aminopyridin-6-yl	1	H	NHSO ₂ NH(4-isoxazolyl)

2138	2-aminopyridin-6-yl	1	H	NHSO ₂ -(4-(3,5-dimethyl)isoxazolyl)
2139	2-aminopyridin-6-yl	1	H	NHSO ₂ NHC ₆ H ₄ -(2-Br)
2140	2-aminopyridin-6-yl	1	H	NHSO ₂ NHC ₆ H ₄ -(3-Br)
2141	2-aminopyridin-6-yl	1	H	NHSO ₂ NHC ₆ H ₄ -(4-Br)
2142	2-aminopyridin-6-yl	1	H	NHSO ₂ NHC ₆ H ₄ -(3-F)
2143	2-aminopyridin-6-yl	1	H	NHSO ₂ NHC ₆ H ₄ -(4-F)
2144	2-aminopyridin-6-yl	1	H	NHSO ₂ NH(2-naphthyl)
2145	2-aminopyridin-6-yl	1	H	NHSO ₂ NH(1-naphthyl)
2146	2-aminopyridin-6-yl	1	H	NHSO ₂ NHCH=CH-Ph
2147	2-aminopyridin-6-yl	1	H	NHSO ₂ NHCH ₂ Ph
2148	2-aminopyridin-6-yl	1	H	NHSO ₂ NHCH ₂ CH=CH-Ph
2149	2-aminopyridin-6-yl	1	H	NHSO ₂ NH-n-Bu
2150	2-aminopyridin-6-yl	1	H	NHSO ₂ NH-i-Bu
2151	2-aminopyridin-6-yl	1	H	NHSO ₂ NH-t-Bu
2152	2-aminoimidazol-5-yl	0	H	NHCOOBn
2153	2-aminoimidazol-5-yl	0	H	NHCO ₂ CH ₂ C ₆ H ₄ -(2-CH ₃)
2154	2-aminoimidazol-5-yl	0	H	NHCO ₂ CH ₂ C ₆ H ₄ -(3-CH ₃)
2155	2-aminoimidazol-5-yl	0	H	NHCO ₂ CH ₂ C ₆ H ₄ -(4-CH ₃)
2156	2-aminoimidazol-5-yl	0	H	NHCO ₂ CH ₂ (2-pyridinyl)
2157	2-aminoimidazol-5-yl	0	H	NHCO ₂ CH ₂ (3-pyridinyl)
2158	2-aminoimidazol-5-yl	0	H	NHCO ₂ CH ₂ (4-pyridinyl)
2159	2-aminoimidazol-5-yl	0	H	NHCO ₂ CH ₂ (2-thiazolyl)
2160	2-aminoimidazol-5-yl	0	H	NHCO ₂ CH ₂ (4-thiazolyl)

2161	2-aminoimidazol- 5-yl	0	H	NHCO ₂ CH ₂ (5- thiazolyl)
2162	2-aminoimidazol- 5-yl	0	H	NHCO ₂ CH ₂ (4- isoxazolyl)
2163	2-aminoimidazol- 5-yl	0	H	NHCO ₂ CH ₂ (2-thienyl)
2164	2-aminoimidazol- 5-yl	0	H	NHCO ₂ n-Bu
2165	2-aminoimidazol- 5-yl	0	H	NHCO ₂ i-Bu
2166	2-aminoimidazol- 5-yl	0	H	NHCO ₂ t-Bu
2167	2-aminoimidazol- 5-yl	0	H	NHSO ₂ Ph
2168	2-aminoimidazol- 5-yl	0	H	NHSO ₂ C ₆ H ₄ - (2-CH ₃)
2169	2-aminoimidazol- 5-yl	0	H	NHSO ₂ C ₆ H ₄ - (3-CH ₃)
2170	2-aminoimidazol- 5-yl	0	H	NHSO ₂ C ₆ H ₄ - (4-CH ₃)
2171	2-aminoimidazol- 5-yl	0	H	NHSO ₂ (2-pyridyl)
2172	2-aminoimidazol- 5-yl	0	H	NHSO ₂ (3-pyridyl)
2173	2-aminoimidazol- 5-yl	0	H	NHSO ₂ (4-pyridyl)
2174	2-aminoimidazol- 5-yl	0	H	NHSO ₂ (2-thiazolyl)
2175	2-aminoimidazol- 5-yl	0	H	NHSO ₂ (4-thiazolyl)
2176	2-aminoimidazol- 5-yl	0	H	NHSO ₂ (4-isoxazolyl)
2177	2-aminoimidazol- 5-yl	0	H	NHSO ₂ -[4-(3,5- dimethyl)isoxazolyl]

2178	2-aminoimidazol- 5-yl	0	H	NHSO ₂ C ₆ H ₄ -(2-Br)
2179	2-aminoimidazol- 5-yl	0	H	NHSO ₂ C ₆ H ₄ -(3-Br)
2180	2-aminoimidazol- 5-yl	0	H	NHSO ₂ C ₆ H ₄ -(2-F)
2181	2-aminoimidazol- 5-yl	0	H	NHSO ₂ C ₆ H ₄ -(3-F)
2182	2-aminoimidazol- 5-yl	0	H	NHSO ₂ C ₆ H ₄ -(4-F)
2183	2-aminoimidazol- 5-yl	0	H	NHSO ₂ (2-naphthyl)
2184	2-aminoimidazol- 5-yl	0	H	NHSO ₂ (1-naphthyl)
2185	2-aminoimidazol- 5-yl	0	H	NHSO ₂ CH=CHPh
2186	2-aminoimidazol- 5-yl	0	H	NHSO ₂ CH ₂ Ph
2187	2-aminoimidazol- 5-yl	0	H	NHSO ₂ CH ₂ CH=CHPh
2188	2-aminoimidazol- 5-yl	0	H	NHSO ₂ -n-Bu
2189	2-aminoimidazol- 5-yl	0	H	NHSO ₂ -i-Bu
2190	2-aminoimidazol- 5-yl	1	H	NHCOOBn
2191	2-aminoimidazol- 5-yl	1	H	NHCO ₂ CH ₂ C ₆ H ₄ -(2-CH ₃)
2192	2-aminoimidazol- 5-yl	1	H	NHCO ₂ CH ₂ C ₆ H ₄ -(3-CH ₃)
2193	2-aminoimidazol- 5-yl	1	H	NHCO ₂ CH ₂ C ₆ H ₄ -(4-CH ₃)
2194	2-aminoimidazol- 5-yl	1	H	NHCO ₂ CH ₂ (2- pyridinyl)

2195	2-aminoimidazol-5-yl	1	H	NHCO ₂ CH ₂ (3-pyridinyl)
2196	2-aminoimidazol-5-yl	1	H	NHCO ₂ CH ₂ (4-pyridinyl)
2197	2-aminoimidazol-5-yl	1	H	NHCO ₂ CH ₂ (2-thiazolyl)
2198	2-aminoimidazol-5-yl	1	H	NHCO ₂ CH ₂ (4-thiazolyl)
2199	2-aminoimidazol-5-yl	1	H	NHCO ₂ CH ₂ (5-thiazolyl)
2200	2-aminoimidazol-5-yl	1	H	NHCO ₂ CH ₂ (4-isoxazolyl)
2201	2-aminoimidazol-5-yl	1	H	NHCO ₂ CH ₂ (2-thienyl)
2202	2-aminoimidazol-5-yl	1	H	NHCO ₂ n-Bu
2203	2-aminoimidazol-5-yl	1	H	NHCO ₂ i-Bu
2204	2-aminoimidazol-5-yl	1	H	NHCO ₂ t-Bu
2205	2-aminoimidazol-5-yl	1	H	NHSO ₂ Ph
2206	2-aminoimidazol-5-yl	1	H	NHSO ₂ C ₆ H ₄ - (2-CH ₃)
2207	2-aminoimidazol-5-yl	1	H	NHSO ₂ C ₆ H ₄ - (3-CH ₃)
2208	2-aminoimidazol-5-yl	1	H	NHSO ₂ C ₆ H ₄ - (4-CH ₃)
2209	2-aminoimidazol-5-yl	1	H	NHSO ₂ (2-pyridyl)
2210	2-aminoimidazol-5-yl	1	H	NHSO ₂ (3-pyridyl)
2211	2-aminoimidazol-5-yl	1	H	NHSO ₂ (4-pyridyl)

2212	2-aminoimidazol- 5-yl	1	H	NHSO ₂ (2-thiaz-olyl)
2213	2-aminoimidazol- 5-yl	1	H	NHSO ₂ (4-isoxazolyl)
2214	2-aminoimidazol- 5-yl	1	H	NHSO ₂ -(4-(3,5- dimethyl)isoxazolyl]
2215	2-aminoimidazol- 5-yl	1	H	NHSO ₂ C ₆ H ₄ -(2-Br)
2216	2-aminoimidazol- 5-yl	1	H	NHSO ₂ C ₆ H ₄ -(3-Br)
2217	2-aminoimidazol- 5-yl	1	H	NHSO ₂ C ₆ H ₄ -(2-F)
2218	2-aminoimidazol- 5-yl	1	H	NHSO ₂ C ₆ H ₄ -(3-F)
2219	2-aminoimidazol- 5-yl	1	H	NHSO ₂ C ₆ H ₄ -(4-F)
2220	2-aminoimidazol- 5-yl	1	H	NHSO ₂ (2-naphthyl)
2221	2-aminoimidazol- 5-yl	1	H	NHSO ₂ (1-naphthyl)
2222	2-aminoimidazol- 5-yl	1	H	NHSO ₂ CH=CHPh
2223	2-aminoimidazol- 5-yl	1	H	NHSO ₂ CH ₂ Ph
2224	2-aminoimidazol- 5-yl	1	H	NHSO ₂ CH ₂ CH=CHPh
2225	2-aminoimidazol- 5-yl	1	H	NHSO ₂ -n-Bu
2226	2-aminoimidazol- 5-yl	1	H	NHSO ₂ -i-Bu
2227	2-aminoimidazol- 5-yl	1	H	NHSO ₂ Ph
2228	2-aminoimidazol- 5-yl	1	H	NHSO ₂ C ₆ H ₄ -(2-CH ₃)

2229	2-aminoimidazol-5-yl	1	H	NHSO ₂ C ₆ H ₄ -(3-CH ₃)
2230	2-aminoimidazol-5-yl	1	H	NHSO ₂ C ₆ H ₄ -(4-CH ₃)
2231	2-aminoimidazol-5-yl	1	H	NHSO ₂ (2-pyridyl)
2232	2-aminoimidazol-5-yl	1	H	NHSO ₂ (3-pyridyl)
2233	2-aminoimidazol-5-yl	1	H	NHSO ₂ (4-pyridyl)
2234	2-aminoimidazol-5-yl	1	H	NHSO ₂ (2-thiazolyl)
2235	2-aminoimidazol-5-yl	1	H	NHSO ₂ (4-isoxazolyl)
2236	2-aminoimidazol-5-yl	1	H	NHSO ₂ -[4-(3,5-dimethyl)isoxazolyl]
2237	2-aminoimidazol-5-yl	1	H	NHSO ₂ C ₆ H ₄ -(2-Br)
2238	2-aminoimidazol-5-yl	1	H	NHSO ₂ C ₆ H ₄ -(3-Br)
2239	2-aminoimidazol-5-yl	1	H	NHSO ₂ C ₆ H ₄ -(2-F)
2240	2-aminoimidazol-5-yl	1	H	NHSO ₂ C ₆ H ₄ -(3-F)
2241	2-aminoimidazol-5-yl	1	H	NHSO ₂ C ₆ H ₄ -(4-F)
2242	2-aminoimidazol-5-yl	1	H	NHCO ₂ CH ₂ Ph
2243	2-aminoimidazol-5-yl	1	H	NHCO ₂ n-Bu
2244	2-aminoimidazol-5-yl	1	H	NHCO ₂ i-Bu
2245	2-aminothiazol-4-yl	0	H	NHSO ₂ Ph
2246	2-aminothiazol-4-yl	0	H	NHSO ₂ C ₆ H ₄ -(2-CH ₃)
2247	2-aminothiazol-4-yl	0	H	NHSO ₂ C ₆ H ₄ -(3-CH ₃)

2248	2-aminothiazol-4-yl	0	H	NHSO ₂ C ₆ H ₄ -(4-CH ₃)
2249	2-aminothiazol-4-yl	0	H	NHSO ₂ (2-pyridyl)
2250	2-aminothiazol-4-yl	0	H	NHSO ₂ (3-pyridyl)
2251	2-aminothiazol-4-yl	0	H	NHSO ₂ (4-pyridyl)
2252	2-aminothiazol-4-yl	0	H	NHSO ₂ (2-thiazolyl)
2253	2-aminothiazol-4-yl	0	H	NHSO ₂ (4-isoxazolyl)
2254	2-aminothiazol-4-yl	0	H	NHSO ₂ -[4-(3,5-dimethyl)isoxazolyl]
2255	2-aminothiazol-4-yl	0	H	NHSO ₂ C ₆ H ₄ -(2-Br)
2256	2-aminothiazol-4-yl	0	H	NHSO ₂ C ₆ H ₄ -(3-Br)
2257	2-aminothiazol-4-yl	0	H	NHSO ₂ C ₆ H ₄ -(2-F)
2258	2-aminothiazol-4-yl	0	H	NHSO ₂ C ₆ H ₄ -(3-F)
2259	2-aminothiazol-4-yl	0	H	NHSO ₂ C ₆ H ₄ -(4-F)
2260	2-aminothiazol-4-yl	0	H	NHCO ₂ CH ₂ Ph
2261	2-aminothiazol-4-yl	0	H	NHCO ₂ n-Bu
2262	2-aminothiazol-4-yl	0	H	NHCO ₂ i-Bu
2263	2-aminothiazol-4-yl	1	H	NHSO ₂ Ph
2264	2-aminothiazol-4-yl	1	H	NHSO ₂ C ₆ H ₄ -(2-CH ₃)
2265	2-aminothiazol-4-yl	1	H	NHSO ₂ C ₆ H ₄ -(3-CH ₃)
2266	2-aminothiazol-4-yl	1	H	NHSO ₂ C ₆ H ₄ -(4-CH ₃)
2267	2-aminothiazol-4-yl	1	H	NHSO ₂ (2-pyridyl)
2268	2-aminothiazol-4-yl	1	H	NHSO ₂ (3-pyridyl)
2269	2-aminothiazol-4-yl	1	H	NHSO ₂ (4-pyridyl)
2270	2-aminothiazol-4-yl	1	H	NHSO ₂ (2-thiazolyl)
2271	2-aminothiazol-4-yl	1	H	NHSO ₂ (4-isoxazolyl)
2272	2-aminothiazol-4-yl	1	H	NHSO ₂ -[4-(3,5-dimethyl)isoxazolyl]
2273	2-aminothiazol-4-yl	1	H	NHSO ₂ C ₆ H ₄ -(2-Br)
2274	2-aminothiazol-4-yl	1	H	NHSO ₂ C ₆ H ₄ -(3-Br)
2275	2-aminothiazol-4-yl	1	H	NHSO ₂ C ₆ H ₄ -(2-F)
2276	2-aminothiazol-4-yl	1	H	NHSO ₂ C ₆ H ₄ -(3-F)
2277	2-aminothiazol-4-yl	1	H	NHSO ₂ C ₆ H ₄ -(4-F)
2278	2-aminothiazol-4-yl	1	H	NHCO ₂ CH ₂ Ph
2279	2-aminothiazol-4-yl	1	H	NHCO ₂ n-Bu
2280	2-aminothiazol-4-yl	1	H	NHCO ₂ i-Bu

2281	2-aminopyridin-6-ylmethyl	0	H	NHSO ₂ Ph
2282	2-aminopyridin-6-ylmethyl	0	H	NHSO ₂ C ₆ H ₄ -(2-CH ₃)
2283	2-aminopyridin-6-ylmethyl	0	H	NHSO ₂ C ₆ H ₄ -(3-CH ₃)
2284	2-aminopyridin-6-ylmethyl	0	H	NHSO ₂ C ₆ H ₄ -(4-CH ₃)
2285	2-aminopyridin-6-ylmethyl	0	H	NHSO ₂ (2-naphthyl)
2286	2-aminopyridin-6-ylmethyl	0	H	NHSO ₂ (1-naphthyl)
2287	2-aminopyridin-6-ylmethyl	0	H	NHSO ₂ (biphenyl)
2288	2-aminopyridin-6-ylmethyl	0	H	NHSO ₂ (2,4,6-trimethylphenyl)
2289	2-aminopyridin-6-ylmethyl	0	H	NHSO ₂ (2-thienyl)
2290	2-aminopyridin-6-ylmethyl	0	H	NHSO ₂ -(4-(3,5-dimethyl)isoxazolyl)
2291	2-aminopyridin-6-ylmethyl	0	H	NHSO ₂ C ₆ H ₄ -(2-Br)
2292	2-aminopyridin-6-ylmethyl	0	H	NHSO ₂ C ₆ H ₄ -(3-Br)
2293	2-aminopyridin-6-ylmethyl	0	H	NHSO ₂ C ₆ H ₄ -(2-F)
2294	2-aminopyridin-6-ylmethyl	0	H	NHSO ₂ C ₆ H ₄ -(3-F)
2295	2-aminopyridin-6-ylmethyl	0	H	NHSO ₂ C ₆ H ₄ -(4-F)
2296	2-aminopyridin-6-ylmethyl	0	H	NHCO ₂ CH ₂ Ph
2297	2-aminopyridin-6-ylmethyl	0	H	NHCO ₂ n-Bu

2298	2-aminopyridin-6-ylmethyl	0	H	NHCO ₂ i-Bu
2299	2-aminopyridin-6-ylmethyl	1	H	NHSO ₂ Ph
2300	2-aminopyridin-6-ylmethyl	1	H	NHSO ₂ C ₆ H ₄ -(2-CH ₃)
2301	2-aminopyridin-6-ylmethyl	1	H	NHSO ₂ C ₆ H ₄ -(3-CH ₃)
2302	2-aminopyridin-6-ylmethyl	1	H	NHSO ₂ C ₆ H ₄ -(4-CH ₃)
2303	2-aminopyridin-6-ylmethyl	1	H	NHSO ₂ (2-naphthyl)
2304	2-aminopyridin-6-ylmethyl	1	H	NHSO ₂ (1-naphthyl)
2305	2-aminopyridin-6-ylmethyl	1	H	NHSO ₂ (biphenyl)
2306	2-aminopyridin-6-ylmethyl	1	H	NHSO ₂ (2,4,6-trimethylphenyl)
2307	2-aminopyridin-6-ylmethyl	1	H	NHSO ₂ (2-thienyl)
2308	2-aminopyridin-6-ylmethyl	1	H	NHSO ₂ -[4-(3,5-dimethyl)isoxazolyl]
2309	2-aminopyridin-6-ylmethyl	1	H	NHSO ₂ C ₆ H ₄ -(2-Br)
2310	2-aminopyridin-6-ylmethyl	1	H	NHSO ₂ C ₆ H ₄ -(3-Br)
2311	2-aminopyridin-6-ylmethyl	1	H	NHSO ₂ C ₆ H ₄ -(2-F)
2312	2-aminopyridin-6-ylmethyl	1	H	NHSO ₂ C ₆ H ₄ -(3-F)
2313	2-aminopyridin-6-ylmethyl	1	H	NHSO ₂ C ₆ H ₄ -(4-F)
2314	2-aminopyridin-6-ylmethyl	1	H	NHCO ₂ CH ₂ Ph


2315	2-aminopyridin-6-ylmethyl	1	H	NHCO ₂ n-Bu
2316	2-aminopyridin-6-ylcarbonyl	0	H	NHSO ₂ Ph
2317	2-aminopyridin-6-ylcarbonyl	0	H	NHSO ₂ C ₆ H ₄ -(2-CH ₃)
2318	2-aminopyridin-6-ylcarbonyl	0	H	NHSO ₂ C ₆ H ₄ -(3-CH ₃)
2319	2-aminopyridin-6-ylcarbonyl	0	H	NHSO ₂ C ₆ H ₄ -(4-CH ₃)
2320	2-aminopyridin-6-ylcarbonyl	0	H	NHSO ₂ (2-naphthyl)
2321	2-aminopyridin-6-ylcarbonyl	0	H	NHSO ₂ (1-naphthyl)
2322	2-aminopyridin-6-ylcarbonyl	0	H	NHSO ₂ (biphenyl)
2323	2-aminopyridin-6-ylcarbonyl	0	H	NHSO ₂ (2,4,6-trimethylphenyl)
2324	2-aminopyridin-6-ylcarbonyl	0	H	NHSO ₂ (2-thienyl)
2325	2-aminopyridin-6-ylcarbonyl	0	H	NHSO ₂ -[4-(3,5-dimethyl)isoxazolyl]
2326	2-aminopyridin-6-ylcarbonyl	0	H	NHSO ₂ C ₆ H ₄ -(2-Br)
2327	2-aminopyridin-6-ylcarbonyl	0	H	NHSO ₂ C ₆ H ₄ -(3-Br)
2328	2-aminopyridin-6-ylcarbonyl	0	H	NHSO ₂ C ₆ H ₄ -(2-F)
2329	2-aminopyridin-6-ylcarbonyl	0	H	NHSO ₂ C ₆ H ₄ -(3-F)
2330	2-aminopyridin-6-ylcarbonyl	0	H	NHSO ₂ C ₆ H ₄ -(4-F)
2331	2-aminopyridin-6-ylcarbonyl	0	H	NHCO ₂ CH ₂ Ph

2332	2-aminopyridin-6-ylcarbonyl	0	H	NHCO ₂ n-Bu
2333	2-aminopyridin-6-ylcarbonyl	0	H	NHCO ₂ i-Bu
2334	2-aminopyridin-6-ylcarbonyl	1	H	NHSO ₂ Ph
2335	2-aminopyridin-6-ylcarbonyl	1	H	NHSO ₂ C ₆ H ₄ -(2-CH ₃)
2336	2-aminopyridin-6-ylcarbonyl	1	H	NHSO ₂ C ₆ H ₄ -(3-CH ₃)
2337	2-aminopyridin-6-ylcarbonyl	1	H	NHSO ₂ C ₆ H ₄ -(4-CH ₃)
2338	2-aminopyridin-6-ylcarbonyl	1	H	NHSO ₂ (2-naphthyl)
2339	2-aminopyridin-6-ylcarbonyl	1	H	NHSO ₂ (1-naphthyl)
2340	2-aminopyridin-6-ylcarbonyl	1	H	NHSO ₂ (biphenyl)
2341	2-aminopyridin-6-ylcarbonyl	1	H	NHSO ₂ (2,4,6-trimethylphenyl)
2342	2-aminopyridin-6-ylcarbonyl	1	H	NHSO ₂ (2-thienyl)
2343	2-aminopyridin-6-ylcarbonyl	1	H	NHSO ₂ -[4-(3,5-dimethyl)isoxazolyl]
2344	2-aminopyridin-6-ylcarbonyl	1	H	NHSO ₂ C ₆ H ₄ -(2-Br)
2345	2-aminopyridin-6-ylcarbonyl	1	H	NHSO ₂ C ₆ H ₄ -(3-Br)
2346	2-aminopyridin-6-ylcarbonyl	1	H	NHSO ₂ C ₆ H ₄ -(2-F)
2347	2-aminopyridin-6-ylcarbonyl	1	H	NHSO ₂ C ₆ H ₄ -(3-F)
2348	2-aminopyridin-6-ylcarbonyl	1	H	NHSO ₂ C ₆ H ₄ -(4-F)

2349	2-aminopyridin-6-ylcarbonyl	1	H	NHCO ₂ CH ₂ Ph
2350	2-aminopyridin-6-ylcarbonyl	1	H	NHCO ₂ n-Bu
2351	2-aminoimidazol-5-ylmethyl	1	H	NHSO ₂ Ph
2352	2-aminoimidazol-5-ylmethyl	1	H	NHSO ₂ C ₆ H ₄ -(2-CH ₃)
2353	2-aminoimidazol-5-ylmethyl	1	H	NHSO ₂ C ₆ H ₄ -(3-CH ₃)
2354	2-aminoimidazol-5-ylmethyl	1	H	NHSO ₂ C ₆ H ₄ -(4-CH ₃)
2355	2-aminoimidazol-5-ylmethyl	1	H	NHSO ₂ (2-naphthyl)
2356	2-aminoimidazol-5-ylmethyl	1	H	NHSO ₂ (1-naphthyl)
2357	2-aminoimidazol-5-ylmethyl	1	H	NHSO ₂ (biphenyl)
2358	2-aminoimidazol-5-ylmethyl	1	H	NHSO ₂ (2,4,6-trimethylphenyl)
2359	2-aminoimidazol-5-ylmethyl	1	H	NHSO ₂ (2-thienyl)
2360	2-aminoimidazol-5-ylmethyl	1	H	NHSO ₂ -[4-(3,5-dimethyl)isoxazolyl]
2361	2-aminoimidazol-5-ylmethyl	1	H	NHSO ₂ C ₆ H ₄ -(2-Br)
2362	2-aminoimidazol-5-ylmethyl	1	H	NHSO ₂ C ₆ H ₄ -(3-Br)
2363	2-aminoimidazol-5-ylmethyl	1	H	NHSO ₂ C ₆ H ₄ -(2-F)
2364	2-aminoimidazol-5-ylmethyl	1	H	NHSO ₂ C ₆ H ₄ -(3-F)
2365	2-aminoimidazol-5-ylmethyl	1	H	NHSO ₂ C ₆ H ₄ -(4-F)

2366	2-aminoimidazol-5-ylmethyl	1	H	NHCO ₂ CH ₂ Ph
2367	2-aminoimidazol-5-ylmethyl	1	H	NHCO ₂ n-Bu
2368	2-amino-1,3,4-triazol-5-yl-carbonyl	0	H	NHSO ₂ Ph
2369	4-imidazolyl-carbonyl	0	H	NHSO ₂ Ph
2370	2-aminoimidazol-5-ylmethyl	0	H	NHSO ₂ Ph

Table 3



Ex. No.	R ¹	r	R ¹⁰	R ¹⁴	R ¹⁵	MS (M+H) ⁺
3001	2- pyridinylamino- methyl	0	Cbz	H	NHSO ₂ Ph	
3002	2- pyridinylamino- methyl	0	SO ₂ Ph	H	NHSO ₂ Ph	
3003	2- pyridinylamino- methyl	0	CO(CH ₂) ₂ Ph	H	NHSO ₂ Ph	
3004	2- pyridinylamino- methyl	0	Bn	H	NHSO ₂ Ph	
3005	2- pyridinylamino- methyl	0	n-Bu	H	NHSO ₂ Ph	
3006	2- pyridinylamino- methyl	0	COCH ₂ (3- indolyl)	H	NHSO ₂ Ph	
3007	2- pyridinylamino- methyl	0	SO ₂ - (biphenyl)	H	NHSO ₂ Ph	
3008	2- pyridinylamino- methyl	0	CO ₂ -n-Bu	H	NHSO ₂ Ph	

3009	2- pyridinylamino- methyl	0	CO ₂ -i-Bu	H	NHSO ₂ Ph	
3010	2- pyridinylamino- methyl	0	CO ₂ -t-Bu	H	NHSO ₂ Ph	
3011	2- pyridinylamino- methyl	0	H	H	NHSO ₂ Ph	
3012	2- pyridinylamino- methyl	0	-(CH ₂) ₄ NH ₂	H	NHSO ₂ Ph	
3013	2- pyridinylamino- methyl	0	COPh	H	NHSO ₂ Ph	
3014	2- pyridinylamino- methyl	0	cyclopropyl- methyl	H	NHSO ₂ Ph	
3015	2- pyridinylamino- methyl	0	SO ₂ -n-Bu	H	NHSO ₂ Ph	
3016	2- pyridinylamino- methyl	0	Cbz	H	NHSO ₂ -(2,4,6- trimethylphen yl)	679.4
3017	2- pyridinylamino- methyl	0	SO ₂ Ph	H	NHSO ₂ -(2,4,6- trimethylphen yl)	
3018	2- pyridinylamino- methyl	0	CO(CH ₂) ₂ Ph	H	NHSO ₂ -(2,4,6- trimethylphen yl)	
3019	2- pyridinylamino- methyl	0	Bn	H	NHSO ₂ -(2,4,6- trimethylphen yl)	

3020	2- pyridinylamino- methyl	0	n-Bu	H	NHSO ₂ -(2,4,6- trimethylphen yl)	
3021	2- pyridinylamino- methyl	0	CO ₂ -n-Bu	H	NHSO ₂ -(2,4,6- trimethylphen yl)	
3022	2- pyridinylamino- methyl	0	CO ₂ -i-Bu	H	NHSO ₂ -(2,4,6- trimethylphen yl)	
3023	2- pyridinylamino- methyl	0	CO ₂ -t-Bu	H	NHSO ₂ -(2,4,6- trimethylphen yl)	
3024	2- pyridinylamino- methyl	0	H	H	NHSO ₂ -(2,4,6- trimethylphen yl)	545.5
3025	2- pyridinylamino- methyl	0	-(CH ₂) ₄ NH ₂	H	NHSO ₂ -(2,4,6- trimethylphen yl)	
3026	2- pyridinylamino- methyl	0	COPh	H	NHSO ₂ -(2,4,6- trimethylphen yl)	
3027	2- pyridinylamino- methyl	0	SO ₂ -n-Bu	H	NHSO ₂ -(2,4,6- trimethylphen yl)	
3028	2- pyridinylamino- methyl	0	Cbz	H	NHCbz	
3029	2- pyridinylamino- methyl	0	SO ₂ Ph	H	NHCbz	
3030	2- pyridinylamino- methyl	0	CO(CH ₂) ₂ Ph	H	NHCbz	

3031	2-	0	Bn	H	NHCbz
	pyridinylamino- methyl				
3032	2-	0	n-Bu	H	NHCbz
	pyridinylamino- methyl				
3033	2-	0	CO ₂ -n-Bu	H	NHCbz
	pyridinylamino- methyl				
3034	2-	0	CO ₂ -i-Bu	H	NHCbz
	pyridinylamino- methyl				
3035	2-	0	CO ₂ -t-Bu	H	NHCbz
	pyridinylamino- methyl				
3036	2-	0	H	H	NHCbz
	pyridinylamino- methyl				
3037	2-	0	-(CH ₂) ₄ NH ₂	H	NHCbz
	pyridinylamino- methyl				
3038	2-	0	COPh	H	NHCbz
	pyridinylamino- methyl				
3039	2-	0	SO ₂ -n-Bu	H	NHCbz
	pyridinylamino- methyl				
3040	2-	0	Cbz	H	NHSO ₂ Ph
	imidazolylamino- methyl				
3041	2-	0	SO ₂ Ph	H	NHSO ₂ Ph
	imidazolylamino- methyl				

3042	2-	0	CO(CH ₂) ₂ Ph	H	NHSO ₂ Ph	
	imidazolylamino-					
	methyl					
3043	2-	0	Bn	H	NHSO ₂ Ph	
	imidazolylamino-					
	methyl					
3044	2-	0	n-Bu	H	NHSO ₂ Ph	
	imidazolylamino-					
	methyl					
3045	2-	0	COCH ₂ (3-indolyl)	H	NHSO ₂ Ph	
	imidazolylamino-					
	- methyl					
3046	2-	0	SO ₂ -(biphenyl)	H	NHSO ₂ Ph	
	imidazolylamino-					
	methyl					
3047	2-	0	CO ₂ -n-Bu	H	NHSO ₂ Ph	
	imidazolylamino-					
	methyl					
3048	2-	0	CO ₂ -i-Bu	H	NHSO ₂ Ph	
	imidazolylamino-					
	methyl					
3049	2-	0	CO ₂ -t-Bu	H	NHSO ₂ Ph	
	imidazolylamino-					
	methyl					
3050	2-	0	H	H	NHSO ₂ Ph	492.3
	imidazolylamino-					
	methyl					
3051	2-	0	-(CH ₂) ₄ NH ₂	H	NHSO ₂ Ph	
	imidazolylamino-					
	methyl					
3052	2-	0	COPh	H	NHSO ₂ Ph	
	imidazolylamino-					
	methyl					

3053	2-	0	cyclopropyl-	H	NHSO ₂ Ph	
	imidazolylamino-		methyl			
	methyl					
3054	2-	0	SO ₂ -n-Bu	H	NHSO ₂ Ph	
	imidazolylamino-					
	methyl					
3055	2-	0	Cbz	H	NHSO ₂ -(2,4,6-	668.4
	imidazolylamino-				trimethylphen	
	methyl				yl)	
3056	2-	0	SO ₂ Ph	H	NHSO ₂ -(2,4,6-	
	imidazolylamino-				trimethylphen	
	methyl				yl)	
3057	2-	0	CO(CH ₂) ₂ Ph	H	NHSO ₂ -(2,4,6-	
	imidazolylamino-				trimethylphen	
	methyl				yl)	
3058	2-	0	Bn	H	NHSO ₂ -(2,4,6-	
	imidazolylamino-				trimethylphen	
	methyl				yl)	
3059	2-	0	n-Bu	H	NHSO ₂ -(2,4,6-	
	imidazolylamino-				trimethylphen	
	methyl				yl)	
3060	2-	0	CO ₂ -n-Bu	H	NHSO ₂ -(2,4,6-	
	imidazolylamino-				trimethylphen	
	methyl				yl)	
3061	2-	0	CO ₂ -i-Bu	H	NHSO ₂ -(2,4,6-	
	imidazolylamino-				trimethylphen	
	methyl				yl)	
3062	2-	0	CO ₂ -t-Bu	H	NHSO ₂ -(2,4,6-	
	imidazolylamino-				trimethylphen	
	methyl				yl)	
3063	2-	0	H	H	NHSO ₂ -(2,4,6-	534.4
	imidazolylamino-				trimethylphen	
	methyl				yl)	

3064	2-	0	$-(\text{CH}_2)_4\text{NH}_2$	H	NHSO ₂ -(2,4,6-trimethylphenyl)
3065	2-	0	COPh	H	NHSO ₂ -(2,4,6-trimethylphenyl)
3066	2-	0	SO ₂ -n-Bu	H	NHSO ₂ -(2,4,6-trimethylphenyl)
3067	2-	0	Cbz	H	NHCbz
3068	2-	0	SO ₂ Ph	H	NHCbz
3069	2-	0	CO(CH ₂) ₂ Ph	H	NHCbz
3070	2-	0	Bn	H	NHCbz
3071	2-	0	n-Bu	H	NHCbz
3072	2-	0	CO ₂ -n-Bu	H	NHCbz
3073	2-	0	CO ₂ -i-Bu	H	NHCbz
3074	2-	0	CO ₂ -t-Bu	H	NHCbz

3075	2-	0	H	H	NHCbz
	imidazolylamino-				
	methyl				
3076	2-	0	-(CH ₂) ₄ NH ₂	H	NHCbz
	imidazolylamino-				
	methyl				
3077	2-	0	COPh	H	NHCbz
	imidazolylamino-				
	methyl				
3078	2-	0	SO ₂ -n-Bu	H	NHCbz
	imidazolylamino-				
	methyl				
3079	2-imidazolinylnyl-	0	Cbz	H	NHSO ₂ Ph
	aminomethyl				
3080	2-imidazolinylnyl-	0	SO ₂ Ph	H	NHSO ₂ Ph
	aminomethyl				
3081	2-imidazolinylnyl-	0	CO(CH ₂) ₂ Ph	H	NHSO ₂ Ph
	aminomethyl				
3082	2-imidazolinylnyl-	0	Bn	H	NHSO ₂ Ph
	aminomethyl				
3083	2-imidazolinylnyl-	0	n-Bu	H	NHSO ₂ Ph
	aminomethyl				
3084	2-imidazolinylnyl-	0	COCH ₂ (3-indolyl)	H	NHSO ₂ Ph
	aminomethyl				
3085	2-imidazolinylnyl-	0	SO ₂ -(biphenyl)	H	NHSO ₂ Ph
	aminomethyl				
3086	2-imidazolinylnyl-	0	CO ₂ -n-Bu	H	NHSO ₂ Ph
	aminomethyl				
3087	2-imidazolinylnyl-	0	CO ₂ -i-Bu	H	NHSO ₂ Ph
	aminomethyl				
3088	2-imidazolinylnyl-	0	CO ₂ -t-Bu	H	NHSO ₂ Ph
	aminomethyl				
3089	2-imidazolinylnyl-	0	H	H	NHSO ₂ Ph
	aminomethyl				

3090	2-imidazoliny- aminomethyl	0	-(CH ₂) ₄ NH ₂	H	NHSO ₂ Ph	
3091	2-imidazoliny- aminomethyl	0	COPh	H	NHSO ₂ Ph	
3092	2-imidazoliny- aminomethyl	0	cyclopropyl- methyl	H	NHSO ₂ Ph	
3093	2-imidazoliny- aminomethyl	0	SO ₂ -n-Bu	H	NHSO ₂ Ph	
3094	2-imidazoliny- aminomethyl	0	Cbz	H	NHSO ₂ -(2,4,6- trimethylphen yl)	
3095	2-imidazoliny- aminomethyl	0	SO ₂ Ph	H	NHSO ₂ -(2,4,6- trimethylphen yl)	
3096	2-imidazoliny- aminomethyl	0	CO(CH ₂) ₂ Ph	H	NHSO ₂ -(2,4,6- trimethylphen yl)	
3097	2-imidazoliny- aminomethyl	0	Bn	H	NHSO ₂ -(2,4,6- trimethylphen yl)	
3098	2-imidazoliny- aminomethyl	0	n-Bu	H	NHSO ₂ -(2,4,6- trimethylphen yl)	
3099	2-imidazoliny- aminomethyl	0	CO ₂ -n-Bu	H	NHSO ₂ -(2,4,6- trimethylphen yl)	
3100	2-imidazoliny- aminomethyl	0	CO ₂ -i-Bu	H	NHSO ₂ -(2,4,6- trimethylphen yl)	
3101	2-imidazoliny- aminomethyl	0	CO ₂ -t-Bu	H	NHSO ₂ -(2,4,6- trimethylphen yl)	
3102	2-imidazoliny- aminomethyl	0	H	H	NHSO ₂ -(2,4,6- trimethylphen yl)	536.3

3103	2-imidazolinylnyl- aminomethyl	0	-(CH ₂) ₄ NH ₂	H	NHSO ₂ -(2,4,6- trimethylphen yl)
3104	2-imidazolinylnyl- aminomethyl	0	COPh	H	NHSO ₂ -(2,4,6- trimethylphen yl)
3105	2-imidazolinylnyl- aminomethyl	0	SO ₂ -n-Bu	H	NHSO ₂ -(2,4,6- trimethylphen yl)
3106	2-imidazolinylnyl- aminomethyl	0	Cbz	H	NHCbz
3107	2-imidazolinylnyl- aminomethyl	0	SO ₂ Ph	H	NHCbz
3108	2-imidazolinylnyl- aminomethyl	0	CO(CH ₂) ₂ Ph	H	NHCbz
3109	2-imidazolinylnyl- aminomethyl	0	Bn	H	NHCbz
3110	2-imidazolinylnyl- aminomethyl	0	n-Bu	H	NHCbz
3111	2-imidazolinylnyl- aminomethyl	0	CO ₂ -n-Bu	H	NHCbz
3112	2-imidazolinylnyl- aminomethyl	0	CO ₂ -i-Bu	H	NHCbz
3113	2-imidazolinylnyl- aminomethyl	0	CO ₂ -t-Bu	H	NHCbz
3114	2-imidazolinylnyl- aminomethyl	0	H	H	NHCbz
3115	2-imidazolinylnyl- aminomethyl	0	-(CH ₂) ₄ NH ₂	H	NHCbz
3116	2-imidazolinylnyl- aminomethyl	0	COPh	H	NHCbz
3117	2-imidazolinylnyl- aminomethyl	0	SO ₂ -n-Bu	H	NHCbz

3118	2-	0	Cbz	H	NHSO ₂ Ph
	benzimidazolyl-				
	aminomethyl				
3119	2-	0	SO ₂ Ph	H	NHSO ₂ Ph
	benzimidazolyl-				
	aminomethyl				
3120	2-	0	CO(CH ₂) ₂ Ph	H	NHSO ₂ Ph
	benzimidazolyl-				
	aminomethyl				
3121	2-	0	Bn	H	NHSO ₂ Ph
	benzimidazolyl-				
	aminomethyl				
3122	2-	0	n-Bu	H	NHSO ₂ Ph
	benzimidazolyl-				
	aminomethyl				
3123	2-	0	COCH ₂ (3-indolyl)	H	NHSO ₂ Ph
	benzimidazolyl-				
	aminomethyl				
3124	2-	0	SO ₂ -(biphenyl)	H	NHSO ₂ Ph
	benzimidazolyl-				
	aminomethyl				
3125	2-	0	CO ₂ -n-Bu	H	NHSO ₂ Ph
	benzimidazolyl-				
	aminomethyl				
3126	2-	0	CO ₂ -i-Bu	H	NHSO ₂ Ph
	benzimidazolyl-				
	aminomethyl				
3127	2-	0	CO ₂ -t-Bu	H	NHSO ₂ Ph
	benzimidazolyl-				
	aminomethyl				
3128	2-	0	H	H	NHSO ₂ Ph
	benzimidazolyl-				
	aminomethyl				

3129	2-	0	$-(CH_2)_4NH_2$	H	NHSO ₂ Ph	
	benzimidazolyl-					
	aminomethyl					
3130	2-	0	COPh	H	NHSO ₂ Ph	
	benzimidazolyl-					
	aminomethyl					
3131	2-	0	cyclopropyl-	H	NHSO ₂ Ph	
	benzimidazolyl-		methyl			
	aminomethyl					
3132	2-	0	SO ₂ -n-Bu	H	NHSO ₂ Ph	
	benzimidazolyl-					
	aminomethyl					
3133	2-	0	Cbz	H	NHSO ₂ -(2,4,6-trimethylphenyl)	718.4
	benzimidazolyl-					
	aminomethyl					
3134	2-	0	SO ₂ Ph	H	NHSO ₂ -(2,4,6-trimethylphenyl)	
	benzimidazolyl-					
	aminomethyl					
3135	2-	0	CO(CH ₂) ₂ Ph	H	NHSO ₂ -(2,4,6-trimethylphenyl)	
	benzimidazolyl-					
	aminomethyl					
3136	2-	0	Bn	H	NHSO ₂ -(2,4,6-trimethylphenyl)	
	benzimidazolyl-					
	aminomethyl					
3137	2-	0	n-Bu	H	NHSO ₂ -(2,4,6-trimethylphenyl)	
	benzimidazolyl-					
	aminomethyl					
3138	2-	0	CO ₂ -n-Bu	H	NHSO ₂ -(2,4,6-trimethylphenyl)	
	benzimidazolyl-					
	aminomethyl					
3139	2-	0	CO ₂ -i-Bu	H	NHSO ₂ -(2,4,6-trimethylphenyl)	
	benzimidazolyl-					
	aminomethyl					

3140	2-	0	CO ₂ -t-Bu	H	NHSO ₂ -(2,4,6-trimethylphenyl)	
3141	2-	0	H	H	NHSO ₂ -(2,4,6-trimethylphenyl)	584.2
3142	2-	0	-(CH ₂) ₄ NH ₂	H	NHSO ₂ -(2,4,6-trimethylphenyl)	
3143	2-	0	COPh	H	NHSO ₂ -(2,4,6-trimethylphenyl)	
3144	2-	0	SO ₂ -n-Bu	H	NHSO ₂ -(2,4,6-trimethylphenyl)	
3145	2-	0	Cbz	H	NHCbz	
3146	2-	0	SO ₂ Ph	H	NHCbz	
3147	2-	0	CO(CH ₂) ₂ Ph	H	NHCbz	
3148	2-	0	Bn	H	NHCbz	
3149	2-	0	n-Bu	H	NHCbz	
3150	2-	0	CO ₂ -n-Bu	H	NHCbz	

3151	2-	0	CO ₂ -i-Bu	H	NHCbz
	benzimidazolyl- aminomethyl				
3152	2-	0	CO ₂ -t-Bu	H	NHCbz
	benzimidazolyl- aminomethyl				
3153	2-	0	H	H	NHCbz
	benzimidazolyl- aminomethyl				
3154	2-	0	-(CH ₂) ₄ NH ₂	H	NHCbz
	benzimidazolyl- aminomethyl				
3155	2-	0	COPh	H	NHCbz
	benzimidazolyl- aminomethyl				
3156	2-	0	SO ₂ -n-Bu	H	NHCbz
	benzimidazolyl- aminomethyl				
3157	7-aza-2-	0	Cbz	H	NHSO ₂ Ph
	benzimidazolyl				
3158	7-aza-2-	0	SO ₂ Ph	H	NHSO ₂ Ph
	benzimidazolyl				
3159	7-aza-2-	0	CO(CH ₂) ₂ Ph	H	NHSO ₂ Ph
	benzimidazolyl				
3160	7-aza-2-	0	Bn	H	NHSO ₂ Ph
	benzimidazolyl				
3161	7-aza-2-	0	n-Bu	H	NHSO ₂ Ph
	benzimidazolyl				
3162	7-aza-2-	0	COCH ₂ (3-indolyl)	H	NHSO ₂ Ph
	benzimidazolyl				
3163	7-aza-2-	0	SO ₂ -(biphenyl)	H	NHSO ₂ Ph
	benzimidazolyl				
3164	7-aza-2-	0	CO ₂ -n-Bu	H	NHSO ₂ Ph
	benzimidazolyl				

3165	7-aza-2- benzimidazolyl	0	CO ₂ -i-Bu	H	NHSO ₂ Ph
3166	7-aza-2- benzimidazolyl	0	CO ₂ -t-Bu	H	NHSO ₂ Ph
3167	7-aza-2- benzimidazolyl	0	H	H	NHSO ₂ Ph
3168	7-aza-2- benzimidazolyl	0	-(CH ₂) ₄ NH ₂	H	NHSO ₂ Ph
3169	7-aza-2- benzimidazolyl	0	COPh	H	NHSO ₂ Ph
3170	7-aza-2- benzimidazolyl	0	cyclopropyl- methyl	H	NHSO ₂ Ph
3171	7-aza-2- benzimidazolyl	0	SO ₂ -n-Bu	H	NHSO ₂ Ph
3172	7-aza-2- benzimidazolyl	0	Cbz	H	NHSO ₂ -(2,4,6- trimethylphen yl)
3173	7-aza-2- benzimidazolyl	0	SO ₂ Ph	H	NHSO ₂ -(2,4,6- trimethylphen yl)
3174	7-aza-2- benzimidazolyl	0	CO(CH ₂) ₂ Ph	H	NHSO ₂ -(2,4,6- trimethylphen yl)
3175	7-aza-2- benzimidazolyl	0	Bn	H	NHSO ₂ -(2,4,6- trimethylphen yl)
3176	7-aza-2- benzimidazolyl	0	n-Bu	H	NHSO ₂ -(2,4,6- trimethylphen yl)
3177	7-aza-2- benzimidazolyl	0	CO ₂ -n-Bu	H	NHSO ₂ -(2,4,6- trimethylphen yl)
3178	7-aza-2- benzimidazolyl	0	CO ₂ -i-Bu	H	NHSO ₂ -(2,4,6- trimethylphen yl)

3179	7-aza-2-benzimidazolyl	0	CO ₂ -t-Bu	H	NHSO ₂ -(2,4,6-trimethylphenyl)
3180	7-aza-2-benzimidazolyl	0	H	H	NHSO ₂ -(2,4,6-trimethylphenyl)
3181	7-aza-2-benzimidazolyl	0	-(CH ₂) ₄ NH ₂	H	NHSO ₂ -(2,4,6-trimethylphenyl)
3182	7-aza-2-benzimidazolyl	0	COPh	H	NHSO ₂ -(2,4,6-trimethylphenyl)
3183	7-aza-2-benzimidazolyl	0	SO ₂ -n-Bu	H	NHSO ₂ -(2,4,6-trimethylphenyl)
3184	7-aza-2-benzimidazolyl	0	Cbz	H	NHCbz
3185	7-aza-2-benzimidazolyl	0	SO ₂ Ph	H	NHCbz
3186	7-aza-2-benzimidazolyl	0	CO(CH ₂) ₂ Ph	H	NHCbz
3187	7-aza-2-benzimidazolyl	0	Bn	H	NHCbz
3188	7-aza-2-benzimidazolyl	0	n-Bu	H	NHCbz
3189	7-aza-2-benzimidazolyl	0	CO ₂ -n-Bu	H	NHCbz
3190	7-aza-2-benzimidazolyl	0	CO ₂ -i-Bu	H	NHCbz
3191	7-aza-2-benzimidazolyl	0	CO ₂ -t-Bu	H	NHCbz
3192	7-aza-2-benzimidazolyl	0	H	H	NHCbz
3193	7-aza-2-benzimidazolyl	0	-(CH ₂) ₄ NH ₂	H	NHCbz

3194	7-aza-2- benzimidazolyl	0	COPh	H	NHCbz
3195	7-aza-2- benzimidazolyl	0	SO ₂ -n-Bu	H	NHCbz
3196	tetrahydropyrimi din-2- ylaminomethyl	0	Cbz	H	NHSO ₂ Ph
3197	tetrahydropyrimi din-2- ylaminomethyl	0	SO ₂ Ph	H	NHSO ₂ Ph
3198	tetrahydropyrimi din-2- ylaminomethyl	0	CO(CH ₂) ₂ Ph	H	NHSO ₂ Ph
3199	tetrahydropyrimi din-2- ylaminomethyl	0	Bn	H	NHSO ₂ Ph
3200	tetrahydropyrimi din-2- ylaminomethyl	0	n-Bu	H	NHSO ₂ Ph
3201	tetrahydropyrimi din-2- ylaminomethyl	0	COCH ₂ (3- indolyl)	H	NHSO ₂ Ph
3202	tetrahydropyrimi din-2- ylaminomethyl	0	SO ₂ - (biphenyl)	H	NHSO ₂ Ph
3203	tetrahydropyrimi din-2- ylaminomethyl	0	CO ₂ -n-Bu	H	NHSO ₂ Ph
3204	tetrahydropyrimi din-2- ylaminomethyl	0	CO ₂ -i-Bu	H	NHSO ₂ Ph
3205	tetrahydropyrimi din-2- ylaminomethyl	0	CO ₂ -t-Bu	H	NHSO ₂ Ph

3206	tetrahydropyrimi	0	H	H	NHSO ₂ Ph
	din-2-				
	ylaminomethyl				
3207	tetrahydropyrimi	0	-(CH ₂) ₄ NH ₂	H	NHSO ₂ Ph
	din-2-				
	ylaminomethyl				
3208	tetrahydropyrimi	0	COPh	H	NHSO ₂ Ph
	din-2-				
	ylaminomethyl				
3209	tetrahydropyrimi	0	cyclopropyl-	H	NHSO ₂ Ph
	din-2-		methyl		
	ylaminomethyl				
3210	tetrahydropyrimi	0	SO ₂ -n-Bu	H	NHSO ₂ Ph
	din-2-				
	ylaminomethyl				
3211	tetrahydropyrimi	0	Cbz	H	NHSO ₂ -(2,4,6-
	din-2-				trimethylphen
	ylaminomethyl				yl)
3212	tetrahydropyrimi	0	SO ₂ Ph	H	NHSO ₂ -(2,4,6-
	din-2-				trimethylphen
	ylaminomethyl				yl)
3213	tetrahydropyrimi	0	CO(CH ₂) ₂ Ph	H	NHSO ₂ -(2,4,6-
	din-2-				trimethylphen
	ylaminomethyl				yl)
3214	tetrahydropyrimi	0	Bn	H	NHSO ₂ -(2,4,6-
	din-2-				trimethylphen
	ylaminomethyl				yl)
3215	tetrahydropyrimi	0	n-Bu	H	NHSO ₂ -(2,4,6-
	din-2-				trimethylphen
	ylaminomethyl				yl)
3216	tetrahydropyrimi	0	CO ₂ -n-Bu	H	NHSO ₂ -(2,4,6-
	din-2-				trimethylphen
	ylaminomethyl				yl)

3217	tetrahydropyrimidin-2-ylaminomethyl	0	CO ₂ -i-Bu	H	NHSO ₂ -(2,4,6-trimethylphenyl)
3218	tetrahydropyrimidin-2-ylaminomethyl	0	CO ₂ -t-Bu	H	NHSO ₂ -(2,4,6-trimethylphenyl)
3219	tetrahydropyrimidin-2-ylaminomethyl	0	H	H	NHSO ₂ -(2,4,6-trimethylphenyl)
3220	tetrahydropyrimidin-2-ylaminomethyl	0	-(CH ₂) ₄ NH ₂	H	NHSO ₂ -(2,4,6-trimethylphenyl)
3221	tetrahydropyrimidin-2-ylaminomethyl	0	COPh	H	NHSO ₂ -(2,4,6-trimethylphenyl)
3222	tetrahydropyrimidin-2-ylaminomethyl	0	SO ₂ -n-Bu	H	NHSO ₂ -(2,4,6-trimethylphenyl)
3223	tetrahydropyrimidin-2-ylaminomethyl	0	Cbz	H	NHCbz
3224	tetrahydropyrimidin-2-ylaminomethyl	0	SO ₂ Ph	H	NHCbz
3225	tetrahydropyrimidin-2-ylaminomethyl	0	CO(CH ₂) ₂ Ph	H	NHCbz
3226	tetrahydropyrimidin-2-ylaminomethyl	0	Bn	H	NHCbz
3227	tetrahydropyrimidin-2-ylaminomethyl	0	n-Bu	H	NHCbz

3228	tetrahydropyrimidin-2-ylaminomethyl	0	CO ₂ -n-Bu	H	NHCbz
3229	tetrahydropyrimidin-2-ylaminomethyl	0	CO ₂ -i-Bu	H	NHCbz
3230	tetrahydropyrimidin-2-ylaminomethyl	0	CO ₂ -t-Bu	H	NHCbz
3231	tetrahydropyrimidin-2-ylaminomethyl	0	H	H	NHCbz
3232	tetrahydropyrimidin-2-ylaminomethyl	0	-(CH ₂) ₄ NH ₂	H	NHCbz
3233	tetrahydropyrimidin-2-ylaminomethyl	0	COPh	H	NHCbz
3234	tetrahydropyrimidin-2-ylaminomethyl	0	SO ₂ -n-Bu	H	NHCbz
3235	2-pyridinylamino-methyl	1	Cbz	H	NHSO ₂ Ph
3236	2-pyridinylamino-methyl	1	SO ₂ Ph	H	NHSO ₂ Ph
3237	2-pyridinylamino-methyl	1	CO(CH ₂) ₂ Ph	H	NHSO ₂ Ph
3238	2-pyridinylamino-methyl	1	Bn	H	NHSO ₂ Ph

3239	2- pyridinylamino- methyl	1	n-Bu	H	NHSO ₂ Ph
3240	2- pyridinylamino- methyl	1	COCH ₂ (3- indolyl)	H	NHSO ₂ Ph
3241	2- pyridinylamino- methyl	1	SO ₂ - (biphenyl)	H	NHSO ₂ Ph
3242	2- pyridinylamino- methyl	1	CO ₂ -n-Bu	H	NHSO ₂ Ph
3243	2- pyridinylamino- methyl	1	CO ₂ -i-Bu	H	NHSO ₂ Ph
3244	2- pyridinylamino- methyl	1	CO ₂ -t-Bu	H	NHSO ₂ Ph
3245	2- pyridinylamino- methyl	1	H	H	NHSO ₂ Ph
3246	2- pyridinylamino- methyl	1	-(CH ₂) ₄ NH ₂	H	NHSO ₂ Ph
3247	2- pyridinylamino- methyl	1	COPh	H	NHSO ₂ Ph
3248	2- pyridinylamino- methyl	1	cyclopropyl- methyl	H	NHSO ₂ Ph
3249	2- pyridinylamino- methyl	1	SO ₂ -n-Bu	H	NHSO ₂ Ph

3250	2- pyridinylamino- methyl	1	Cbz	H	NHSO ₂ -(2,4,6- trimethylphen yl)
3251	2- pyridinylamino- methyl	1	SO ₂ Ph	H	NHSO ₂ -(2,4,6- trimethylphen yl)
3252	2- pyridinylamino- methyl	1	CO(CH ₂) ₂ Ph	H	NHSO ₂ -(2,4,6- trimethylphen yl)
3253	2- pyridinylamino- methyl	1	Bn	H	NHSO ₂ -(2,4,6- trimethylphen yl)
3254	2- pyridinylamino- methyl	1	n-Bu	H	NHSO ₂ -(2,4,6- trimethylphen yl)
3255	2- pyridinylamino- methyl	1	CO ₂ -n-Bu	H	NHSO ₂ -(2,4,6- trimethylphen yl)
3256	2- pyridinylamino- methyl	1	CO ₂ -i-Bu	H	NHSO ₂ -(2,4,6- trimethylphen yl)
3257	2- pyridinylamino- methyl	1	CO ₂ -t-Bu	H	NHSO ₂ -(2,4,6- trimethylphen yl)
3258	2- pyridinylamino- methyl	1	H	H	NHSO ₂ -(2,4,6- trimethylphen yl)
3259	2- pyridinylamino- methyl	1	-(CH ₂) ₄ NH ₂	H	NHSO ₂ -(2,4,6- trimethylphen yl)
3260	2- pyridinylamino- methyl	1	COPh	H	NHSO ₂ -(2,4,6- trimethylphen yl)

3261	2- pyridinylamino- methyl	1	SO ₂ -n-Bu	H	NHSO ₂ -(2,4,6- trimethylphen yl)
3262	2- pyridinylamino- methyl	1	Cbz	H	NHCbz
3263	2- pyridinylamino- methyl	1	SO ₂ Ph	H	NHCbz
3264	2- pyridinylamino- methyl	1	CO(CH ₂) ₂ Ph	H	NHCbz
3265	2- pyridinylamino- methyl	1	Bn	H	NHCbz
3266	2- pyridinylamino- methyl	1	n-Bu	H	NHCbz
3267	2- pyridinylamino- methyl	1	CO ₂ -n-Bu	H	NHCbz
3268	2- pyridinylamino- methyl	1	CO ₂ -i-Bu	H	NHCbz
3269	2- pyridinylamino- methyl	1	CO ₂ -t-Bu	H	NHCbz
3270	2- pyridinylamino- methyl	1	H	H	NHCbz
3271	2- pyridinylamino- methyl	1	-(CH ₂) ₄ NH ₂	H	NHCbz

3272	2- pyridinylamino- methyl	1	COPh	H	NHCbz
3273	2- pyridinylamino- methyl	1	SO ₂ -n-Bu	H	NHCbz
3274	2- imidazolylamino- methyl	1	Cbz	H	NHSO ₂ Ph
3275	2- imidazolylamino- methyl	1	SO ₂ Ph	H	NHSO ₂ Ph
3276	2- imidazolylamino- methyl	1	CO(CH ₂) ₂ Ph	H	NHSO ₂ Ph
3277	2- imidazolylamino- methyl	1	Bn	H	NHSO ₂ Ph
3278	2- imidazolylamino- methyl	1	n-Bu	H	NHSO ₂ Ph
3279	2- imidazolylamino- methyl	1	COCH ₂ (3- indolyl)	H	NHSO ₂ Ph
3280	2- imidazolylamino- methyl	1	SO ₂ - (biphenyl)	H	NHSO ₂ Ph
3281	2- imidazolylamino- methyl	1	CO ₂ -n-Bu	H	NHSO ₂ Ph
3282	2- imidazolylamino- methyl	1	CO ₂ -i-Bu	H	NHSO ₂ Ph

3283	2-	1	CO ₂ -t-Bu	H	NHSO ₂ Ph
	imidazolylamino-				
	methyl				
3284	2-	1	H	H	NHSO ₂ Ph
	imidazolylamino-				
	methyl				
3285	2-	1	-(CH ₂) ₄ NH ₂	H	NHSO ₂ Ph
	imidazolylamino-				
	methyl				
3286	2-	1	COPh	H	NHSO ₂ Ph
	imidazolylamino-				
	methyl				
3287	2-	1	cyclopropyl-	H	NHSO ₂ Ph
	imidazolylamino-		methyl		
	methyl				
3288	2-	1	SO ₂ -n-Bu	H	NHSO ₂ Ph
	imidazolylamino-				
	methyl				
3289	2-	1	Cbz	H	NHSO ₂ -(2,4,6-
	imidazolylamino-				trimethylphen
	methyl				yl)
3290	2-	1	SO ₂ Ph	H	NHSO ₂ -(2,4,6-
	imidazolylamino-				trimethylphen
	methyl				yl)
3291	2-	1	CO(CH ₂) ₂ Ph	H	NHSO ₂ -(2,4,6-
	imidazolylamino-				trimethylphen
	methyl				yl)
3292	2-	1	Bn	H	NHSO ₂ -(2,4,6-
	imidazolylamino-				trimethylphen
	methyl				yl)
3293	2-	1	n-Bu	H	NHSO ₂ -(2,4,6-
	imidazolylamino-				trimethylphen
	methyl				yl)

3294	2- imidazolylamino- methyl	1	CO ₂ -n-Bu	H	NHSO ₂ -(2,4,6- trimethylphen yl)
3295	2- imidazolylamino- methyl	1	CO ₂ -i-Bu	H	NHSO ₂ -(2,4,6- trimethylphen yl)
3296	2- imidazolylamino- methyl	1	CO ₂ -t-Bu	H	NHSO ₂ -(2,4,6- trimethylphen yl)
3297	2- imidazolylamino- methyl	1	H	H	NHSO ₂ -(2,4,6- trimethylphen yl)
3298	2- imidazolylamino- methyl	1	-(CH ₂) ₄ NH ₂	H	NHSO ₂ -(2,4,6- trimethylphen yl)
3299	2- imidazolylamino- methyl	1	COPh	H	NHSO ₂ -(2,4,6- trimethylphen yl)
3300	2- imidazolylamino- methyl	1	SO ₂ -n-Bu	H	NHSO ₂ -(2,4,6- trimethylphen yl)
3301	2- imidazolylamino- methyl	1	Cbz	H	NHCbz
3302	2- imidazolylamino- methyl	1	SO ₂ Ph	H	NHCbz
3303	2- imidazolylamino- methyl	1	CO(CH ₂) ₂ Ph	H	NHCbz
3304	2- imidazolylamino- methyl	1	Bn	H	NHCbz

3305	2- imidazolylamino- methyl	1	n-Bu	H	NHCbz
3306	2- imidazolylamino- methyl	1	CO ₂ -n-Bu	H	NHCbz
3307	2- imidazolylamino- methyl	1	CO ₂ -i-Bu	H	NHCbz
3308	2- imidazolylamino- methyl	1	CO ₂ -t-Bu	H	NHCbz
3309	2- imidazolylamino- methyl	1	H	H	NHCbz
3310	2- imidazolylamino- methyl	1	-(CH ₂) ₄ NH ₂	H	NHCbz
3311	2- imidazolylamino- methyl	1	COPh	H	NHCbz
3312	2- imidazolylamino- methyl	1	SO ₂ -n-Bu	H	NHCbz
3313	2-imidazolinyl- aminomethyl	1	Cbz	H	NHSO ₂ Ph
3314	2-imidazolinyl- aminomethyl	1	SO ₂ Ph	H	NHSO ₂ Ph
3315	2-imidazolinyl- aminomethyl	1	CO(CH ₂) ₂ Ph	H	NHSO ₂ Ph
3316	2-imidazolinyl- aminomethyl	1	Bn	H	NHSO ₂ Ph
3317	2-imidazolinyl- aminomethyl	1	n-Bu	H	NHSO ₂ Ph

3318	2-imidazoliny- aminomethyl	1	COCH ₂ (3- indolyl)	H	NHSO ₂ Ph
3319	2-imidazoliny- aminomethyl	1	SO ₂ - (biphenyl)	H	NHSO ₂ Ph
3320	2-imidazoliny- aminomethyl	1	CO ₂ -n-Bu	H	NHSO ₂ Ph
3321	2-imidazoliny- aminomethyl	1	CO ₂ -i-Bu	H	NHSO ₂ Ph
3322	2-imidazoliny- aminomethyl	1	CO ₂ -t-Bu	H	NHSO ₂ Ph
3323	2-imidazoliny- aminomethyl	1	H	H	NHSO ₂ Ph
3324	2-imidazoliny- aminomethyl	1	-(CH ₂) ₄ NH ₂	H	NHSO ₂ Ph
3325	2-imidazoliny- aminomethyl	1	COPh	H	NHSO ₂ Ph
3326	2-imidazoliny- aminomethyl	1	cyclopropyl- methyl	H	NHSO ₂ Ph
3327	2-imidazoliny- aminomethyl	1	SO ₂ -n-Bu	H	NHSO ₂ Ph
3328	2-imidazoliny- aminomethyl	1	Cbz	H	NHSO ₂ -(2,4,6- trimethylphen yl)
3329	2-imidazoliny- aminomethyl	1	SO ₂ Ph	H	NHSO ₂ -(2,4,6- trimethylphen yl)
3330	2-imidazoliny- aminomethyl	1	CO(CH ₂) ₂ Ph	H	NHSO ₂ -(2,4,6- trimethylphen yl)
3331	2-imidazoliny- aminomethyl	1	Bn	H	NHSO ₂ -(2,4,6- trimethylphen yl)
3332	2-imidazoliny- aminomethyl	1	n-Bu	H	NHSO ₂ -(2,4,6- trimethylphen yl)

3333	2-imidazolinyl- aminomethyl	1	CO ₂ -n-Bu	H	NHSO ₂ -(2,4,6- trimethylphen yl)
3334	2-imidazolinyl- aminomethyl	1	CO ₂ -i-Bu	H	NHSO ₂ -(2,4,6- trimethylphen yl)
3335	2-imidazolinyl- aminomethyl	1	CO ₂ -t-Bu	H	NHSO ₂ -(2,4,6- trimethylphen yl)
3336	2-imidazolinyl- aminomethyl	1	H	H	NHSO ₂ -(2,4,6- trimethylphen yl)
3337	2-imidazolinyl- aminomethyl	1	-(CH ₂) ₄ NH ₂	H	NHSO ₂ -(2,4,6- trimethylphen yl)
3338	2-imidazolinyl- aminomethyl	1	COPh	H	NHSO ₂ -(2,4,6- trimethylphen yl)
3339	2-imidazolinyl- aminomethyl	1	SO ₂ -n-Bu	H	NHSO ₂ -(2,4,6- trimethylphen yl)
3340	2-imidazolinyl- aminomethyl	1	Cbz	H	NHCbz
3341	2-imidazolinyl- aminomethyl	1	SO ₂ Ph	H	NHCbz
3342	2-imidazolinyl- aminomethyl	1	CO(CH ₂) ₂ Ph	H	NHCbz
3343	2-imidazolinyl- aminomethyl	1	Bn	H	NHCbz
3344	2-imidazolinyl- aminomethyl	1	n-Bu	H	NHCbz
3345	2-imidazolinyl- aminomethyl	1	CO ₂ -n-Bu	H	NHCbz
3346	2-imidazolinyl- aminomethyl	1	CO ₂ -i-Bu	H	NHCbz

3347	2-imidazoliny- aminomethyl	1	CO ₂ -t-Bu	H	NHCbz
3348	2-imidazoliny- aminomethyl	1	H	H	NHCbz
3349	2-imidazoliny- aminomethyl	1	-(CH ₂) ₄ NH ₂	H	NHCbz
3350	2-imidazoliny- aminomethyl	1	COPh	H	NHCbz
3351	2-imidazoliny- aminomethyl	1	SO ₂ -n-Bu	H	NHCbz
3352	2- benzimidazolyl- aminomethyl	1	Cbz	H	NHSO ₂ Ph
3353	2- benzimidazolyl- aminomethyl	1	SO ₂ Ph	H	NHSO ₂ Ph
3354	2- benzimidazolyl- aminomethyl	1	CO(CH ₂) ₂ Ph	H	NHSO ₂ Ph
3355	2- benzimidazolyl- aminomethyl	1	Bn	H	NHSO ₂ Ph
3356	2- benzimidazolyl- aminomethyl	1	n-Bu	H	NHSO ₂ Ph
3357	2- benzimidazolyl- aminomethyl	1	COCH ₂ (3- indolyl)	H	NHSO ₂ Ph
3358	2- benzimidazolyl- aminomethyl	1	SO ₂ - (biphenyl)	H	NHSO ₂ Ph
3359	2- benzimidazolyl- aminomethyl	1	CO ₂ -n-Bu	H	NHSO ₂ Ph

3360	2-	1	CO ₂ -i-Bu	H	NHSO ₂ Ph
	benzimidazolyl-				
	aminomethyl				
3361	2-	1	CO ₂ -t-Bu	H	NHSO ₂ Ph
	benzimidazolyl-				
	aminomethyl				
3362	2-	1	H	H	NHSO ₂ Ph
	benzimidazolyl-				
	aminomethyl				
3363	2-	1	-(CH ₂) ₄ NH ₂	H	NHSO ₂ Ph
	benzimidazolyl-				
	aminomethyl				
3364	2-	1	COPh	H	NHSO ₂ Ph
	benzimidazolyl-				
	aminomethyl				
3365	2-	1	cyclopropyl-	H	NHSO ₂ Ph
	benzimidazolyl-		methyl		
	aminomethyl				
3366	2-	1	SO ₂ -n-Bu	H	NHSO ₂ Ph
	benzimidazolyl-				
	aminomethyl				
3367	2-	1	Cbz	H	NHSO ₂ -(2,4,6-
	benzimidazolyl-				trimethylphen
	aminomethyl				yl)
3368	2-	1	SO ₂ Ph	H	NHSO ₂ -(2,4,6-
	benzimidazolyl-				trimethylphen
	aminomethyl				yl)
3369	2-	1	CO(CH ₂) ₂ Ph	H	NHSO ₂ -(2,4,6-
	benzimidazolyl-				trimethylphen
	aminomethyl				yl)
3370	2-	1	Bn	H	NHSO ₂ -(2,4,6-
	benzimidazolyl-				trimethylphen
	aminomethyl				yl)

3371	2- benzimidazolyl- aminomethyl	1	n-Bu	H	NHSO ₂ -(2,4,6- trimethylphen yl)
3372	2- benzimidazolyl- aminomethyl	1	CO ₂ -n-Bu	H	NHSO ₂ -(2,4,6- trimethylphen yl)
3373	2- benzimidazolyl- aminomethyl	1	CO ₂ -i-Bu	H	NHSO ₂ -(2,4,6- trimethylphen yl)
3374	2- benzimidazolyl- aminomethyl	1	CO ₂ -t-Bu	H	NHSO ₂ -(2,4,6- trimethylphen yl)
3375	2- benzimidazolyl- aminomethyl	1	H	H	NHSO ₂ -(2,4,6- trimethylphen yl)
3376	2- benzimidazolyl- aminomethyl	1	-(CH ₂) ₄ NH ₂	H	NHSO ₂ -(2,4,6- trimethylphen yl)
3377	2- benzimidazolyl- aminomethyl	1	COPh	H	NHSO ₂ -(2,4,6- trimethylphen yl)
3378	2- benzimidazolyl- aminomethyl	1	SO ₂ -n-Bu	H	NHSO ₂ -(2,4,6- trimethylphen yl)
3379	2- benzimidazolyl- aminomethyl	1	Cbz	H	NHCbz
3380	2- benzimidazolyl- aminomethyl	1	SO ₂ Ph	H	NHCbz
3381	2- benzimidazolyl- aminomethyl	1	CO(CH ₂) ₂ Ph	H	NHCbz

3382	2- benzimidazolyl- aminomethyl	1	Bn	H	NHCbz
3383	2- benzimidazolyl- aminomethyl	1	n-Bu	H	NHCbz
3384	2- benzimidazolyl- aminomethyl	1	CO ₂ -n-Bu	H	NHCbz
3385	2- benzimidazolyl- aminomethyl	1	CO ₂ -i-Bu	H	NHCbz
3386	2- benzimidazolyl- aminomethyl	1	CO ₂ -t-Bu	H	NHCbz
3387	2- benzimidazolyl- aminomethyl	1	H	H	NHCbz
3388	2- benzimidazolyl- aminomethyl	1	-(CH ₂) ₄ NH ₂	H	NHCbz
3389	2- benzimidazolyl- aminomethyl	1	COPh	H	NHCbz
3390	2- benzimidazolyl- aminomethyl	1	SO ₂ -n-Bu	H	NHCbz
3391	7-aza-2- benzimidazolyl	1	Cbz	H	NHSO ₂ Ph
3392	7-aza-2- benzimidazolyl	1	SO ₂ Ph	H	NHSO ₂ Ph
3393	7-aza-2- benzimidazolyl	1	CO(CH ₂) ₂ Ph	H	NHSO ₂ Ph
3394	7-aza-2- benzimidazolyl	1	Bn	H	NHSO ₂ Ph

3395	7-aza-2- benzimidazolyl	1	n-Bu	H	NHSO ₂ Ph
3396	7-aza-2- benzimidazolyl	1	COCH ₂ (3- indolyl)	H	NHSO ₂ Ph
3397	7-aza-2- benzimidazolyl	1	SO ₂ - (biphenyl)	H	NHSO ₂ Ph
3398	7-aza-2- benzimidazolyl	1	CO ₂ -n-Bu	H	NHSO ₂ Ph
3399	7-aza-2- benzimidazolyl	1	CO ₂ -i-Bu	H	NHSO ₂ Ph
3400	7-aza-2- benzimidazolyl	1	CO ₂ -t-Bu	H	NHSO ₂ Ph
3401	7-aza-2- benzimidazolyl	1	H	H	NHSO ₂ Ph
3402	7-aza-2- benzimidazolyl	1	-(CH ₂) ₄ NH ₂	H	NHSO ₂ Ph
3403	7-aza-2- benzimidazolyl	1	COPh	H	NHSO ₂ Ph
3404	7-aza-2- benzimidazolyl	1	cyclopropyl- methyl	H	NHSO ₂ Ph
3405	7-aza-2- benzimidazolyl	1	SO ₂ -n-Bu	H	NHSO ₂ Ph
3406	7-aza-2- benzimidazolyl	1	Cbz	H	NHSO ₂ -(2,4,6- trimethylphen yl)
3407	7-aza-2- benzimidazolyl	1	SO ₂ Ph	H	NHSO ₂ -(2,4,6- trimethylphen yl)
3408	7-aza-2- benzimidazolyl	1	CO(CH ₂) ₂ Ph	H	NHSO ₂ -(2,4,6- trimethylphen yl)
3409	7-aza-2- benzimidazolyl	1	Bn	H	NHSO ₂ -(2,4,6- trimethylphen yl)

3410	7-aza-2-benzimidazolyl	1	n-Bu	H	NHSO ₂ -(2,4,6-trimethylphenyl)
3411	7-aza-2-benzimidazolyl	1	CO ₂ -n-Bu	H	NHSO ₂ -(2,4,6-trimethylphenyl)
3412	7-aza-2-benzimidazolyl	1	CO ₂ -i-Bu	H	NHSO ₂ -(2,4,6-trimethylphenyl)
3413	7-aza-2-benzimidazolyl	1	CO ₂ -t-Bu	H	NHSO ₂ -(2,4,6-trimethylphenyl)
3414	7-aza-2-benzimidazolyl	1	H	H	NHSO ₂ -(2,4,6-trimethylphenyl)
3415	7-aza-2-benzimidazolyl	1	-(CH ₂) ₄ NH ₂	H	NHSO ₂ -(2,4,6-trimethylphenyl)
3416	7-aza-2-benzimidazolyl	1	COPh	H	NHSO ₂ -(2,4,6-trimethylphenyl)
3417	7-aza-2-benzimidazolyl	1	SO ₂ -n-Bu	H	NHSO ₂ -(2,4,6-trimethylphenyl)
3418	7-aza-2-benzimidazolyl	1	Cbz	H	NHCbz
3419	7-aza-2-benzimidazolyl	1	SO ₂ Ph	H	NHCbz
3420	7-aza-2-benzimidazolyl	1	CO(CH ₂) ₂ Ph	H	NHCbz
3421	7-aza-2-benzimidazolyl	1	Bn	H	NHCbz
3422	7-aza-2-benzimidazolyl	1	n-Bu	H	NHCbz

3423	7-aza-2- benzimidazolyl	1	CO ₂ -n-Bu	H	NHCbz
3424	7-aza-2- benzimidazolyl	1	CO ₂ -i-Bu	H	NHCbz
3425	7-aza-2- benzimidazolyl	1	CO ₂ -t-Bu	H	NHCbz
3426	7-aza-2- benzimidazolyl	1	H	H	NHCbz
3427	7-aza-2- benzimidazolyl	1	-(CH ₂) ₄ NH ₂	H	NHCbz
3428	7-aza-2- benzimidazolyl	1	COPh	H	NHCbz
3429	7-aza-2- benzimidazolyl	1	SO ₂ -n-Bu	H	NHCbz
3430	tetrahydropyrimi din-2- ylaminomethyl	1	Cbz	H	NHSO ₂ Ph
3431	tetrahydropyrimi din-2- ylaminomethyl	1	SO ₂ Ph	H	NHSO ₂ Ph
3432	tetrahydropyrimi din-2- ylaminomethyl	1	CO(CH ₂) ₂ Ph	H	NHSO ₂ Ph
3433	tetrahydropyrimi din-2- ylaminomethyl	1	Bn	H	NHSO ₂ Ph
3434	tetrahydropyrimi din-2- ylaminomethyl	1	n-Bu	H	NHSO ₂ Ph
3435	tetrahydropyrimi din-2- ylaminomethyl	1	COCH ₂ (3- indolyl)	H	NHSO ₂ Ph
3436	tetrahydropyrimi din-2- ylaminomethyl	1	SO ₂ - (biphenyl)	H	NHSO ₂ Ph


3437	tetrahydropyrimi din-2- ylaminomethyl	1	CO ₂ -n-Bu	H	NHSO ₂ Ph
3438	tetrahydropyrimi din-2- ylaminomethyl	1	CO ₂ -i-Bu	H	NHSO ₂ Ph
3439	tetrahydropyrimi din-2- ylaminomethyl	1	CO ₂ -t-Bu	H	NHSO ₂ Ph
3440	tetrahydropyrimi din-2- ylaminomethyl	1	H	H	NHSO ₂ Ph
3441	tetrahydropyrimi din-2- ylaminomethyl	1	-(CH ₂) ₄ NH ₂	H	NHSO ₂ Ph
3442	tetrahydropyrimi din-2- ylaminomethyl	1	COPh	H	NHSO ₂ Ph
3443	tetrahydropyrimi din-2- ylaminomethyl	1	cyclopropyl- methyl	H	NHSO ₂ Ph
3444	tetrahydropyrimi din-2- ylaminomethyl	1	SO ₂ -n-Bu	H	NHSO ₂ Ph
3445	tetrahydropyrimi din-2- ylaminomethyl	1	Cbz	H	NHSO ₂ -(2,4,6- trimethylphen yl)
3446	tetrahydropyrimi din-2- ylaminomethyl	1	SO ₂ Ph	H	NHSO ₂ -(2,4,6- trimethylphen yl)
3447	tetrahydropyrimi din-2- ylaminomethyl	1	CO(CH ₂) ₂ Ph	H	NHSO ₂ -(2,4,6- trimethylphen yl)

3448	tetrahydropyrimi din-2- ylaminomethyl	1	Bn	H	NHSO ₂ -(2,4,6- trimethylphen yl)
3449	tetrahydropyrimi din-2- ylaminomethyl	1	n-Bu	H	NHSO ₂ -(2,4,6- trimethylphen yl)
3450	tetrahydropyrimi din-2- ylaminomethyl	1	CO ₂ -n-Bu	H	NHSO ₂ -(2,4,6- trimethylphen yl)
3451	tetrahydropyrimi din-2- ylaminomethyl	1	CO ₂ -i-Bu	H	NHSO ₂ -(2,4,6- trimethylphen yl)
3452	tetrahydropyrimi din-2- ylaminomethyl	1	CO ₂ -t-Bu	H	NHSO ₂ -(2,4,6- trimethylphen yl)
3453	tetrahydropyrimi din-2- ylaminomethyl	1	H	H	NHSO ₂ -(2,4,6- trimethylphen yl)
3454	tetrahydropyrimi din-2- ylaminomethyl	1	-(CH ₂) ₄ NH ₂	H	NHSO ₂ -(2,4,6- trimethylphen yl)
3455	tetrahydropyrimi din-2- ylaminomethyl	1	COPh	H	NHSO ₂ -(2,4,6- trimethylphen yl)
3456	tetrahydropyrimi din-2- ylaminomethyl	1	SO ₂ -n-Bu	H	NHSO ₂ -(2,4,6- trimethylphen yl)
3457	tetrahydropyrimi din-2- ylaminomethyl	1	Cbz	H	NHCbz
3458	tetrahydropyrimi din-2- ylaminomethyl	1	SO ₂ Ph	H	NHCbz

3459	tetrahydropyrimi din-2- ylaminomethyl	1	CO(CH ₂) ₂ Ph	H	NHCbz	
3460	tetrahydropyrimi din-2- ylaminomethyl	1	Bn	H	NHCbz	
3461	tetrahydropyrimi din-2- ylaminomethyl	1	n-Bu	H	NHCbz	
3462	tetrahydropyrimi din-2- ylaminomethyl	1	CO ₂ -n-Bu	H	NHCbz	
3463	tetrahydropyrimi din-2- ylaminomethyl	1	CO ₂ -i-Bu	H	NHCbz	
3464	tetrahydropyrimi din-2- ylaminomethyl	1	CO ₂ -t-Bu	H	NHCbz	
3465	tetrahydropyrimi din-2- ylaminomethyl	1	H	H	NHCbz	
3466	tetrahydropyrimi din-2- ylaminomethyl	1	-(CH ₂) ₄ NH ₂	H	NHCbz	
3467	tetrahydropyrimi din-2- ylaminomethyl	1	COPh	H	NHCbz	
3468	imidazol-2- ylaminomethyl	0	CO ₂ Me	H	NHSO ₂ -(2,4,6- trimethylphen yl)	592.4
3469	benzamidazol-2- ylaminomethyl	0	Bn	H	NHSO ₂ -(2,4,6- trimethylphen yl)	674.3

3470	benzamidazol-2-ylaminomethyl	0	CO ₂ Me	H	NHSO ₂ -(2,4,6-trimethylphenyl)	642.3
3471	benzamidazol-2-ylaminomethyl	0	CO ₂ Bu	H	NHSO ₂ -(2,4,6-trimethylphenyl)	684.4
3472	imidazol-2-ylaminomethyl	0	CO ₂ CH ₂ (3-pyr)	H	NHSO ₂ -(2,4,6-trimethylphenyl)	669.4
3473	imidazol-2-ylaminomethyl	0	H	H	NHSO ₂ -(2,6-trimethylphenyl)	520.3
3474	imidazol-2-ylaminomethyl	0	H	H	NHSO ₂ biphenyl	568.3
3475	imidazolin-2-ylaminomethyl	0	Cbz	H	NHSO ₂ (2-naphthyl)	678.1
3476	imidazolin-2-ylaminomethyl	0	H	H	NHSO ₂ biphenyl	570.2

Table 4



Ex. No.	R ¹	r	R ¹⁰	R ¹⁴	R ¹⁵
4001	2-pyridinylamino-methyl	0	Cbz	H	NHSO ₂ Ph
4002	2-pyridinylamino-methyl	0	SO ₂ Ph	H	NHSO ₂ Ph
4003	2-pyridinylamino-methyl	0	CO(CH ₂) ₂ Ph	H	NHSO ₂ Ph
4004	2-pyridinylamino-methyl	0	Bn	H	NHSO ₂ Ph
4005	2-pyridinylamino-methyl	0	n-Bu	H	NHSO ₂ Ph
4006	2-pyridinylamino-methyl	0	COCH ₂ (3-indolyl)	H	NHSO ₂ Ph
4007	2-pyridinylamino-methyl	0	SO ₂ -(biphenyl)	H	NHSO ₂ Ph
4008	2-pyridinylamino-methyl	0	CO ₂ -n-Bu	H	NHSO ₂ Ph
4009	2-pyridinylamino-methyl	0	CO ₂ -i-Bu	H	NHSO ₂ Ph
4010	2-pyridinylamino-methyl	0	CO ₂ -t-Bu	H	NHSO ₂ Ph
4011	2-pyridinylamino-methyl	0	H	H	NHSO ₂ Ph
4012	2-pyridinylamino-methyl	0	-(CH ₂) ₄ NH ₂	H	NHSO ₂ Ph

4013	2-pyridinylamino- methyl	0	COPh	H	NHSO ₂ Ph
4014	2-pyridinylamino- methyl	0	cyclopropyl- 1-methyl	H	NHSO ₂ Ph
4015	2-pyridinylamino- methyl	0	SO ₂ -n-Bu	H	NHSO ₂ Ph
4016	2-pyridinylamino- methyl	0	Cbz	H	NHSO ₂ -(2,4,6- trimethylphenyl)
4017	2-pyridinylamino- methyl	0	SO ₂ Ph	H	NHSO ₂ -(2,4,6- trimethylphenyl)
4018	2-pyridinylamino- methyl	0	CO(CH ₂) ₂ Ph	H	NHSO ₂ -(2,4,6- trimethylphenyl)
4019	2-pyridinylamino- methyl	0	Bn	H	NHSO ₂ -(2,4,6- trimethylphenyl)
4020	2-pyridinylamino- methyl	0	n-Bu	H	NHSO ₂ -(2,4,6- trimethylphenyl)
4021	2-pyridinylamino- methyl	0	CO ₂ -n-Bu	H	NHSO ₂ -(2,4,6- trimethylphenyl)
4022	2-pyridinylamino- methyl	0	CO ₂ -i-Bu	H	NHSO ₂ -(2,4,6- trimethylphenyl)
4023	2-pyridinylamino- methyl	0	CO ₂ -t-Bu	H	NHSO ₂ -(2,4,6- trimethylphenyl)
4024	2-pyridinylamino- methyl	0	H	H	NHSO ₂ -(2,4,6- trimethylphenyl)
4025	2-pyridinylamino- methyl	0	-(CH ₂) ₄ NH ₂	H	NHSO ₂ -(2,4,6- trimethylphenyl)
4026	2-pyridinylamino- methyl	0	COPh	H	NHSO ₂ -(2,4,6- trimethylphenyl)
4027	2-pyridinylamino- methyl	0	SO ₂ -n-Bu	H	NHSO ₂ -(2,4,6- trimethylphenyl)
4028	2-pyridinylamino- methyl	0	Cbz	H	NHCbz
4029	2-pyridinylamino- methyl	0	SO ₂ Ph	H	NHCbz

4030	2-pyridinylamino- methyl	0	CO(CH ₂) ₂ Ph	H	NHCbz
4031	2-pyridinylamino- methyl	0	Bn	H	NHCbz
4032	2-pyridinylamino- methyl	0	n-Bu	H	NHCbz
4033	2-pyridinylamino- methyl	0	CO ₂ -n-Bu	H	NHCbz
4034	2-pyridinylamino- methyl	0	CO ₂ -i-Bu	H	NHCbz
4035	2-pyridinylamino- methyl	0	CO ₂ -t-Bu	H	NHCbz
4036	2-pyridinylamino- methyl	0	H	H	NHCbz
4037	2-pyridinylamino- methyl	0	-(CH ₂) ₄ NH ₂	H	NHCbz
4038	2-pyridinylamino- methyl	0	COPh	H	NHCbz
4039	2-pyridinylamino- methyl	0	SO ₂ -n-Bu	H	NHCbz
4040	2-imidazolylamino- methyl	0	Cbz	H	NHSO ₂ Ph
4041	2-imidazolylamino- methyl	0	SO ₂ Ph	H	NHSO ₂ Ph
4042	2-imidazolylamino- methyl	0	CO(CH ₂) ₂ Ph	H	NHSO ₂ Ph
4043	2-imidazolylamino- methyl	0	Bn	H	NHSO ₂ Ph
4044	2-imidazolylamino- methyl	0	n-Bu	H	NHSO ₂ Ph
4045	2-imidazolylamino- methyl	0	COCH ₂ (3-indolyl)	H	NHSO ₂ Ph
4046	2-imidazolylamino- methyl	0	SO ₂ -(biphenyl)	H	NHSO ₂ Ph

4047	2-imidazolylamino- methyl	0	CO ₂ -n-Bu	H	NHSO ₂ Ph
4048	2-imidazolylamino- methyl	0	CO ₂ -i-Bu	H	NHSO ₂ Ph
4049	2-imidazolylamino- methyl	0	CO ₂ -t-Bu	H	NHSO ₂ Ph
4050	2-imidazolylamino- methyl	0	H	H	NHSO ₂ Ph
4051	2-imidazolylamino- methyl	0	-(CH ₂) ₄ NH ₂	H	NHSO ₂ Ph
4052	2-imidazolylamino- methyl	0	COPh	H	NHSO ₂ Ph
4053	2-imidazolylamino- methyl	0	cyclopropyl- 1-methyl	H	NHSO ₂ Ph
4054	2-imidazolylamino- methyl	0	SO ₂ -n-Bu	H	NHSO ₂ Ph
4055	2-imidazolylamino- methyl	0	Cbz	H	NHSO ₂ -(2,4,6- trimethylphenyl)
4056	2-imidazolylamino- methyl	0	SO ₂ Ph	H	NHSO ₂ -(2,4,6- trimethylphenyl)
4057	2-imidazolylamino- methyl	0	CO(CH ₂) ₂ Ph	H	NHSO ₂ -(2,4,6- trimethylphenyl)
4058	2-imidazolylamino- methyl	0	Bn	H	NHSO ₂ -(2,4,6- trimethylphenyl)
4059	2-imidazolylamino- methyl	0	n-Bu	H	NHSO ₂ -(2,4,6- trimethylphenyl)
4060	2-imidazolylamino- methyl	0	CO ₂ -n-Bu	H	NHSO ₂ -(2,4,6- trimethylphenyl)
4061	2-imidazolylamino- methyl	0	CO ₂ -i-Bu	H	NHSO ₂ -(2,4,6- trimethylphenyl)
4062	2-imidazolylamino- methyl	0	CO ₂ -t-Bu	H	NHSO ₂ -(2,4,6- trimethylphenyl)
4063	2-imidazolylamino- methyl	0	H	H	NHSO ₂ -(2,4,6- trimethylphenyl)

4064	2-imidazolylamino-methyl	0	-(CH ₂) ₄ NH ₂	H	NHSO ₂ -(2,4,6-trimethylphenyl)
4065	2-imidazolylamino-methyl	0	COPh	H	NHSO ₂ -(2,4,6-trimethylphenyl)
4066	2-imidazolylamino-methyl	0	SO ₂ -n-Bu	H	NHSO ₂ -(2,4,6-trimethylphenyl)
4067	2-imidazolylamino-methyl	0	Cbz	H	NHCbz
4068	2-imidazolylamino-methyl	0	SO ₂ Ph	H	NHCbz
4069	2-imidazolylamino-methyl	0	CO(CH ₂) ₂ Ph	H	NHCbz
4070	2-imidazolylamino-methyl	0	Bn	H	NHCbz
4071	2-imidazolylamino-methyl	0	n-Bu	H	NHCbz
4072	2-imidazolylamino-methyl	0	CO ₂ -n-Bu	H	NHCbz
4073	2-imidazolylamino-methyl	0	CO ₂ -i-Bu	H	NHCbz
4074	2-imidazolylamino-methyl	0	CO ₂ -t-Bu	H	NHCbz
4075	2-imidazolylamino-methyl	0	H	H	NHCbz
4076	2-imidazolylamino-methyl	0	-(CH ₂) ₄ NH ₂	H	NHCbz
4077	2-imidazolylamino-methyl	0	COPh	H	NHCbz
4078	2-imidazolylamino-methyl	0	SO ₂ -n-Bu	H	NHCbz
4079	2-imidazolinyl-aminomethyl	0	Cbz	H	NHSO ₂ Ph
4080	2-imidazolinyl-aminomethyl	0	SO ₂ Ph	H	NHSO ₂ Ph

4081	2-imidazoliny- aminomethyl	0	CO(CH ₂) ₂ Ph	H	NHSO ₂ Ph
4082	2-imidazoliny- aminomethyl	0	Bn	H	NHSO ₂ Ph
4083	2-imidazoliny- aminomethyl	0	n-Bu	H	NHSO ₂ Ph
4084	2-imidazoliny- aminomethyl	0	COCH ₂ (3- indolyl)	H	NHSO ₂ Ph
4085	2-imidazoliny- aminomethyl	0	SO ₂ - (biphenyl)	H	NHSO ₂ Ph
4086	2-imidazoliny- aminomethyl	0	CO ₂ -n-Bu	H	NHSO ₂ Ph
4087	2-imidazoliny- aminomethyl	0	CO ₂ -i-Bu	H	NHSO ₂ Ph
4088	2-imidazoliny- aminomethyl	0	CO ₂ -t-Bu	H	NHSO ₂ Ph
4089	2-imidazoliny- aminomethyl	0	H	H	NHSO ₂ Ph
4090	2-imidazoliny- aminomethyl	0	-(CH ₂) ₄ NH ₂	H	NHSO ₂ Ph
4091	2-imidazoliny- aminomethyl	0	COPh	H	NHSO ₂ Ph
4092	2-imidazoliny- aminomethyl	0	cyclopropy l-methyl	H	NHSO ₂ Ph
4093	2-imidazoliny- aminomethyl	0	SO ₂ -n-Bu	H	NHSO ₂ Ph
4094	2-imidazoliny- aminomethyl	0	Cbz	H	NHSO ₂ -(2,4,6- trimethylphenyl)
4095	2-imidazoliny- aminomethyl	0	SO ₂ Ph	H	NHSO ₂ -(2,4,6- trimethylphenyl)
4096	2-imidazoliny- aminomethyl	0	CO(CH ₂) ₂ Ph	H	NHSO ₂ -(2,4,6- trimethylphenyl)
4097	2-imidazoliny- aminomethyl	0	Bn	H	NHSO ₂ -(2,4,6- trimethylphenyl)

4098	2-imidazoliny- aminomethyl	0	n-Bu	H	NHSO ₂ -(2,4,6- trimethylphenyl)
4099	2-imidazoliny- aminomethyl	0	CO ₂ -n-Bu	H	NHSO ₂ -(2,4,6- trimethylphenyl)
4100	2-imidazoliny- aminomethyl	0	CO ₂ -i-Bu	H	NHSO ₂ -(2,4,6- trimethylphenyl)
4101	2-imidazoliny- aminomethyl	0	CO ₂ -t-Bu	H	NHSO ₂ -(2,4,6- trimethylphenyl)
4102	2-imidazoliny- aminomethyl	0	H	H	NHSO ₂ -(2,4,6- trimethylphenyl)
4103	2-imidazoliny- aminomethyl	0	-(CH ₂) ₄ NH ₂	H	NHSO ₂ -(2,4,6- trimethylphenyl)
4104	2-imidazoliny- aminomethyl	0	COPh	H	NHSO ₂ -(2,4,6- trimethylphenyl)
4105	2-imidazoliny- aminomethyl	0	SO ₂ -n-Bu	H	NHSO ₂ -(2,4,6- trimethylphenyl)
4106	2-imidazoliny- aminomethyl	0	Cbz	H	NHCbz
4107	2-imidazoliny- aminomethyl	0	SO ₂ Ph	H	NHCbz
4108	2-imidazoliny- aminomethyl	0	CO(CH ₂) ₂ Ph	H	NHCbz
4109	2-imidazoliny- aminomethyl	0	Bn	H	NHCbz
4110	2-imidazoliny- aminomethyl	0	n-Bu	H	NHCbz
4111	2-imidazoliny- aminomethyl	0	CO ₂ -n-Bu	H	NHCbz
4112	2-imidazoliny- aminomethyl	0	CO ₂ -i-Bu	H	NHCbz
4113	2-imidazoliny- aminomethyl	0	CO ₂ -t-Bu	H	NHCbz
4114	2-imidazoliny- aminomethyl	0	H	H	NHCbz

4115	2-imidazolinyl- aminomethyl	0	-(CH ₂) ₄ NH ₂	H	NHCbz
4116	2-imidazolinyl- aminomethyl	0	COPh	H	NHCbz
4117	2-imidazolinyl- aminomethyl	0	SO ₂ -n-Bu	H	NHCbz
4118	2-benzimidazolyl- aminomethyl	0	Cbz	H	NHSO ₂ Ph
4119	2-benzimidazolyl- aminomethyl	0	SO ₂ Ph	H	NHSO ₂ Ph
4120	2-benzimidazolyl- aminomethyl	0	CO(CH ₂) ₂ Ph	H	NHSO ₂ Ph
4121	2-benzimidazolyl- aminomethyl	0	Bn	H	NHSO ₂ Ph
4122	2-benzimidazolyl- aminomethyl	0	n-Bu	H	NHSO ₂ Ph
4123	2-benzimidazolyl- aminomethyl	0	COCH ₂ (3- indolyl)	H	NHSO ₂ Ph
4124	2-benzimidazolyl- aminomethyl	0	SO ₂ - (biphenyl)	H	NHSO ₂ Ph
4125	2-benzimidazolyl- aminomethyl	0	CO ₂ -n-Bu	H	NHSO ₂ Ph
4126	2-benzimidazolyl- aminomethyl	0	CO ₂ -i-Bu	H	NHSO ₂ Ph
4127	2-benzimidazolyl- aminomethyl	0	CO ₂ -t-Bu	H	NHSO ₂ Ph
4128	2-benzimidazolyl- aminomethyl	0	H	H	NHSO ₂ Ph
4129	2-benzimidazolyl- aminomethyl	0	-(CH ₂) ₄ NH ₂	H	NHSO ₂ Ph
4130	2-benzimidazolyl- aminomethyl	0	COPh	H	NHSO ₂ Ph
4131	2-benzimidazolyl- aminomethyl	0	cyclopropy 1-methyl	H	NHSO ₂ Ph

4132	2-benzimidazolyl- aminomethyl	0	SO ₂ -n-Bu	H	NHSO ₂ Ph
4133	2-benzimidazolyl- aminomethyl	0	Cbz	H	NHSO ₂ -(2,4,6- trimethylphenyl)
4134	2-benzimidazolyl- aminomethyl	0	SO ₂ Ph	H	NHSO ₂ -(2,4,6- trimethylphenyl)
4135	2-benzimidazolyl- aminomethyl	0	CO(CH ₂) ₂ Ph	H	NHSO ₂ -(2,4,6- trimethylphenyl)
4136	2-benzimidazolyl- aminomethyl	0	Bn	H	NHSO ₂ -(2,4,6- trimethylphenyl)
4137	2-benzimidazolyl- aminomethyl	0	n-Bu	H	NHSO ₂ -(2,4,6- trimethylphenyl)
4138	2-benzimidazolyl- aminomethyl	0	CO ₂ -n-Bu	H	NHSO ₂ -(2,4,6- trimethylphenyl)
4139	2-benzimidazolyl- aminomethyl	0	CO ₂ -i-Bu	H	NHSO ₂ -(2,4,6- trimethylphenyl)
4140	2-benzimidazolyl- aminomethyl	0	CO ₂ -t-Bu	H	NHSO ₂ -(2,4,6- trimethylphenyl)
4141	2-benzimidazolyl- aminomethyl	0	H	H	NHSO ₂ -(2,4,6- trimethylphenyl)
4142	2-benzimidazolyl- aminomethyl	0	-(CH ₂) ₄ NH ₂	H	NHSO ₂ -(2,4,6- trimethylphenyl)
4143	2-benzimidazolyl- aminomethyl	0	COPh	H	NHSO ₂ -(2,4,6- trimethylphenyl)
4144	2-benzimidazolyl- aminomethyl	0	SO ₂ -n-Bu	H	NHSO ₂ -(2,4,6- trimethylphenyl)
4145	2-benzimidazolyl- aminomethyl	0	Cbz	H	NHCbz
4146	2-benzimidazolyl- aminomethyl	0	SO ₂ Ph	H	NHCbz
4147	2-benzimidazolyl- aminomethyl	0	CO(CH ₂) ₂ Ph	H	NHCbz
4148	2-benzimidazolyl- aminomethyl	0	Bn	H	NHCbz

4149	2-benzimidazolyl- aminomethyl	0	n-Bu	H	NHCbz
4150	2-benzimidazolyl- aminomethyl	0	CO ₂ -n-Bu	H	NHCbz
4151	2-benzimidazolyl- aminomethyl	0	CO ₂ -i-Bu	H	NHCbz
4152	2-benzimidazolyl- aminomethyl	0	CO ₂ -t-Bu	H	NHCbz
4153	2-benzimidazolyl- aminomethyl	0	H	H	NHCbz
4154	2-benzimidazolyl- aminomethyl	0	-(CH ₂) ₄ NH ₂	H	NHCbz
4155	2-benzimidazolyl- aminomethyl	0	COPh	H	NHCbz
4156	2-benzimidazolyl- aminomethyl	0	SO ₂ -n-Bu	H	NHCbz
4157	7-aza-2- benzimidazolyl	0	Cbz	H	NHSO ₂ Ph
4158	7-aza-2- benzimidazolyl	0	SO ₂ Ph	H	NHSO ₂ Ph
4159	7-aza-2- benzimidazolyl	0	CO(CH ₂) ₂ Ph	H	NHSO ₂ Ph
4160	7-aza-2- benzimidazolyl	0	Bn	H	NHSO ₂ Ph
4161	7-aza-2- benzimidazolyl	0	n-Bu	H	NHSO ₂ Ph
4162	7-aza-2- benzimidazolyl	0	COCH ₂ (3- indolyl)	H	NHSO ₂ Ph
4163	7-aza-2- benzimidazolyl	0	SO ₂ - (biphenyl)	H	NHSO ₂ Ph
4164	7-aza-2- benzimidazolyl	0	CO ₂ -n-Bu	H	NHSO ₂ Ph
4165	7-aza-2- benzimidazolyl	0	CO ₂ -i-Bu	H	NHSO ₂ Ph

4166	7-aza-2- benzimidazolyl	0	CO ₂ -t-Bu	H	NHSO ₂ Ph
4167	7-aza-2- benzimidazolyl	0	H	H	NHSO ₂ Ph
4168	7-aza-2- benzimidazolyl	0	-(CH ₂) ₄ NH ₂	H	NHSO ₂ Ph
4169	7-aza-2- benzimidazolyl	0	COPh	H	NHSO ₂ Ph
4170	7-aza-2- benzimidazolyl	0	cyclopropyl-methyl	H	NHSO ₂ Ph
4171	7-aza-2- benzimidazolyl	0	SO ₂ -n-Bu	H	NHSO ₂ Ph
4172	7-aza-2- benzimidazolyl	0	Cbz	H	NHSO ₂ -(2,4,6-trimethylphenyl)
4173	7-aza-2- benzimidazolyl	0	SO ₂ Ph	H	NHSO ₂ -(2,4,6-trimethylphenyl)
4174	7-aza-2- benzimidazolyl	0	CO(CH ₂) ₂ Ph	H	NHSO ₂ -(2,4,6-trimethylphenyl)
4175	7-aza-2- benzimidazolyl	0	Bn	H	NHSO ₂ -(2,4,6-trimethylphenyl)
4176	7-aza-2- benzimidazolyl	0	n-Bu	H	NHSO ₂ -(2,4,6-trimethylphenyl)
4177	7-aza-2- benzimidazolyl	0	CO ₂ -n-Bu	H	NHSO ₂ -(2,4,6-trimethylphenyl)
4178	7-aza-2- benzimidazolyl	0	CO ₂ -i-Bu	H	NHSO ₂ -(2,4,6-trimethylphenyl)
4179	7-aza-2- benzimidazolyl	0	CO ₂ -t-Bu	H	NHSO ₂ -(2,4,6-trimethylphenyl)
4180	7-aza-2- benzimidazolyl	0	H	H	NHSO ₂ -(2,4,6-trimethylphenyl)
4181	7-aza-2- benzimidazolyl	0	-(CH ₂) ₄ NH ₂	H	NHSO ₂ -(2,4,6-trimethylphenyl)
4182	7-aza-2- benzimidazolyl	0	COPh	H	NHSO ₂ -(2,4,6-trimethylphenyl)

4183	7-aza-2- benzimidazolyl	0	SO ₂ -n-Bu	H	NHSO ₂ -(2,4,6- trimethylphenyl)
4184	7-aza-2- benzimidazolyl	0	Cbz	H	NHCbz
4185	7-aza-2- benzimidazolyl	0	SO ₂ Ph	H	NHCbz
4186	7-aza-2- benzimidazolyl	0	CO(CH ₂) ₂ Ph	H	NHCbz
4187	7-aza-2- benzimidazolyl	0	Bn	H	NHCbz
4188	7-aza-2- benzimidazolyl	0	n-Bu	H	NHCbz
4189	7-aza-2- benzimidazolyl	0	CO ₂ -n-Bu	H	NHCbz
4190	7-aza-2- benzimidazolyl	0	CO ₂ -i-Bu	H	NHCbz
4191	7-aza-2- benzimidazolyl	0	CO ₂ -t-Bu	H	NHCbz
4192	7-aza-2- benzimidazolyl	0	H	H	NHCbz
4193	7-aza-2- benzimidazolyl	0	-(CH ₂) ₄ NH ₂	H	NHCbz
4194	7-aza-2- benzimidazolyl	0	COPh	H	NHCbz
4195	7-aza-2- benzimidazolyl	0	SO ₂ -n-Bu	H	NHCbz
4196	tetrahydropyrimidin -2-ylaminomethyl	0	Cbz	H	NHSO ₂ Ph
4197	tetrahydropyrimidin -2-ylaminomethyl	0	SO ₂ Ph	H	NHSO ₂ Ph
4198	tetrahydropyrimidin -2-ylaminomethyl	0	CO(CH ₂) ₂ Ph	H	NHSO ₂ Ph
4199	tetrahydropyrimidin -2-ylaminomethyl	0	Bn	H	NHSO ₂ Ph

4200	tetrahydropyrimidin	0	n-Bu	H	NHSO ₂ Ph
	-2-ylaminomethyl				
4201	tetrahydropyrimidin	0	COCH ₂ (3-indolyl)	H	NHSO ₂ Ph
	-2-ylaminomethyl				
4202	tetrahydropyrimidin	0	SO ₂ -(biphenyl)	H	NHSO ₂ Ph
	-2-ylaminomethyl				
4203	tetrahydropyrimidin	0	CO ₂ -n-Bu	H	NHSO ₂ Ph
	-2-ylaminomethyl				
4204	tetrahydropyrimidin	0	CO ₂ -i-Bu	H	NHSO ₂ Ph
	-2-ylaminomethyl				
4205	tetrahydropyrimidin	0	CO ₂ -t-Bu	H	NHSO ₂ Ph
	-2-ylaminomethyl				
4206	tetrahydropyrimidin	0	H	H	NHSO ₂ Ph
	-2-ylaminomethyl				
4207	tetrahydropyrimidin	0	-(CH ₂) ₄ NH ₂	H	NHSO ₂ Ph
	-2-ylaminomethyl				
4208	tetrahydropyrimidin	0	COPh	H	NHSO ₂ Ph
	-2-ylaminomethyl				
4209	tetrahydropyrimidin	0	cyclopropyl-methyl	H	NHSO ₂ Ph
	-2-ylaminomethyl				
4210	tetrahydropyrimidin	0	SO ₂ -n-Bu	H	NHSO ₂ Ph
	-2-ylaminomethyl				
4211	tetrahydropyrimidin	0	Cbz	H	NHSO ₂ -(2,4,6-trimethylphenyl)
	-2-ylaminomethyl				
4212	tetrahydropyrimidin	0	SO ₂ Ph	H	NHSO ₂ -(2,4,6-trimethylphenyl)
	-2-ylaminomethyl				
4213	tetrahydropyrimidin	0	CO(CH ₂) ₂ Ph	H	NHSO ₂ -(2,4,6-trimethylphenyl)
	-2-ylaminomethyl				
4214	tetrahydropyrimidin	0	Bn	H	NHSO ₂ -(2,4,6-trimethylphenyl)
	-2-ylaminomethyl				
4215	tetrahydropyrimidin	0	n-Bu	H	NHSO ₂ -(2,4,6-trimethylphenyl)
	-2-ylaminomethyl				
4216	tetrahydropyrimidin	0	CO ₂ -n-Bu	H	NHSO ₂ -(2,4,6-trimethylphenyl)
	-2-ylaminomethyl				

4217	tetrahydropyrimidin	0	CO ₂ -i-Bu	H	NHSO ₂ -(2,4,6-trimethylphenyl)
	-2-ylaminomethyl				
4218	tetrahydropyrimidin	0	CO ₂ -t-Bu	H	NHSO ₂ -(2,4,6-trimethylphenyl)
	-2-ylaminomethyl				
4219	tetrahydropyrimidin	0	H	H	NHSO ₂ -(2,4,6-trimethylphenyl)
	-2-ylaminomethyl				
4220	tetrahydropyrimidin	0	-(CH ₂) ₄ NH ₂	H	NHSO ₂ -(2,4,6-trimethylphenyl)
	-2-ylaminomethyl				
4221	tetrahydropyrimidin	0	COPh	H	NHSO ₂ -(2,4,6-trimethylphenyl)
	-2-ylaminomethyl				
4222	tetrahydropyrimidin	0	SO ₂ -n-Bu	H	NHSO ₂ -(2,4,6-trimethylphenyl)
	-2-ylaminomethyl				
4223	tetrahydropyrimidin	0	Cbz	H	NHCbz
	-2-ylaminomethyl				
4224	tetrahydropyrimidin	0	SO ₂ Ph	H	NHCbz
	-2-ylaminomethyl				
4225	tetrahydropyrimidin	0	CO(CH ₂) ₂ Ph	H	NHCbz
	-2-ylaminomethyl				
4226	tetrahydropyrimidin	0	Bn	H	NHCbz
	-2-ylaminomethyl				
4227	tetrahydropyrimidin	0	n-Bu	H	NHCbz
	-2-ylaminomethyl				
4228	tetrahydropyrimidin	0	CO ₂ -n-Bu	H	NHCbz
	-2-ylaminomethyl				
4229	tetrahydropyrimidin	0	CO ₂ -i-Bu	H	NHCbz
	-2-ylaminomethyl				
4230	tetrahydropyrimidin	0	CO ₂ -t-Bu	H	NHCbz
	-2-ylaminomethyl				
4231	tetrahydropyrimidin	0	H	H	NHCbz
	-2-ylaminomethyl				
4232	tetrahydropyrimidin	0	-(CH ₂) ₄ NH ₂	H	NHCbz
	-2-ylaminomethyl				
4233	tetrahydropyrimidin	0	COPh	H	NHCbz
	-2-ylaminomethyl				

4234	tetrahydropyrimidin -2-ylaminomethyl	0	SO ₂ -n-Bu	H	NHCbz
4235	2-pyridinylamino- methyl	1	Cbz	H	NHSO ₂ Ph
4236	2-pyridinylamino- methyl	1	SO ₂ Ph	H	NHSO ₂ Ph
4237	2-pyridinylamino- methyl	1	CO(CH ₂) ₂ Ph	H	NHSO ₂ Ph
4238	2-pyridinylamino- methyl	1	Bn	H	NHSO ₂ Ph
4239	2-pyridinylamino- methyl	1	n-Bu	H	NHSO ₂ Ph
4240	2-pyridinylamino- methyl	1	COCH ₂ (3- indolyl)	H	NHSO ₂ Ph
4241	2-pyridinylamino- methyl	1	SO ₂ - (biphenyl)	H	NHSO ₂ Ph
4242	2-pyridinylamino- methyl	1	CO ₂ -n-Bu	H	NHSO ₂ Ph
4243	2-pyridinylamino- methyl	1	CO ₂ -i-Bu	H	NHSO ₂ Ph
4244	2-pyridinylamino- methyl	1	CO ₂ -t-Bu	H	NHSO ₂ Ph
4245	2-pyridinylamino- methyl	1	H	H	NHSO ₂ Ph
4246	2-pyridinylamino- methyl	1	-(CH ₂) ₄ NH ₂	H	NHSO ₂ Ph
4247	2-pyridinylamino- methyl	1	COPh	H	NHSO ₂ Ph
4248	2-pyridinylamino- methyl	1	cyclopropy l-methyl	H	NHSO ₂ Ph
4249	2-pyridinylamino- methyl	1	SO ₂ -n-Bu	H	NHSO ₂ Ph
4250	2-pyridinylamino- methyl	1	Cbz	H	NHSO ₂ -(2,4,6- trimethylphenyl)

4251	2-pyridinylamino- methyl	1	SO ₂ Ph	H	NHSO ₂ -(2,4,6- trimethylphenyl)
4252	2-pyridinylamino- methyl	1	CO(CH ₂) ₂ Ph	H	NHSO ₂ -(2,4,6- trimethylphenyl)
4253	2-pyridinylamino- methyl	1	Bn	H	NHSO ₂ -(2,4,6- trimethylphenyl)
4254	2-pyridinylamino- methyl	1	n-Bu	H	NHSO ₂ -(2,4,6- trimethylphenyl)
4255	2-pyridinylamino- methyl	1	CO ₂ -n-Bu	H	NHSO ₂ -(2,4,6- trimethylphenyl)
4256	2-pyridinylamino- methyl	1	CO ₂ -i-Bu	H	NHSO ₂ -(2,4,6- trimethylphenyl)
4257	2-pyridinylamino- methyl	1	CO ₂ -t-Bu	H	NHSO ₂ -(2,4,6- trimethylphenyl)
4258	2-pyridinylamino- methyl	1	H	H	NHSO ₂ -(2,4,6- trimethylphenyl)
4259	2-pyridinylamino- methyl	1	-(CH ₂) ₄ NH ₂	H	NHSO ₂ -(2,4,6- trimethylphenyl)
4260	2-pyridinylamino- methyl	1	COPh	H	NHSO ₂ -(2,4,6- trimethylphenyl)
4261	2-pyridinylamino- methyl	1	SO ₂ -n-Bu	H	NHSO ₂ -(2,4,6- trimethylphenyl)
4262	2-pyridinylamino- methyl	1	Cbz	H	NHCbz
4263	2-pyridinylamino- methyl	1	SO ₂ Ph	H	NHCbz
4264	2-pyridinylamino- methyl	1	CO(CH ₂) ₂ Ph	H	NHCbz
4265	2-pyridinylamino- methyl	1	Bn	H	NHCbz
4266	2-pyridinylamino- methyl	1	n-Bu	H	NHCbz
4267	2-pyridinylamino- methyl	1	CO ₂ -n-Bu	H	NHCbz

4268	2-pyridinylamino-methyl	1	CO ₂ -i-Bu	H	NHCbz
4269	2-pyridinylamino-methyl	1	CO ₂ -t-Bu	H	NHCbz
4270	2-pyridinylamino-methyl	1	H	H	NHCbz
4271	2-pyridinylamino-methyl	1	-(CH ₂) ₄ NH ₂	H	NHCbz
4272	2-pyridinylamino-methyl	1	COPh	H	NHCbz
4273	2-pyridinylamino-methyl	1	SO ₂ -n-Bu	H	NHCbz
4274	2-imidazolylamino-methyl	1	Cbz	H	NHSO ₂ Ph
4275	2-imidazolylamino-methyl	1	SO ₂ Ph	H	NHSO ₂ Ph
4276	2-imidazolylamino-methyl	1	CO(CH ₂) ₂ Ph	H	NHSO ₂ Ph
4277	2-imidazolylamino-methyl	1	Bn	H	NHSO ₂ Ph
4278	2-imidazolylamino-methyl	1	n-Bu	H	NHSO ₂ Ph
4279	2-imidazolylamino-methyl	1	COCH ₂ (3-indolyl)	H	NHSO ₂ Ph
4280	2-imidazolylamino-methyl	1	SO ₂ - (biphenyl)	H	NHSO ₂ Ph
4281	2-imidazolylamino-methyl	1	CO ₂ -n-Bu	H	NHSO ₂ Ph
4282	2-imidazolylamino-methyl	1	CO ₂ -i-Bu	H	NHSO ₂ Ph
4283	2-imidazolylamino-methyl	1	CO ₂ -t-Bu	H	NHSO ₂ Ph
4284	2-imidazolylamino-methyl	1	H	H	NHSO ₂ Ph

4285	2-imidazolylamino-methyl	1	-(CH ₂) ₄ NH ₂	H	NHSO ₂ Ph
4286	2-imidazolylamino-methyl	1	COPh	H	NHSO ₂ Ph
4287	2-imidazolylamino-methyl	1	cyclopropyl-methyl	H	NHSO ₂ Ph
4288	2-imidazolylamino-methyl	1	SO ₂ -n-Bu	H	NHSO ₂ Ph
4289	2-imidazolylamino-methyl	1	Cbz	H	NHSO ₂ -(2,4,6-trimethylphenyl)
4290	2-imidazolylamino-methyl	1	SO ₂ Ph	H	NHSO ₂ -(2,4,6-trimethylphenyl)
4291	2-imidazolylamino-methyl	1	CO(CH ₂) ₂ Ph	H	NHSO ₂ -(2,4,6-trimethylphenyl)
4292	2-imidazolylamino-methyl	1	Bn	H	NHSO ₂ -(2,4,6-trimethylphenyl)
4293	2-imidazolylamino-methyl	1	n-Bu	H	NHSO ₂ -(2,4,6-trimethylphenyl)
4294	2-imidazolylamino-methyl	1	CO ₂ -n-Bu	H	NHSO ₂ -(2,4,6-trimethylphenyl)
4295	2-imidazolylamino-methyl	1	CO ₂ -i-Bu	H	NHSO ₂ -(2,4,6-trimethylphenyl)
4296	2-imidazolylamino-methyl	1	CO ₂ -t-Bu	H	NHSO ₂ -(2,4,6-trimethylphenyl)
4297	2-imidazolylamino-methyl	1	H	H	NHSO ₂ -(2,4,6-trimethylphenyl)
4298	2-imidazolylamino-methyl	1	-(CH ₂) ₄ NH ₂	H	NHSO ₂ -(2,4,6-trimethylphenyl)
4299	2-imidazolylamino-methyl	1	COPh	H	NHSO ₂ -(2,4,6-trimethylphenyl)
4300	2-imidazolylamino-methyl	1	SO ₂ -n-Bu	H	NHSO ₂ -(2,4,6-trimethylphenyl)
4301	2-imidazolylamino-methyl	1	Cbz	H	NHCbz

4302	2-imidazolylamino- methyl	1	SO ₂ Ph	H	NHCbz
4303	2-imidazolylamino- methyl	1	CO(CH ₂) ₂ Ph	H	NHCbz
4304	2-imidazolylamino- methyl	1	Bn	H	NHCbz
4305	2-imidazolylamino- methyl	1	n-Bu	H	NHCbz
4306	2-imidazolylamino- methyl	1	CO ₂ -n-Bu	H	NHCbz
4307	2-imidazolylamino- methyl	1	CO ₂ -i-Bu	H	NHCbz
4308	2-imidazolylamino- methyl	1	CO ₂ -t-Bu	H	NHCbz
4309	2-imidazolylamino- methyl	1	H	H	NHCbz
4310	2-imidazolylamino- methyl	1	-(CH ₂) ₄ NH ₂	H	NHCbz
4311	2-imidazolylamino- methyl	1	COPh	H	NHCbz
4312	2-imidazolylamino- methyl	1	SO ₂ -n-Bu	H	NHCbz
4313	2-imidazoliny- aminomethyl	1	Cbz	H	NHSO ₂ Ph
4314	2-imidazoliny- aminomethyl	1	SO ₂ Ph	H	NHSO ₂ Ph
4315	2-imidazoliny- aminomethyl	1	CO(CH ₂) ₂ Ph	H	NHSO ₂ Ph
4316	2-imidazoliny- aminomethyl	1	Bn	H	NHSO ₂ Ph
4317	2-imidazoliny- aminomethyl	1	n-Bu	H	NHSO ₂ Ph
4318	2-imidazoliny- aminomethyl	1	COCH ₂ (3- indolyl)	H	NHSO ₂ Ph

4319	2-imidazoliny- aminomethyl	1	SO ₂ - (biphenyl)	H	NHSO ₂ Ph
4320	2-imidazoliny- aminomethyl	1	CO ₂ -n-Bu	H	NHSO ₂ Ph
4321	2-imidazoliny- aminomethyl	1	CO ₂ -i-Bu	H	NHSO ₂ Ph
4322	2-imidazoliny- aminomethyl	1	CO ₂ -t-Bu	H	NHSO ₂ Ph
4323	2-imidazoliny- aminomethyl	1	H	H	NHSO ₂ Ph
4324	2-imidazoliny- aminomethyl	1	-(CH ₂) ₄ NH ₂	H	NHSO ₂ Ph
4325	2-imidazoliny- aminomethyl	1	COPh	H	NHSO ₂ Ph
4326	2-imidazoliny- aminomethyl	1	cyclopropy l-methyl	H	NHSO ₂ Ph
4327	2-imidazoliny- aminomethyl	1	SO ₂ -n-Bu	H	NHSO ₂ Ph
4328	2-imidazoliny- aminomethyl	1	Cbz	H	NHSO ₂ -(2,4,6- trimethylphenyl)
4329	2-imidazoliny- aminomethyl	1	SO ₂ Ph	H	NHSO ₂ -(2,4,6- trimethylphenyl)
4330	2-imidazoliny- aminomethyl	1	CO(CH ₂) ₂ Ph	H	NHSO ₂ -(2,4,6- trimethylphenyl)
4331	2-imidazoliny- aminomethyl	1	Bn	H	NHSO ₂ -(2,4,6- trimethylphenyl)
4332	2-imidazoliny- aminomethyl	1	n-Bu	H	NHSO ₂ -(2,4,6- trimethylphenyl)
4333	2-imidazoliny- aminomethyl	1	CO ₂ -n-Bu	H	NHSO ₂ -(2,4,6- trimethylphenyl)
4334	2-imidazoliny- aminomethyl	1	CO ₂ -i-Bu	H	NHSO ₂ -(2,4,6- trimethylphenyl)
4335	2-imidazoliny- aminomethyl	1	CO ₂ -t-Bu	H	NHSO ₂ -(2,4,6- trimethylphenyl)

4336	2-imidazoliny- aminomethyl	1	H	H	NHSO ₂ -(2,4,6- trimethylphenyl)
4337	2-imidazoliny- aminomethyl	1	-(CH ₂) ₄ NH ₂	H	NHSO ₂ -(2,4,6- trimethylphenyl)
4338	2-imidazoliny- aminomethyl	1	COPh	H	NHSO ₂ -(2,4,6- trimethylphenyl)
4339	2-imidazoliny- aminomethyl	1	SO ₂ -n-Bu	H	NHSO ₂ -(2,4,6- trimethylphenyl)
4340	2-imidazoliny- aminomethyl	1	Cbz	H	NHCbz
4341	2-imidazoliny- aminomethyl	1	SO ₂ Ph	H	NHCbz
4342	2-imidazoliny- aminomethyl	1	CO(CH ₂) ₂ Ph	H	NHCbz
4343	2-imidazoliny- aminomethyl	1	Bn	H	NHCbz
4344	2-imidazoliny- aminomethyl	1	n-Bu	H	NHCbz
4345	2-imidazoliny- aminomethyl	1	CO ₂ -n-Bu	H	NHCbz
4346	2-imidazoliny- aminomethyl	1	CO ₂ -i-Bu	H	NHCbz
4347	2-imidazoliny- aminomethyl	1	CO ₂ -t-Bu	H	NHCbz
4348	2-imidazoliny- aminomethyl	1	H	H	NHCbz
4349	2-imidazoliny- aminomethyl	1	-(CH ₂) ₄ NH ₂	H	NHCbz
4350	2-imidazoliny- aminomethyl	1	COPh	H	NHCbz
4351	2-imidazoliny- aminomethyl	1	SO ₂ -n-Bu	H	NHCbz
4352	2-benzimidazolyl- aminomethyl	1	Cbz	H	NHSO ₂ Ph

4353	2-benzimidazolyl- aminomethyl	1	SO ₂ Ph	H	NHSO ₂ Ph
4354	2-benzimidazolyl- aminomethyl	1	CO(CH ₂) ₂ Ph	H	NHSO ₂ Ph
4355	2-benzimidazolyl- aminomethyl	1	Bn	H	NHSO ₂ Ph
4356	2-benzimidazolyl- aminomethyl	1	n-Bu	H	NHSO ₂ Ph
4357	2-benzimidazolyl- aminomethyl	1	COCH ₂ (3- indolyl)	H	NHSO ₂ Ph
4358	2-benzimidazolyl- aminomethyl	1	SO ₂ - (biphenyl)	H	NHSO ₂ Ph
4359	2-benzimidazolyl- aminomethyl	1	CO ₂ -n-Bu	H	NHSO ₂ Ph
4360	2-benzimidazolyl- aminomethyl	1	CO ₂ -i-Bu	H	NHSO ₂ Ph
4361	2-benzimidazolyl- aminomethyl	1	CO ₂ -t-Bu	H	NHSO ₂ Ph
4362	2-benzimidazolyl- aminomethyl	1	H	H	NHSO ₂ Ph
4363	2-benzimidazolyl- aminomethyl	1	-(CH ₂) ₄ NH ₂	H	NHSO ₂ Ph
4364	2-benzimidazolyl- aminomethyl	1	COPh	H	NHSO ₂ Ph
4365	2-benzimidazolyl- aminomethyl	1	cyclopropy 1-methyl	H	NHSO ₂ Ph
4366	2-benzimidazolyl- aminomethyl	1	SO ₂ -n-Bu	H	NHSO ₂ Ph
4367	2-benzimidazolyl- aminomethyl	1	Cbz	H	NHSO ₂ -(2,4,6- trimethylphenyl)
4368	2-benzimidazolyl- aminomethyl	1	SO ₂ Ph	H	NHSO ₂ -(2,4,6- trimethylphenyl)
4369	2-benzimidazolyl- aminomethyl	1	CO(CH ₂) ₂ Ph	H	NHSO ₂ -(2,4,6- trimethylphenyl)

4370	2-benzimidazolyl- aminomethyl	1	Bn	H	NHSO ₂ -(2,4,6- trimethylphenyl)
4371	2-benzimidazolyl- aminomethyl	1	n-Bu	H	NHSO ₂ -(2,4,6- trimethylphenyl)
4372	2-benzimidazolyl- aminomethyl	1	CO ₂ -n-Bu	H	NHSO ₂ -(2,4,6- trimethylphenyl)
4373	2-benzimidazolyl- aminomethyl	1	CO ₂ -i-Bu	H	NHSO ₂ -(2,4,6- trimethylphenyl)
4374	2-benzimidazolyl- aminomethyl	1	CO ₂ -t-Bu	H	NHSO ₂ -(2,4,6- trimethylphenyl)
4375	2-benzimidazolyl- aminomethyl	1	H	H	NHSO ₂ -(2,4,6- trimethylphenyl)
4376	2-benzimidazolyl- aminomethyl	1	-(CH ₂) ₄ NH ₂	H	NHSO ₂ -(2,4,6- trimethylphenyl)
4377	2-benzimidazolyl- aminomethyl	1	COPh	H	NHSO ₂ -(2,4,6- trimethylphenyl)
4378	2-benzimidazolyl- aminomethyl	1	SO ₂ -n-Bu	H	NHSO ₂ -(2,4,6- trimethylphenyl)
4379	2-benzimidazolyl- aminomethyl	1	Cbz	H	NHCbz
4380	2-benzimidazolyl- aminomethyl	1	SO ₂ Ph	H	NHCbz
4381	2-benzimidazolyl- aminomethyl	1	CO(CH ₂) ₂ Ph	H	NHCbz
4382	2-benzimidazolyl- aminomethyl	1	Bn	H	NHCbz
4383	2-benzimidazolyl- aminomethyl	1	n-Bu	H	NHCbz
4384	2-benzimidazolyl- aminomethyl	1	CO ₂ -n-Bu	H	NHCbz
4385	2-benzimidazolyl- aminomethyl	1	CO ₂ -i-Bu	H	NHCbz
4386	2-benzimidazolyl- aminomethyl	1	CO ₂ -t-Bu	H	NHCbz

4387	2-benzimidazolyl- aminomethyl	1	H	H	NHCbz
4388	2-benzimidazolyl- aminomethyl	1	-(CH ₂) ₄ NH ₂	H	NHCbz
4389	2-benzimidazolyl- aminomethyl	1	COPh	H	NHCbz
4390	2-benzimidazolyl- aminomethyl	1	SO ₂ -n-Bu	H	NHCbz
4391	7-aza-2- benzimidazolyl	1	Cbz	H	NHSO ₂ Ph
4392	7-aza-2- benzimidazolyl	1	SO ₂ Ph	H	NHSO ₂ Ph
4393	7-aza-2- benzimidazolyl	1	CO(CH ₂) ₂ Ph	H	NHSO ₂ Ph
4394	7-aza-2- benzimidazolyl	1	Bn	H	NHSO ₂ Ph
4395	7-aza-2- benzimidazolyl	1	n-Bu	H	NHSO ₂ Ph
4396	7-aza-2- benzimidazolyl	1	COCH ₂ (3- indolyl)	H	NHSO ₂ Ph
4397	7-aza-2- benzimidazolyl	1	SO ₂ - (biphenyl)	H	NHSO ₂ Ph
4398	7-aza-2- benzimidazolyl	1	CO ₂ -n-Bu	H	NHSO ₂ Ph
4399	7-aza-2- benzimidazolyl	1	CO ₂ -i-Bu	H	NHSO ₂ Ph
4400	7-aza-2- benzimidazolyl	1	CO ₂ -t-Bu	H	NHSO ₂ Ph
4401	7-aza-2- benzimidazolyl	1	H	H	NHSO ₂ Ph
4402	7-aza-2- benzimidazolyl	1	-(CH ₂) ₄ NH ₂	H	NHSO ₂ Ph
4403	7-aza-2- benzimidazolyl	1	COPh	H	NHSO ₂ Ph


4404	7-aza-2-benzimidazolyl	1	cyclopropyl-methyl	H	NHSO ₂ Ph
4405	7-aza-2-benzimidazolyl	1	SO ₂ -n-Bu	H	NHSO ₂ Ph
4406	7-aza-2-benzimidazolyl	1	Cbz	H	NHSO ₂ -(2,4,6-trimethylphenyl)
4407	7-aza-2-benzimidazolyl	1	SO ₂ Ph	H	NHSO ₂ -(2,4,6-trimethylphenyl)
4408	7-aza-2-benzimidazolyl	1	CO(CH ₂) ₂ Ph	H	NHSO ₂ -(2,4,6-trimethylphenyl)
4409	7-aza-2-benzimidazolyl	1	Bn	H	NHSO ₂ -(2,4,6-trimethylphenyl)
4410	7-aza-2-benzimidazolyl	1	n-Bu	H	NHSO ₂ -(2,4,6-trimethylphenyl)
4411	7-aza-2-benzimidazolyl	1	CO ₂ -n-Bu	H	NHSO ₂ -(2,4,6-trimethylphenyl)
4412	7-aza-2-benzimidazolyl	1	CO ₂ -i-Bu	H	NHSO ₂ -(2,4,6-trimethylphenyl)
4413	7-aza-2-benzimidazolyl	1	CO ₂ -t-Bu	H	NHSO ₂ -(2,4,6-trimethylphenyl)
4414	7-aza-2-benzimidazolyl	1	H	H	NHSO ₂ -(2,4,6-trimethylphenyl)
4415	7-aza-2-benzimidazolyl	1	-(CH ₂) ₄ NH ₂	H	NHSO ₂ -(2,4,6-trimethylphenyl)
4416	7-aza-2-benzimidazolyl	1	COPh	H	NHSO ₂ -(2,4,6-trimethylphenyl)
4417	7-aza-2-benzimidazolyl	1	SO ₂ -n-Bu	H	NHSO ₂ -(2,4,6-trimethylphenyl)
4418	7-aza-2-benzimidazolyl	1	Cbz	H	NHCbz
4419	7-aza-2-benzimidazolyl	1	SO ₂ Ph	H	NHCbz
4420	7-aza-2-benzimidazolyl	1	CO(CH ₂) ₂ Ph	H	NHCbz

4421	7-aza-2- benzimidazolyl	1	Bn	H	NHCbz
4422	7-aza-2- benzimidazolyl	1	n-Bu	H	NHCbz
4423	7-aza-2- benzimidazolyl	1	CO ₂ -n-Bu	H	NHCbz
4424	7-aza-2- benzimidazolyl	1	CO ₂ -i-Bu	H	NHCbz
4425	7-aza-2- benzimidazolyl	1	CO ₂ -t-Bu	H	NHCbz
4426	7-aza-2- benzimidazolyl	1	H	H	NHCbz
4427	7-aza-2- benzimidazolyl	1	-(CH ₂) ₄ NH ₂	H	NHCbz
4428	7-aza-2- benzimidazolyl	1	COPh	H	NHCbz
4429	7-aza-2- benzimidazolyl	1	SO ₂ -n-Bu	H	NHCbz
4430	tetrahydropyrimidin -2-ylaminomethyl	1	Cbz	H	NHSO ₂ Ph
4431	tetrahydropyrimidin -2-ylaminomethyl	1	SO ₂ Ph	H	NHSO ₂ Ph
4432	tetrahydropyrimidin -2-ylaminomethyl	1	CO(CH ₂) ₂ Ph	H	NHSO ₂ Ph
4433	tetrahydropyrimidin -2-ylaminomethyl	1	Bn	H	NHSO ₂ Ph
4434	tetrahydropyrimidin -2-ylaminomethyl	1	n-Bu	H	NHSO ₂ Ph
4435	tetrahydropyrimidin -2-ylaminomethyl	1	COCH ₂ (3- indolyl)	H	NHSO ₂ Ph
4436	tetrahydropyrimidin -2-ylaminomethyl	1	SO ₂ - (biphenyl)	H	NHSO ₂ Ph
4437	tetrahydropyrimidin -2-ylaminomethyl	1	CO ₂ -n-Bu	H	NHSO ₂ Ph

4438	tetrahydropyrimidin -2-ylaminomethyl	1	CO ₂ -i-Bu	H	NHSO ₂ Ph
4439	tetrahydropyrimidin -2-ylaminomethyl	1	CO ₂ -t-Bu	H	NHSO ₂ Ph
4440	tetrahydropyrimidin -2-ylaminomethyl	1	H	H	NHSO ₂ Ph
4441	tetrahydropyrimidin -2-ylaminomethyl	1	-(CH ₂) ₄ NH ₂	H	NHSO ₂ Ph
4442	tetrahydropyrimidin -2-ylaminomethyl	1	COPh	H	NHSO ₂ Ph
4443	tetrahydropyrimidin -2-ylaminomethyl	1	cyclopropyl 1-methyl	H	NHSO ₂ Ph
4444	tetrahydropyrimidin -2-ylaminomethyl	1	SO ₂ -n-Bu	H	NHSO ₂ Ph
4445	tetrahydropyrimidin -2-ylaminomethyl	1	Cbz	H	NHSO ₂ -(2,4,6- trimethylphenyl)
4446	tetrahydropyrimidin -2-ylaminomethyl	1	SO ₂ Ph	H	NHSO ₂ -(2,4,6- trimethylphenyl)
4447	tetrahydropyrimidin -2-ylaminomethyl	1	CO(CH ₂) ₂ Ph	H	NHSO ₂ -(2,4,6- trimethylphenyl)
4448	tetrahydropyrimidin -2-ylaminomethyl	1	Bn	H	NHSO ₂ -(2,4,6- trimethylphenyl)
4449	tetrahydropyrimidin -2-ylaminomethyl	1	n-Bu	H	NHSO ₂ -(2,4,6- trimethylphenyl)
4450	tetrahydropyrimidin -2-ylaminomethyl	1	CO ₂ -n-Bu	H	NHSO ₂ -(2,4,6- trimethylphenyl)
4451	tetrahydropyrimidin -2-ylaminomethyl	1	CO ₂ -i-Bu	H	NHSO ₂ -(2,4,6- trimethylphenyl)
4452	tetrahydropyrimidin -2-ylaminomethyl	1	CO ₂ -t-Bu	H	NHSO ₂ -(2,4,6- trimethylphenyl)
4453	tetrahydropyrimidin -2-ylaminomethyl	1	H	H	NHSO ₂ -(2,4,6- trimethylphenyl)
4454	tetrahydropyrimidin -2-ylaminomethyl	1	-(CH ₂) ₄ NH ₂	H	NHSO ₂ -(2,4,6- trimethylphenyl)

4455	tetrahydropyrimidin -2-ylaminomethyl	1	COPh	H	NHSO ₂ -(2,4,6- trimethylphenyl)
4456	tetrahydropyrimidin -2-ylaminomethyl	1	SO ₂ -n-Bu	H	NHSO ₂ -(2,4,6- trimethylphenyl)
4457	tetrahydropyrimidin -2-ylaminomethyl	1	Cbz	H	NHCbz
4458	tetrahydropyrimidin -2-ylaminomethyl	1	SO ₂ Ph	H	NHCbz
4459	tetrahydropyrimidin -2-ylaminomethyl	1	CO(CH ₂) ₂ Ph	H	NHCbz
4460	tetrahydropyrimidin -2-ylaminomethyl	1	Bn	H	NHCbz
4461	tetrahydropyrimidin -2-ylaminomethyl	1	n-Bu	H	NHCbz
4462	tetrahydropyrimidin -2-ylaminomethyl	1	CO ₂ -n-Bu	H	NHCbz
4463	tetrahydropyrimidin -2-ylaminomethyl	1	CO ₂ -i-Bu	H	NHCbz
4464	tetrahydropyrimidin -2-ylaminomethyl	1	CO ₂ -t-Bu	H	NHCbz
4465	tetrahydropyrimidin -2-ylaminomethyl	1	H	H	NHCbz
4466	tetrahydropyrimidin -2-ylaminomethyl	1	(CH ₂) ₄ NH ₂	H	NHCbz
4467	tetrahydropyrimidin -2-ylaminomethyl	1	COPh	H	NHCbz

Table 5



Ex. No.	R ¹	Σ	R ^{10a}	R ¹⁴	R ¹⁵
5001	2-pyridinylamino- methyl	0	Cbz	H	NHSO ₂ Ph
5002	2-pyridinylamino- methyl	0	SO ₂ Ph	H	NHSO ₂ Ph
5003	2-pyridinylamino- methyl	0	CO(CH ₂) ₂ Ph	H	NHSO ₂ Ph
5004	2-pyridinylamino- methyl	0	Bn	H	NHSO ₂ Ph
5005	2-pyridinylamino- methyl	0	n-Bu	H	NHSO ₂ Ph
5006	2-pyridinylamino- methyl	0	COCH ₂ (3- indolyl)	H	NHSO ₂ Ph
5007	2-pyridinylamino- methyl	0	SO ₂ -(bi phenyl)	H	NHSO ₂ Ph
5008	2-pyridinylamino- methyl	0	CO ₂ -n-Bu	H	NHSO ₂ Ph
5009	2-pyridinylamino- methyl	0	CO ₂ -i-Bu	H	NHSO ₂ Ph
5010	2-pyridinylamino- methyl	0	CO ₂ -t-Bu	H	NHSO ₂ Ph
5011	2-pyridinylamino- methyl	0	-(CH ₂) ₄ NH ₂	H	NHSO ₂ Ph
5012	2-pyridinylamino- methyl	0	COPh	H	NHSO ₂ Ph

5013	2-pyridinylamino-methyl	0	cyclopropyl-methyl	H	NHSO ₂ Ph
5014	2-pyridinylamino-methyl	0	SO ₂ -n-Bu	H	NHSO ₂ Ph
5015	2-pyridinylamino-methyl	0	Cbz	H	NHSO ₂ -(2,4,6-trimethylphenyl)
5016	2-pyridinylamino-methyl	0	SO ₂ Ph	H	NHSO ₂ -(2,4,6-trimethylphenyl)
5017	2-pyridinylamino-methyl	0	CO(CH ₂) ₂ Ph	H	NHSO ₂ -(2,4,6-trimethylphenyl)
5018	2-pyridinylamino-methyl	0	Bn	H	NHSO ₂ -(2,4,6-trimethylphenyl)
5019	2-pyridinylamino-methyl	0	n-Bu	H	NHSO ₂ -(2,4,6-trimethylphenyl)
5020	2-pyridinylamino-methyl	0	CO ₂ -n-Bu	H	NHSO ₂ -(2,4,6-trimethylphenyl)
5021	2-pyridinylamino-methyl	0	CO ₂ -i-Bu	H	NHSO ₂ -(2,4,6-trimethylphenyl)
5022	2-pyridinylamino-methyl	0	CO ₂ -t-Bu	H	NHSO ₂ -(2,4,6-trimethylphenyl)
5023	2-pyridinylamino-methyl	0	-(CH ₂) ₄ NH ₂	H	NHSO ₂ -(2,4,6-trimethylphenyl)
5024	2-pyridinylamino-methyl	0	COPh	H	NHSO ₂ -(2,4,6-trimethylphenyl)
5025	2-pyridinylamino-methyl	0	SO ₂ -n-Bu	H	NHSO ₂ -(2,4,6-trimethylphenyl)
5026	2-pyridinylamino-methyl	0	Cbz	H	NHCbz
5027	2-pyridinylamino-methyl	0	SO ₂ Ph	H	NHCbz
5028	2-pyridinylamino-methyl	0	CO(CH ₂) ₂ Ph	H	NHCbz
5029	2-pyridinylamino-methyl	0	Bn	H	NHCbz

5030	2-pyridinylamino-methyl	0	n-Bu	H	NHCbz
5031	2-pyridinylamino-methyl	0	CO ₂ -n-Bu	H	NHCbz
5032	2-pyridinylamino-methyl	0	CO ₂ -i-Bu	H	NHCbz
5033	2-pyridinylamino-methyl	0	CO ₂ -t-Bu	H	NHCbz
5034	2-pyridinylamino-methyl	0	-(CH ₂) ₄ NH ₂	H	NHCbz
5035	2-pyridinylamino-methyl	0	COPh	H	NHCbz
5036	2-pyridinylamino-methyl	0	SO ₂ -n-Bu	H	NHCbz
5037	2-imidazolylamino-methyl	0	Cbz	H	NHSO ₂ Ph
5038	2-imidazolylamino-methyl	0	SO ₂ Ph	H	NHSO ₂ Ph
5039	2-imidazolylamino-methyl	0	CO(CH ₂) ₂ Ph	H	NHSO ₂ Ph
5040	2-imidazolylamino-methyl	0	Bn	H	NHSO ₂ Ph
5041	2-imidazolylamino-methyl	0	n-Bu	H	NHSO ₂ Ph
5042	2-imidazolylamino-methyl	0	COCH ₂ (3-indolyl)	H	NHSO ₂ Ph
5043	2-imidazolylamino-methyl	0	SO ₂ -(bi-phenyl)	H	NHSO ₂ Ph
5044	2-imidazolylamino-methyl	0	CO ₂ -n-Bu	H	NHSO ₂ Ph
5045	2-imidazolylamino-methyl	0	CO ₂ -i-Bu	H	NHSO ₂ Ph
5046	2-imidazolylamino-methyl	0	CO ₂ -t-Bu	H	NHSO ₂ Ph

5047	2-imidazolylamino- methyl	0	-(CH ₂) ₄ NH ₂	H	NHSO ₂ Ph
5048	2-imidazolylamino- methyl	0	COPh	H	NHSO ₂ Ph
5049	2-imidazolylamino- methyl	0	cyclo propyl- methyl	H	NHSO ₂ Ph
5050	2-imidazolylamino- methyl	0	SO ₂ -n-Bu	H	NHSO ₂ Ph
5051	2-imidazolylamino- methyl	0	Cbz	H	NHSO ₂ -(2,4,6- trimethylphenyl)
5052	2-imidazolylamino- methyl	0	SO ₂ Ph	H	NHSO ₂ -(2,4,6- trimethylphenyl)
5053	2-imidazolylamino- methyl	0	CO(CH ₂) ₂ Ph	H	NHSO ₂ -(2,4,6- trimethylphenyl)
5054	2-imidazolylamino- methyl	0	Bn	H	NHSO ₂ -(2,4,6- trimethylphenyl)
5055	2-imidazolylamino- methyl	0	n-Bu	H	NHSO ₂ -(2,4,6- trimethylphenyl)
5056	2-imidazolylamino- methyl	0	CO ₂ -n-Bu	H	NHSO ₂ -(2,4,6- trimethylphenyl)
5057	2-imidazolylamino- methyl	0	CO ₂ -i-Bu	H	NHSO ₂ -(2,4,6- trimethylphenyl)
5058	2-imidazolylamino- methyl	0	CO ₂ -t-Bu	H	NHSO ₂ -(2,4,6- trimethylphenyl)
5059	2-imidazolylamino- methyl	0	-(CH ₂) ₄ NH ₂	H	NHSO ₂ -(2,4,6- trimethylphenyl)
5060	2-imidazolylamino- methyl	0	COPh	H	NHSO ₂ -(2,4,6- trimethylphenyl)
5061	2-imidazolylamino- methyl	0	SO ₂ -n-Bu	H	NHSO ₂ -(2,4,6- trimethylphenyl)
5062	2-imidazolylamino- methyl	0	Cbz	H	NHCbz
5063	2-imidazolylamino- methyl	0	SO ₂ Ph	H	NHCbz

5064	2-imidazolylamino- methyl	0	CO(CH ₂) ₂ Ph	H	NHCbz
5065	2-imidazolylamino- methyl	0	Bn	H	NHCbz
5066	2-imidazolylamino- methyl	0	n-Bu	H	NHCbz
5067	2-imidazolylamino- methyl	0	CO ₂ -n-Bu	H	NHCbz
5068	2-imidazolylamino- methyl	0	CO ₂ -i-Bu	H	NHCbz
5069	2-imidazolylamino- methyl	0	CO ₂ -t-Bu	H	NHCbz
5070	2-imidazolylamino- methyl	0	-(CH ₂) ₄ NH ₂	H	NHCbz
5071	2-imidazolylamino- methyl	0	COPh	H	NHCbz
5072	2-imidazolylamino- methyl	0	SO ₂ -n-Bu	H	NHCbz
5073	2-imidazoliny- aminomethyl	0	Cbz	H	NHSO ₂ Ph
5074	2-imidazoliny- aminomethyl	0	SO ₂ Ph	H	NHSO ₂ Ph
5075	2-imidazoliny- aminomethyl	0	CO(CH ₂) ₂ Ph	H	NHSO ₂ Ph
5076	2-imidazoliny- aminomethyl	0	Bn	H	NHSO ₂ Ph
5077	2-imidazoliny- aminomethyl	0	n-Bu	H	NHSO ₂ Ph
5078	2-imidazoliny- aminomethyl	0	COCH ₂ (3- indolyl)	H	NHSO ₂ Ph
5079	2-imidazoliny- aminomethyl	0	SO ₂ -(bi phenyl)	H	NHSO ₂ Ph
5080	2-imidazoliny- aminomethyl	0	CO ₂ -n-Bu	H	NHSO ₂ Ph

5081	2-imidazoliny- aminomethyl	0	CO ₂ -i-Bu	H	NHSO ₂ Ph
5082	2-imidazoliny- aminomethyl	0	CO ₂ -t-Bu	H	NHSO ₂ Ph
5083	2-imidazoliny- aminomethyl	0	-(CH ₂) ₄ NH ₂	H	NHSO ₂ Ph
5084	2-imidazoliny- aminomethyl	0	COPh	H	NHSO ₂ Ph
5085	2-imidazoliny- aminomethyl	0	cyclo propyl- methyl	H	NHSO ₂ Ph
5086	2-imidazoliny- aminomethyl	0	SO ₂ -n-Bu	H	NHSO ₂ Ph
5087	2-imidazoliny- aminomethyl	0	Cbz	H	NHSO ₂ -(2,4,6- trimethylphenyl)
5088	2-imidazoliny- aminomethyl	0	SO ₂ Ph	H	NHSO ₂ -(2,4,6- trimethylphenyl)
5089	2-imidazoliny- aminomethyl	0	CO(CH ₂) ₂ Ph	H	NHSO ₂ -(2,4,6- trimethylphenyl)
5090	2-imidazoliny- aminomethyl	0	Bn	H	NHSO ₂ -(2,4,6- trimethylphenyl)
5091	2-imidazoliny- aminomethyl	0	n-Bu	H	NHSO ₂ -(2,4,6- trimethylphenyl)
5092	2-imidazoliny- aminomethyl	0	CO ₂ -n-Bu	H	NHSO ₂ -(2,4,6- trimethylphenyl)
5093	2-imidazoliny- aminomethyl	0	CO ₂ -i-Bu	H	NHSO ₂ -(2,4,6- trimethylphenyl)
5094	2-imidazoliny- aminomethyl	0	CO ₂ -t-Bu	H	NHSO ₂ -(2,4,6- trimethylphenyl)
5095	2-imidazoliny- aminomethyl	0	-(CH ₂) ₄ NH ₂	H	NHSO ₂ -(2,4,6- trimethylphenyl)
5096	2-imidazoliny- aminomethyl	0	COPh	H	NHSO ₂ -(2,4,6- trimethylphenyl)
5097	2-imidazoliny- aminomethyl	0	SO ₂ -n-Bu	H	NHSO ₂ -(2,4,6- trimethylphenyl)

5098	2-imidazoliny- aminomethyl	0	Cbz	H	NHCbz
5099	2-imidazoliny- aminomethyl	0	SO ₂ Ph	H	NHCbz
5100	2-imidazoliny- aminomethyl	0	CO(CH ₂) ₂ Ph	H	NHCbz
5101	2-imidazoliny- aminomethyl	0	Bn	H	NHCbz
5102	2-imidazoliny- aminomethyl	0	n-Bu	H	NHCbz
5103	2-imidazoliny- aminomethyl	0	CO ₂ -n-Bu	H	NHCbz
5104	2-imidazoliny- aminomethyl	0	CO ₂ -i-Bu	H	NHCbz
5105	2-imidazoliny- aminomethyl	0	CO ₂ -t-Bu	H	NHCbz
5106	2-imidazoliny- aminomethyl	0	-(CH ₂) ₄ NH ₂	H	NHCbz
5107	2-imidazoliny- aminomethyl	0	COPh	H	NHCbz
5108	2-imidazoliny- aminomethyl	0	SO ₂ -n-Bu	H	NHCbz
5109	2-benzimidazolyl- aminomethyl	0	Cbz	H	NHSO ₂ Ph
5110	2-benzimidazolyl- aminomethyl	0	SO ₂ Ph	H	NHSO ₂ Ph
5111	2-benzimidazolyl- aminomethyl	0	CO(CH ₂) ₂ Ph	H	NHSO ₂ Ph
5112	2-benzimidazolyl- aminomethyl	0	Bn	H	NHSO ₂ Ph
5113	2-benzimidazolyl- aminomethyl	0	n-Bu	H	NHSO ₂ Ph
5114	2-benzimidazolyl- aminomethyl	0	COCH ₂ (3- indolyl)	H	NHSO ₂ Ph

5115	2-benzimidazolyl-aminomethyl	0	SO ₂ -(bi phenyl)	H	NHSO ₂ Ph
5116	2-benzimidazolyl-aminomethyl	0	CO ₂ -n-Bu	H	NHSO ₂ Ph
5117	2-benzimidazolyl-aminomethyl	0	CO ₂ -i-Bu	H	NHSO ₂ Ph
5118	2-benzimidazolyl-aminomethyl	0	CO ₂ -t-Bu	H	NHSO ₂ Ph
5119	2-benzimidazolyl-aminomethyl	0	-(CH ₂) ₄ NH ₂	H	NHSO ₂ Ph
5120	2-benzimidazolyl-aminomethyl	0	COPh	H	NHSO ₂ Ph
5121	2-benzimidazolyl-aminomethyl	0	cyclo propyl-methyl	H	NHSO ₂ Ph
5122	2-benzimidazolyl-aminomethyl	0	SO ₂ -n-Bu	H	NHSO ₂ Ph
5123	2-benzimidazolyl-aminomethyl	0	Cbz	H	NHSO ₂ -(2,4,6-trimethylphenyl)
5124	2-benzimidazolyl-aminomethyl	0	SO ₂ Ph	H	NHSO ₂ -(2,4,6-trimethylphenyl)
5125	2-benzimidazolyl-aminomethyl	0	CO(CH ₂) ₂ Ph	H	NHSO ₂ -(2,4,6-trimethylphenyl)
5126	2-benzimidazolyl-aminomethyl	0	Bn	H	NHSO ₂ -(2,4,6-trimethylphenyl)
5127	2-benzimidazolyl-aminomethyl	0	n-Bu	H	NHSO ₂ -(2,4,6-trimethylphenyl)
5128	2-benzimidazolyl-aminomethyl	0	CO ₂ -n-Bu	H	NHSO ₂ -(2,4,6-trimethylphenyl)
5129	2-benzimidazolyl-aminomethyl	0	CO ₂ -i-Bu	H	NHSO ₂ -(2,4,6-trimethylphenyl)
5130	2-benzimidazolyl-aminomethyl	0	CO ₂ -t-Bu	H	NHSO ₂ -(2,4,6-trimethylphenyl)
5131	2-benzimidazolyl-aminomethyl	0	-(CH ₂) ₄ NH ₂	H	NHSO ₂ -(2,4,6-trimethylphenyl)

5132	2-benzimidazolyl- aminomethyl	0	COPh	H	NHSO ₂ -(2,4,6- trimethylphenyl)
5133	2-benzimidazolyl- aminomethyl	0	SO ₂ -n-Bu	H	NHSO ₂ -(2,4,6- trimethylphenyl)
5134	2-benzimidazolyl- aminomethyl	0	Cbz	H	NHCbz
5135	2-benzimidazolyl- aminomethyl	0	SO ₂ Ph	H	NHCbz
5136	2-benzimidazolyl- aminomethyl	0	CO(CH ₂) ₂ Ph	H	NHCbz
5137	2-benzimidazolyl- aminomethyl	0	Bn	H	NHCbz
5138	2-benzimidazolyl- aminomethyl	0	n-Bu	H	NHCbz
5139	2-benzimidazolyl- aminomethyl	0	CO ₂ -n-Bu	H	NHCbz
5140	2-benzimidazolyl- aminomethyl	0	CO ₂ -i-Bu	H	NHCbz
5141	2-benzimidazolyl- aminomethyl	0	CO ₂ -t-Bu	H	NHCbz
5142	2-benzimidazolyl- aminomethyl	0	-(CH ₂) ₄ NH ₂	H	NHCbz
5143	2-benzimidazolyl- aminomethyl	0	COPh	H	NHCbz
5144	2-benzimidazolyl- aminomethyl	0	SO ₂ -n-Bu	H	NHCbz
5145	7-aza-2- benzimidazolyl	0	Cbz	H	NHSO ₂ Ph
5146	7-aza-2- benzimidazolyl	0	SO ₂ Ph	H	NHSO ₂ Ph
5147	7-aza-2- benzimidazolyl	0	CO(CH ₂) ₂ Ph	H	NHSO ₂ Ph
5148	7-aza-2- benzimidazolyl	0	Bn	H	NHSO ₂ Ph

5149	7-aza-2-benzimidazolyl	0	n-Bu	H	NHSO ₂ Ph
5150	7-aza-2-benzimidazolyl	0	COCH ₂ (3-indolyl)	H	NHSO ₂ Ph
5151	7-aza-2-benzimidazolyl	0	SO ₂ -(bi-phenyl)	H	NHSO ₂ Ph
5152	7-aza-2-benzimidazolyl	0	CO ₂ -n-Bu	H	NHSO ₂ Ph
5153	7-aza-2-benzimidazolyl	0	CO ₂ -i-Bu	H	NHSO ₂ Ph
5154	7-aza-2-benzimidazolyl	0	CO ₂ -t-Bu	H	NHSO ₂ Ph
5155	7-aza-2-benzimidazolyl	0	-(CH ₂) ₄ NH ₂	H	NHSO ₂ Ph
5156	7-aza-2-benzimidazolyl	0	COPh	H	NHSO ₂ Ph
5157	7-aza-2-benzimidazolyl	0	cyclopropyl-methyl	H	NHSO ₂ Ph
5158	7-aza-2-benzimidazolyl	0	SO ₂ -n-Bu	H	NHSO ₂ Ph
5159	7-aza-2-benzimidazolyl	0	Cbz	H	NHSO ₂ -(2,4,6-trimethylphenyl)
5160	7-aza-2-benzimidazolyl	0	SO ₂ Ph	H	NHSO ₂ -(2,4,6-trimethylphenyl)
5161	7-aza-2-benzimidazolyl	0	CO(CH ₂) ₂ Ph	H	NHSO ₂ -(2,4,6-trimethylphenyl)
5162	7-aza-2-benzimidazolyl	0	Bn	H	NHSO ₂ -(2,4,6-trimethylphenyl)
5163	7-aza-2-benzimidazolyl	0	n-Bu	H	NHSO ₂ -(2,4,6-trimethylphenyl)
5164	7-aza-2-benzimidazolyl	0	CO ₂ -n-Bu	H	NHSO ₂ -(2,4,6-trimethylphenyl)
5165	7-aza-2-benzimidazolyl	0	CO ₂ -i-Bu	H	NHSO ₂ -(2,4,6-trimethylphenyl)

5166	7-aza-2- benzimidazolyl	0	CO ₂ -t-Bu	H	NHSO ₂ -(2,4,6- trimethylphenyl)
5167	7-aza-2- benzimidazolyl	0	-(CH ₂) ₄ NH ₂	H	NHSO ₂ -(2,4,6- trimethylphenyl)
5168	7-aza-2- benzimidazolyl	0	COPh	H	NHSO ₂ -(2,4,6- trimethylphenyl)
5169	7-aza-2- benzimidazolyl	0	SO ₂ -n-Bu	H	NHSO ₂ -(2,4,6- trimethylphenyl)
5170	7-aza-2- benzimidazolyl	0	Cbz	H	NHCbz
5171	7-aza-2- benzimidazolyl	0	SO ₂ Ph	H	NHCbz
5172	7-aza-2- benzimidazolyl	0	CO(CH ₂) ₂ Ph	H	NHCbz
5173	7-aza-2- benzimidazolyl	0	Bn	H	NHCbz
5174	7-aza-2- benzimidazolyl	0	n-Bu	H	NHCbz
5175	7-aza-2- benzimidazolyl	0	CO ₂ -n-Bu	H	NHCbz
5176	7-aza-2- benzimidazolyl	0	CO ₂ -i-Bu	H	NHCbz
5177	7-aza-2- benzimidazolyl	0	CO ₂ -t-Bu	H	NHCbz
5178	7-aza-2- benzimidazolyl	0	-(CH ₂) ₄ NH ₂	H	NHCbz
5179	7-aza-2- benzimidazolyl	0	COPh	H	NHCbz
5180	7-aza-2- benzimidazolyl	0	SO ₂ -n-Bu	H	NHCbz
5181	tetrahydropyrimidin -2-ylaminomethyl	0	Cbz	H	NHSO ₂ Ph
5182	tetrahydropyrimidin -2-ylaminomethyl	0	SO ₂ Ph	H	NHSO ₂ Ph

5183	tetrahydropyrimidin	0	CO(CH ₂) ₂ Ph	H	NHSO ₂ Ph
	-2-ylaminomethyl				
5184	tetrahydropyrimidin	0	Bn	H	NHSO ₂ Ph
	-2-ylaminomethyl				
5185	tetrahydropyrimidin	0	n-Bu	H	NHSO ₂ Ph
	-2-ylaminomethyl				
5186	tetrahydropyrimidin	0	COCH ₂ (3-indolyl)	H	NHSO ₂ Ph
	-2-ylaminomethyl				
5187	tetrahydropyrimidin	0	SO ₂ -(bi phenyl)	H	NHSO ₂ Ph
	-2-ylaminomethyl				
5188	tetrahydropyrimidin	0	CO ₂ -n-Bu	H	NHSO ₂ Ph
	-2-ylaminomethyl				
5189	tetrahydropyrimidin	0	CO ₂ -i-Bu	H	NHSO ₂ Ph
	-2-ylaminomethyl				
5190	tetrahydropyrimidin	0	CO ₂ -t-Bu	H	NHSO ₂ Ph
	-2-ylaminomethyl				
5191	tetrahydropyrimidin	0	-(CH ₂) ₄ NH ₂	H	NHSO ₂ Ph
	-2-ylaminomethyl				
5192	tetrahydropyrimidin	0	COPh	H	NHSO ₂ Ph
	-2-ylaminomethyl				
5193	tetrahydropyrimidin	0	cyclo propyl-methyl	H	NHSO ₂ Ph
	-2-ylaminomethyl				
5194	tetrahydropyrimidin	0	SO ₂ -n-Bu	H	NHSO ₂ Ph
	-2-ylaminomethyl				
5195	tetrahydropyrimidin	0	Cbz	H	NHSO ₂ -(2,4,6-trimethylphenyl)
	-2-ylaminomethyl				
5196	tetrahydropyrimidin	0	SO ₂ Ph	H	NHSO ₂ -(2,4,6-trimethylphenyl)
	-2-ylaminomethyl				
5197	tetrahydropyrimidin	0	CO(CH ₂) ₂ Ph	H	NHSO ₂ -(2,4,6-trimethylphenyl)
	-2-ylaminomethyl				
5198	tetrahydropyrimidin	0	Bn	H	NHSO ₂ -(2,4,6-trimethylphenyl)
	-2-ylaminomethyl				
5199	tetrahydropyrimidin	0	n-Bu	H	NHSO ₂ -(2,4,6-trimethylphenyl)
	-2-ylaminomethyl				

5200	tetrahydropyrimidin -2-ylaminomethyl	0	CO ₂ -n-Bu	H	NHSO ₂ -(2,4,6- trimethylphenyl)
5201	tetrahydropyrimidin -2-ylaminomethyl	0	CO ₂ -i-Bu	H	NHSO ₂ -(2,4,6- trimethylphenyl)
5202	tetrahydropyrimidin -2-ylaminomethyl	0	CO ₂ -t-Bu	H	NHSO ₂ -(2,4,6- trimethylphenyl)
5203	tetrahydropyrimidin -2-ylaminomethyl	0	-(CH ₂) ₄ NH ₂	H	NHSO ₂ -(2,4,6- trimethylphenyl)
5204	tetrahydropyrimidin -2-ylaminomethyl	0	COPh	H	NHSO ₂ -(2,4,6- trimethylphenyl)
5205	tetrahydropyrimidin -2-ylaminomethyl	0	SO ₂ -n-Bu	H	NHSO ₂ -(2,4,6- trimethylphenyl)
5206	tetrahydropyrimidin -2-ylaminomethyl	0	Cbz	H	NHCbz
5207	tetrahydropyrimidin -2-ylaminomethyl	0	SO ₂ Ph	H	NHCbz
5208	tetrahydropyrimidin -2-ylaminomethyl	0	CO(CH ₂) ₂ Ph	H	NHCbz
5209	tetrahydropyrimidin -2-ylaminomethyl	0	Bn	H	NHCbz
5210	tetrahydropyrimidin -2-ylaminomethyl	0	n-Bu	H	NHCbz
5211	tetrahydropyrimidin -2-ylaminomethyl	0	CO ₂ -n-Bu	H	NHCbz
5212	tetrahydropyrimidin -2-ylaminomethyl	0	CO ₂ -i-Bu	H	NHCbz
5213	tetrahydropyrimidin -2-ylaminomethyl	0	CO ₂ -t-Bu	H	NHCbz
5214	tetrahydropyrimidin -2-ylaminomethyl	0	-(CH ₂) ₄ NH ₂	H	NHCbz
5215	tetrahydropyrimidin -2-ylaminomethyl	0	COPh	H	NHCbz
5216	tetrahydropyrimidin -2-ylaminomethyl	0	SO ₂ -n-Bu	H	NHCbz

5217	2-pyridinylamino-methyl	1	Cbz	H	NHSO ₂ Ph
5218	2-pyridinylamino-methyl	1	SO ₂ Ph	H	NHSO ₂ Ph
5219	2-pyridinylamino-methyl	1	CO(CH ₂) ₂ Ph	H	NHSO ₂ Ph
5220	2-pyridinylamino-methyl	1	Bn	H	NHSO ₂ Ph
5221	2-pyridinylamino-methyl	1	n-Bu	H	NHSO ₂ Ph
5222	2-pyridinylamino-methyl	1	COCH ₂ (3-indolyl)	H	NHSO ₂ Ph
5223	2-pyridinylamino-methyl	1	SO ₂ -(bi-phenyl)	H	NHSO ₂ Ph
5224	2-pyridinylamino-methyl	1	CO ₂ -n-Bu	H	NHSO ₂ Ph
5225	2-pyridinylamino-methyl	1	CO ₂ -i-Bu	H	NHSO ₂ Ph
5226	2-pyridinylamino-methyl	1	CO ₂ -t-Bu	H	NHSO ₂ Ph
5227	2-pyridinylamino-methyl	1	-(CH ₂) ₄ NH ₂	H	NHSO ₂ Ph
5228	2-pyridinylamino-methyl	1	COPh	H	NHSO ₂ Ph
5229	2-pyridinylamino-methyl	1	cyclopropyl-methyl	H	NHSO ₂ Ph
5230	2-pyridinylamino-methyl	1	SO ₂ -n-Bu	H	NHSO ₂ Ph
5231	2-pyridinylamino-methyl	1	Cbz	H	NHSO ₂ -(2,4,6-trimethylphenyl)
5232	2-pyridinylamino-methyl	1	SO ₂ Ph	H	NHSO ₂ -(2,4,6-trimethylphenyl)
5233	2-pyridinylamino-methyl	1	CO(CH ₂) ₂ Ph	H	NHSO ₂ -(2,4,6-trimethylphenyl)

5234	2-pyridinylamino-methyl	1	Bn	H	NHSO ₂ -(2,4,6-trimethylphenyl)
5235	2-pyridinylamino-methyl	1	n-Bu	H	NHSO ₂ -(2,4,6-trimethylphenyl)
5236	2-pyridinylamino-methyl	1	CO ₂ -n-Bu	H	NHSO ₂ -(2,4,6-trimethylphenyl)
5237	2-pyridinylamino-methyl	1	CO ₂ -i-Bu	H	NHSO ₂ -(2,4,6-trimethylphenyl)
5238	2-pyridinylamino-methyl	1	CO ₂ -t-Bu	H	NHSO ₂ -(2,4,6-trimethylphenyl)
5239	2-pyridinylamino-methyl	1	-(CH ₂) ₄ NH ₂	H	NHSO ₂ -(2,4,6-trimethylphenyl)
5240	2-pyridinylamino-methyl	1	COPh	H	NHSO ₂ -(2,4,6-trimethylphenyl)
5241	2-pyridinylamino-methyl	1	SO ₂ -n-Bu	H	NHSO ₂ -(2,4,6-trimethylphenyl)
5242	2-pyridinylamino-methyl	1	Cbz	H	NHCbz
5243	2-pyridinylamino-methyl	1	SO ₂ Ph	H	NHCbz
5244	2-pyridinylamino-methyl	1	CO(CH ₂) ₂ Ph	H	NHCbz
5245	2-pyridinylamino-methyl	1	Bn	H	NHCbz
5246	2-pyridinylamino-methyl	1	n-Bu	H	NHCbz
5247	2-pyridinylamino-methyl	1	CO ₂ -n-Bu	H	NHCbz
5248	2-pyridinylamino-methyl	1	CO ₂ -i-Bu	H	NHCbz
5249	2-pyridinylamino-methyl	1	CO ₂ -t-Bu	H	NHCbz
5250	2-pyridinylamino-methyl	1	-(CH ₂) ₄ NH ₂	H	NHCbz

5251	2-pyridinylamino- methyl	1	COPh	H	NHCbz
5252	2-pyridinylamino- methyl	1	SO ₂ -n-Bu	H	NHCbz
5253	2-imidazolylamino- methyl	1	Cbz	H	NHSO ₂ Ph
5254	2-imidazolylamino- methyl	1	SO ₂ Ph	H	NHSO ₂ Ph
5255	2-imidazolylamino- methyl	1	CO(CH ₂) ₂ Ph	H	NHSO ₂ Ph
5256	2-imidazolylamino- methyl	1	Bn	H	NHSO ₂ Ph
5257	2-imidazolylamino- methyl	1	n-Bu	H	NHSO ₂ Ph
5258	2-imidazolylamino- methyl	1	COCH ₂ (3- indolyl)	H	NHSO ₂ Ph
5259	2-imidazolylamino- methyl	1	SO ₂ -(bi phenyl)	H	NHSO ₂ Ph
5260	2-imidazolylamino- methyl	1	CO ₂ -n-Bu	H	NHSO ₂ Ph
5261	2-imidazolylamino- methyl	1	CO ₂ -i-Bu	H	NHSO ₂ Ph
5262	2-imidazolylamino- methyl	1	CO ₂ -t-Bu	H	NHSO ₂ Ph
5263	2-imidazolylamino- methyl	1	-(CH ₂) ₄ NH ₂	H	NHSO ₂ Ph
5264	2-imidazolylamino- methyl	1	COPh	H	NHSO ₂ Ph
5265	2-imidazolylamino- methyl	1	cyclo propyl- methyl	H	NHSO ₂ Ph
5266	2-imidazolylamino- methyl	1	SO ₂ -n-Bu	H	NHSO ₂ Ph
5267	2-imidazolylamino- methyl	1	Cbz	H	NHSO ₂ -(2,4,6- trimethylphenyl)

5268	2-imidazolylamino-methyl	1	SO ₂ Ph	H	NHSO ₂ -(2,4,6-trimethylphenyl)
5269	2-imidazolylamino-methyl	1	CO(CH ₂) ₂ Ph	H	NHSO ₂ -(2,4,6-trimethylphenyl)
5270	2-imidazolylamino-methyl	1	Bn	H	NHSO ₂ -(2,4,6-trimethylphenyl)
5271	2-imidazolylamino-methyl	1	n-Bu	H	NHSO ₂ -(2,4,6-trimethylphenyl)
5272	2-imidazolylamino-methyl	1	CO ₂ -n-Bu	H	NHSO ₂ -(2,4,6-trimethylphenyl)
5273	2-imidazolylamino-methyl	1	CO ₂ -i-Bu	H	NHSO ₂ -(2,4,6-trimethylphenyl)
5274	2-imidazolylamino-methyl	1	CO ₂ -t-Bu	H	NHSO ₂ -(2,4,6-trimethylphenyl)
5275	2-imidazolylamino-methyl	1	-(CH ₂) ₄ NH ₂	H	NHSO ₂ -(2,4,6-trimethylphenyl)
5276	2-imidazolylamino-methyl	1	COPh	H	NHSO ₂ -(2,4,6-trimethylphenyl)
5277	2-imidazolylamino-methyl	1	SO ₂ -n-Bu	H	NHSO ₂ -(2,4,6-trimethylphenyl)
5278	2-imidazolylamino-methyl	1	Cbz	H	NHCbz
5279	2-imidazolylamino-methyl	1	SO ₂ Ph	H	NHCbz
5280	2-imidazolylamino-methyl	1	CO(CH ₂) ₂ Ph	H	NHCbz
5281	2-imidazolylamino-methyl	1	Bn	H	NHCbz
5282	2-imidazolylamino-methyl	1	n-Bu	H	NHCbz
5283	2-imidazolylamino-methyl	1	CO ₂ -n-Bu	H	NHCbz
5284	2-imidazolylamino-methyl	1	CO ₂ -i-Bu	H	NHCbz

5285	2-imidazolylamino- methyl	1	CO ₂ -t-Bu	H	NHCbz
5286	2-imidazolylamino- methyl	1	-(CH ₂) ₄ NH ₂	H	NHCbz
5287	2-imidazolylamino- methyl	1	COPh	H	NHCbz
5288	2-imidazolylamino- methyl	1	SO ₂ -n-Bu	H	NHCbz
5289	2-imidazoliny- aminomethyl	1	Cbz	H	NHSO ₂ Ph
5290	2-imidazoliny- aminomethyl	1	SO ₂ Ph	H	NHSO ₂ Ph
5291	2-imidazoliny- aminomethyl	1	CO(CH ₂) ₂ Ph	H	NHSO ₂ Ph
5292	2-imidazoliny- aminomethyl	1	Bn	H	NHSO ₂ Ph
5293	2-imidazoliny- aminomethyl	1	n-Bu	H	NHSO ₂ Ph
5294	2-imidazoliny- aminomethyl	1	COCH ₂ (3- indolyl)	H	NHSO ₂ Ph
5295	2-imidazoliny- aminomethyl	1	SO ₂ -(bi phenyl)	H	NHSO ₂ Ph
5296	2-imidazoliny- aminomethyl	1	CO ₂ -n-Bu	H	NHSO ₂ Ph
5297	2-imidazoliny- aminomethyl	1	CO ₂ -i-Bu	H	NHSO ₂ Ph
5298	2-imidazoliny- aminomethyl	1	CO ₂ -t-Bu	H	NHSO ₂ Ph
5299	2-imidazoliny- aminomethyl	1	-(CH ₂) ₄ NH ₂	H	NHSO ₂ Ph
5300	2-imidazoliny- aminomethyl	1	COPh	H	NHSO ₂ Ph
5301	2-imidazoliny- aminomethyl	1	cyclo propyl- methyl	H	NHSO ₂ Ph

5302	2-imidazoliny- aminomethyl	1	SO ₂ -n-Bu	H	NHSO ₂ Ph
5303	2-imidazoliny- aminomethyl	1	Cbz	H	NHSO ₂ -(2,4,6- trimethylphenyl)
5304	2-imidazoliny- aminomethyl	1	SO ₂ Ph	H	NHSO ₂ -(2,4,6- trimethylphenyl)
5305	2-imidazoliny- aminomethyl	1	CO(CH ₂) ₂ Ph	H	NHSO ₂ -(2,4,6- trimethylphenyl)
5306	2-imidazoliny- aminomethyl	1	Bn	H	NHSO ₂ -(2,4,6- trimethylphenyl)
5307	2-imidazoliny- aminomethyl	1	n-Bu	H	NHSO ₂ -(2,4,6- trimethylphenyl)
5308	2-imidazoliny- aminomethyl	1	CO ₂ -n-Bu	H	NHSO ₂ -(2,4,6- trimethylphenyl)
5309	2-imidazoliny- aminomethyl	1	CO ₂ -i-Bu	H	NHSO ₂ -(2,4,6- trimethylphenyl)
5310	2-imidazoliny- aminomethyl	1	CO ₂ -t-Bu	H	NHSO ₂ -(2,4,6- trimethylphenyl)
5311	2-imidazoliny- aminomethyl	1	-(CH ₂) ₄ NH ₂	H	NHSO ₂ -(2,4,6- trimethylphenyl)
5312	2-imidazoliny- aminomethyl	1	COPh	H	NHSO ₂ -(2,4,6- trimethylphenyl)
5313	2-imidazoliny- aminomethyl	1	SO ₂ -n-Bu	H	NHSO ₂ -(2,4,6- trimethylphenyl)
5314	2-imidazoliny- aminomethyl	1	Cbz	H	NHCbz
5315	2-imidazoliny- aminomethyl	1	SO ₂ Ph	H	NHCbz
5316	2-imidazoliny- aminomethyl	1	CO(CH ₂) ₂ Ph	H	NHCbz
5317	2-imidazoliny- aminomethyl	1	Bn	H	NHCbz
5318	2-imidazoliny- aminomethyl	1	n-Bu	H	NHCbz

5319	2-imidazolinyl- aminomethyl	1	CO ₂ -n-Bu	H	NHCbz
5320	2-imidazolinyl- aminomethyl	1	CO ₂ -i-Bu	H	NHCbz
5321	2-imidazolinyl- aminomethyl	1	CO ₂ -t-Bu	H	NHCbz
5322	2-imidazolinyl- aminomethyl	1	-(CH ₂) ₄ NH ₂	H	NHCbz
5323	2-imidazolinyl- aminomethyl	1	COPh	H	NHCbz
5324	2-imidazolinyl- aminomethyl	1	SO ₂ -n-Bu	H	NHCbz
5325	2-benzimidazolyl- aminomethyl	1	Cbz	H	NHSO ₂ Ph
5326	2-benzimidazolyl- aminomethyl	1	SO ₂ Ph	H	NHSO ₂ Ph
5327	2-benzimidazolyl- aminomethyl	1	CO(CH ₂) ₂ Ph	H	NHSO ₂ Ph
5328	2-benzimidazolyl- aminomethyl	1	Bn	H	NHSO ₂ Ph
5329	2-benzimidazolyl- aminomethyl	1	n-Bu	H	NHSO ₂ Ph
5330	2-benzimidazolyl- aminomethyl	1	COCH ₂ (3- indolyl)	H	NHSO ₂ Ph
5331	2-benzimidazolyl- aminomethyl	1	SO ₂ -(bi phenyl)	H	NHSO ₂ Ph
5332	2-benzimidazolyl- aminomethyl	1	CO ₂ -n-Bu	H	NHSO ₂ Ph
5333	2-benzimidazolyl- aminomethyl	1	CO ₂ -i-Bu	H	NHSO ₂ Ph
5334	2-benzimidazolyl- aminomethyl	1	CO ₂ -t-Bu	H	NHSO ₂ Ph
5335	2-benzimidazolyl- aminomethyl	1	-(CH ₂) ₄ NH ₂	H	NHSO ₂ Ph

5336	2-benzimidazolyl-aminomethyl	1	COPh	H	NHSO ₂ Ph
5337	2-benzimidazolyl-aminomethyl	1	cyclopropyl-methyl	H	NHSO ₂ Ph
5338	2-benzimidazolyl-aminomethyl	1	SO ₂ -n-Bu	H	NHSO ₂ Ph
5339	2-benzimidazolyl-aminomethyl	1	Cbz	H	NHSO ₂ -(2,4,6-trimethylphenyl)
5340	2-benzimidazolyl-aminomethyl	1	SO ₂ Ph	H	NHSO ₂ -(2,4,6-trimethylphenyl)
5341	2-benzimidazolyl-aminomethyl	1	CO(CH ₂) ₂ Ph	H	NHSO ₂ -(2,4,6-trimethylphenyl)
5342	2-benzimidazolyl-aminomethyl	1	Bn	H	NHSO ₂ -(2,4,6-trimethylphenyl)
5343	2-benzimidazolyl-aminomethyl	1	n-Bu	H	NHSO ₂ -(2,4,6-trimethylphenyl)
5344	2-benzimidazolyl-aminomethyl	1	CO ₂ -n-Bu	H	NHSO ₂ -(2,4,6-trimethylphenyl)
5345	2-benzimidazolyl-aminomethyl	1	CO ₂ -i-Bu	H	NHSO ₂ -(2,4,6-trimethylphenyl)
5346	2-benzimidazolyl-aminomethyl	1	CO ₂ -t-Bu	H	NHSO ₂ -(2,4,6-trimethylphenyl)
5347	2-benzimidazolyl-aminomethyl	1	-(CH ₂) ₄ NH ₂	H	NHSO ₂ -(2,4,6-trimethylphenyl)
5348	2-benzimidazolyl-aminomethyl	1	COPh	H	NHSO ₂ -(2,4,6-trimethylphenyl)
5349	2-benzimidazolyl-aminomethyl	1	SO ₂ -n-Bu	H	NHSO ₂ -(2,4,6-trimethylphenyl)
5350	2-benzimidazolyl-aminomethyl	1	Cbz	H	NHCbz
5351	2-benzimidazolyl-aminomethyl	1	SO ₂ Ph	H	NHCbz
5352	2-benzimidazolyl-aminomethyl	1	CO(CH ₂) ₂ Ph	H	NHCbz

5353	2-benzimidazolyl- aminomethyl	1	Bn	H	NHCbz
5354	2-benzimidazolyl- aminomethyl	1	n-Bu	H	NHCbz
5355	2-benzimidazolyl- aminomethyl	1	CO ₂ -n-Bu	H	NHCbz
5356	2-benzimidazolyl- aminomethyl	1	CO ₂ -i-Bu	H	NHCbz
5357	2-benzimidazolyl- aminomethyl	1	CO ₂ -t-Bu	H	NHCbz
5358	2-benzimidazolyl- aminomethyl	1	-(CH ₂) ₄ NH ₂	H	NHCbz
5359	2-benzimidazolyl- aminomethyl	1	COPh	H	NHCbz
5360	2-benzimidazolyl- aminomethyl	1	SO ₂ -n-Bu	H	NHCbz
5361	7-aza-2- benzimidazolyl	1	Cbz	H	NHSO ₂ Ph
5362	7-aza-2- benzimidazolyl	1	SO ₂ Ph	H	NHSO ₂ Ph
5363	7-aza-2- benzimidazolyl	1	CO(CH ₂) ₂ Ph	H	NHSO ₂ Ph
5364	7-aza-2- benzimidazolyl	1	Bn	H	NHSO ₂ Ph
5365	7-aza-2- benzimidazolyl	1	n-Bu	H	NHSO ₂ Ph
5366	7-aza-2- benzimidazolyl	1	COCH ₂ (3- indolyl)	H	NHSO ₂ Ph
5367	7-aza-2- benzimidazolyl	1	SO ₂ -(bi phenyl)	H	NHSO ₂ Ph
5368	7-aza-2- benzimidazolyl	1	CO ₂ -n-Bu	H	NHSO ₂ Ph
5369	7-aza-2- benzimidazolyl	1	CO ₂ -i-Bu	H	NHSO ₂ Ph


5370	7-aza-2- benzimidazolyl	1	CO ₂ -t-Bu	H	NHSO ₂ Ph
5371	7-aza-2- benzimidazolyl	1	-(CH ₂) ₄ NH ₂	H	NHSO ₂ Ph
5372	7-aza-2- benzimidazolyl	1	COPh	H	NHSO ₂ Ph
5373	7-aza-2- benzimidazolyl	1	cyclo propyl- methyl	H	NHSO ₂ Ph
5374	7-aza-2- benzimidazolyl	1	SO ₂ -n-Bu	H	NHSO ₂ Ph
5375	7-aza-2- benzimidazolyl	1	Cbz	H	NHSO ₂ -(2,4,6- trimethylphenyl)
5376	7-aza-2- benzimidazolyl	1	SO ₂ Ph	H	NHSO ₂ -(2,4,6- trimethylphenyl)
5377	7-aza-2- benzimidazolyl	1	CO(CH ₂) ₂ Ph	H	NHSO ₂ -(2,4,6- trimethylphenyl)
5378	7-aza-2- benzimidazolyl	1	Bn	H	NHSO ₂ -(2,4,6- trimethylphenyl)
5379	7-aza-2- benzimidazolyl	1	n-Bu	H	NHSO ₂ -(2,4,6- trimethylphenyl)
5380	7-aza-2- benzimidazolyl	1	CO ₂ -n-Bu	H	NHSO ₂ -(2,4,6- trimethylphenyl)
5381	7-aza-2- benzimidazolyl	1	CO ₂ -i-Bu	H	NHSO ₂ -(2,4,6- trimethylphenyl)
5382	7-aza-2- benzimidazolyl	1	CO ₂ -t-Bu	H	NHSO ₂ -(2,4,6- trimethylphenyl)
5383	7-aza-2- benzimidazolyl	1	-(CH ₂) ₄ NH ₂	H	NHSO ₂ -(2,4,6- trimethylphenyl)
5384	7-aza-2- benzimidazolyl	1	COPh	H	NHSO ₂ -(2,4,6- trimethylphenyl)
5385	7-aza-2- benzimidazolyl	1	SO ₂ -n-Bu	H	NHSO ₂ -(2,4,6- trimethylphenyl)
5386	7-aza-2- benzimidazolyl	1	Cbz	H	NHCbz

5387	7-aza-2- benzimidazolyl	1	SO ₂ Ph	H	NHCbz
5388	7-aza-2- benzimidazolyl	1	CO(CH ₂) ₂ Ph	H	NHCbz
5389	7-aza-2- benzimidazolyl	1	Bn	H	NHCbz
5390	7-aza-2- benzimidazolyl	1	n-Bu	H	NHCbz
5391	7-aza-2- benzimidazolyl	1	CO ₂ -n-Bu	H	NHCbz
5392	7-aza-2- benzimidazolyl	1	CO ₂ -i-Bu	H	NHCbz
5393	7-aza-2- benzimidazolyl	1	CO ₂ -t-Bu	H	NHCbz
5394	7-aza-2- benzimidazolyl	1	-(CH ₂) ₄ NH ₂	H	NHCbz
5395	7-aza-2- benzimidazolyl	1	COPh	H	NHCbz
5396	7-aza-2- benzimidazolyl	1	SO ₂ -n-Bu	H	NHCbz
5397	tetrahydropyrimidin -2-ylaminomethyl	1	Cbz	H	NHSO ₂ Ph
5398	tetrahydropyrimidin -2-ylaminomethyl	1	SO ₂ Ph	H	NHSO ₂ Ph
5399	tetrahydropyrimidin -2-ylaminomethyl	1	CO(CH ₂) ₂ Ph	H	NHSO ₂ Ph
5400	tetrahydropyrimidin -2-ylaminomethyl	1	Bn	H	NHSO ₂ Ph
5401	tetrahydropyrimidin -2-ylaminomethyl	1	n-Bu	H	NHSO ₂ Ph
5402	tetrahydropyrimidin -2-ylaminomethyl	1	COCH ₂ (3- indolyl)	H	NHSO ₂ Ph
5403	tetrahydropyrimidin -2-ylaminomethyl	1	SO ₂ -(bi phenyl)	H	NHSO ₂ Ph

5404	tetrahydropyrimidin -2-ylaminomethyl	1	CO ₂ -n-Bu	H	NHSO ₂ Ph
5405	tetrahydropyrimidin -2-ylaminomethyl	1	CO ₂ -i-Bu	H	NHSO ₂ Ph
5406	tetrahydropyrimidin -2-ylaminomethyl	1	CO ₂ -t-Bu	H	NHSO ₂ Ph
5407	tetrahydropyrimidin -2-ylaminomethyl	1	-(CH ₂) ₄ NH ₂	H	NHSO ₂ Ph
5408	tetrahydropyrimidin -2-ylaminomethyl	1	COPh	H	NHSO ₂ Ph
5409	tetrahydropyrimidin -2-ylaminomethyl	1	cyclo propyl- methyl	H	NHSO ₂ Ph
5410	tetrahydropyrimidin -2-ylaminomethyl	1	SO ₂ -n-Bu	H	NHSO ₂ Ph
5411	tetrahydropyrimidin -2-ylaminomethyl	1	Cbz	H	NHSO ₂ -(2,4,6- trimethylphenyl)
5412	tetrahydropyrimidin -2-ylaminomethyl	1	SO ₂ Ph	H	NHSO ₂ -(2,4,6- trimethylphenyl)
5413	tetrahydropyrimidin -2-ylaminomethyl	1	CO(CH ₂) ₂ Ph	H	NHSO ₂ -(2,4,6- trimethylphenyl)
5414	tetrahydropyrimidin -2-ylaminomethyl	1	Bn	H	NHSO ₂ -(2,4,6- trimethylphenyl)
5415	tetrahydropyrimidin -2-ylaminomethyl	1	n-Bu	H	NHSO ₂ -(2,4,6- trimethylphenyl)
5416	tetrahydropyrimidin -2-ylaminomethyl	1	CO ₂ -n-Bu	H	NHSO ₂ -(2,4,6- trimethylphenyl)
5417	tetrahydropyrimidin -2-ylaminomethyl	1	CO ₂ -i-Bu	H	NHSO ₂ -(2,4,6- trimethylphenyl)
5418	tetrahydropyrimidin -2-ylaminomethyl	1	CO ₂ -t-Bu	H	NHSO ₂ -(2,4,6- trimethylphenyl)
5419	tetrahydropyrimidin -2-ylaminomethyl	1	-(CH ₂) ₄ NH ₂	H	NHSO ₂ -(2,4,6- trimethylphenyl)
5420	tetrahydropyrimidin -2-ylaminomethyl	1	COPh	H	NHSO ₂ -(2,4,6- trimethylphenyl)

5421	tetrahydropyrimidin -2-ylaminomethyl	1	SO ₂ -n-Bu	H	NHSO ₂ -(2,4,6- trimethylphenyl)
5422	tetrahydropyrimidin -2-ylaminomethyl	1	Cbz	H	NHCbz
5423	tetrahydropyrimidin -2-ylaminomethyl	1	SO ₂ Ph	H	NHCbz
5424	tetrahydropyrimidin -2-ylaminomethyl	1	CO(CH ₂) ₂ Ph	H	NHCbz
5425	tetrahydropyrimidin -2-ylaminomethyl	1	Bn	H	NHCbz
5426	tetrahydropyrimidin -2-ylaminomethyl	1	n-Bu	H	NHCbz
5427	tetrahydropyrimidin -2-ylaminomethyl	1	CO ₂ -n-Bu	H	NHCbz
5428	tetrahydropyrimidin -2-ylaminomethyl	1	CO ₂ -i-Bu	H	NHCbz
5429	tetrahydropyrimidin -2-ylaminomethyl	1	CO ₂ -t-Bu	H	NHCbz
5430	tetrahydropyrimidin -2-ylaminomethyl	1	-(CH ₂) ₄ NH ₂	H	NHCbz
5431	tetrahydropyrimidin -2-ylaminomethyl	1	COPh	H	NHCbz
5432	tetrahydropyrimidin -2-ylaminomethyl	1	SO ₂ -n-Bu	H	NHCbz

Table 6



Ex. No.	R ¹	r	R ^{10a}	R ¹⁴	R ¹⁵
6001	2-pyridinylamino-methyl	0	Cbz	H	NHSO ₂ Ph
6002	2-pyridinylamino-methyl	0	SO ₂ Ph	H	NHSO ₂ Ph
6003	2-pyridinylamino-methyl	0	CO(CH ₂) ₂ Ph	H	NHSO ₂ Ph
6004	2-pyridinylamino-methyl	0	Bn	H	NHSO ₂ Ph
6005	2-pyridinylamino-methyl	0	n-Bu	H	NHSO ₂ Ph
6006	2-pyridinylamino-methyl	0	COCH ₂ (3-indolyl)	H	NHSO ₂ Ph
6007	2-pyridinylamino-methyl	0	SO ₂ -(biphenyl)	H	NHSO ₂ Ph
6008	2-pyridinylamino-methyl	0	CO ₂ -n-Bu	H	NHSO ₂ Ph
6009	2-pyridinylamino-methyl	0	CO ₂ -i-Bu	H	NHSO ₂ Ph
6010	2-pyridinylamino-methyl	0	CO ₂ -t-Bu	H	NHSO ₂ Ph
6011	2-pyridinylamino-methyl	0	-(CH ₂) ₄ NH ₂	H	NHSO ₂ Ph
6012	2-pyridinylamino-methyl	0	COPh	H	NHSO ₂ Ph

6013	2-pyridinylamino- methyl	0	cyclopropyl- methyl	H	NHSO ₂ Ph
6014	2-pyridinylamino- methyl	0	SO ₂ -n-Bu	H	NHSO ₂ Ph
6015	2-pyridinylamino- methyl	0	Cbz	H	NHSO ₂ -(2,4,6- trimethylphenyl)
6016	2-pyridinylamino- methyl	0	SO ₂ Ph	H	NHSO ₂ -(2,4,6- trimethylphenyl)
6017	2-pyridinylamino- methyl	0	CO(CH ₂) ₂ Ph	H	NHSO ₂ -(2,4,6- trimethylphenyl)
6018	2-pyridinylamino- methyl	0	Bn	H	NHSO ₂ -(2,4,6- trimethylphenyl)
6019	2-pyridinylamino- methyl	0	n-Bu	H	NHSO ₂ -(2,4,6- trimethylphenyl)
6020	2-pyridinylamino- methyl	0	CO ₂ -n-Bu	H	NHSO ₂ -(2,4,6- trimethylphenyl)
6021	2-pyridinylamino- methyl	0	CO ₂ -i-Bu	H	NHSO ₂ -(2,4,6- trimethylphenyl)
6022	2-pyridinylamino- methyl	0	CO ₂ -t-Bu	H	NHSO ₂ -(2,4,6- trimethylphenyl)
6023	2-pyridinylamino- methyl	0	-(CH ₂) ₄ NH ₂	H	NHSO ₂ -(2,4,6- trimethylphenyl)
6024	2-pyridinylamino- methyl	0	COPh	H	NHSO ₂ -(2,4,6- trimethylphenyl)
6025	2-pyridinylamino- methyl	0	SO ₂ -n-Bu	H	NHSO ₂ -(2,4,6- trimethylphenyl)
6026	2-pyridinylamino- methyl	0	Cbz	H	NHCbz
6027	2-pyridinylamino- methyl	0	SO ₂ Ph	H	NHCbz
6028	2-pyridinylamino- methyl	0	CO(CH ₂) ₂ Ph	H	NHCbz
6029	2-pyridinylamino- methyl	0	Bn	H	NHCbz

6030	2-pyridinylamino- methyl	0	n-Bu	H	NHCbz
6031	2-pyridinylamino- methyl	0	CO ₂ -n-Bu	H	NHCbz
6032	2-pyridinylamino- methyl	0	CO ₂ -i-Bu	H	NHCbz
6033	2-pyridinylamino- methyl	0	CO ₂ -t-Bu	H	NHCbz
6034	2-pyridinylamino- methyl	0	-(CH ₂) ₄ NH ₂	H	NHCbz
6035	2-pyridinylamino- methyl	0	COPh	H	NHCbz
6036	2-pyridinylamino- methyl	0	SO ₂ -n-Bu	H	NHCbz
6037	2-imidazolylamino- methyl	0	Cbz	H	NHSO ₂ Ph
6038	2-imidazolylamino- methyl	0	SO ₂ Ph	H	NHSO ₂ Ph
6039	2-imidazolylamino- methyl	0	CO(CH ₂) ₂ Ph	H	NHSO ₂ Ph
6040	2-imidazolylamino- methyl	0	Bn	H	NHSO ₂ Ph
6041	2-imidazolylamino- methyl	0	n-Bu	H	NHSO ₂ Ph
6042	2-imidazolylamino- methyl	0	COCH ₂ (3- indolyl)	H	NHSO ₂ Ph
6043	2-imidazolylamino- methyl	0	SO ₂ - (biphenyl)	H	NHSO ₂ Ph
6044	2-imidazolylamino- methyl	0	CO ₂ -n-Bu	H	NHSO ₂ Ph
6045	2-imidazolylamino- methyl	0	CO ₂ -i-Bu	H	NHSO ₂ Ph
6046	2-imidazolylamino- methyl	0	CO ₂ -t-Bu	H	NHSO ₂ Ph

6047	2-imidazolylamino- methyl	0	-(CH ₂) ₄ NH ₂	H	NHSO ₂ Ph
6048	2-imidazolylamino- methyl	0	COPh	H	NHSO ₂ Ph
6049	2-imidazolylamino- methyl	0	cyclopropyl- methyl	H	NHSO ₂ Ph
6050	2-imidazolylamino- methyl	0	SO ₂ -n-Bu	H	NHSO ₂ Ph
6051	2-imidazolylamino- methyl	0	Cbz	H	NHSO ₂ -(2,4,6- trimethylphenyl)
6052	2-imidazolylamino- methyl	0	SO ₂ Ph	H	NHSO ₂ -(2,4,6- trimethylphenyl)
6053	2-imidazolylamino- methyl	0	CO(CH ₂) ₂ Ph	H	NHSO ₂ -(2,4,6- trimethylphenyl)
6054	2-imidazolylamino- methyl	0	Bn	H	NHSO ₂ -(2,4,6- trimethylphenyl)
6055	2-imidazolylamino- methyl	0	n-Bu	H	NHSO ₂ -(2,4,6- trimethylphenyl)
6056	2-imidazolylamino- methyl	0	CO ₂ -n-Bu	H	NHSO ₂ -(2,4,6- trimethylphenyl)
6057	2-imidazolylamino- methyl	0	CO ₂ -i-Bu	H	NHSO ₂ -(2,4,6- trimethylphenyl)
6058	2-imidazolylamino- methyl	0	CO ₂ -t-Bu	H	NHSO ₂ -(2,4,6- trimethylphenyl)
6059	2-imidazolylamino- methyl	0	-(CH ₂) ₄ NH ₂	H	NHSO ₂ -(2,4,6- trimethylphenyl)
6060	2-imidazolylamino- methyl	0	COPh	H	NHSO ₂ -(2,4,6- trimethylphenyl)
6061	2-imidazolylamino- methyl	0	SO ₂ -n-Bu	H	NHSO ₂ -(2,4,6- trimethylphenyl)
6062	2-imidazolylamino- methyl	0	Cbz	H	NHCbz
6063	2-imidazolylamino- methyl	0	SO ₂ Ph	H	NHCbz

6064	2-imidazolylamino- methyl	0	CO(CH ₂) ₂ Ph	H	NHCbz
6065	2-imidazolylamino- methyl	0	Bn	H	NHCbz
6066	2-imidazolylamino- methyl	0	n-Bu	H	NHCbz
6067	2-imidazolylamino- methyl	0	CO ₂ -n-Bu	H	NHCbz
6068	2-imidazolylamino- methyl	0	CO ₂ -i-Bu	H	NHCbz
6069	2-imidazolylamino- methyl	0	CO ₂ -t-Bu	H	NHCbz
6070	2-imidazolylamino- methyl	0	-(CH ₂) ₄ NH ₂	H	NHCbz
6071	2-imidazolylamino- methyl	0	COPh	H	NHCbz
6072	2-imidazolylamino- methyl	0	SO ₂ -n-Bu	H	NHCbz
6073	2-imidazoliny- aminomethyl	0	Cbz	H	NHSO ₂ Ph
6074	2-imidazoliny- aminomethyl	0	SO ₂ Ph	H	NHSO ₂ Ph
6075	2-imidazoliny- aminomethyl	0	CO(CH ₂) ₂ Ph	H	NHSO ₂ Ph
6076	2-imidazoliny- aminomethyl	0	Bn	H	NHSO ₂ Ph
6077	2-imidazoliny- aminomethyl	0	n-Bu	H	NHSO ₂ Ph
6078	2-imidazoliny- aminomethyl	0	COCH ₂ (3- indolyl)	H	NHSO ₂ Ph
6079	2-imidazoliny- aminomethyl	0	SO ₂ - (biphenyl)	H	NHSO ₂ Ph
6080	2-imidazoliny- aminomethyl	0	CO ₂ -n-Bu	H	NHSO ₂ Ph

6081	2-imidazoliny- aminomethyl	0	CO ₂ -i-Bu	H	NHSO ₂ Ph
6082	2-imidazoliny- aminomethyl	0	CO ₂ -t-Bu	H	NHSO ₂ Ph
6083	2-imidazoliny- aminomethyl	0	-(CH ₂) ₄ NH ₂	H	NHSO ₂ Ph
6084	2-imidazoliny- aminomethyl	0	COPh	H	NHSO ₂ Ph
6085	2-imidazoliny- aminomethyl	0	cyclopropyl- methyl	H	NHSO ₂ Ph
6086	2-imidazoliny- aminomethyl	0	SO ₂ -n-Bu	H	NHSO ₂ Ph
6087	2-imidazoliny- aminomethyl	0	Cbz	H	NHSO ₂ -(2,4,6- trimethylphenyl)
6088	2-imidazoliny- aminomethyl	0	SO ₂ Ph	H	NHSO ₂ -(2,4,6- trimethylphenyl)
6089	2-imidazoliny- aminomethyl	0	CO(CH ₂) ₂ Ph	H	NHSO ₂ -(2,4,6- trimethylphenyl)
6090	2-imidazoliny- aminomethyl	0	Bn	H	NHSO ₂ -(2,4,6- trimethylphenyl)
6091	2-imidazoliny- aminomethyl	0	n-Bu	H	NHSO ₂ -(2,4,6- trimethylphenyl)
6092	2-imidazoliny- aminomethyl	0	CO ₂ -n-Bu	H	NHSO ₂ -(2,4,6- trimethylphenyl)
6093	2-imidazoliny- aminomethyl	0	CO ₂ -i-Bu	H	NHSO ₂ -(2,4,6- trimethylphenyl)
6094	2-imidazoliny- aminomethyl	0	CO ₂ -t-Bu	H	NHSO ₂ -(2,4,6- trimethylphenyl)
6095	2-imidazoliny- aminomethyl	0	-(CH ₂) ₄ NH ₂	H	NHSO ₂ -(2,4,6- trimethylphenyl)
6096	2-imidazoliny- aminomethyl	0	COPh	H	NHSO ₂ -(2,4,6- trimethylphenyl)
6097	2-imidazoliny- aminomethyl	0	SO ₂ -n-Bu	H	NHSO ₂ -(2,4,6- trimethylphenyl)

6098	2-imidazoliny- aminomethyl	0	Cbz	H	NHCbz
6099	2-imidazoliny- aminomethyl	0	SO ₂ Ph	H	NHCbz
6100	2-imidazoliny- aminomethyl	0	CO(CH ₂) ₂ Ph	H	NHCbz
6101	2-imidazoliny- aminomethyl	0	Bn	H	NHCbz
6102	2-imidazoliny- aminomethyl	0	n-Bu	H	NHCbz
6103	2-imidazoliny- aminomethyl	0	CO ₂ -n-Bu	H	NHCbz
6104	2-imidazoliny- aminomethyl	0	CO ₂ -i-Bu	H	NHCbz
6105	2-imidazoliny- aminomethyl	0	CO ₂ -t-Bu	H	NHCbz
6106	2-imidazoliny- aminomethyl	0	-(CH ₂) ₄ NH ₂	H	NHCbz
6107	2-imidazoliny- aminomethyl	0	COPh	H	NHCbz
6108	2-imidazoliny- aminomethyl	0	SO ₂ -n-Bu	H	NHCbz
6109	2-benzimidazolyl- aminomethyl	0	Cbz	H	NHSO ₂ Ph
6110	2-benzimidazolyl- aminomethyl	0	SO ₂ Ph	H	NHSO ₂ Ph
6111	2-benzimidazolyl- aminomethyl	0	CO(CH ₂) ₂ Ph	H	NHSO ₂ Ph
6112	2-benzimidazolyl- aminomethyl	0	Bn	H	NHSO ₂ Ph
6113	2-benzimidazolyl- aminomethyl	0	n-Bu	H	NHSO ₂ Ph
6114	2-benzimidazolyl- aminomethyl	0	COCH ₂ (3- indolyl)	H	NHSO ₂ Ph

6115	2-benzimidazolyl- aminomethyl	0	SO ₂ - (biphenyl)	H	NHSO ₂ Ph
6116	2-benzimidazolyl- aminomethyl	0	CO ₂ -n-Bu	H	NHSO ₂ Ph
6117	2-benzimidazolyl- aminomethyl	0	CO ₂ -i-Bu	H	NHSO ₂ Ph
6118	2-benzimidazolyl- aminomethyl	0	CO ₂ -t-Bu	H	NHSO ₂ Ph
6119	2-benzimidazolyl- aminomethyl	0	-(CH ₂) ₄ NH ₂	H	NHSO ₂ Ph
6120	2-benzimidazolyl- aminomethyl	0	COPh	H	NHSO ₂ Ph
6121	2-benzimidazolyl- aminomethyl	0	cyclopropyl- methyl	H	NHSO ₂ Ph
6122	2-benzimidazolyl- aminomethyl	0	SO ₂ -n-Bu	H	NHSO ₂ Ph
6123	2-benzimidazolyl- aminomethyl	0	Cbz	H	NHSO ₂ -(2,4,6- trimethylphenyl)
6124	2-benzimidazolyl- aminomethyl	0	SO ₂ Ph	H	NHSO ₂ -(2,4,6- trimethylphenyl)
6125	2-benzimidazolyl- aminomethyl	0	CO(CH ₂) ₂ Ph	H	NHSO ₂ -(2,4,6- trimethylphenyl)
6126	2-benzimidazolyl- aminomethyl	0	Bn	H	NHSO ₂ -(2,4,6- trimethylphenyl)
6127	2-benzimidazolyl- aminomethyl	0	n-Bu	H	NHSO ₂ -(2,4,6- trimethylphenyl)
6128	2-benzimidazolyl- aminomethyl	0	CO ₂ -n-Bu	H	NHSO ₂ -(2,4,6- trimethylphenyl)
6129	2-benzimidazolyl- aminomethyl	0	CO ₂ -i-Bu	H	NHSO ₂ -(2,4,6- trimethylphenyl)
6130	2-benzimidazolyl- aminomethyl	0	CO ₂ -t-Bu	H	NHSO ₂ -(2,4,6- trimethylphenyl)
6131	2-benzimidazolyl- aminomethyl	0	-(CH ₂) ₄ NH ₂	H	NHSO ₂ -(2,4,6- trimethylphenyl)

6132	2-benzimidazolyl- aminomethyl	0	COPh	H	NHSO ₂ -(2,4,6- trimethylphenyl)
6133	2-benzimidazolyl- aminomethyl	0	SO ₂ -n-Bu	H	NHSO ₂ -(2,4,6- trimethylphenyl)
6134	2-benzimidazolyl- aminomethyl	0	Cbz	H	NHCbz
6135	2-benzimidazolyl- aminomethyl	0	SO ₂ Ph	H	NHCbz
6136	2-benzimidazolyl- aminomethyl	0	CO(CH ₂) ₂ Ph	H	NHCbz
6137	2-benzimidazolyl- aminomethyl	0	Bn	H	NHCbz
6138	2-benzimidazolyl- aminomethyl	0	n-Bu	H	NHCbz
6139	2-benzimidazolyl- aminomethyl	0	CO ₂ -n-Bu	H	NHCbz
6140	2-benzimidazolyl- aminomethyl	0	CO ₂ -i-Bu	H	NHCbz
6141	2-benzimidazolyl- aminomethyl	0	CO ₂ -t-Bu	H	NHCbz
6142	2-benzimidazolyl- aminomethyl	0	-(CH ₂) ₄ NH ₂	H	NHCbz
6143	2-benzimidazolyl- aminomethyl	0	COPh	H	NHCbz
6144	2-benzimidazolyl- aminomethyl	0	SO ₂ -n-Bu	H	NHCbz
6145	7-aza-2- benzimidazolyl	0	Cbz	H	NHSO ₂ Ph
6146	7-aza-2- benzimidazolyl	0	SO ₂ Ph	H	NHSO ₂ Ph
6147	7-aza-2- benzimidazolyl	0	CO(CH ₂) ₂ Ph	H	NHSO ₂ Ph
6148	7-aza-2- benzimidazolyl	0	Bn	H	NHSO ₂ Ph

6149	7-aza-2- benzimidazolyl	0	n-Bu	H	NHSO ₂ Ph
6150	7-aza-2- benzimidazolyl	0	COCH ₂ (3- indolyl)	H	NHSO ₂ Ph
6151	7-aza-2- benzimidazolyl	0	SO ₂ - (biphenyl)	H	NHSO ₂ Ph
6152	7-aza-2- benzimidazolyl	0	CO ₂ -n-Bu	H	NHSO ₂ Ph
6153	7-aza-2- benzimidazolyl	0	CO ₂ -i-Bu	H	NHSO ₂ Ph
6154	7-aza-2- benzimidazolyl	0	CO ₂ -t-Bu	H	NHSO ₂ Ph
6155	7-aza-2- benzimidazolyl	0	-(CH ₂) ₄ NH ₂	H	NHSO ₂ Ph
6156	7-aza-2- benzimidazolyl	0	COPh	H	NHSO ₂ Ph
6157	7-aza-2- benzimidazolyl	0	cyclopropyl- methyl	H	NHSO ₂ Ph
6158	7-aza-2- benzimidazolyl	0	SO ₂ -n-Bu	H	NHSO ₂ Ph
6159	7-aza-2- benzimidazolyl	0	Cbz	H	NHSO ₂ -(2,4,6- trimethylphenyl)
6160	7-aza-2- benzimidazolyl	0	SO ₂ Ph	H	NHSO ₂ -(2,4,6- trimethylphenyl)
6161	7-aza-2- benzimidazolyl	0	CO(CH ₂) ₂ Ph	H	NHSO ₂ -(2,4,6- trimethylphenyl)
6162	7-aza-2- benzimidazolyl	0	Bn	H	NHSO ₂ -(2,4,6- trimethylphenyl)
6163	7-aza-2- benzimidazolyl	0	n-Bu	H	NHSO ₂ -(2,4,6- trimethylphenyl)
6164	7-aza-2- benzimidazolyl	0	CO ₂ -n-Bu	H	NHSO ₂ -(2,4,6- trimethylphenyl)
6165	7-aza-2- benzimidazolyl	0	CO ₂ -i-Bu	H	NHSO ₂ -(2,4,6- trimethylphenyl)

6166	7-aza-2-benzimidazolyl	0	CO ₂ -t-Bu	H	NHSO ₂ -(2,4,6-trimethylphenyl)
6167	7-aza-2-benzimidazolyl	0	-(CH ₂) ₄ NH ₂	H	NHSO ₂ -(2,4,6-trimethylphenyl)
6168	7-aza-2-benzimidazolyl	0	COPh	H	NHSO ₂ -(2,4,6-trimethylphenyl)
6169	7-aza-2-benzimidazolyl	0	SO ₂ -n-Bu	H	NHSO ₂ -(2,4,6-trimethylphenyl)
6170	7-aza-2-benzimidazolyl	0	Cbz	H	NHCbz
6171	7-aza-2-benzimidazolyl	0	SO ₂ Ph	H	NHCbz
6172	7-aza-2-benzimidazolyl	0	CO(CH ₂) ₂ Ph	H	NHCbz
6173	7-aza-2-benzimidazolyl	0	Bn	H	NHCbz
6174	7-aza-2-benzimidazolyl	0	n-Bu	H	NHCbz
6175	7-aza-2-benzimidazolyl	0	CO ₂ -n-Bu	H	NHCbz
6176	7-aza-2-benzimidazolyl	0	CO ₂ -i-Bu	H	NHCbz
6177	7-aza-2-benzimidazolyl	0	CO ₂ -t-Bu	H	NHCbz
6178	7-aza-2-benzimidazolyl	0	-(CH ₂) ₄ NH ₂	H	NHCbz
6179	7-aza-2-benzimidazolyl	0	COPh	H	NHCbz
6180	7-aza-2-benzimidazolyl	0	SO ₂ -n-Bu	H	NHCbz
6181	tetrahydropyrimidin-2-ylaminomethyl	0	Cbz	H	NHSO ₂ Ph
6182	tetrahydropyrimidin-2-ylaminomethyl	0	SO ₂ Ph	H	NHSO ₂ Ph

6183	tetrahydropyrimidin	0	CO(CH ₂) ₂ Ph	H	NHSO ₂ Ph
	-2-ylaminomethyl				
6184	tetrahydropyrimidin	0	Bn	H	NHSO ₂ Ph
	-2-ylaminomethyl				
6185	tetrahydropyrimidin	0	n-Bu	H	NHSO ₂ Ph
	-2-ylaminomethyl				
6186	tetrahydropyrimidin	0	COCH ₂ (3-indolyl)	H	NHSO ₂ Ph
	-2-ylaminomethyl				
6187	tetrahydropyrimidin	0	SO ₂ -(biphenyl)	H	NHSO ₂ Ph
	-2-ylaminomethyl				
6188	tetrahydropyrimidin	0	CO ₂ -n-Bu	H	NHSO ₂ Ph
	-2-ylaminomethyl				
6189	tetrahydropyrimidin	0	CO ₂ -i-Bu	H	NHSO ₂ Ph
	-2-ylaminomethyl				
6190	tetrahydropyrimidin	0	CO ₂ -t-Bu	H	NHSO ₂ Ph
	-2-ylaminomethyl				
6191	tetrahydropyrimidin	0	-(CH ₂) ₄ NH ₂	H	NHSO ₂ Ph
	-2-ylaminomethyl				
6192	tetrahydropyrimidin	0	COPh	H	NHSO ₂ Ph
	-2-ylaminomethyl				
6193	tetrahydropyrimidin	0	cyclopropyl-methyl	H	NHSO ₂ Ph
	-2-ylaminomethyl				
6194	tetrahydropyrimidin	0	SO ₂ -n-Bu	H	NHSO ₂ Ph
	-2-ylaminomethyl				
6195	tetrahydropyrimidin	0	Cbz	H	NHSO ₂ -(2,4,6-trimethylphenyl)
	-2-ylaminomethyl				
6196	tetrahydropyrimidin	0	SO ₂ Ph	H	NHSO ₂ -(2,4,6-trimethylphenyl)
	-2-ylaminomethyl				
6197	tetrahydropyrimidin	0	CO(CH ₂) ₂ Ph	H	NHSO ₂ -(2,4,6-trimethylphenyl)
	-2-ylaminomethyl				
6198	tetrahydropyrimidin	0	Bn	H	NHSO ₂ -(2,4,6-trimethylphenyl)
	-2-ylaminomethyl				
6199	tetrahydropyrimidin	0	n-Bu	H	NHSO ₂ -(2,4,6-trimethylphenyl)
	-2-ylaminomethyl				

6200	tetrahydropyrimidin	0	CO ₂ -n-Bu	H	NHSO ₂ -(2,4,6-trimethylphenyl)
	-2-ylaminomethyl				
6201	tetrahydropyrimidin	0	CO ₂ -i-Bu	H	NHSO ₂ -(2,4,6-trimethylphenyl)
	-2-ylaminomethyl				
6202	tetrahydropyrimidin	0	CO ₂ -t-Bu	H	NHSO ₂ -(2,4,6-trimethylphenyl)
	-2-ylaminomethyl				
6203	tetrahydropyrimidin	0	-(CH ₂) ₄ NH ₂	H	NHSO ₂ -(2,4,6-trimethylphenyl)
	-2-ylaminomethyl				
6204	tetrahydropyrimidin	0	COPh	H	NHSO ₂ -(2,4,6-trimethylphenyl)
	-2-ylaminomethyl				
6205	tetrahydropyrimidin	0	SO ₂ -n-Bu	H	NHSO ₂ -(2,4,6-trimethylphenyl)
	-2-ylaminomethyl				
6206	tetrahydropyrimidin	0	Cbz	H	NHCbz
	-2-ylaminomethyl				
6207	tetrahydropyrimidin	0	SO ₂ Ph	H	NHCbz
	-2-ylaminomethyl				
6208	tetrahydropyrimidin	0	CO(CH ₂) ₂ Ph	H	NHCbz
	-2-ylaminomethyl				
6209	tetrahydropyrimidin	0	Bn	H	NHCbz
	-2-ylaminomethyl				
6210	tetrahydropyrimidin	0	n-Bu	H	NHCbz
	-2-ylaminomethyl				
6211	tetrahydropyrimidin	0	CO ₂ -n-Bu	H	NHCbz
	-2-ylaminomethyl				
6212	tetrahydropyrimidin	0	CO ₂ -i-Bu	H	NHCbz
	-2-ylaminomethyl				
6213	tetrahydropyrimidin	0	CO ₂ -t-Bu	H	NHCbz
	-2-ylaminomethyl				
6214	tetrahydropyrimidin	0	-(CH ₂) ₄ NH ₂	H	NHCbz
	-2-ylaminomethyl				
6215	tetrahydropyrimidin	0	COPh	H	NHCbz
	-2-ylaminomethyl				
6216	tetrahydropyrimidin	0	SO ₂ -n-Bu	H	NHCbz
	-2-ylaminomethyl				

6217	2-pyridinylamino- methyl	1	Cbz	H	NHSO ₂ Ph
6218	2-pyridinylamino- methyl	1	SO ₂ Ph	H	NHSO ₂ Ph
6219	2-pyridinylamino- methyl	1	CO(CH ₂) ₂ Ph	H	NHSO ₂ Ph
6220	2-pyridinylamino- methyl	1	Bn	H	NHSO ₂ Ph
6221	2-pyridinylamino- methyl	1	n-Bu	H	NHSO ₂ Ph
6222	2-pyridinylamino- methyl	1	COCH ₂ (3-indolyl)	H	NHSO ₂ Ph
6223	2-pyridinylamino- methyl	1	SO ₂ -(biphenyl)	H	NHSO ₂ Ph
6224	2-pyridinylamino- methyl	1	CO ₂ -n-Bu	H	NHSO ₂ Ph
6225	2-pyridinylamino- methyl	1	CO ₂ -i-Bu	H	NHSO ₂ Ph
6226	2-pyridinylamino- methyl	1	CO ₂ -t-Bu	H	NHSO ₂ Ph
6227	2-pyridinylamino- methyl	1	-(CH ₂) ₄ NH ₂	H	NHSO ₂ Ph
6228	2-pyridinylamino- methyl	1	COPh	H	NHSO ₂ Ph
6229	2-pyridinylamino- methyl	1	cyclopropyl-methyl	H	NHSO ₂ Ph
6230	2-pyridinylamino- methyl	1	SO ₂ -n-Bu	H	NHSO ₂ Ph
6231	2-pyridinylamino- methyl	1	Cbz	H	NHSO ₂ -(2,4,6-trimethylphenyl)
6232	2-pyridinylamino- methyl	1	SO ₂ Ph	H	NHSO ₂ -(2,4,6-trimethylphenyl)
6233	2-pyridinylamino- methyl	1	CO(CH ₂) ₂ Ph	H	NHSO ₂ -(2,4,6-trimethylphenyl)

6234	2-pyridinylamino-methyl	1	Bn	H	NHSO ₂ -(2,4,6-trimethylphenyl)
6235	2-pyridinylamino-methyl	1	n-Bu	H	NHSO ₂ -(2,4,6-trimethylphenyl)
6236	2-pyridinylamino-methyl	1	CO ₂ -n-Bu	H	NHSO ₂ -(2,4,6-trimethylphenyl)
6237	2-pyridinylamino-methyl	1	CO ₂ -i-Bu	H	NHSO ₂ -(2,4,6-trimethylphenyl)
6238	2-pyridinylamino-methyl	1	CO ₂ -t-Bu	H	NHSO ₂ -(2,4,6-trimethylphenyl)
6239	2-pyridinylamino-methyl	1	-(CH ₂) ₄ NH ₂	H	NHSO ₂ -(2,4,6-trimethylphenyl)
6240	2-pyridinylamino-methyl	1	COPh	H	NHSO ₂ -(2,4,6-trimethylphenyl)
6241	2-pyridinylamino-methyl	1	SO ₂ -n-Bu	H	NHSO ₂ -(2,4,6-trimethylphenyl)
6242	2-pyridinylamino-methyl	1	Cbz	H	NHCbz
6243	2-pyridinylamino-methyl	1	SO ₂ Ph	H	NHCbz
6244	2-pyridinylamino-methyl	1	CO(CH ₂) ₂ Ph	H	NHCbz
6245	2-pyridinylamino-methyl	1	Bn	H	NHCbz
6246	2-pyridinylamino-methyl	1	n-Bu	H	NHCbz
6247	2-pyridinylamino-methyl	1	CO ₂ -n-Bu	H	NHCbz
6248	2-pyridinylamino-methyl	1	CO ₂ -i-Bu	H	NHCbz
6249	2-pyridinylamino-methyl	1	CO ₂ -t-Bu	H	NHCbz
6250	2-pyridinylamino-methyl	1	-(CH ₂) ₄ NH ₂	H	NHCbz

6251	2-pyridinylamino- methyl	1	COPh	H	NHCbz
6252	2-pyridinylamino- methyl	1	SO ₂ -n-Bu	H	NHCbz
6253	2-imidazolylamino- methyl	1	Cbz	H	NHSO ₂ Ph
6254	2-imidazolylamino- methyl	1	SO ₂ Ph	H	NHSO ₂ Ph
6255	2-imidazolylamino- methyl	1	CO(CH ₂) ₂ Ph	H	NHSO ₂ Ph
6256	2-imidazolylamino- methyl	1	Bn	H	NHSO ₂ Ph
6257	2-imidazolylamino- methyl	1	n-Bu	H	NHSO ₂ Ph
6258	2-imidazolylamino- methyl	1	COCH ₂ (3-indolyl)	H	NHSO ₂ Ph
6259	2-imidazolylamino- methyl	1	SO ₂ -(biphenyl)	H	NHSO ₂ Ph
6260	2-imidazolylamino- methyl	1	CO ₂ -n-Bu	H	NHSO ₂ Ph
6261	2-imidazolylamino- methyl	1	CO ₂ -i-Bu	H	NHSO ₂ Ph
6262	2-imidazolylamino- methyl	1	CO ₂ -t-Bu	H	NHSO ₂ Ph
6263	2-imidazolylamino- methyl	1	-(CH ₂) ₄ NH ₂	H	NHSO ₂ Ph
6264	2-imidazolylamino- methyl	1	COPh	H	NHSO ₂ Ph
6265	2-imidazolylamino- methyl	1	cyclopropyl-methyl	H	NHSO ₂ Ph
6266	2-imidazolylamino- methyl	1	SO ₂ -n-Bu	H	NHSO ₂ Ph
6267	2-imidazolylamino- methyl	1	Cbz	H	NHSO ₂ -(2,4,6-trimethylphenyl)

6268	2-imidazolylamino-methyl	1	SO ₂ Ph	H	NHSO ₂ -(2,4,6-trimethylphenyl)
6269	2-imidazolylamino-methyl	1	CO(CH ₂) ₂ Ph	H	NHSO ₂ -(2,4,6-trimethylphenyl)
6270	2-imidazolylamino-methyl	1	Bn	H	NHSO ₂ -(2,4,6-trimethylphenyl)
6271	2-imidazolylamino-methyl	1	n-Bu	H	NHSO ₂ -(2,4,6-trimethylphenyl)
6272	2-imidazolylamino-methyl	1	CO ₂ -n-Bu	H	NHSO ₂ -(2,4,6-trimethylphenyl)
6273	2-imidazolylamino-methyl	1	CO ₂ -i-Bu	H	NHSO ₂ -(2,4,6-trimethylphenyl)
6274	2-imidazolylamino-methyl	1	CO ₂ -t-Bu	H	NHSO ₂ -(2,4,6-trimethylphenyl)
6275	2-imidazolylamino-methyl	1	-(CH ₂) ₄ NH ₂	H	NHSO ₂ -(2,4,6-trimethylphenyl)
6276	2-imidazolylamino-methyl	1	COPh	H	NHSO ₂ -(2,4,6-trimethylphenyl)
6277	2-imidazolylamino-methyl	1	SO ₂ -n-Bu	H	NHSO ₂ -(2,4,6-trimethylphenyl)
6278	2-imidazolylamino-methyl	1	Cbz	H	NHCbz
6279	2-imidazolylamino-methyl	1	SO ₂ Ph	H	NHCbz
6280	2-imidazolylamino-methyl	1	CO(CH ₂) ₂ Ph	H	NHCbz
6281	2-imidazolylamino-methyl	1	Bn	H	NHCbz
6282	2-imidazolylamino-methyl	1	n-Bu	H	NHCbz
6283	2-imidazolylamino-methyl	1	CO ₂ -n-Bu	H	NHCbz
6284	2-imidazolylamino-methyl	1	CO ₂ -i-Bu	H	NHCbz

6285	2-imidazolylamino- methyl	1	CO ₂ -t-Bu	H	NHCbz
6286	2-imidazolylamino- methyl	1	-(CH ₂) ₄ NH ₂	H	NHCbz
6287	2-imidazolylamino- methyl	1	COPh	H	NHCbz
6288	2-imidazolylamino- methyl	1	SO ₂ -n-Bu	H	NHCbz
6289	2-imidazolinylnyl- aminomethyl	1	Cbz	H	NHSO ₂ Ph
6290	2-imidazolinylnyl- aminomethyl	1	SO ₂ Ph	H	NHSO ₂ Ph
6291	2-imidazolinylnyl- aminomethyl	1	CO(CH ₂) ₂ Ph	H	NHSO ₂ Ph
6292	2-imidazolinylnyl- aminomethyl	1	Bn	H	NHSO ₂ Ph
6293	2-imidazolinylnyl- aminomethyl	1	n-Bu	H	NHSO ₂ Ph
6294	2-imidazolinylnyl- aminomethyl	1	COCH ₂ (3- indolyl)	H	NHSO ₂ Ph
6295	2-imidazolinylnyl- aminomethyl	1	SO ₂ - (biphenyl)	H	NHSO ₂ Ph
6296	2-imidazolinylnyl- aminomethyl	1	CO ₂ -n-Bu	H	NHSO ₂ Ph
6297	2-imidazolinylnyl- aminomethyl	1	CO ₂ -i-Bu	H	NHSO ₂ Ph
6298	2-imidazolinylnyl- aminomethyl	1	CO ₂ -t-Bu	H	NHSO ₂ Ph
6299	2-imidazolinylnyl- aminomethyl	1	-(CH ₂) ₄ NH ₂	H	NHSO ₂ Ph
6300	2-imidazolinylnyl- aminomethyl	1	COPh	H	NHSO ₂ Ph
6301	2-imidazolinylnyl- aminomethyl	1	cyclopropyl- methyl	H	NHSO ₂ Ph

6302	2-imidazoliny- aminomethyl	1	SO ₂ -n-Bu	H	NHSO ₂ Ph
6303	2-imidazoliny- aminomethyl	1	Cbz	H	NHSO ₂ -(2,4,6- trimethylphenyl)
6304	2-imidazoliny- aminomethyl	1	SO ₂ Ph	H	NHSO ₂ -(2,4,6- trimethylphenyl)
6305	2-imidazoliny- aminomethyl	1	CO(CH ₂) ₂ Ph	H	NHSO ₂ -(2,4,6- trimethylphenyl)
6306	2-imidazoliny- aminomethyl	1	Bn	H	NHSO ₂ -(2,4,6- trimethylphenyl)
6307	2-imidazoliny- aminomethyl	1	n-Bu	H	NHSO ₂ -(2,4,6- trimethylphenyl)
6308	2-imidazoliny- aminomethyl	1	CO ₂ -n-Bu	H	NHSO ₂ -(2,4,6- trimethylphenyl)
6309	2-imidazoliny- aminomethyl	1	CO ₂ -i-Bu	H	NHSO ₂ -(2,4,6- trimethylphenyl)
6310	2-imidazoliny- aminomethyl	1	CO ₂ -t-Bu	H	NHSO ₂ -(2,4,6- trimethylphenyl)
6311	2-imidazoliny- aminomethyl	1	-(CH ₂) ₄ NH ₂	H	NHSO ₂ -(2,4,6- trimethylphenyl)
6312	2-imidazoliny- aminomethyl	1	COPh	H	NHSO ₂ -(2,4,6- trimethylphenyl)
6313	2-imidazoliny- aminomethyl	1	SO ₂ -n-Bu	H	NHSO ₂ -(2,4,6- trimethylphenyl)
6314	2-imidazoliny- aminomethyl	1	Cbz	H	NHCbz
6315	2-imidazoliny- aminomethyl	1	SO ₂ Ph	H	NHCbz
6316	2-imidazoliny- aminomethyl	1	CO(CH ₂) ₂ Ph	H	NHCbz
6317	2-imidazoliny- aminomethyl	1	Bn	H	NHCbz
6318	2-imidazoliny- aminomethyl	1	n-Bu	H	NHCbz

6319	2-imidazoliny- aminomethyl	1	CO ₂ -n-Bu	H	NHCbz
6320	2-imidazoliny- aminomethyl	1	CO ₂ -i-Bu	H	NHCbz
6321	2-imidazoliny- aminomethyl	1	CO ₂ -t-Bu	H	NHCbz
6322	2-imidazoliny- aminomethyl	1	-(CH ₂) ₄ NH ₂	H	NHCbz
6323	2-imidazoliny- aminomethyl	1	COPh	H	NHCbz
6324	2-imidazoliny- aminomethyl	1	SO ₂ -n-Bu	H	NHCbz
6325	2-benzimidazolyl- aminomethyl	1	Cbz	H	NHSO ₂ Ph
6326	2-benzimidazolyl- aminomethyl	1	SO ₂ Ph	H	NHSO ₂ Ph
6327	2-benzimidazolyl- aminomethyl	1	CO(CH ₂) ₂ Ph	H	NHSO ₂ Ph
6328	2-benzimidazolyl- aminomethyl	1	Bn	H	NHSO ₂ Ph
6329	2-benzimidazolyl- aminomethyl	1	n-Bu	H	NHSO ₂ Ph
6330	2-benzimidazolyl- aminomethyl	1	COCH ₂ (3- indolyl)	H	NHSO ₂ Ph
6331	2-benzimidazolyl- aminomethyl	1	SO ₂ - (biphenyl)	H	NHSO ₂ Ph
6332	2-benzimidazolyl- aminomethyl	1	CO ₂ -n-Bu	H	NHSO ₂ Ph
6333	2-benzimidazolyl- aminomethyl	1	CO ₂ -i-Bu	H	NHSO ₂ Ph
6334	2-benzimidazolyl- aminomethyl	1	CO ₂ -t-Bu	H	NHSO ₂ Ph
6335	2-benzimidazolyl- aminomethyl	1	-(CH ₂) ₄ NH ₂	H	NHSO ₂ Ph

6336	2-benzimidazolyl-aminomethyl	1	COPh	H	NHSO ₂ Ph
6337	2-benzimidazolyl-aminomethyl	1	cyclopropyl-methyl	H	NHSO ₂ Ph
6338	2-benzimidazolyl-aminomethyl	1	SO ₂ -n-Bu	H	NHSO ₂ Ph
6339	2-benzimidazolyl-aminomethyl	1	Cbz	H	NHSO ₂ -(2,4,6-trimethylphenyl)
6340	2-benzimidazolyl-aminomethyl	1	SO ₂ Ph	H	NHSO ₂ -(2,4,6-trimethylphenyl)
6341	2-benzimidazolyl-aminomethyl	1	CO(CH ₂) ₂ Ph	H	NHSO ₂ -(2,4,6-trimethylphenyl)
6342	2-benzimidazolyl-aminomethyl	1	Bn	H	NHSO ₂ -(2,4,6-trimethylphenyl)
6343	2-benzimidazolyl-aminomethyl	1	n-Bu	H	NHSO ₂ -(2,4,6-trimethylphenyl)
6344	2-benzimidazolyl-aminomethyl	1	CO ₂ -n-Bu	H	NHSO ₂ -(2,4,6-trimethylphenyl)
6345	2-benzimidazolyl-aminomethyl	1	CO ₂ -i-Bu	H	NHSO ₂ -(2,4,6-trimethylphenyl)
6346	2-benzimidazolyl-aminomethyl	1	CO ₂ -t-Bu	H	NHSO ₂ -(2,4,6-trimethylphenyl)
6347	2-benzimidazolyl-aminomethyl	1	-(CH ₂) ₄ NH ₂	H	NHSO ₂ -(2,4,6-trimethylphenyl)
6348	2-benzimidazolyl-aminomethyl	1	COPh	H	NHSO ₂ -(2,4,6-trimethylphenyl)
6349	2-benzimidazolyl-aminomethyl	1	SO ₂ -n-Bu	H	NHSO ₂ -(2,4,6-trimethylphenyl)
6350	2-benzimidazolyl-aminomethyl	1	Cbz	H	NHCbz
6351	2-benzimidazolyl-aminomethyl	1	SO ₂ Ph	H	NHCbz
6352	2-benzimidazolyl-aminomethyl	1	CO(CH ₂) ₂ Ph	H	NHCbz

6353	2-benzimidazolyl- aminomethyl	1	Bn	H	NHCbz
6354	2-benzimidazolyl- aminomethyl	1	n-Bu	H	NHCbz
6355	2-benzimidazolyl- aminomethyl	1	CO ₂ -n-Bu	H	NHCbz
6356	2-benzimidazolyl- aminomethyl	1	CO ₂ -i-Bu	H	NHCbz
6357	2-benzimidazolyl- aminomethyl	1	CO ₂ -t-Bu	H	NHCbz
6358	2-benzimidazolyl- aminomethyl	1	-(CH ₂) ₄ NH ₂	H	NHCbz
6359	2-benzimidazolyl- aminomethyl	1	COPh	H	NHCbz
6360	2-benzimidazolyl- aminomethyl	1	SO ₂ -n-Bu	H	NHCbz
6361	7-aza-2- benzimidazolyl	1	Cbz	H	NHSO ₂ Ph
6362	7-aza-2- benzimidazolyl	1	SO ₂ Ph	H	NHSO ₂ Ph
6363	7-aza-2- benzimidazolyl	1	CO(CH ₂) ₂ Ph	H	NHSO ₂ Ph
6364	7-aza-2- benzimidazolyl	1	Bn	H	NHSO ₂ Ph
6365	7-aza-2- benzimidazolyl	1	n-Bu	H	NHSO ₂ Ph
6366	7-aza-2- benzimidazolyl	1	COCH ₂ (3- indolyl)	H	NHSO ₂ Ph
6367	7-aza-2- benzimidazolyl	1	SO ₂ - (biphenyl)	H	NHSO ₂ Ph
6368	7-aza-2- benzimidazolyl	1	CO ₂ -n-Bu	H	NHSO ₂ Ph
6369	7-aza-2- benzimidazolyl	1	CO ₂ -i-Bu	H	NHSO ₂ Ph

6370	7-aza-2- benzimidazolyl	1	CO ₂ -t-Bu	H	NHSO ₂ Ph
6371	7-aza-2- benzimidazolyl	1	-(CH ₂) ₄ NH ₂	H	NHSO ₂ Ph
6372	7-aza-2- benzimidazolyl	1	COPh	H	NHSO ₂ Ph
6373	7-aza-2- benzimidazolyl	1	cyclopropyl- methyl	H	NHSO ₂ Ph
6374	7-aza-2- benzimidazolyl	1	SO ₂ -n-Bu	H	NHSO ₂ Ph
6375	7-aza-2- benzimidazolyl	1	Cbz	H	NHSO ₂ -(2,4,6- trimethylphenyl)
6376	7-aza-2- benzimidazolyl	1	SO ₂ Ph	H	NHSO ₂ -(2,4,6- trimethylphenyl)
6377	7-aza-2- benzimidazolyl	1	CO(CH ₂) ₂ Ph	H	NHSO ₂ -(2,4,6- trimethylphenyl)
6378	7-aza-2- benzimidazolyl	1	Bn	H	NHSO ₂ -(2,4,6- trimethylphenyl)
6379	7-aza-2- benzimidazolyl	1	n-Bu	H	NHSO ₂ -(2,4,6- trimethylphenyl)
6380	7-aza-2- benzimidazolyl	1	CO ₂ -n-Bu	H	NHSO ₂ -(2,4,6- trimethylphenyl)
6381	7-aza-2- benzimidazolyl	1	CO ₂ -i-Bu	H	NHSO ₂ -(2,4,6- trimethylphenyl)
6382	7-aza-2- benzimidazolyl	1	CO ₂ -t-Bu	H	NHSO ₂ -(2,4,6- trimethylphenyl)
6383	7-aza-2- benzimidazolyl	1	-(CH ₂) ₄ NH ₂	H	NHSO ₂ -(2,4,6- trimethylphenyl)
6384	7-aza-2- benzimidazolyl	1	COPh	H	NHSO ₂ -(2,4,6- trimethylphenyl)
6385	7-aza-2- benzimidazolyl	1	SO ₂ -n-Bu	H	NHSO ₂ -(2,4,6- trimethylphenyl)
6386	7-aza-2- benzimidazolyl	1	Cbz	H	NHCbz

6387	7-aza-2- benzimidazolyl	1	SO ₂ Ph	H	NHCbz
6388	7-aza-2- benzimidazolyl	1	CO(CH ₂) ₂ Ph	H	NHCbz
6389	7-aza-2- benzimidazolyl	1	Bn	H	NHCbz
6390	7-aza-2- benzimidazolyl	1	n-Bu	H	NHCbz
6391	7-aza-2- benzimidazolyl	1	CO ₂ -n-Bu	H	NHCbz
6392	7-aza-2- benzimidazolyl	1	CO ₂ -i-Bu	H	NHCbz
6393	7-aza-2- benzimidazolyl	1	CO ₂ -t-Bu	H	NHCbz
6394	7-aza-2- benzimidazolyl	1	-(CH ₂) ₄ NH ₂	H	NHCbz
6395	7-aza-2- benzimidazolyl	1	COPh	H	NHCbz
6396	7-aza-2- benzimidazolyl	1	SO ₂ -n-Bu	H	NHCbz
6397	tetrahydropyrimidin -2-ylaminomethyl	1	Cbz	H	NHSO ₂ Ph
6398	tetrahydropyrimidin -2-ylaminomethyl	1	SO ₂ Ph	H	NHSO ₂ Ph
6399	tetrahydropyrimidin -2-ylaminomethyl	1	CO(CH ₂) ₂ Ph	H	NHSO ₂ Ph
6400	tetrahydropyrimidin -2-ylaminomethyl	1	Bn	H	NHSO ₂ Ph
6401	tetrahydropyrimidin -2-ylaminomethyl	1	n-Bu	H	NHSO ₂ Ph
6402	tetrahydropyrimidin -2-ylaminomethyl	1	COCH ₂ (3- indolyl)	H	NHSO ₂ Ph
6403	tetrahydropyrimidin -2-ylaminomethyl	1	SO ₂ - (biphenyl)	H	NHSO ₂ Ph


6404	tetrahydropyrimidin -2-ylaminomethyl	1	CO ₂ -n-Bu	H	NHSO ₂ Ph
6405	tetrahydropyrimidin -2-ylaminomethyl	1	CO ₂ -i-Bu	H	NHSO ₂ Ph
6406	tetrahydropyrimidin -2-ylaminomethyl	1	CO ₂ -t-Bu	H	NHSO ₂ Ph
6407	tetrahydropyrimidin -2-ylaminomethyl	1	-(CH ₂) ₄ NH ₂	H	NHSO ₂ Ph
6408	tetrahydropyrimidin -2-ylaminomethyl	1	COPh	H	NHSO ₂ Ph
6409	tetrahydropyrimidin -2-ylaminomethyl	1	cyclopropyl- methyl	H	NHSO ₂ Ph
6410	tetrahydropyrimidin -2-ylaminomethyl	1	SO ₂ -n-Bu	H	NHSO ₂ Ph
6411	tetrahydropyrimidin -2-ylaminomethyl	1	Cbz	H	NHSO ₂ -(2,4,6- trimethylphenyl)
6412	tetrahydropyrimidin -2-ylaminomethyl	1	SO ₂ Ph	H	NHSO ₂ -(2,4,6- trimethylphenyl)
6413	tetrahydropyrimidin -2-ylaminomethyl	1	CO(CH ₂) ₂ Ph	H	NHSO ₂ -(2,4,6- trimethylphenyl)
6414	tetrahydropyrimidin -2-ylaminomethyl	1	Bn	H	NHSO ₂ -(2,4,6- trimethylphenyl)
6415	tetrahydropyrimidin -2-ylaminomethyl	1	n-Bu	H	NHSO ₂ -(2,4,6- trimethylphenyl)
6416	tetrahydropyrimidin -2-ylaminomethyl	1	CO ₂ -n-Bu	H	NHSO ₂ -(2,4,6- trimethylphenyl)
6417	tetrahydropyrimidin -2-ylaminomethyl	1	CO ₂ -i-Bu	H	NHSO ₂ -(2,4,6- trimethylphenyl)
6418	tetrahydropyrimidin -2-ylaminomethyl	1	CO ₂ -t-Bu	H	NHSO ₂ -(2,4,6- trimethylphenyl)
6419	tetrahydropyrimidin -2-ylaminomethyl	1	-(CH ₂) ₄ NH ₂	H	NHSO ₂ -(2,4,6- trimethylphenyl)
6420	tetrahydropyrimidin -2-ylaminomethyl	1	COPh	H	NHSO ₂ -(2,4,6- trimethylphenyl)

6421	tetrahydropyrimidin 1	SO ₂ -n-Bu	H	NHSO ₂ -(2,4,6-trimethylphenyl)
	-2-ylaminomethyl			
6422	tetrahydropyrimidin 1	Cbz	H	NHCbz
	-2-ylaminomethyl			
6423	tetrahydropyrimidin 1	SO ₂ Ph	H	NHCbz
	-2-ylaminomethyl			
6424	tetrahydropyrimidin 1	CO(CH ₂) ₂ Ph	H	NHCbz
	-2-ylaminomethyl			
6425	tetrahydropyrimidin 1	Bn	H	NHCbz
	-2-ylaminomethyl			
6426	tetrahydropyrimidin 1	n-Bu	H	NHCbz
	-2-ylaminomethyl			
6427	tetrahydropyrimidin 1	CO ₂ -n-Bu	H	NHCbz
	-2-ylaminomethyl			
6428	tetrahydropyrimidin 1	CO ₂ -i-Bu	H	NHCbz
	-2-ylaminomethyl			
6429	tetrahydropyrimidin 1	CO ₂ -t-Bu	H	NHCbz
	-2-ylaminomethyl			
6430	tetrahydropyrimidin 1	-(CH ₂) ₄ NH ₂	H	NHCbz
	-2-ylaminomethyl			
6431	tetrahydropyrimidin 1	COPh	H	NHCbz
	-2-ylaminomethyl			
6432	tetrahydropyrimidin 1	SO ₂ -n-Bu	H	NHCbz
	-2-ylaminomethyl			

CLAIMS


WHAT IS CLAIMED IS:

5 1. A compound of Formula I:



10 and pharmaceutically acceptable salt forms thereof,
wherein:

0 is selected from



15


A is selected from $-N(R^{10})-$, $-C(R^{11})-$ or $-O-$;

A¹ is selected from -O- or -N(R¹⁰)-;

20

Z is a spiro-fused 4-7 membered ring system (including the spiro atom) containing 0-2 heteroatoms selected from O, S, or N, said ring system optionally being substituted on carbon with keto, or being substituted on carbon or nitrogen independently with 0-2 R⁹ or R¹⁰ or R^{10a};

R^1 is selected from:



- 5 B is independently selected from $-\text{CH}_2-$, $-\text{O}-$, $-\text{N}(\text{R}^2)-$, or $-\text{C}(=\text{O})-$;

B¹ is independently selected from -CH₂- or -N(R³)-;

- 10 D is $-N(R^2)-$, $-O-$, $-S-$, $-C(=O)-$ or $-SO_2-$;

E-F is $-C(R^4)=C(R^5)-$, $-N=C(R^4)-$, $-C(R^4)=N-$, or $-C(R^4) \gamma C(R^5) \gamma -$;

- 15 J, K, L and M are independently selected from $-C(R^4)-$,
 $-C(R^5)-$ or $-N-$, provided that at least one of J, K,
L and M is not $-N-$;

- R² is selected from: H, C₁-C₆ alkyl, (C₁-C₆ alkyl)carbonyl, (C₁-C₆ alkoxy)carbonyl; (C₁-C₆ alkyl)aminocarbonyl, C₃-C₆ alkenyl, C₃-C₇

cycloalkyl, C₄-C₁₁ cycloalkylalkyl, aryl,
heteroaryl(C₁-C₆ alkyl)carbonyl,
heteroarylcarbonyl, aryl C₁-C₆ alkyl, (C₁-C₆
alkyl)carbonyl, arylcarbonyl, C₁-C₆ alkylsulfonyl,
5 arylsulfonyl, aryl(C₁-C₆ alkyl)sulfonyl,
heteroarylsulfonyl, heteroaryl(C₁-C₆
alkyl)sulfonyl, aryloxy carbonyl, aryl(C₁-C₆
alkoxy)carbonyl, wherein said aryl groups are
substituted with 0-2 substituents independently
10 selected from the group consisting of C₁-C₄ alkyl,
C₁-C₄ alkoxy, halo, CF₃, and nitro;

R³ is selected from: H, C₁-C₆ alkyl, C₃-C₇ cycloalkyl, C₄-
C₁₁ cycloalkylalkyl, aryl, aryl(C₁-C₆ alkyl)-, or
15 heteroaryl(C₁-C₆ alkyl)-;

R⁴ and R⁵ are independently selected from: H, C₁-C₄
alkoxy, NR²R³, halogen, NO₂, CN, CF₃, C₁-C₆ alkyl,
C₃-C₆ alkenyl, C₃-C₇ cycloalkyl, C₄-C₁₁
20 cycloalkylalkyl, aryl, aryl(C₁-C₆ alkyl)-, (C₁-C₆
alkyl)carbonyl, (C₁-C₆ alkoxy)carbonyl,
arylcarbonyl;

alternatively, when substituents on adjacent atoms, R⁴
25 and R⁵ can be taken together with the carbon atoms
to which they are attached to form a 5-7 membered
carbocyclic or 5-7 membered heterocyclic aromatic
or non-aromatic ring system, said carbocyclic or
heterocyclic ring being optionally substituted with
30 0-2 groups independently selected from: C₁-C₄
alkyl, C₁-C₄ alkoxy, halo, cyano, amino, CF₃, or
NO₂;

R⁶ is selected from: H, C₁-C₄ alkyl, or benzyl;
35

R^7 and R^8 are independently selected from: H, C_1 - C_6 alkyl, C_3 - C_7 cycloalkyl, C_4 - C_{11} cycloalkylalkyl, aryl, aryl(C_1 - C_6 alkyl)-, or heteroaryl(C_0 - C_6 alkyl)-;

5

U is selected from:

- $N(R^6)(CH_2)_n$ -,
 - $N(R^6)(CH_2)_mO$ -,
 - $N(R^6)(CH_2)_mN(R^7)$ -,
 - $N(R^6)(CH_2)_nS(O)_p$ -,
 - $N(R^6)C(=O)(CH_2)_n$ -,
 - $N(R^6)(CH_2)_mC(=O)$ -;

10

V is selected from:

- $(CH_2)_n$ -,
 - $(CH_2)_mO-(CH_2)_n$ -,
 - $(CH_2)_mN(R^7)(CH_2)_n$ -,
 - $(CH_2)_nS(O)_p(CH_2)_n$ -,
 - $(CH_2)_mN(R^7)C(=O)(CH_2)_n$ -,
 - $(CH_2)_nC(=O)N(R^7)(CH_2)_n$ -,
 - $(CH_2)_nC(=O)(CH_2)_n$ -;

15

20

R^9 is selected from H, C_1 - C_4 alkyl, C_1 - C_4 alkoxy, aryl, aryl(C_1 - C_6 alkyl)-, (C_1 - C_4 alkoxy)carbonyl, (C_1 - C_4 alkyl)carbonyl, C_1 - C_4 alkylsulfonyl, or C_1 - C_4 alkylaminosulfonyl;

25

R^{10} is selected from: H, CO_2R^{17} , $C(=O)R^{17}$, $C(=O)NR^{17}R^{20}$, $-SO_2R^{17}$, $-SO_2NR^{17}R^{20}$, C_1 - C_6 alkyl substituted with 0-1 R^{15} , C_3 - C_6 alkenyl substituted with 0-1 R^{15} , C_3 - C_7 cycloalkyl substituted with 0-1 R^{15} , C_4 - C_{11} cycloalkylalkyl substituted with 0-1 R^{15} , aryl substituted with 0-1 R^{15} or 0-2 R^{11} , or aryl(C_1 - C_6 alkyl)- substituted with 0-1 R^{15} or 0-2 R^{11} ;

30

35


R^{10a} is selected from: CO₂R¹⁷, C(=O)R¹⁷, C(=O)NR¹⁷R²⁰,
 -SO₂R¹⁷, -SO₂NR¹⁷R²⁰, C₁-C₆ alkyl substituted with 0-
 1 R¹⁵, C₃-C₆ alkenyl substituted with 0-1 R¹⁵, C₃-C₇
 cycloalkyl substituted with 0-1 R¹⁵, C₄-C₁₁
 5 cycloalkylalkyl substituted with 0-1 R¹⁵, aryl
 substituted with 0-1 R¹⁵ or 0-2 R¹¹, or aryl(C₁-C₆
 alkyl)- substituted with 0-1 R¹⁵ or 0-2 R¹¹;

R¹¹ is selected from H, C₁-C₄ alkyl, C₁-C₄ alkoxy, aryl,
 10 aryl(C₁-C₆ alkyl)-, (C₁-C₄ alkoxy)carbonyl, (C₁-C₄
 alkyl)carbonyl, C₁-C₄ alkylsulfonyl, or C₁-C₄
 alkylaminosulfonyl;

W is selected from:
 15 C₁-C₄ alkylene,
 - (C(R¹²)₂)_qO(C(R¹²)₂)_q-,
 - (C(R¹²)₂)_qC(=O)(C(R¹²)₂)_q-,
 - (C(R¹²)₂)_qC(=O)N(R¹³)-,
 -C(=O)-N(R¹³)-(C(R¹²)₂)_q-;

20 X is - (C(R¹²)₂)_qC(R¹²)(R¹⁴)-C(R¹²)(R¹⁵)-;

alternatively, W and X can be taken together to be



25 R¹² is selected from H, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆
 alkynyl, C₃-C₇ cycloalkyl, C₄-C₁₀ cycloalkylalkyl,
 (C₁-C₄ alkyl)carbonyl, aryl, or aryl(C₁-C₆ alkyl)-;

30 R¹³ is selected from H, C₁-C₆ alkyl, C₃-C₇
 cycloalkylmethyl, or aryl(C₁-C₆ alkyl)-

R¹⁴ is selected from:


H, C₁-C₆ alkylthio(C₁-C₆ alkyl)-, aryl(C₁-C₁₀ alkylthioalkyl)-, aryl(C₁-C₁₀ alkoxyalkyl)-, C₁-C₁₀ alkyl, C₁-C₁₀ alkoxyalkyl, C₁-C₆ hydroxyalkyl, C₂-C₁₀ alkenyl, C₂-C₁₀ alkynyl, C₃-C₁₀ cycloalkyl, C₃-C₁₀ cycloalkylalkyl, aryl(C₁-C₆ alkyl)-, heteroaryl(C₁-C₆ alkyl)-, aryl, heteroaryl, CO₂R¹⁷, C(=O)R¹⁷, or CONR¹⁷R²⁰, provided that any of the above alkyl, cycloalkyl, aryl or heteroaryl groups may optionally be substituted independently with 0-1 R¹⁶ or 0-2 R¹¹;

R¹⁵ is selected from:

H, R¹⁶, C₁-C₁₀ alkyl, C₁-C₁₀ alkoxyalkyl, C₁-C₁₀ alkylaminoalkyl, C₁-C₁₀ dialkylaminoalkyl, (C₁-C₁₀ alkyl)carbonyl, aryl(C₀-C₆ alkyl)carbonyl, C₁-C₁₀ alkenyl, C₁-C₁₀ alkynyl, C₃-C₁₀ cycloalkyl, C₃-C₁₀ cycloalkylalkyl, aryl(C₁-C₆ alkyl)-, heteroaryl(C₁-C₆ alkyl)-, aryl, heteroaryl, CO₂R¹⁷, C(=O)R¹⁷, CONR¹⁷R²⁰, SO₂R¹⁷, or SO₂NR¹⁷R²⁰, provided that any of the above alkyl, cycloalkyl, aryl or heteroaryl groups may optionally be substituted independently with 0-2 R¹¹;

Y is selected from:

-COR¹⁹, -SO₃H, -PO₃H, tetrazolyl, -CONHNHSO₂CF₃, -CONHSO₂R¹⁷, -CONHSO₂NHR¹⁷, -NHCOCF₃, -NHCONHSO₂R¹⁷, -NHSO₂R¹⁷, -OPO₃H₂, -OSO₃H, -PO₃H₂, -SO₃H, -SO₂NHCOR¹⁷, -SO₂NHCO₂R¹⁷,



R¹⁶ is selected from:

-N(R²⁰)-C(=O)-O-R¹⁷,

-N(R²⁰)-C(=O)-R¹⁷,
-N(R²⁰)-C(=O)-NH-R¹⁷,
-N(R²⁰)SO₂-R¹⁷, or
-N(R²⁰)SO₂-NR²⁰R¹⁷;

5

R¹⁷ is selected from:

C₁-C₁₀ alkyl, C₃-C₁₁ cycloalkyl, aryl(C₁-C₆ alkyl)-, (C₁-C₆ alkyl)aryl, heteroaryl(C₁-C₆ alkyl)-, (C₁-C₆ alkyl)heteroaryl, arylaryl(C₁-C₆ alkyl)-, heteroarylaryl(C₁-C₆ alkyl)-, arylheteroaryl(C₁-C₆ alkyl)-, heteroarylheteroaryl(C₁-C₆ alkyl)-, heteroaryl, or aryl, wherein said aryl or heteroaryl groups are optionally substituted with 0-3 substituents independently selected from the group consisting of: C₁-C₄ alkyl, C₁-C₄ alkoxy, aryl, halo, cyano, amino, CF₃, and NO₂;

10

15

R¹⁸ is selected from:

H,
-C(=O)-O-R¹⁷,
-C(=O)-R¹⁷,
-C(=O)-NH-R¹⁷,
-SO₂-R¹⁷, or
-SO₂-NR²⁰R¹⁷;

20

25

R¹⁹ is selected from:

hydroxy,
C₁-C₁₀ alkyloxy,
C₃-C₁₁ cycloalkyloxy,
aryloxy,
aryl(C₁-C₆ alkoxy)-,
C₃-C₁₀ alkylcarbonyloxyalkyloxy,
C₃-C₁₀ alkoxycarbonyloxyalkyloxy,
C₂-C₁₀ alkoxycarbonylalkyloxy,
C₅-C₁₀ cycloalkylcarbonyloxyalkyloxy,
C₅-C₁₀ cycloalkoxycarbonyloxyalkyloxy,

30

35


- C₅-C₁₀ cycloalkoxycarbonylalkyloxy,
 C₇-C₁₁ aryloxycarbonylalkyloxy,
 C₈-C₁₂ aryloxycarbonyloxyalkyloxy,
 C₈-C₁₂ arylcarbonyloxyalkyloxy,
 5 C₅-C₁₀ alkoxyalkylcarbonyloxyalkyloxy,
 C₅-C₁₀ (5-alkyl-1,3-dioxo-cyclopenten-2-one-
 yl)methyloxy,
 C₁₀-C₁₄ (5-aryl-1,3-dioxo-cyclopenten-2-one-
 yl)methyloxy, or
 10 (R¹¹) (R¹²)N-(C₁-C₁₀ alkoxy)-;
- R²⁰ is selected from: H, C₁-C₆ alkyl, C₃-C₇ cycloalkyl,
 C₄-C₁₁ cycloalkylalkyl, aryl, aryl(C₁-C₆ alkyl)-, or
 heteroaryl(C₁-C₆ alkyl)-;
- 15 m is 1-2;
 n is 0-2;
 p is 0-2;
 q is 0-2; and
 20 r is 0-2;

provided that:

n, q, and r are chosen such that the number of in-chain
 atoms between R¹ and Y is in the range of 8-18.

25

2. A compound of Claim 1 of the Formula I:




30


(I)

and pharmaceutically acceptable salt forms thereof
 wherein:

35 Q is selected from:



R¹ is selected from:



5 D is -N(R²)-, -O-, -S-, -C(=O)- or -SO₂-;

E-F is -C(R⁴)=C(R⁵)-, -N=C(R⁴)-, -C(R⁴)=N-, or
-C(R⁴)₂C(R⁵)₂-;

10 J, K, L and M are independently selected from -C(R⁴)-, -C(R⁵)- or -N-, provided that at least one of J, K, L and M is not -N-;

R² is selected from: H, C₁-C₆ alkyl, (C₁-C₆ alkyl)carbonyl, (C₁-C₆ alkoxy)carbonyl; (C₁-C₆ alkyl)aminocarbonyl, C₃-C₆ alkenyl, C₃-C₇ cycloalkyl, C₄-C₁₁ cycloalkylalkyl, aryl, heteroaryl (C₁-C₆ alkyl)carbonyl, heteroarylcarbonyl, aryl(C₁-C₆ alkyl)-, (C₁-C₆ alkyl)carbonyl, arylcarbonyl, C₁-C₆ alkylsulfonyl, arylsulfonyl, aryl(C₁-C₆ alkyl)sulfonyl,

heteroarylsulfonyl, heteroaryl(C₁-C₆
alkyl)sulfonyl, aryloxy carbonyl, or aryl(C₁-C₆
alkoxy)carbonyl, wherein said aryl groups are
substituted with 0-2 substituents independently
5 selected from the group consisting of C₁-C₄ alkyl,
C₁-C₄ alkoxy, halo, CF₃, and nitro;

R³ is selected from: H, C₁-C₆ alkyl, C₃-C₇ cycloalkyl,
C₄-C₁₁ cycloalkylalkyl, aryl, aryl(C₁-C₆ alkyl)-, or
10 heteroaryl(C₁-C₆ alkyl)-;

R⁴ and R⁵ are independently selected from: H, C₁-C₄
alkoxy, NR²R³, halogen, NO₂, CN, CF₃, C₁-C₆ alkyl,
C₃-C₆ alkenyl, C₃-C₇ cycloalkyl, C₄-C₁₁
15 cycloalkylalkyl, aryl, aryl(C₁-C₆ alkyl)-, (C₁-C₆
alkyl)carbonyl, (C₁-C₆ alkoxy)carbonyl,
arylcarbonyl, or

alternatively, when substituents on adjacent atoms, R⁴
20 and R⁵ can be taken together with the carbon atoms
to which they are attached to form a 5-7 membered
carbocyclic or 5-7 membered heterocyclic aromatic
or non-aromatic ring system, said carbocyclic or
heterocyclic ring being optionally substituted with
25 0-2 groups independently selected from: C₁-C₄
alkyl, C₁-C₄ alkoxy, halo, cyano, amino, CF₃, or
NO₂;

R⁶ is selected from: H, C₁-C₄ alkyl, or benzyl;
30

R⁷ and R⁸ are independently selected from: H, C₁-C₆
alkyl, C₃-C₇ cycloalkyl, C₄-C₁₁ cycloalkylalkyl,
aryl, aryl(C₁-C₆ alkyl)-, or heteroaryl(C₀-C₆
alkyl)-;
35

U is selected from:

$-\text{N}(\text{R}^6)(\text{CH}_2)_n-$,
 $-\text{N}(\text{R}^6)(\text{CH}_2)_m\text{O}-$,
 $-\text{N}(\text{R}^6)(\text{CH}_2)_m\text{N}(\text{R}^7)-$
 $-\text{N}(\text{R}^6)(\text{CH}_2)_n\text{S}(\text{O})_p-$
5 $-\text{N}(\text{R}^6)\text{C}(=\text{O})(\text{CH}_2)_n-$;

V is selected from:

$-(\text{CH}_2)_n-$,
 $-(\text{CH}_2)_m\text{O}-(\text{CH}_2)_n-$,
10 $-(\text{CH}_2)_m\text{N}(\text{R}^7)(\text{CH}_2)_n-$,
 $-(\text{CH}_2)_n\text{S}(\text{O})_p(\text{CH}_2)_n-$,
 $-(\text{CH}_2)_m\text{N}(\text{R}^7)\text{C}(=\text{O})(\text{CH}_2)_n-$,
 $-(\text{CH}_2)_n\text{C}(=\text{O})\text{N}(\text{R}^7)(\text{CH}_2)_n-$,
 $-(\text{CH}_2)_n\text{C}(=\text{O})(\text{CH}_2)_n-$;

15

R^9 is selected from H, C_1 - C_4 alkyl, C_1 - C_4 alkoxy, aryl,
aryl(C_1 - C_6 alkyl)-, (C_1 - C_4 alkoxy)carbonyl, (C_1 - C_4
alkyl)carbonyl, C_1 - C_4 alkylsulfonyl, or C_1 - C_4
alkylaminosulfonyl;

20

R^{10} is selected from: H, CO_2R^{17} , $\text{C}(=\text{O})\text{R}^{17}$, $\text{C}(=\text{O})\text{NR}^{17}\text{R}^{20}$,
 $-\text{SO}_2\text{R}^{17}$, $-\text{SO}_2\text{NR}^{17}\text{R}^{20}$, C_1 - C_6 alkyl substituted with 0-
1 R^{15} , C_3 - C_6 alkenyl substituted with 0-1 R^{15} , C_3 - C_7
cycloalkyl substituted with 0-1 R^{15} , C_4 - C_{11}
25 cycloalkylalkyl substituted with 0-1 R^{15} , aryl
substituted with 0-1 R^{15} or 0-2 R^{11} , or aryl(C_1 - C_6
alkyl)- substituted with 0-1 R^{15} or 0-2 R^{11} ;

25

R^{10a} is selected from: CO_2R^{17} , $\text{C}(=\text{O})\text{R}^{17}$, $\text{C}(=\text{O})\text{NR}^{17}\text{R}^{20}$,
30 $-\text{SO}_2\text{R}^{17}$, $-\text{SO}_2\text{NR}^{17}\text{R}^{20}$, C_1 - C_6 alkyl substituted with 0-
1 R^{15} , C_3 - C_6 alkenyl substituted with 0-1 R^{15} , C_3 - C_7
cycloalkyl substituted with 0-1 R^{15} , C_4 - C_{11}
cycloalkylalkyl substituted with 0-1 R^{15} , aryl
substituted with 0-1 R^{15} or 0-2 R^{11} , or aryl(C_1 - C_6
35 alkyl)- substituted with 0-1 R^{15} or 0-2 R^{11} ;

35

R¹¹ is selected from H, C₁-C₄ alkyl, C₁-C₄ alkoxy, aryl, aryl(C₁-C₆ alkyl)-, (C₁-C₄ alkoxy)carbonyl, (C₁-C₄ alkyl)carbonyl, C₁-C₄ alkylsulfonyl, or C₁-C₄ alkylaminosulfonyl;

5

W is selected from:

C₁-C₄ alkylene,

- (C(R¹²)₂)_qO(C(R¹²)₂)_q-,

- (C(R¹²)₂)_qC(=O)(C(R¹²)₂)_q-,

10


- (C(R¹²)₂)_qC(=O)N(R¹³)-,

-C(=O)-N(R¹³)-(C(R¹²)₂)_q-;

X is - (C(R¹²)₂)_qC(R¹²)(R¹⁴)-C(R¹²)(R¹⁵)-;

15

alternatively, W and X can be taken together to be



R¹² is selected from H, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₇ cycloalkyl,

20

C₄-C₁₀ cycloalkylalkyl, (C₁-C₄ alkyl)carbonyl, aryl, or aryl(C₁-C₆ alkyl)-;

R¹³ is selected from H, C₁-C₆ alkyl, C₃-C₇ cycloalkylmethyl, or aryl(C₁-C₆ alkyl)-;

25

R¹⁴ is selected from:

H, C₁-C₆ alkylthio(C₁-C₆ alkyl)-, aryl(C₁-C₁₀ alkylthioalkyl)-, aryl(C₁-C₁₀ alkoxyalkyl)-, C₁-C₁₀ alkyl, C₁-C₁₀ alkoxyalkyl, C₁-C₆ hydroxyalkyl,

30




C₂-C₁₀ alkenyl, C₂-C₁₀ alkynyl, C₃-C₁₀ cycloalkyl, C₃-C₁₀ cycloalkylalkyl, aryl(C₁-C₆ alkyl)-, heteroaryl(C₁-C₆ alkyl)-, aryl, heteroaryl, CO₂R¹⁷, C(=O)R¹⁷, or CONR¹⁷R²⁰, provided that any of the

above alkyl, cycloalkyl, aryl or heteroaryl groups may optionally be substituted independently with 0-1 R¹⁶ or 0-2 R¹¹;

- 5 R¹⁵ is selected from:
 H, R¹⁶, C₁-C₁₀ alkyl, C₁-C₁₀ alkoxyalkyl,
 C₁-C₁₀ alkylaminoalkyl, C₁-C₁₀ dialkylaminoalkyl,
 (C₁-C₁₀ alkyl)carbonyl, aryl(C₀-C₆ alkyl)carbonyl,
 C₁-C₁₀ alkenyl, C₁-C₁₀ alkynyl, C₃-C₁₀ cycloalkyl,
 10 C₃-C₁₀ cycloalkylalkyl, aryl(C₁-C₆ alkyl)-,
 heteroaryl(C₁-C₆ alkyl)-, aryl, heteroaryl, CO₂R¹⁷,
 C(=O)R¹⁷, CONR¹⁷R²⁰, SO₂R¹⁷, or SO₂NR¹⁷R²⁰, provided
 that any of the above alkyl, cycloalkyl, aryl or
 heteroaryl groups may optionally be substituted
 15 independently with 0-2 R¹¹;

Y is selected from:

- COR¹⁹, -SO₃H, -PO₃H, tetrazolyl, -CONHNHSO₂CF₃,
 -CONHSO₂R¹⁷, -CONHSO₂NHR¹⁷, -NHCOCF₃, -NHCONHSO₂R¹⁷,
 20 -NHSO₂R¹⁷, -OPO₃H₂, -OSO₃H, -PO₃H₂, -SO₃H,
 -SO₂NHCOR¹⁷, -SO₂NHCO₂R¹⁷,



- 25 R¹⁶ is selected from:
 -N(R²⁰)-C(=O)-O-R¹⁷,
 -N(R²⁰)-C(=O)-R¹⁷,
 -N(R²⁰)-C(=O)-NH-R¹⁷,
 -N(R²⁰)SO₂-R¹⁷, or
 30 -N(R²⁰)SO₂-NR²⁰R¹⁷;

R¹⁷ is selected from:

C₁-C₁₀ alkyl, C₃-C₁₁ cycloalkyl, aryl(C₁-C₆ alkyl)-, (C₁-C₆ alkyl)aryl, heteroaryl(C₁-C₆ alkyl)-, (C₁-C₆ alkyl)heteroaryl, arylaryl(C₁-C₆ alkyl)-, heteroarylaryl(C₁-C₆ alkyl)-, arylheteroaryl(C₁-C₆ alkyl)-, heteroarylheteroaryl(C₁-C₆ alkyl)-, heteroaryl, or aryl, wherein said aryl or heteroaryl groups are optionally substituted with 0-3 substituents independently selected from the group consisting of: C₁-C₄ alkyl, C₁-C₄ alkoxy, aryl, halo, cyano, amino, CF₃, and NO₂;

R¹⁸ is selected from:

H,
-C(=O)-O-R¹⁷,
-C(=O)-R¹⁷,
-C(=O)-NH-R¹⁷,
-SO₂-R¹⁷, or
-SO₂-NR²⁰R¹⁷;

R¹⁹ is selected from:

hydroxy,
C₁-C₁₀ alkyloxy,
C₃-C₁₁ cycloalkyloxy,
aryloxy,
aryl(C₁-C₆ alkoxy)-,
C₃-C₁₀ alkylcarbonyloxyalkyloxy,
C₃-C₁₀ alkoxy carbonyloxyalkyloxy,
C₂-C₁₀ alkoxy carbonylalkyloxy,
C₅-C₁₀ cycloalkylcarbonyloxyalkyloxy,
C₅-C₁₀ cycloalkoxy carbonyloxyalkyloxy,
C₅-C₁₀ cycloalkoxy carbonylalkyloxy,
C₇-C₁₁ aryloxy carbonylalkyloxy,
C₈-C₁₂ aryloxy carbonyloxyalkyloxy,
C₈-C₁₂ arylcarbonyloxyalkyloxy,
C₅-C₁₀ alkoxyalkylcarbonyloxyalkyloxy,

C₅-C₁₀ (5-alkyl-1,3-dioxo-cyclopenten-2-one-yl)methyloxy,

C₁₀-C₁₄ (5-aryl-1,3-dioxo-cyclopenten-2-one-yl)methyloxy, or

5 (R¹¹) (R¹²)N-(C₁-C₁₀ alkoxy)-;

R²⁰ selected from: H, C₁-C₆ alkyl, C₃-C₇ cycloalkyl, C₄-C₁₁ cycloalkylalkyl, aryl, aryl(C₁-C₆ alkyl)-, or heteroaryl(C₁-C₆ alkyl)-;

10

m is 1-2;

n is 0-2;

p is 0-2;

q is 0-2; and

15 r is 0-2;

provided that:


n, q, and r are chosen such that the number of in-chain atoms between R¹ and Y is in the range of 8-18.

20


3. A compound of Claim 1 of the Formula I and pharmaceutically acceptable salt forms thereof wherein:

25

Q is selected from:



R^1 is selected from:



wherein the above heterocycles are optionally substituted with 0-2 substituents selected from the group consisting of: NH_2 , halogen, NO_2 , CN , CF_3 , $\text{C}_1\text{-C}_4$ alkoxy, $\text{C}_1\text{-C}_6$ alkyl, and $\text{C}_3\text{-C}_7$ cycloalkyl;

R^2 is selected from: H, $\text{C}_1\text{-C}_4$ alkyl or benzyl;

U is $-\text{NH}(\text{CH}_2)_n-$;

10

V is $-(\text{CH}_2)_n-$;

R^{10} is selected from: H, CO_2R^{17} , $\text{C}(=\text{O})\text{R}^{17}$, $\text{CONR}^{17}\text{R}^{20}$, $-\text{SO}_2\text{R}^{17}$, $-\text{SO}_2\text{NR}^{17}\text{R}^{20}$, $\text{C}_1\text{-C}_6$ alkyl substituted with 0-1 R^{15} , $\text{C}_3\text{-C}_6$ alkenyl substituted with 0-1 R^{15} , $\text{C}_3\text{-C}_7$ cycloalkyl substituted with 0-1 R^{15} , $\text{C}_4\text{-C}_{11}$ cycloalkylalkyl substituted with 0-1 R^{15} , aryl substituted with 0-1 R^{15} or 0-2 R^{11} , or aryl($\text{C}_1\text{-C}_6$ alkyl)- substituted with 0-1 R^{15} or 0-2 R^{11} ;

20

R^{10a} is selected from: CO_2R^{17} , $\text{C}(=\text{O})\text{R}^{17}$, $\text{CONR}^{17}\text{R}^{20}$, $-\text{SO}_2\text{R}^{17}$, $-\text{SO}_2\text{NR}^{17}\text{R}^{20}$, $\text{C}_1\text{-C}_6$ alkyl substituted with 0-1 R^{15} , $\text{C}_3\text{-C}_6$ alkenyl substituted with 0-1 R^{15} , $\text{C}_3\text{-C}_7$ cycloalkyl substituted with 0-1 R^{15} , $\text{C}_4\text{-C}_{11}$ cycloalkylalkyl substituted with 0-1 R^{15} , aryl substituted with 0-1 R^{15} or 0-2 R^{11} , or aryl($\text{C}_1\text{-C}_6$ alkyl)- substituted with 0-1 R^{15} or 0-2 R^{11} ;

25

R^{11} is selected from H, $\text{C}_1\text{-C}_4$ alkyl, $\text{C}_1\text{-C}_4$ alkoxy, aryl, aryl($\text{C}_1\text{-C}_6$ alkyl)-, ($\text{C}_1\text{-C}_4$ alkoxy)carbonyl, ($\text{C}_1\text{-C}_4$ alkyl)carbonyl, $\text{C}_1\text{-C}_4$ alkylsulfonyl, or $\text{C}_1\text{-C}_4$ alkylaminosulfonyl;

30

W is $-\text{C}(=\text{O})-\text{N}(\text{R}^{13})-$;

35

X is $-\text{CH}(\text{R}^{14})-\text{CH}(\text{R}^{15})-$;

R¹³ is H or CH₃;

R¹⁴ is selected from:

- 5 H, C₁-C₁₀ alkyl, aryl, or heteroaryl, wherein said
 aryl or heteroaryl groups are optionally
 substituted with 0-3 substituents independently
 selected from the group consisting of: C₁-C₄ alkyl,
 C₁-C₄ alkoxy, aryl, halo, cyano, amino, CF₃, and
10 NO₂;

R¹⁵ is H or R¹⁶;

Y is -C(=O)R¹⁹;

15

R¹⁶ is selected from:

- N(R²⁰)-C(=O)-O-R¹⁷,
 -N(R²⁰)-C(=O)-R¹⁷,
 -N(R²⁰)-C(=O)-NH-R¹⁷,
20 -N(R²⁰)SO₂-R¹⁷, or
 -N(R²⁰)SO₂-N(R²⁰)R¹⁷;

R¹⁷ is selected from:

- C₁-C₁₀ alkyl, C₃-C₁₁ cycloalkyl, aryl(C₁-C₆ alkyl)-,
25 (C₁-C₆ alkyl)aryl, heteroaryl(C₁-C₆ alkyl)-, (C₁-C₆
 alkyl)heteroaryl, arylaryl(C₁-C₆ alkyl)-,
 heteroarylaryl(C₁-C₆ alkyl)-, arylheteroaryl(C₁-C₆
 alkyl)-, heteroarylheteroaryl(C₁-C₆ alkyl)-,
 heteroaryl, or aryl, wherein said aryl or
30 heteroaryl groups are optionally substituted with
 0-3 substituents independently selected from the
 group consisting of: C₁-C₄ alkyl, C₁-C₄ alkoxy,
 aryl, halo, cyano, amino, CF₃, and NO₂;


- 35 R¹⁹ is selected from:
 hydroxy,

C₁-C₁₀ alkoxy,
methylcarbonyloxymethoxy-,
ethylcarbonyloxymethoxy-,
t-butylcarbonyloxymethoxy-,
5 cyclohexylcarbonyloxymethoxy-,
1-(methylcarbonyloxy)ethoxy-,
1-(ethylcarbonyloxy)ethoxy-,
1-(t-butylcarbonyloxy)ethoxy-,
1-(cyclohexylcarbonyloxy)ethoxy-,
10 i-propyloxycarbonyloxymethoxy-,
t-butyloxycarbonyloxymethoxy-,
1-(i-propyloxycarbonyloxy)ethoxy-,
1-(cyclohexyloxycarbonyloxy)ethoxy-,
1-(t-butyloxycarbonyloxy)ethoxy-,
15 dimethylaminoethoxy-,
diethylaminoethoxy-,
(5-methyl-1,3-dioxacyclopenten-2-on-4-yl)methoxy-,
(5-(t-butyl)-1,3-dioxacyclopenten-2-on-4-yl)methoxy-,
20 (1,3-dioxa-5-phenyl-cyclopenten-2-on-4-yl)methoxy-,
or
1-(2-(2-methoxypropyl)carbonyloxy)ethoxy-;


R²⁰ is H or CH₃; and
25 n is 0-1.

4. A compound of Claim 1 of the Formula I and
30 pharmaceutically acceptable salt forms thereof wherein:

Q is selected from:



R¹ is selected from:



R^2 is selected from: H, C_1 - C_4 alkyl, or benzyl;

5

U is $-NH(CH_2)_n-$;

V is $-(CH_2)_n-$;

- 10 R^{10} is selected from: H, CO_2R^{17} , $C(=O)R^{17}$, $C(=O)NR^{17}R^{20}$, $-SO_2R^{17}$, $-SO_2NR^{17}R^{20}$, C_1 - C_6 alkyl substituted with 0-1 R^{15} , C_3 - C_6 alkenyl substituted with 0-1 R^{15} , C_3 - C_7 cycloalkyl substituted with 0-1 R^{15} , C_4 - C_{11} cycloalkylalkyl substituted with 0-1 R^{15} , aryl

substituted with 0-1 R¹⁵ or 0-2 R¹¹, or aryl(C₁-C₆ alkyl)- substituted with 0-1 R¹⁵ or 0-2 R¹¹;

5 R^{10a} is selected from: CO₂R¹⁷, C(=O)R¹⁷, CONR¹⁷R²⁰,
-SO₂R¹⁷, -SO₂NR¹⁷R²⁰, C₁-C₆ alkyl substituted with 0-1 R¹⁵, C₃-C₆ alkenyl substituted with 0-1 R¹⁵, C₃-C₇ cycloalkyl substituted with 0-1 R¹⁵, C₄-C₁₁ cycloalkylalkyl substituted with 0-1 R¹⁵, aryl substituted with 0-1 R¹⁵ or 0-2 R¹¹, or aryl(C₁-C₆ alkyl)- substituted with 0-1 R¹⁵ or 0-2 R¹¹;

10 R¹¹ is selected from H, C₁-C₄ alkyl, C₁-C₄ alkoxy, aryl, aryl(C₁-C₆ alkyl)-, (C₁-C₄ alkoxy)carbonyl, (C₁-C₄ alkyl)carbonyl, C₁-C₄ alkylsulfonyl, or C₁-C₄ alkylaminosulfonyl;

W is -C(=O)-N(R¹³)-;


20 X is -CH(R¹⁴)-CH(R¹⁵)-;
R¹³ is H or CH₃;

R¹⁴ is selected from:
H, C₁-C₁₀ alkyl, aryl, or heteroaryl, wherein said
25 aryl or heteroaryl groups are optionally substituted with 0-3 substituents independently selected from the group consisting of: C₁-C₄ alkyl, C₁-C₄ alkoxy, aryl, halo, cyano, amino, CF₃, and NO₂;

30 R¹⁵ is H or R¹⁶;

Y is -C(=O)R¹⁹;

35 R¹⁶ is selected from:
-N(R²⁰)-C(=O)-O-R¹⁷,



R¹⁷ is selected from:

- 5 C₁-C₁₀ alkyl, C₃-C₁₁ cycloalkyl, aryl(C₁-C₆ alkyl)-, (C₁-C₆ alkyl)aryl, heteroaryl(C₁-C₆ alkyl)-, (C₁-C₆ alkyl)heteroaryl, arylaryl(C₁-C₆ alkyl)-, heteroarylaryl(C₁-C₆ alkyl)-, arylheteroaryl(C₁-C₆ alkyl)-, heteroarylheteroaryl(C₁-C₆ alkyl)-, heteroaryl, or aryl, wherein said aryl or heteroaryl groups are optionally substituted with 0-3 substituents independently selected from the group consisting of: C₁-C₄ alkyl, C₁-C₄ alkoxy, aryl, halo, cyano, amino, CF₃, and NO₂;

15

R¹⁹ is selected from:

- hydroxy,
C₁-C₁₀ alkoxy,
methylcarbonyloxymethoxy-,
20 ethylcarbonyloxymethoxy-,
t-butylcarbonyloxymethoxy-,
cyclohexylcarbonyloxymethoxy-,
1-(methylcarbonyloxy)ethoxy-,
1-(ethylcarbonyloxy)ethoxy-,
25 1-(t-butylcarbonyloxy)ethoxy-,
1-(cyclohexylcarbonyloxy)ethoxy-,
i-propyloxycarbonyloxymethoxy-,
t-butyloxycarbonyloxymethoxy-,
1-(i-propyloxycarbonyloxy)ethoxy-,
30 1-(cyclohexyloxycarbonyloxy)ethoxy-,
1-(t-butyloxycarbonyloxy)ethoxy-,
dimethylaminoethoxy-,
diethylaminoethoxy-,
(5-methyl-1,3-dioxacyclopenten-2-on-4-yl)methoxy-,
35 (5-(t-butyl)-1,3-dioxacyclopenten-2-on-4-yl)methoxy-,

(1,3-dioxa-5-phenyl-cyclopenten-2-on-4-yl)methoxy-,
or
1-(2-(2-methoxypropyl)carbonyloxy)ethoxy-;

5 R²⁰ is H or CH₃; and

n is 0-1.

10 5. A compound of Claim 1 and enantiomeric or
diasteriomer forms thereof, or mixtures of
enantiomeric or diastereomeric forms thereof, and
pharmaceutically acceptable salt forms thereof, selected
from the group consisting of:

15

(S)-2-phenylsulfonylamino-3-[[[8-(2-
pyridinylaminomethyl)-]-1-oxa-2-azaspiro-
[4,5]-dec-2-en-3-yl]carbonylamino]propionic
acid,

20

(S)-2-benzyloxycarbonylamino-3-[[[8-(2-
pyridinylaminomethyl)-]-1-oxa-2-azaspiro-
[4,5]-dec-2-en-3-yl]carbonylamino]propionic
acid,

25

(S)-2-[(2,4,6-trimethylphenyl)sulfonyl]amino-3-
[[[8-(2-pyridinylaminomethyl)-]-1-oxa-2-
azaspiro-[4,5]-dec-2-en-3-
yl]carbonylamino]propionic acid,

30

(S)-2-[(3,5-dimethylisoxazol-4-yl)sulfonyl]amino-3-
[[[8-(2-pyridinylaminomethyl)-]-1-oxa-2-
azaspiro-[4,5]-dec-2-en-3-
yl]carbonylamino]propionic acid,

(S)-2-phenylsulfonylamino-3-[[[8-[(6-aminopyridin-
2-yl)methyl]-]-1-oxa-2,8-diazaspiro-[4,5]-dec-
2-en-3-yl]carbonylamino]propionic acid,

- (S)-2-phenylsulfonylamino-3-[[[8-[(6-aminopyridin-2-yl)methyl]]-1-oxa-2,8-diazaspiro-[4,4]-non-2-en-3-yl]carbonylamino]propionic acid,
- 5 (S)-2-phenylsulfonylamino-3-[[[8-(2-pyridinylaminomethyl)-]-1-oxa-2-azaspiro-[4,4]-non-2-en-3-yl]carbonylamino]propionic acid,
- 10 (S)-2-phenylsulfonylamino-3-[[[8-[2-(4,5-dihydroimidazol-2-yl)aminomethyl]]-]-1-oxa-2-azaspiro-[4,5]-dec-2-en-3-yl]carbonylamino]propionic acid,
- 15 (S)-2-[(2-methylphenyl)sulfonyl]amino-3-[[[8-(2-pyridinylaminomethyl)-]-1-oxa-2-azaspiro-[4,5]-dec-2-en-3-yl]carbonylamino]propionic acid,
- 20 (S)-2-[(2-chloro-4-methylphenyl)sulfonyl]amino-3-[[[8-(2-pyridinylaminomethyl)-]-1-oxa-2-azaspiro-[4,5]-dec-2-en-3-yl]carbonylamino]propionic acid,
- 25 (S)-2-[(4-biphenyl)sulfonyl]amino-3-[[[8-(2-pyridinylaminomethyl)-]-1-oxa-2-azaspiro-[4,5]-dec-2-en-3-yl]carbonylamino]propionic acid,
- 30 (S)-2-[(2-bromophenyl)sulfonyl]amino-3-[[[8-(2-pyridinylaminomethyl)-]-1-oxa-2-azaspiro-[4,5]-dec-2-en-3-yl]carbonylamino]propionic acid,
- 35 (S)-2-[(1-naphthyl)sulfonyl]amino-3-[[[8-(2-pyridinylaminomethyl)-]-1-oxa-2-azaspiro-[4,5]-dec-2-en-3-yl]carbonylamino]propionic acid.

- (S)-2-phenylsulfonylamino-3-[[[8-(2-imidazolylaminomethyl)-]-1-oxa-2-azaspiro-[4,5]-dec-2-en-3-yl]carbonylamino]propionic acid,
- 5 (S)-2-benzyloxycarbonylamino-3-[[[8-(2-imidazolylaminomethyl)-]-1-oxa-2-azaspiro-[4,5]-dec-2-en-3-yl]carbonylamino]propionic acid,
- 10 (S)-2-[(2,4,6-trimethylphenyl)sulfonyl]amino-3-[[[8-(2-imidazolylaminomethyl)-]-1-oxa-2-azaspiro-[4,5]-dec-2-en-3-yl]carbonylamino]propionic acid,
- 15 (S)-2-[(2,6-dimethylphenyl)sulfonyl]amino-3-[[[8-(2-imidazolylaminomethyl)-]-1-oxa-2-azaspiro-[4,5]-dec-2-en-3-yl]carbonylamino]propionic acid,
- 20 (S)-2-[(2,6-dichlorophenyl)sulfonyl]amino-3-[[[8-(2-imidazolylaminomethyl)-]-1-oxa-2-azaspiro-[4,5]-dec-2-en-3-yl]carbonylamino]propionic acid,
- (S)-2-[(2,6-dimethyl-4-phenyl)phenylsulfonyl]amino-3-[[[8-(2-imidazolylaminomethyl)-]-1-oxa-2-azaspiro-[4,5]-dec-2-en-3-yl]carbonylamino]propionic acid,
- 25 (S)-2-[(2-naphthyl)sulfonyl]amino-3-[[[8-(2-imidazolylaminomethyl)-]-1-oxa-2-azaspiro-[4,5]-dec-2-en-3-yl]carbonylamino]propionic acid,
- 30 (S)-2-[biphenylsulfonyl]amino-3-[[[8-(2-imidazolylaminomethyl)-]-1-oxa-2-azaspiro-[4,5]-dec-2-en-3-yl]carbonylamino]propionic acid,
- 35 (S)-2-phenylsulfonylamino-3-[[7-benzyloxycarbonyl-8-(2-imidazolylaminomethyl)-1-oxa-2,7-diazaspiro-[4,4]-non-2-en-3-yl]carbonylamino]propionic acid,

- (S)-2-benzyloxycarbonylamino-3-[[7-benzyloxycarbonyl-8-(2-imidazolylaminomethyl)-1-oxa-2,7-diazaspiro-[4,4]-non-2-en-3-yl]carbonylamino]propionic acid,
- 5 (S)-2-[(2,4,6-trimethylphenyl)sulfonyl]amino-3-[[7-benzyloxycarbonyl-8-(2-imidazolylaminomethyl)-1-oxa-2,7-diazaspiro-[4,4]-non-2-en-3-yl]carbonylamino]propionic acid,
- 10 (S)-2-[(2,6-dimethylphenyl)sulfonyl]amino-3-[[7-benzyloxycarbonyl-8-(2-imidazolylaminomethyl)-1-oxa-2,7-diazaspiro-[4,4]-non-2-en-3-yl]carbonylamino]propionic acid,
- 15 (S)-2-[(2,6-dichlorophenyl)sulfonyl]amino-3-[[7-benzyloxycarbonyl-8-(2-imidazolylaminomethyl)-1-oxa-2,7-diazaspiro-[4,4]-non-2-en-3-yl]carbonylamino]propionic acid,
- 20 (S)-2-[(2,6-dimethyl-4-phenyl)phenylsulfonyl]amino-3-[[7-benzyloxycarbonyl-8-(2-imidazolylaminomethyl)-1-oxa-2,7-diazaspiro-[4,4]-non-2-en-3-yl]carbonylamino]propionic acid,
- 25 (S)-2-[(2-naphthyl)sulfonyl]amino-3-[[7-benzyloxycarbonyl-8-(2-imidazolylaminomethyl)-1-oxa-2,7-diazaspiro-[4,4]-non-2-en-3-yl]carbonylamino]propionic acid,
- 30 (S)-2-biphenylsulfonylamino-3-[[7-benzyloxycarbonyl-8-(2-imidazolylaminomethyl)-1-oxa-2,7-diazaspiro-[4,4]-non-2-en-3-yl]carbonylamino]propionic acid,
- 35 (S)-2-phenylsulfonylamino-3-[[8-(2-imidazolylaminomethyl)-1-oxa-2,7-diazaspiro-[4,4]-non-2-en-3-yl]carbonylamino]propionic acid,
- (S)-2-benzyloxycarbonylamino-3-[[8-(2-imidazolylaminomethyl)-1-oxa-2,7-diazaspiro-

- [4,4]-non-2-en-3-yl]carbonylamino]propionic acid,
- 5 (S)-2-[(2,4,6-trimethylphenyl)sulfonyl]amino-3-[[8-(2-imidazolylaminomethyl)-1-oxa-2,7-diazaspiro-[4,4]-non-2-en-3-yl]carbonylamino]propionic acid,
- 10 (S)-2-[(2,6-dimethylphenyl)sulfonyl]amino-3-[[8-(2-imidazolylaminomethyl)-1-oxa-2,7-diazaspiro-[4,4]-non-2-en-3-yl]carbonylamino]propionic acid,
- 15 (S)-2-[(2,6-dichlorophenyl)sulfonyl]amino-3-[[8-(2-imidazolylaminomethyl)-1-oxa-2,7-diazaspiro-[4,4]-non-2-en-3-yl]carbonylamino]propionic acid,
- 20 (S)-2-[(2,6-dimethyl-4-phenyl)phenylsulfonyl]amino-3-[[8-(2-imidazolylaminomethyl)-1-oxa-2,7-diazaspiro-[4,4]-non-2-en-3-yl]carbonylamino]propionic acid,
- (S)-2-[(2-naphthyl)sulfonyl]amino-3-[[8-(2-imidazolylaminomethyl)-1-oxa-2,7-diazaspiro-[4,4]-non-2-en-3-yl]carbonylamino]propionic acid,
- 25 (S)-2-[biphenylsulfonyl]amino-3-[[8-(2-imidazolylaminomethyl)-1-oxa-2,7-diazaspiro-[4,4]-non-2-en-3-yl]carbonylamino]propionic acid,
- 30 (S)-2-phenylsulfonylamino-3-[[7-benzyloxycarbonyl-8-(2-pyridinylaminomethyl)-1-oxa-2,7-diazaspiro-[4,4]-non-2-en-3-yl]carbonylamino]propionic acid,
- (S)-2-benzyloxycarbonylamino-3-[[7-benzyloxycarbonyl-8-(2-pyridinylaminomethyl)-1-oxa-2,7-diazaspiro-[4,4]-non-2-en-3-yl]carbonylamino]propionic acid,
- 35 (S)-2-[(2,4,6-trimethylphenyl)sulfonyl]amino-3-[[7-benzyloxycarbonyl-8-(2-pyridinylaminomethyl)-

- 1-oxa-2,7-diazaspiro-[4,4]-non-2-en-3-yl]carbonylamino]propionic acid,
- 5 (S)-2-[(2,6-dimethylphenyl)sulfonyl]amino-3-[[7-benzyloxycarbonyl-8-(2-pyridinylaminomethyl)-1-oxa-2,7-diazaspiro-[4,4]-non-2-en-3-yl]carbonylamino]propionic acid,
- 10 (S)-2-[(2,6-dichlorophenyl)sulfonyl]amino-3-[[7-benzyloxycarbonyl-8-(2-pyridinylaminomethyl)-1-oxa-2,7-diazaspiro-[4,4]-non-2-en-3-yl]carbonylamino]propionic acid,
- 15 (S)-2-[(2,6-dimethyl-4-phenyl)phenylsulfonyl]amino-3-[[7-benzyloxycarbonyl-8-(2-pyridinylaminomethyl)-1-oxa-2,7-diazaspiro-[4,4]-non-2-en-3-yl]carbonylamino]propionic acid,
- 20 (S)-2-[(2-naphthyl)sulfonyl]amino-3-[[7-benzyloxycarbonyl-8-(2-pyridinylaminomethyl)-1-oxa-2,7-diazaspiro-[4,4]-non-2-en-3-yl]carbonylamino]propionic acid,
- 25 (S)-2-phenylsulfonylamino-3-[[7-benzyloxycarbonyl-8-(4,5-dihydroimidazol-2-yl)aminomethyl-1-oxa-2,7-diazaspiro-[4,4]-non-2-en-3-yl]carbonylamino]propionic acid,
- 30 (S)-2-benzyloxycarbonylamino-3-[[7-benzyloxycarbonyl-8-(4,5-dihydroimidazol-2-yl)aminomethyl-1-oxa-2,7-diazaspiro-[4,4]-non-2-en-3-yl]carbonylamino]propionic acid,
- 35 (S)-2-[(2,4,6-trimethylphenyl)sulfonyl]amino-3-[[7-benzyloxycarbonyl-8-(4,5-dihydroimidazol-2-yl)aminomethyl-1-oxa-2,7-diazaspiro-[4,4]-non-2-en-3-yl]carbonylamino]propionic acid,

- (S)-2-[(2,6-dimethylphenyl)sulfonyl]amino-3-[[7-benzyloxycarbonyl-8-(4,5-dihydroimidazol-2-yl)aminomethyl-1-oxa-2,7-diazaspiro-[4,4]-non-2-en-3-yl]carbonylamino]propionic acid,
- 5 (S)-2-[(2,6-dichlorophenyl)sulfonyl]amino-3-[[7-benzyloxycarbonyl-8-(4,5-dihydroimidazol-2-yl)aminomethyl-1-oxa-2,7-diazaspiro-[4,4]-non-2-en-3-yl]carbonylamino]propionic acid,
- 10 (S)-2-[(2,6-dimethyl-4-phenyl)phenylsulfonyl]amino-3-[[7-benzyloxycarbonyl-8-(4,5-dihydroimidazol-2-yl)aminomethyl-1-oxa-2,7-diazaspiro-[4,4]-non-2-en-3-yl]carbonylamino]propionic acid,
- 15 (S)-2-[(2-naphthyl)sulfonyl]amino-3-[[7-benzyloxycarbonyl-8-(4,5-dihydroimidazol-2-yl)aminomethyl-1-oxa-2,7-diazaspiro-[4,4]-non-2-en-3-yl]carbonylamino]propionic acid,
- 20 (S)-2-[biphenylsulfonyl]amino-3-[[7-benzyloxycarbonyl-8-(4,5-dihydroimidazol-2-yl)aminomethyl-1-oxa-2,7-diazaspiro-[4,4]-non-2-en-3-yl]carbonylamino]propionic acid,
- 25 (S)-2-phenylsulfonylamino-3-[[8-(4,5-dihydroimidazol-2-yl)aminomethyl-1-oxa-2,7-diazaspiro-[4,4]-non-2-en-3-yl]carbonylamino]propionic acid,
- 30 (S)-2-benzyloxycarbonylamino-3-[[8-(4,5-dihydroimidazol-2-yl)aminomethyl-1-oxa-2,7-diazaspiro-[4,4]-non-2-en-3-yl]carbonylamino]propionic acid,
- 35 (S)-2-[(2,4,6-trimethylphenyl)sulfonyl]amino-3-[[8-(4,5-dihydroimidazol-2-yl)aminomethyl-1-oxa-2,7-diazaspiro-[4,4]-non-2-en-3-yl]carbonylamino]propionic acid,
- (S)-2-[(2,6-dimethylphenyl)sulfonyl]amino-3-[[8-(4,5-dihydroimidazol-2-yl)aminomethyl-1-oxa-

- 2,7-diazaspiro-[4,4]-non-2-en-3-yl]carbonylamino]propionic acid,
(S)-2-[(2,6-dichlorophenyl)sulfonyl]amino-3-[[8-(4,5-dihydroimidazol-2-yl)aminomethyl-1-oxa-2,7-diazaspiro-[4,4]-non-2-en-3-yl]carbonylamino]propionic acid,
(S)-2-[(2,6-dimethyl-4-phenyl)phenylsulfonyl]amino-3-[[8-(4,5-dihydroimidazol-2-yl)aminomethyl-1-oxa-2,7-diazaspiro-[4,4]-non-2-en-3-yl]carbonylamino]propionic acid,
(S)-2-[(2-naphthyl)sulfonyl]amino-3-[[8-(4,5-dihydroimidazol-2-yl)aminomethyl-1-oxa-2,7-diazaspiro-[4,4]-non-2-en-3-yl]carbonylamino]propionic acid,
(S)-2-[biphenylsulfonyl]amino-3-[[8-(4,5-dihydroimidazol-2-yl)aminomethyl-1-oxa-2,7-diazaspiro-[4,4]-non-2-en-3-yl]carbonylamino]propionic acid, and
(S)-2-[(2,4,6-trimethylphenyl)sulfonyl]amino-3-[[8-(2-benzimidazolyl)aminomethyl-1-oxa-2,7-diazaspiro-[4,4]-non-2-en-3-yl]carbonylamino]propionic acid.

6. A method for the treatment of cancer metastasis, diabetic retinopathy, neovascular glaucoma, thrombosis, restenosis, osteoporosis, or macular degeneration which comprises administering to a host in need of such treatment a therapeutically effective amount of a compound of Claim 1-5.

7. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of Claim 1-5.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 97/04567

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C07D413/12 C07D413/14 C07D498/10 A61K31/42

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 95 14683 A (THE DU PONT MERCK PHARMACEUTICAL COMPANY) 1 June 1995 cited in the application see page 249 - page 252; claims ---	1-4,6,7
A	EP 0 529 858 A (TAKEDA CHEMICAL INDUSTRIES LTD) 3 March 1993 see page 2, line 1 - line 31; claims ---	1-4,6,7
A	WO 95 14682 A (THE DU PONT MERCK PHARMACEUTICAL COMPANY) 1 June 1995 see claims ---	1-4,6,7
P,A	WO 96 37492 A (THE DU PONT MERCK PHARMACEUTICAL COMPANY) 28 November 1996 cited in the application see claims -----	1-4,6,7

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- *&* document member of the same patent family

Date of the actual completion of the international search

4 July 1997

Date of mailing of the international search report

11.07.97

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

Henry, J

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 97/04567

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claim(s) 6
is(are) directed to a method of treatment of the human/animal
body, the search has been carried out and based on the alleged
effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such
an extent that no meaningful International Search can be carried out, specifically:
In view of the large number of compounds which are defined by the wording
of the claims, the search has been performed on the general idea and
compounds mentioned in the examples of the description.
Claims searched incompletely: 1-4,6,7
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☐ The additional search fees were accompanied by the applicant's protest.☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 97/04567

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9514683 A	01-06-95	AU 1098095 A	13-06-95
		CA 2174838 A	01-06-95
		CZ 9601419 A	13-11-96
		EP 0730590 A	11-09-96
		FI 962184 A	23-05-96
		HR 940952 A	30-04-97
		HU 74690 A	28-01-97
		NO 962096 A	23-05-96
		PL 314591 A	16-09-96
		SK 66696 A	06-11-96
		ZA 9409337 A	24-05-96
EP 0529858 A	03-03-93	AU 646966 B	10-03-94
		AU 2090892 A	25-02-93
		CA 2076619 A	24-02-93
		CN 1069730 A	10-03-93
		CN 1078968 A	01-12-93
		GR 1001405 B	30-11-93
		HU 9500497 A	28-09-95
		JP 6025285 A	01-02-94
		US 5294713 A	15-03-94
WO 9514682 A	01-06-95	US 5446056 A	29-08-95
		AU 677481 B	24-04-97
		AU 1097895 A	13-06-95
		CA 2174415 A	01-06-95
		EP 0730589 A	11-09-96
		NZ 276631 A	24-06-97
		ZA 9409291 A	23-05-96
WO 9637492 A	28-11-96	AU 5876296 A	11-12-96